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Abstract
Background. Health economic evaluations of interventions against infec-
tious diseases are commonly based on the predictions of compartmental
models such as ordinary differential equation (ODE) systems and Markov
models (MMs). In contrast to standard MMs, ODE systems of infectious dis-
eases are commonly dynamic and account for the effects of herd immunity.
This is crucial to prevent overestimation of infection prevalence.
Despite their computational effort, ODE systems including whole distri-
butions on model parameters are considered the “gold standard” in infec-
tious disease modelling. However, the literature mainly contains ODE-based
models which only include a predefined value on each model parameter and
thus do not account for parameter uncertainty. As a consequence, proba-
bilistic sensitivity analysis, a crucial component of health economic evalua-
tions, cannot be conducted straightforwardly.
Methodology. We present an approach to a dynamic MM under a
Bayesian framework. The stochastic MM incorporates a probability distri-
bution on each model parameter. We extend a static MM by incorporating
the force of infection into the state allocation algorithm. The corresponding
output is based on dynamic changes in population prevalence. In contrast to
deterministic ODE-based models including a predefined value for each pa-
rameter, probabilistic sensitivity analysis can be conducted straightforwardly.
The main motivation for our approach was to conduct a cost-effectiveness
analysis of human papillomavirus vaccination.
Results. We introduce a case study of a fictional sexually transmitted in-
vii
fection. By means of this example, we show that our methodology produces
results which are comparable to the “gold standard” of an ODE system in a
Bayesian framework.
When applied to a cost-effectiveness analysis of human papillomavirus
vaccination, our method indicates that universal vaccination (including both
sexes) is cost-effective. A comparison of universal to female-only vaccina-
tion and cervical screening-only results in an Incremental Cost-Effectiveness
Ratio (ICER) of e 11,600 and e 1,500, respectively.
Conclusions. The dynamic Bayesian MM is suitable to include a high
number of states and age cohorts, which are for example required in con-
clusive human papillomavirus modelling. In contrast to deterministic ODE
systems, the setting is fully probabilistic at manageable computational ef-
fort.
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Chapter 1
Introduction
1.1 Background of research
Vaccines against infectious diseases offer major health benefits to soci-
ety [279, 386] and have been instrumental in the prevention of conditions
previously causing egregious burden from the public health perspective.
Examples include the worldwide eradication of smallpox [378] and the ex-
tremely low incidence of tetanus, diphteria, congenital rubella syndrome,
mumps and measles in the Western world [282]. However, despite being
frequently successful from a clinical point of view, vaccination programmes
are often costly and complex to apply to the target population. Given that
publicly funded health care systems such as the UK National Health Ser-
vice face increasing budget limitations, health interventions (including vacci-
nation programmes) are increasingly subject to cost-effectiveness analysis
(CEA) [51,281] as a pre-requisite to their implementation.
In a CEA, the impact of the interventions under investigation is evaluated
through an outcome in effectiveness, such as the quality of life or life years
gained, medical conditions avoided etc. The costs of the different interven-
tions to increase the effectiveness by one unit are then compared [268].
Much of the recent research in health economics has been focussed
on grounding CEA on sound statistical bases, increasingly often following a
1
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Bayesian approach [22,276,329]. Unlike a standard statistical or epidemio-
logical analysis, where the objective is to produce a form of inference (e.g.
to evaluate treatment efficacy [320] or to estimate the prevalence of a dis-
ease [208]), health economic evaluations aim at identifying the best course
of action, given the current evidence. Here, “best” means to exclusively fo-
cus on interventions which are effective and at the same time affordable to
public health insurance systems.
Several sources of uncertainty play a role in health economic evalua-
tions, including structural and parameter uncertainty. The first refers to the
simplifications and scientific judgements made [41], e.g. with respect to the
natural history of disease and the corresponding interventions. For example,
not all body areas affected by a certain pathogen are necessarily consid-
ered, and not all treatments against the health condition under investigation
are necessarily compared. This can considerably influence the decisions
made based on health economic evaluations. A study showed that the ef-
fects of structural uncertainty are ignored often (in 78 out of 90 model-based
submissions to the National Health Service (NHS) [40]). A second source
of uncertainty, parameter uncertainty, is especially relevant in the case of
infectious disease. For instance, the actual mechanisms of pathogen trans-
mission are often not fully understood and there is substantial uncertainty on
parameters such as the probability of infection per contact, which are some-
times based mostly on expert judgement. Therefore, it is essential to assess
the impact of parameter uncertainty on the decision making outcome, a pro-
cess typically known as Probabilistic Sensitivity Analysis (PSA) [22,24,51].
PSA is usually based on a simulation approach [22, 45, 246, 272, 288,
372]: uncertainty about the relevant parameters is described by a suitable
probability distribution, from which a large sample of values is obtained,
e.g. via Markov Chain Monte Carlo (MCMC) sampling under a Bayesian
framework or using bootstrap in a frequentist approach. These are used
to induce a distribution over the possible decisions and can be analysed
2
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to determine the impact of parameter uncertainty on the decision-making
process. If the optimal decision varies substantially across the simulations,
then the decision-making process is sensitive to the uncertainty in the model
parameters. As a consequence, further research needs to be conducted as
recommended by the health technology assessment bodies.
The National Institute for Health and Care Excellence (NICE) is arguably
the leading health technology assessment agency in the world. In the UK,
NICE is responsible for providing guidance and advice on whether proposed
interventions should be publicly funded. Over the years, NICE has de-
veloped a set of criteria and guidelines that drive the analytic process of
CEA [268]. Crucially, these involve the explicit necessity of PSA.
Interestingly, however, in the UK the assessment and appraisal of vac-
cines falls under the remit of the Joint Committee for Vaccines and Im-
munisations, an independent expert advisory committee to the ministers
and health departments. Since 2009, the Health Protection Regulation
obliges the Secretary of State to ensure that recommendations for national
vaccination programmes are based on an assessment demonstrating cost-
effectiveness [198]. However, there are currently no vaccine-specific guide-
lines for developing clinical or cost-effectiveness evidence. One of the rea-
sons for this circumstance is perhaps the intrinsic complexity of infectious
disease modelling, which is typically performed through compartmental mod-
els [371, 376]. These are highly complicated mathematical tools capable of
simulating the natural history of disease infection and progression.
1.2 Compartmental models
In pathogens transmissible among humans, compartmental models need
to account for population dynamics and the effects of herd immunity [12];
due to lower infection prevalence, the introduction of a preventive measure
such as vaccination induces a reduced risk of pathogen exposure. Only dy-
3
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namic models are able to account for these effects and as a consequence
to prevent incorrect predictions [129, 291]. Furthermore, in order to per-
form a full PSA, it is necessary to quantify the joint uncertainty in the model
parameters, resulting in a probabilistic model output. Thus, a dynamic com-
partmental methodology that is able to incorporate stochastic variations in
the model parameters is the most appropriate choice of model.
Several subgroups of compartmental models are presented in the liter-
ature on infectious disease transmission modelling; these are either deter-
ministic or stochastic models. In a deterministic model, the same set of pa-
rameter values and initial conditions always results in the same model out-
put. In contrast, a stochastic model produces different output each time the
model is run, accounting for randomness. The parameters of deterministic
models are commonly assigned one predefined value, e.g. a point estimate
(mean, median, mode); however, assigning suitable probability distributions
is also possible. Stochastic models are based on stochastic processes;
therefore, the states of the model have distributions. However, as for deter-
ministic models, a corresponding model parameter can either consist of a
single value, or a whole distribution of values.
A common approach to deterministic models is given by systems of
Ordinary Differential Equations (ODEs). These can be extended to ac-
count for chance variation by a so-called “error term” which is based on a
stochastic process, resulting in systems of Stochastic Differential Equations
(SDEs). In addition, stochastic models based on discrete- and continuous-
time stochastic processes (such as Poisson processes, Bernoulli processes
or Markov processes) are presented for infectious diseases; however, only
models based on Markov processes are common in the health economics
literature. These are often termed multi-state or Markov models (MMs).
Compartmental models differ in the ways of accounting for i) dynamic
interactions between members of the population, as well as ii) parame-
ter uncertainty and thus the eligibility to conduct PSA in a straightforward
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way. From the technical point of view, dynamic compartmental models are
usually fitted by solving systems of ODEs. While these automatically deal
with features such as herd immunity (and thus are considered the “indus-
try standard” in infectious disease modelling), they are almost invariably
characterised by a notable computational effort. An ODE-based model in a
Bayesian context would increase this effort to a level which would no longer
be computationally feasible, especially if the model were highly complex
(e.g. including a large number of states or age cohorts). One important
consequence is that, in most cases, epidemiological and economic mod-
elling for infectious disease performed by means of ODEs does not account
for parameter uncertainty.
In the context of deterministic ODE-based models, methods such as
Monte Carlo Sampling and Latin Hypercube Sampling [255] can be used to
incorporate distributions on the model outcome, as shown in [35, 203, 204].
Latin Hypercube Sampling was developed to reduce the amount of simula-
tions required by Monte Carlo Sampling, based on a technique of stratified
sampling, ensuring that extreme values of the distribution are sampled with
precision [255]. However, applying these sampling methods is rather com-
plex and computationally intensive. In addition, they are prone to result in
incorrect predictions on the natural history of disease since parameter un-
certainty is not accounted for directly in the compartmental model, but only
in retrospect.
The difficulties in accounting for parameter uncertainty in ODE systems
might be one of the reasons why the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) guideline for best modelling prac-
tice in infectious disease suggests that PSA is not a fundamental compo-
nent of health economic assessment [291]. This recommendation is given in
contrast with NICE and virtually any other disease area. As a consequence,
most economic models for vaccines only consider deterministic sensitivity
analysis, which is based on selecting a grid of “plausible” values for a sub-
5
CHAPTER 1. INTRODUCTION
set of model parameters in order to assess the robustness of the decision-
making process. This approach is however not recommended in general, as
it fails to account for potential correlation among the parameters [15,22,51].
An alternative compartmental specification is given by MMs. As de-
scribed above, a MM is based on a Markov process which is a specific case
of a stochastic process, defined by a Markov property. In a MM, the move-
ments of individuals across the states is thus governed by this property.
Typically it is assumed that the chance of leaving the current state depends
only on (some of) the past state(s). However, especially in the health eco-
nomic literature, the Markov property is often relaxed, and movements can
additionally depend on specific covariates. MMs are used to model disease
progression over time across a finite set of states. Although MMs can also
be computationally intensive, it is generally feasible to incorporate distribu-
tions on the model parameters (e.g. using a Bayesian framework) or to use
re-sampling methods such as the bootstrap to characterise the uncertainty
in the model parameters. Perhaps for this reason, MMs are a very popu-
lar tool in health economic evaluation. Nevertheless, a major limitation in
infectious disease transmission modelling and economic evaluations of the
related interventions is that in their standard format, MMs are intrinsically
static, i.e. they do not account for population dynamics [53] and the effects
of herd immunity.
However, it is possible to indirectly account for herd immunity in static
MMs as shown by [16, 82, 83, 365, 370]. Once a vaccine is introduced in
a population at a specific coverage rate, these authors reduce pathogen
prevalence in unvaccinated people through multiplication by adjustment fac-
tors. Another possibility is to lower transition probabilities to the state of
infection proportionally on vaccine-specific parameters (such as coverage,
efficacy and compliance rates). In indirect adjustment approaches, popu-
lation dynamics, mixing patterns between people and dynamic changes in
pathogen prevalence are not considered. Thus, these are not comparable to
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a fully dynamic approach and commonly result in under- or overestimation
of pathogen prevalence. The quality of the corresponding model outcome
could be improved through extensive calibration to prevalence data collected
after vaccine introduction; however, these prevalence data are not available
for newly introduced vaccines. Thus, this approach is not recommended in
general. Further details are discussed in Sections 4.4.2 and 4.6 as well as
Appendices B.3 and B.4.
1.3 Contributions
With a view to simplifying the process of PSA in health economic models
of interventions for infectious diseases, we introduce in this PhD thesis an
extension to standard discrete-time MMs, which we term dynamic Bayesian
MMs. Discrete-time MMs are frequently used in the health economics litera-
ture. Continuous-time MMs are also presented; however, due to their higher
effort on implementation and computation, these are not very common. The
expression “Bayesian” refers to the inference conducted. Dynamic interac-
tions between people are considered through the force of infection of the
pathogen, which is a function of the probability of infection transmission,
contact patterns between people, and infection prevalence (as understood
in [371]). We directly include the force of infection, which automatically ac-
counts for the effects of herd immunity, into the state allocation algorithm of
a standard MM. In other words, the movement of a susceptible individual to
the state of infection is directly represented by the dynamic force of infec-
tion. Our approach does not involve ODEs. A publication introducing our
methodology was submitted to the journal Medical Decision Making.
A direct inclusion of the force of infection into the state allocation algo-
rithm of a MM [92, 156] or its direct consideration in a model based on a
stochastic process [20, 141, 155] was presented previously by several au-
thors; details on these models are given in Section 2.3. Three of these
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models [20, 141, 156] are implemented in a Bayesian framework. However,
in contrast to our dynamic Bayesian MM, these models are only suitable to
include a low number of states due to computational limitations and consist
of no more than four states. Our dynamic Bayesian MM is especially suit-
able to incorporate an extensive number of states as described below and
shown in Chapter 5 for the application to human papillomavirus modelling.
Another difference to our approach is that these authors do not conduct a
health economic evaluation. In the health economics literature, to the best
of our knowledge, no approach of a dynamic stochastic model including a
high number of states is presented. Another aspect worth mentioning is that
stochastic models account for chance variation in the model output but not
necessarily for parameter uncertainty. However, this is essential in infectious
disease (especially if sexually transmitted) for a number of reasons.
Due to ethical constraints, clinical trials on most influential parameters
such as the probability of pathogen transmission between individuals cannot
be conducted to resolve parameter uncertainty; however, data from obser-
vational studies are available for certain pathogens. Data on partner acquisi-
tion rates are obtained through surveys and commonly include a lot of noise
as a consequence of societal expectations. Depending on the quality of the
literature information, evidence synthesis can contribute to a considerable
reduction in the amount of parameter uncertainty. The probabilistic output
of the dynamic Bayesian MM can be processed into a PSA as an essential
part of a CEA without the necessity of further simulation approaches.
Application to human papillomavirus modelling
The main motivation for the development of the dynamic Bayesian MM was
to identify the most cost-effective (i. e. affordable and beneficial to society)
intervention strategy against human papillomavirus (HPV). HPV is mainly
sexually transmitted and can induce neoplastic malignant and benign le-
sions in a variety of body regions, especially in the cervix and anogenital
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area [127]. The virus places a considerable clinical and economic burden
on public health providers; additionally, it has high impact on quality of life
and life expectancy of affected individuals [257, 260]. At present, a vaccine
against HPV is recommended for teenage females in most Western coun-
tries, and males are commonly not included in HPV vaccination schedules.
The aim of research is to compare predictions of the dynamic Bayesian
MM on the natural history of HPV infection and disease progression in dif-
ferent intervention scenarios to investigate the impact of i) the inclusion of
a large number of HPV-induced diseases; ii) the effects of herd immunity;
and, most importantly, iii) the extension of the HPV vaccination schedule
to males.
In contrast to the vast majority of HPV models in the literature which only
account for cervical cancer, the dynamic Bayesian MM structure consists of
a large number of states, including anogenital warts, HPV-induced cancers
and precancerous stages of the cervix, vagina, vulva, penis, anus, as well
as head and neck. We observe a “virtual” population consisting of multiple
age cohorts which enter the model and move between the states over a
pre-specified follow-up period. The movement to the state of HPV infection
is directly represented by the dynamic force of infection. Thus, in contrast
to standard MMs, acquiring the HPV infection becomes dynamic and de-
pends on the HPV transmission probability per partnership, sexual mixing
behaviour as well as HPV prevalence in the mating partners. As a conse-
quence, herd immunity is accounted for, which is especially important in con-
text of CEAs of preventive interventions such as vaccination. We account
for three different interventions: in female-only and universal vaccination (in-
cluding both sexes), the youngest age cohorts have the chance to receive
the vaccine at a pre-specified uptake rate; in addition, cervical screening
is offered to females at age-specific rates. In contrast, in screening-only,
cervical screening is the only preventive measure.
At the end of the follow-up, the model outcome on the number of indi-
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viduals in the states over the whole observation time period is processed in
terms of a CEA, comparing costs and benefits of universal vaccination to
those of female-only vaccination and screening-only, respectively. Due to
the fact that our model is implemented in a Bayesian framework, parameter
uncertainty is accounted for, which increases the predictive qualities. Fur-
thermore, PSA can be conducted straightforwardly once the model outcome
is available. A paper on the HPV model describing the findings of the natural
history of disease and the corresponding CEA is published in [178].
1.4 Contents of PhD thesis
This PhD thesis is structured in two parts. The first part (including Chap-
ters 2 and 3) introduces compartmental models for health economic evalua-
tions and the dynamic Bayesian Markov model. In the second part (including
Chapters 4 - 6), the dynamic Bayesian Markov model is specified to conduct
a CEA of HPV vaccination.
Chapter 2 gives an extensive overview on compartmental methodology,
especially focussing on ODE-based and MMs. Most importantly, the con-
tribution of the dynamic Bayesian MM is described in detail, including the
calculation of the force of infection, its integration into the state allocation al-
gorithm, and model implications. In addition, hybrid models which combine
static and dynamic methodology are introduced.
In Chapter 3, three different methodologies (a deterministic ODE-based
model, a Bayesian ODE-based model and the dynamic Bayesian MM) de-
scribed in Chapter 2 are compared in practice. The term “deterministic”
refers to the nature of the parameters, whereas the term “Bayesian” refers
to the inference conducted. A case study on a chronic sexually transmit-
ted infection is introduced, and the outcome of the three models on infec-
tion prevalence as well as the results of the corresponding CEAs are com-
pared. This includes three different calibration approaches; the implications
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of visual calibration, frequentist probabilistic and Bayesian calibration are
shown. A selection of the corresponding programme code is presented in
Appendix A.
Chapter 4 describes the literature review on the CEA models of differ-
ent HPV vaccination strategies. This includes details on the databases
searched, the corresponding search word combinations as well as a sum-
mary on the most important findings on model assumptions and results.
The summary is arranged according to model assumptions (including vac-
cination strategies), methodologies, and model outcome. Summary tables
including details on all publications retrieved are presented in Appendix B.
In Chapter 5, the specification of the dynamic Bayesian MM for the CEA
of HPV vaccination is described in detail. This includes assumptions on
interventions, the model structure, sexual mixing and a selection of transition
probabilities in females. Further details on the model structure, transition
probabilities in both sexes, sources of prior information and posterior results
are presented in Appendices C-F.
Chapter 6 presents the results, including convergence and autocorre-
lation diagnostics, visual calibration of a selection of states to data, the
natural history of HPV-induced diseases as well as the health economic
evaluation including PSA. More extensive calibration results are displayed
in Appendix G.
The thesis ends with a summary and final conclusion, describing advan-
tages and limitations of the dynamic Bayesian methodology in comparison
to ODE-based models. Furthermore, the results of the CEA of HPV vacci-
nation strategies are summarized.
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Part I
A dynamic Markov model in a
Bayesian framework

Chapter 2
Compartmental models
2.1 Introduction
Statistical models are designed to make statements on the general popula-
tion through random samples. The overall population of individuals affected
by a certain infectious disease cannot be observed. However, it is possible
to simulate the natural history of disease infection and progression through
suitable statistical methodology, involving the observation of a random sam-
ple of individuals over a pre-specified follow-up period. The purpose of in-
fectious disease modelling is to result in most reliable predictions on the
implications of infectious diseases. A large variety of modelling approaches
are available; yet, compartmental models are most widely used in the health
economics literature.
This chapter gives a general overview on compartmental models and
mainly focusses on two categories which are represented by Ordinary Dif-
ferential Equation (ODE)-based models and Markov models (MMs). These
two can be combined into so-called hybrid models. Stochastic modelling
approaches based on Stochastic Differential Equations (SDEs) are briefly
explained. Following the description of established methodology, we intro-
duce our contribution of a dynamic Bayesian MM, including details on the
calculation of the force of infection, its direct integration into the estima-
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tion of the acquisition of the infectious agent, and model implications in the
Bayesian framework.
2.2 Overview
Compartmental models consist of a set S of mutually exclusive and exhaus-
tive states describing disease infection and progression. We indicate the
elements of S as s = 1, . . . , S. Members of a “virtual” population move
across the states over a pre-specified time horizon. Compartmental mod-
els are population-based; thus, individual members of the population are
indistinguishable, and only proportions of the population in the states can
be evaluated.
Figure 2.1 shows an example of a compartmental model incorporating
the natural disease history of a chronic sexually transmitted infection (STI)
with S = 5 states. The assumptions encoded by this structure are that the
whole population initially is in the state Susceptible (indexed by s = 1), from
which a proportion can move to the state Infected (s = 2). Following this,
a proportion of the population moves to an Asymptomatic state (s = 3). A
progression to the state Morbid (s = 4) induces the development of dis-
ease symptoms. The state Dead (s = 5) can be reached from any state;
people die due to any cause or as a consequence of being in the state Mor-
bid. Compared to the average population, the latter have a higher risk of
death. A transition from one state to another is defined according to suitable
transition parameters [380]. They are indicated as φr,s, where r, s ∈ S repre-
sent the original and target state, respectively. We consider an open model
structure in which people which are alive are able to proliferate at a rate χ,
resulting in a replenishment of the pool of susceptibles at risk of contracting
the infection.
Compartmental models may differ in three important characteristics. The
first is the specification of time. The most realistic option is to allow transi-
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Figure 2.1: Model structure of a hypothetical chronic sexually transmitted infection
consisting of five states. The arrows represent the possible transitions.
These are governed by the parameters φr,s with indices r, s ∈ S repre-
senting origin and target states, respectively. The replenishment of the
pool of susceptibles by newborns proceeds at a rate χ.
tions among the states to happen at any point in time t > 0; this is a so-called
“continuous-time approach”. Alternatively, it is possible to assume that tran-
sitions occur in discrete time where only one transition is possible within a
pre-defined time interval It = [t, t+ κ), where κ determines the correspond-
ing interval width, commonly referred to as cycle. Depending on the medical
context, κ can be specified in terms of daily, weekly, monthly or yearly cy-
cles. The second difference concerns the way in which population dynam-
ics are considered: models including a force of infection which accounts for
population prevalence are referred to as dynamic, while those that include
a fixed force of infection and thus ignore the effects of herd immunity are
termed static. A third characteristic is that compartmental models are ei-
ther deterministic or stochastic. In a deterministic model, the same model
output is always obtained for the same values of the model parameters. In
contrast, a stochastic model accounts for chance variation and results in
different output even if the values of the parameters do not change.
In addition, different approaches to model parameter specification exist,
which may have major impact on the outcome of health economic evalu-
ations. Depending on the compartmental methodology used, the induced
effort on implementation and computation does not necessarily allow the
inclusion of probability distributions on all model parameters. In that case,
model parameters are assigned fixed values. Commonly, these are inferred
through a relevant summary (e.g. mean, median or mode), for example ob-
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tained from available data. The point estimate is then used as a plug-in
for the corresponding parameter. In contrast, if probability distributions are
assigned to parameters, parameter uncertainty is propagated through the
infection progression. While frequentist versions of this strategy exist (e.g.
based on bootstrap), this type of modelling is most naturally handled within
a Bayesian paradigm.
2.2.1 Ordinary Differential Equation models
ODE systems are deterministic by definition. The rate of change in the mem-
bers of a population within a given state is modelled in continuous time; thus,
the corresponding parameters are transition rates and we denote them as
ρr,s(t), with r, s ∈ S representing again the origin and target states, respec-
tively. In principle, transition rates can depend on t, but do not necessarily
have to. The number of people transitioning in each state at t is multiplied
by the corresponding transition rates to obtain the inflow and outflow to and
from a state. The difference between the number of people entering and
leaving a state corresponds to the derivative of the number of those in the
respective state.
Back to our example, we define the vector n(t) = (n1(t), . . . , nS(t))
′,
where ns(t) is the number of people in state s at time t, and χ is the prolifer-
ation rate. The corresponding ODE system is given by the set of equations
dn1(t)
dt
= χ[n1(t) + n2(t) + n3(t) + n4(t)]− ρ1,2(t)n1(t)− ρ1,5n1(t)
dn2(t)
dt
= ρ1,2(t)n1(t)− ρ2,3n2(t)− ρ2,5n2(t)
dn3(t)
dt
= ρ2,3n2(t)− ρ3,4n3(t)− ρ3,5n3(t)
dn4(t)
dt
= ρ3,4n3(t)− ρ4,5n4(t)
dn5(t)
dt
= ρ1,5n1(t) + ρ2,5n2(t) + ρ3,5n3(t) + ρ4,5n4(t).
(2.1)
The rate of change in the number of people in each state at each point in
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time t is subject to population dynamics and exposure to sources of infec-
tion. The transition to the state of infection is determined by the dynamic,
time-specific force of infection of the pathogen, indicated by ρ1,2(t) in (2.1).
This is a function of the probability of pathogen transmission, partner acqui-
sition rates and population prevalence.
In a deterministic ODE system, a point estimate (e.g. mean, median or
mode) is usually taken from available data to inform the model parameters.
In that case, parameter uncertainty is not accounted for; as a consequence,
the corresponding model output can be incorrect. An example for a point
estimate is given by a summary statistic on disease incidence. The term
incidence is often reported as a rate per 100,000 people at risk and refers
to newly acquired disease within a pre-defined period of time. An incidence
rate can thus for example be used to inform the transition rate of suscepti-
bles to the state of infection. In addition, scenario analyses are often also
performed, for example by plugging in more extreme estimates (e.g. lower
or upper quantiles) for the parameters. As mentioned earlier, this is not
equivalent to the application of a full PSA.
Theoretically, it is possible to assign a suitable probability distribution to
each parameter of an ODE-based model, for example in a Bayesian con-
text. The uncertainty is then propagated through the estimation procedure,
which again generates a full distribution of outcomes. This type of model
can be analysed using for instance Markov Chain Monte Carlo (MCMC)
samplers such as WinBUGS [355] (via the interface WBDiff [247]) or Stan [4],
a very promising tool, which in general performs extremely well with rela-
tively complex systems. Both include ODE solvers and can be linked to the
statistical programming language R.
However, WBDiff is generally computationally intensive and the ODE
solvers provided by Stan struggled in “stiff”1 regions of ODE systems until
1An ODE is termed stiff if the solution of the function varies slowly in the beginning,
followed by a sudden rapid change [262].
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the very latest releases. The underlying numerical solver became unstable
unless the step-size was set to very small values. The newest release (2.14)
seems to have overcome this issue and thus Stan looks very promising for
future developments [5].
More importantly, in realistic problems including a large number of states
and complex structures, ODE models including probability distributions on
all model parameters may be impractical since the model needs to be run for
a large number of simulations to ensure convergence of each parameter and
thus the ODE system has to be solved repeatedly for each parameter com-
bination. The increase in the computational time is mainly induced by the
length of the observation time horizon, the overall amount of parameters with
assigned probability distributions, the complexity of contacts, the number of
differential equations in the ODE system and their nature (stiff, non-stiff, or
a combination of both). Consequently, complex ODE-based models which
incorporate a distribution on each model parameter are rare exceptions in
the literature on infectious disease transmission modelling [33].
Accounting for parameter uncertainty does not mean that an ODE sys-
tem is no longer deterministic. However, deterministic ODE systems can
be extended to introduce chance variation in the model output by the inclu-
sion of an “error term” on the coefficient (i.e. the transition rate) of the ODE.
This error term is indicated by a stochastic process [286]. This results in so-
called Stochastic Differential Equations (SDEs). In infectious disease, SDEs
are especially used when the spread of pathogens in small populations is
modelled; in that case, chance variation plays an important role since the
pathogen could go extinct under certain conditions, but does not necessarily
have to. If a deterministic ODE system was used in that case, the pathogen
would either always or never go extinct which is not realistic [60]. A simple
SDE model is for example given by
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dS
dt
= −(ρ+ σFG(t))S(t)
dI
dt
= (ρ+ σFG(t))I(t),
where ρ is a transition rate, S(t) and I(t) are the number of susceptible and
infectious people over time, respectively, σF is the scaling parameter of the
stochastic process, and G(t) represents the stochastic process.
A stochastic process is a family of random variables {XλF} and is in-
dexed by λF ∈ ΛF. A stochastic process can either be specified in con-
tinuous or discrete time. In a continuous time process, ΛF is defined as a
time interval or the whole real line. In contrast, in a discrete time process,
ΛF is either defined in N or Z [343]. Specific cases of stochastic processes
are given by Poisson and Markov processes. A Poisson process can for
example be applied to estimate the number of people in a certain state over
time, e.g. in context of a SDE. If time series data are available, these can
be used to estimate the corresponding event rate, e.g. through maximum
likelihood estimation or a Bayesian approach. Once the event rate is known,
future predictions can be made. A Poisson process can as well be a Markov
process. A Markov process is defined through the Markov assumption as
described in the following.
2.2.2 Markov models
A Markov model is based on a Markov chain. A Markov chain contains a
continuous or discrete set of states, the so-called state space. We focus
on discrete state space, including a predefined number of mutually exclu-
sive and exhaustive states. The main characteristic of a Markov chain is the
Markov assumption which says that the conditional distribution of a future
state given the present and the past states is equal to the conditional distri-
bution of the future state given the present state and the k∗ previous states,
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where k∗ ∈ {0, 1, 2}. However, the Markov assumption can be relaxed by
accounting for covariates (e.g. age and sex), time-specific population preva-
lence, population dynamics or time spent in the current state in the transition
parameters. The Markov assumption is frequently relaxed in the transition
parameters of MMs in the health economic literature through the inclusion
of covariates.
If the time spent in the current state influences the transition to a future
state, a so-called semi-Markov model can be implemented. This is for ex-
ample the case in chronic infectious diseases with periods of exacerbation;
the longer the patient was in a state of remission, the higher the risk of exac-
erbation. The Markov assumption is then relaxed by accounting for the time
spent in the current state [73]. However, semi-Markov models are beyond
the scope of this PhD thesis and thus not explained in further detail.
As for ODE-based models, MMs can be implemented for continuous
time; for consistency, we will briefly describe these and refer to [128] for
more extensive detail. As suggested earlier, in the former, the rates of
change are calculated dynamically through differentiation, while in the latter,
the transitions are described by a Markov process. This continuous-time
Markov process can account for population dynamics and is defined by a
transition rate matrix Q and the corresponding initial state distribution. The
time spent in a state is described through exponentially distributed rates.
The probability distribution on the state space p is given by the Kolmogorov
Forward Equation [128]
dp(t)
dt
= p(t)Q.
Solving this differential equation given the initial condition p(0) results in
the state distribution p(t) of the Markov process at time point t,
p(t) = p(0)etQ.
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This solution is based on the exponential of the transition rate matrix and
can thus be computationally intensive for large matrices if many states are
included in the model [14]; however, a solution can also be obtained through
an ODE solver, e.g. based on the Runge-Kutta method [309].
Continuous-time MMs have the advantage that transitions across the
states are possible at any point in time t. However, the vast majority of MMs
in the health economic literature is based on a discrete-time approach [363]
and thus these are described in more detail in this section. In a discrete-time
MM, members of the population move across the states according to a set of
transition probabilities only once per time interval (commonly referred to as
“Markov cycle”). These probabilities can be arranged in a matrix Π = (pir,s),
whose elements represent the transition probabilities for movements from
an original state r to a target state s. For the model structure of Figure 2.1,
the transition probability matrix is defined as
Π =

pi1,1 pi1,2 0 0 pi1,5
0 pi2,2 pi2,3 0 pi2,5
0 0 pi3,3 pi3,4 pi3,5
0 0 0 pi4,4 pi4,5
0 0 0 0 1

,
implying that, for example, a susceptible either acquires the infection (with
probability pi1,2), dies (with probability pi1,5), or remains susceptible, which
occurs with probability pi1,1 = 1− pi1,2 − pi1,5.
If we define the vector nt = (n1t, . . . , nSt)
′, where nst is the number of
people in state s and at each time interval It, then transitions across the
states from one time interval to the next are calculated as
nt+1 = Πnt. (2.2)
The number of people in the states are integers and are thus rounded up or
off once the state allocation algorithm was run. MMs are relatively straight-
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forward to implement and are commonly used to model the progression of
non-communicable conditions such as cardiovascular disease and cancer.
Therefore, they are established in the health economic literature and well-
known to both clinicians and decision makers. However, the process of
pathogen transmission is not estimated correctly by MMs presented in the
literature (apart from [92, 156]). A transition of susceptibles to the state of
infection is commonly represented by a static transition parameter which
does not consider changes in the population prevalence over time. These
especially occur after the introduction of a preventive intervention such as
vaccination into a fully susceptible population.
The predictions of static MMs on population prevalence are commonly
incorrect (although notable exceptions include scenarios with very low vac-
cine coverage or pathogens that cannot be transmitted between humans,
e.g. tetanus). In the worst case, the whole model outcome on infection
prevalence and the related CEA can be incorrect, e.g. because of the impact
of an unrecognised shift in the age of infection of childhood diseases. Some
childhood diseases are relatively harmless in young children but prone to
lead to serious health issues in adults. The consequences of incorrect pre-
dictions of static MMs on population health and induced costs, e.g. through
hospitalisation and treatment, can be dire [53].
As for ODE-based models, a dynamic force of infection could be incor-
porated into the transition probabilities to account for the effects of herd
immunity. To the best of our knowledge, the health economic literature does
not include any dynamic Markov models. A dynamic hidden MM is pre-
sented by Cooper and Lipsitch [92] and a dynamic Bayesian MM by Gibson
and Renshaw [156]; however, these models only include a small number of
states, are implemented in continuous time, and the authors do not conduct
a health economic evaluation.
24
2.3. Dynamic Bayesian Markov models
2.2.3 Hybrid models
An interface between static and dynamic alternatives is given by the so-
called hybrid models. These are combinations of the two different versions
of models. First a dynamic transmission model, commonly based on ODEs,
is implemented to estimate infection prevalence. Then the prevalence esti-
mate is used as input for the natural history model of disease progression,
which is for example a static MM or microsimulation model. As a conse-
quence, the disease acquisition is estimated in a dynamic way. These ap-
proaches are often used in human papillomavirus modelling. Examples in
the health economics literature include [215,339].
While useful in some circumstances, a hybrid approach has several draw-
backs. First, the transmission models involved commonly include fixed val-
ues on model parameters (rather than whole distributions). Consequently,
even if PSA is performed on the disease progression part of the hybrid
model, it does not refer to the crucial disease transmission component. Sec-
ond, hybrid models are extremely complex since they consist of two sepa-
rate components based on different methodologies. These are run sequen-
tially since an interim step is necessary to include the estimated prevalence
results into the disease progression model.
2.3 Dynamic Bayesian Markov models
To overcome the limitations discussed above and with a view to extending
the modelling framework for health economic evaluation of interventions in
infectious disease, the main idea behind our proposed model is to add a
force of infection which depends on population dynamics and prevalence
into a discrete-time MM setting. As a consequence, the transition probabil-
ities from the state Susceptible to the state Infected are directly defined by
the dynamic force of infection.
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Specifically, we set up our model so that the force of infection is calcu-
lated separately within each cycle of the state allocation algorithm corre-
sponding to (2.2) as a function of
• the probability of pathogen transmission per contact, which we indicate
as β;
• the rate of contacts between susceptible and infectious members of
the population ω; and
• the time-dependent pathogen prevalence
ψt =
It
Nt
,
where It represents the number of people in the state of infection and,
assuming that state S indicates death,
Nt =
S−1∑
s=1
nst
is the number of those alive at time interval It. Depending on the
medical context, prevalence might be specific to covariates such as
age and sex, and cycle length is adjusted.
The force of infection is recalculated at each Markov cycle as
ρt = βωψt. (2.3)
Since ω is a rate, (2.3) also results in a transition rate. Assuming that ρt re-
mains constant within each time interval, the corresponding time-dependent
transition probability for the discrete-time MM is estimated as
pi1,2,t = 1− e−ρt . (2.4)
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The estimation is only approximate due to the competing risk of death and
the assumption of uniformity within the intervals It. This assumption is not
likely to hold if the disease is characterised by very fast transmission, or
when events associated with the infection are likely to occur in short periods
of time. In these cases, it is perhaps advisable to reduce the length of the
cycles κ and the duration of the follow up.
This probability can be multiplied by the proportion of the population in
the state Susceptible to provide an estimation of the contingent of move-
ments to the state Infected, effectively including dynamic, time-dependent
changes in the population prevalence in the corresponding transitions.
The dynamic Bayesian MM can be implemented for closed as well as
open populations, accounting for deaths, births (as shown in Section 3.3)
and the entering of healthy individuals (as described in Section 5.2). In
comparison to hybrid models, our approach does not require two separate
modules for disease transmission and progression. In addition, computa-
tional time is reduced by fitting models that do not involve complex ODEs,
while still allowing for mixing patterns within the population.
A third potential advantage of the dynamic MM framework is that it is
fairly simple to incorporate probability distributions on all model parameters,
even if the model is complex with an extremely large number of parameters
and states. In contrast, the related computational effort in a comparable
ODE-based model would be extremely high. As a consequence, at the cur-
rent stage of research, the literature does not present any complex ODE-
based models which incorporate a high number of model parameters with
assigned probability distributions [33].
Accounting for parameter uncertainty is particularly relevant because, for
obvious ethical and practical reasons, it is invariably difficult (if possible at
all) to obtain and use experimental evidence to inform the pathogen trans-
mission probability β and the active contact rate ω — arguably the crucial
parameters. Often observational studies or expert opinions are the only
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available information with the consequence that large uncertainty remains
over the most likely range, let alone the “true” value of the parameters. A
Bayesian approach may provide great benefit in allowing this uncertainty to
be fully propagated and perhaps in integrating different sources of evidence
(e.g. using evidence synthesis [380]); this indeed has been advocated for
MMs in the health economics literature [22,93,380] and is described in more
detail in Section 5.6.
In a Bayesian dynamic MM setting, it is possible to assign prior distri-
butions to the parameters (β, ω) to represent the state of science — if data
are available, these are updated into posterior distributions although it is
possible to still propagate uncertainty in the priors even when no data on
pathogen transmission or active contacts are observed. In addition, the
quantity ψt is estimated as a function of transition probabilities, which can
be modelled using suitable distributions. This modelling process induces a
probability distribution on ψt and a fortiori also on ρt, which is defined as a
function of the three parameters (β, ω, ψt). Thus, the corresponding transi-
tion probabilities pi1,2,t are modelled probabilistically, meaning that uncertainty
in the population dynamics is propagated through the economic model.
As suggested earlier, another crucial aspect in infectious disease mod-
elling (and more generally in statistical analysis) is that of calibration of the
model output [151, 366]. In a Bayesian framework, the transition probabil-
ities can be calibrated directly in the process of updating the prior into the
corresponding posterior distributions. For example, available data on the
proportion of the population progressing to a more severe state following in-
fection as observed in large population registries can be used to update the
prior distribution of the corresponding transition probability. Furthermore,
the Bayesian framework enables the calibration of the numbers of people in
the states directly in the state allocation algorithm, using available time se-
ries data for a specific time frame of follow-up as described in Section 3.5.
Finally and specifically for the purpose of economic evaluation, the dy-
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namic BMM has the advantage that PSA can be performed “for free”, once
the model output is produced. In a Bayesian framework, the MCMC simu-
lations for all the model parameters can be combined to obtain a full char-
acterisation of the uncertainty in the decision-making process. This can be
post-processed (e.g. using the R package BCEA [3]) to produce relevant sum-
maries such as the cost-effectiveness plane, the cost-effectiveness accept-
ability curve (CEAC) and the analysis of the value of information. We report
these in details in the next chapter. A publication describing the methodol-
ogy of the dynamic Bayesian MM is in preparation and will be submitted to
the journal Medical Decision Making.
We present a discrete-time rather than a continuous-time MM since these
are commonly used in the health economics literature and thus well-known
to both clinicians and decision makers. In addition, the related effort on im-
plementation and computation is lower, especially if the state space contains
a large number of states as for the application to human papillomavirus de-
scribed in Chapter 5. In a continuous-time MM, the model outcome on the
time spent in each state can either be obtained through solving the expo-
nential of the transition rate matrix or a numerical approximation procedure
by means of an ODE solver. Both are extremely computationally and mem-
ory intensive for large state space, and the latter might require many time
steps and thus is prone to approximation error [14].
Our approach is comparable to Cooper and Lipsitch’s dynamic version
of a hidden Markov model on hospital infections in continuous time [92].
Hidden Markov models are for example used if infection prevalence cannot
be measured with precision. This is the case in hospital infections since
the majority of infected people are asymptomatic carriers. In [92], observed
pathogen prevalence is estimated through a Poisson model, whereas re-
alised prevalence is estimated through two hidden states in a dynamic conti-
nuous-time Markov chain. Transmission of the pathogen is modelled through
a dynamic force of infection, accounting for the rate of transmission, rate of
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pathogen carriage before hospital admission, discharge rate from the ward,
and pathogen prevalence. The model differs from our approach through
i) the frequentist setting; ii) the continuous-time approach; iii) the hidden
Markov chain and the Poisson observation model; iv) the parameters con-
sidered in the force of infection, and v) the context, which is not related to
health economics. Adapting this model to a Bayesian framework would con-
siderably increase computational effort and thus is possibly not feasible at
present.
Forrester and Pettit [141] present a stochastic model on the estimation
of transmission rates of methicillin-resistant staphylococcus aureus. Their
compartmental model is based on stochastic processes, accounting for the
force of colonization which is assumed to follow a binomial distribution. A
transition between the states is defined as a stochastic event. The transition
rates are estimated by fitting the model to data, both through a frequentist
and a Bayesian approach.
Auranen et al. [20] present a Bayesian hierarchical model to estimate
the duration of immunity to haemophilus influenzae. The force of infection is
defined as the event rate of a Poisson process.
Other stochastic approaches are presented by Gibson and Austin [155]
and Gibson and Renshaw [156]. In [155], the authors model the spread of a
plant disease by a stochastic process, where the probability of an infectious
plant to infect a susceptible plant is a function of infection rate and position
of infected and susceptible plants. In [156], a continuous-time MM is fitted
to partially observed data through a Bayesian approach. An example of a
smallpox epidemic is presented; the force of infection is directly incorporated
in the transition probabilities of the MM.
These stochastic formulations provide valuable contributions in infectious
disease modelling; however, due to their computational complexity, to date,
mainly small population sizes are considered [212], and an inclusion of an
extensive number of states is not feasible.
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2.4 Conclusion
This chapter provided an overview on infectious disease transmission mod-
elling through compartmental models, particularly focussing on ODE-based
and MMs. In order to result in correct model predictions, a dynamic method-
ology incorporating the effects of herd immunity is essential. At the same
time, the methodology used should enable accounting for parameter uncer-
tainty. By doing so, PSA as part of a full CEA can be performed straightfor-
wardly. Both aspects are fulfilled by our contribution of a dynamic Bayesian
MM which was introduced in this chapter. We avoid the limitation of stan-
dard MMs which by definition do not account for population dynamics and
time dependent changes in prevalence. Furthermore, when compared to a
Bayesian ODE-based model, the computational effort of a Bayesian MM is
considerably lower; it commonly does not induce computational issues.
The next chapter compares a deterministic ODE-based model (includ-
ing point estimators as parameter values), a Bayesian ODE-based model
and the dynamic Bayesian MM in practice through a case study of a fic-
tional chronic sexually transmitted infection. The terms “deterministic” and
“Bayesian” refer to the nature of the parameters and inference conducted,
respectively. In the next chapter, the prevalence outputs as well as the re-
sults of a CEA of the three models are evaluated, and PSA is conducted for
the two Bayesian models.
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Chapter 3
Case study for comparison of
compartmental models
3.1 Introduction
3.1.1 Parameter, methodological and structural uncertainty
The impact of uncertainty on the predictions of models of infectious diseases
can be considerably high. Uncertainty originates from different sources and
is mainly explained through parameter, methodological and structural uncer-
tainty. In the literature, structural uncertainty is also referred to as model un-
certainty [52]. Parameter uncertainty (i.e. uncertainty on the realised value
of a parameter) is usually adressed in the vast majority of health economics
literature – either in a univariate or in a multivariate setting through deter-
ministic or, more properly, probabilistic sensitivity analysis. Another form of
uncertainty is given by methodological uncertainty. According to [239,332],
methodological uncertainty refers to the nature of the model assumptions
and methodology used, for example i) the time horizon of the follow-up,
ii) the discount rate, iii) the methodological approach of measuring quality of
life (e.g. time trade-off [18] or standard gamble [146] method), and most im-
portantly v) the choice of the mathematical modelling approach. Structural
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uncertainty commonly includes i) how many relevant health states are con-
sidered and thus ii) whether all possible implications of the infectious agents
are incorporated into the model, iii) the number of interventions compared
(omitting relevant interventions could result in falsified CEA results), iv) in-
corporation of time dependency and risk factors into continuous- or discrete
time transition parameters [8, 41, 332], and v) whether dynamic changes in
prevalence are considered.
In contrast to parameter uncertainty, structural uncertainty is only ac-
counted for in rare cases by implementing several models in parallel with
different structure [54] or by accounting for model discrepancy. This is pos-
sibly a consequence of the instructions given in the relevant ISPOR guide-
line [52]. This ISPOR guideline states that fully accounting for structural
uncertainty might not be feasible due to time constraints and thus recom-
mends summarizing sources of structural uncertainty with respect to future
research. In contrast, the NICE guideline [268] recommends to conduct
deterministic sensitivity analysis and scenario analysis to compare cost-
effectiveness outcomes of models with different structure; however, a more
systematic approach as described in the following is not recommended.
Four systematic approaches to investigate structural uncertainty are given
by i) model averaging, ii) model selection, iii) parameterization and iv) inves-
tigating model discrepancy. In model averaging, a variety of models with
different structure or assumptions are implemented and the overall costs
and QALYs are calculated for each model. Afterwards, the correspond-
ing measures of cost-effectiveness are calculated through the (weighted)
average of costs and QALYs of all implemented models. Model selection
includes the calculation of maximum likelihood information criteria (Akaike
Information Criteria, AIC) or Bayesian Information Criteria (BIC); the model
with the best fit to the data results in lowest AIC or BIC, respectively, and
is thus selected. Parameterization refers to the inclusion of one or several
additional model parameters with suitable distributions to account for uncer-
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tainty in the selection of a specific methodology. For example, if it is not
known whether transition probabilities of survival are best estimated by a
Weibull or a Gamma distribution, this uncertainty could be incorporated as
an additional model parameter. A discrepancy approach estimates the de-
viation of a set of possible models from “reality” by an error term. Sets of
models can either be closed, implying that one of the models reflects the
truth, or open, implying that no model in the set is perfect [8,41,332].
Ignoring structural uncertainty can result in an over- or underestima-
tion of the cost-effectiveness of the interventions under investigation; un-
der certain circumstances, these differences can be so high that a deci-
sion in favour of the intervention has to be reversed [41]. However, this is
not necessarily the case and the literature shows several examples were
accounting for structural uncertainty did not change the decision since the
corresponding measures of cost-effectiveness were still well below [41] or
clearly above [239] the threshold of cost-effectiveness for model scenarios
compared.
In this chapter, we describe methodological uncertainty in several ways:
through a case study, we firstly investigate the impact of the choice of method-
ology on model predictions and secondly, we evaluate the shortcomings of
models including fixed values rather than whole distributions on parame-
ters. We consider again the fictional chronic STI described in Chapter 2
and compare our methodology of a dynamic Bayesian MM to both an ODE
system with fixed parameter values and a Bayesian ODE-based model. De-
terministic and probabilistic methodologies are defined in Section 2.2.1. The
literature shows that model parameters can also be classified into determin-
istic and stochastic, as shown for fixed and random effects models in [227].
A deterministic model parameter is then defined as a fixed value, whereas
a stochastic parameter is assigned a suitable distribution. Thus, we refer to
the ODE system including fixed parameter values as a deterministic ODE
system. In the following, we denote the Bayesian Markov model as BMM,
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the Bayesian ODE system as BODE, and the deterministic ODE system as
dODE. The main aim of model comparison is to evaluate whether our BMM
produces results that are in line with the BODE. We consider BODEs as
the “gold standard” in infectious disease modelling with respect to CEA; this
is a consequence of their continuous-time approach, dynamic nature and
suitability to incorporate parameter uncertainty. Structural uncertainty is not
investigated in a systematic way; however, we describe possible sources
and implications.
3.1.2 Inclusion of data
First we consider the case in which we do not have access to individual-
level, prevalence and time series data on the natural history of the STI. If
models in health economics include a large number of parameters, individual-
level data to inform each parameter are rarely available. Therefore, we
conduct the analysis including exclusively informative prior distributions in-
formed through aggregate data and expert opinion. The main purpose of
this analysis is to evaluate whether the outputs of the dODE, BODE and
BMM are comparable. The outputs of the three models are not calibrated
to prevalence or time series data; model calibration would reduce potential
differences in results. We focus on differences in outputs of the three mod-
els and approaches to explain and minimise these. In addition, we evaluate
whether the BMM is able to reproduce the output of the “gold standard” of
the BODE.
In Section 3.4, we assume to have access to individual-level, time series
and prevalence data; since the case study is a fictional example, we simu-
late these data. The time series data are simulated by running the dODE for
a follow-up period of five years as described in Section 3.5.2. Simulation of
the prevalence data is conducted through a slightly modified version of the
dODE termed prevSim as described in Section 3.5.1. The prevalence data
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are used to conduct visual calibration approaches in the dODE, BODE and
BMM. The time series data are used to conduct systematic calibration ap-
proaches - a frequentist probabilistic calibration approach in the dODE and
Bayesian calibration approaches in the BODE and BMM. The time series
data are not produced from the Bayesian models themselves and do thus
not necessarily fit to the corresponding outcome well.
The main purpose of using different calibration approaches is to eval-
uate their advantages, disadvantages and accuracy with respect to out-
come of natural history of disease and health economic evaluations. In
Section 3.5.1, we conduct the visual calibration approach for the dODE,
BODE and BMM. The three models are calibrated visually to the simulated
prevalence data. As a next step, systematic calibration approaches are ap-
plied in Section 3.5.2. The systematic calibration approaches vary between
the three models; the dODE is calibrated through a frequentist probabilis-
tic calibration approach, whereas the two Bayesian models are calibrated
through what we term a Bayesian calibration approach; this is equivalent to
Bayesian inference.
In a Bayesian framework, data can be considered in several ways. We
include simulated data on a selection of parameters to update the priors
into the corresponding posteriors. However, this only ensures that the cor-
responding parameters are informed by available evidence. Despite poste-
rior sampling, it could still be possible that the predicted outcome implied
by the Bayesian models was not comparable to high-quality data obtained
from large data registries. Therefore, in addition to posterior sampling of
the model parameters, we use the simulated time series data to update the
posteriors on the number of people in the states. In fact, this is an addi-
tional process of Bayesian inference, updating the model outcome through
additional data.
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3.1.3 Sampling techniques
The statistical sampling technique of Markov Chain Monte Carlo (MCMC)
simulation is used in different ways in the case study. Therefore, this chap-
ter includes a brief summary on this methodology. Furthermore, essential
diagnostic techniques to assess convergence and autocorrelation are de-
scribed.
3.2 Markov Chain Monte Carlo simulation
Bayesian inference requires the computation of posterior distributions. A
simulation method to obtain samples from these is given by Markov Chain
Monte Carlo (MCMC) simulation. MCMC simulation was developed to sim-
ulate from distributions which are not analytically tractable, or if an analytic
solution requires extensive calculation. One example is given by posterior
distributions, which involve the solution of rather complex integrals [151].
The core idea behind MCMC methods is to construct a Markov chain
which has the posterior distribution as its stationary distribution [269]. In
MCMC methods, the transition kernels are built so that the limit distribu-
tion coincides with the stationary distribution. This is achieved by proposing
kernels that ensure that the chain is irreducible1, aperiodic2 and positive-
recurrent3 [175,301].
A Markov chain is a particular case of a Markov model as explained in
Section 2.2.2. In a Markov chain, the conditional distribution of the future
state of the process given the current and past states depends only on its
current state. In a Markov chain of order k∗, this additionally depends on
1Irreducible implies that any set S can be reached from any other set T with nonzero
probability, where S and T have nonzero probability themselves.
2Aperiodic implies that the greatest common denominator of the set of times for which
the chain starting at a given state can return to that same state is equal to 1.
3Positive-recurrent implies that the chain can return to a set S, where S has nonzero
probability in an infinite number of steps.
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the k∗ − 1 past states. A Markov chain of first order can thus be expressed
mathematically as [22]
P (Xt+1|X0, X1, ..., Xt) = P (Xt+1|Xt),
where X0, X1, ..., Xt represent a sequence of random variables, and t is the
time point of the simulation.
The Fundamental Theorem of Markov Chains states that for any irre-
ducible, aperiodic, positive-recurrent Markov chain there exists a unique sta-
tionary (also called equilibrium or target) distribution which is related to the
expected returned value of the Markov chain at its possible states [48,292].
This theorem guarantees that the limit distribution of a MCMC sample will be
the stationary distribution. The MCMC simulations are run until convergence
to the stationary distribution p∗ is achieved. The distribution p∗ is stationary
with respect to the Markov chain, and thus [48]
Xt ∼ p∗
Xt+1 ∼ p∗.
The most widely used MCMC method is the Metropolis-Hastings algo-
rithm. It is based on successively sampling from a proposal distribution
q(x|x∗) and imposing a random rejection step at each transition. The pro-
posal distribution is in principle an arbitrary distribution from which we can
sample efficiently [154,181].
When implementing an MCMC method, the first simulations (the so-
called “burn-in period”) are omitted to ensure that the distribution of the
current state is close enough to the stationary distribution. Suitable con-
vergence checks have to be performed to see whether the chain has con-
verged. Convergence can be for example checked visually through trace
plots. Usually, two or more chains with different inital values are run in par-
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allel. If convergence is reached, a trace plot shows that the different chains
have mixed properly, and thus the corresponding plot looks like a “big cater-
pillar”. Another more formal method to investigate proper convergence is
the Gelman and Rubin statistic as described in Section 3.2.2. In addition
to improper convergence, MCMC simulation can induce issues with auto-
correlation (see Section 3.2.3). Since the future state of the process only
depends on its current state, two random variables Xt and Xt+1 which are
only one time step t apart are often highly correlated. Thus, thinning is
required which implies that consecutive samples are no longer considered.
Once the stationary distribution was found, it can be sampled from; this
process is called posterior sampling. After successful diagnostics to ensure
that there are no issues with convergence and autocorrelation, inference
can be conducted on the resulting posterior distribution, e.g. to estimate the
corresponding mean, quantiles, or credible intervals. For example, the mean
E(θ|data) of a posterior distribution can be estimated as [22]
E(θ|data) = 1
S∗
S∗∑
s∗=1
θ(s∗),
where θ(1), θ(2), ..., θ(S∗) represent samples of the posterior distribution of the
parameter θ.
In this PhD thesis, exclusively the Gibbs sampler [152] in the software
JAGS [293] and WinBUGS [355] is used to conduct MCMC estimation. The
Gibbs sampler is a special case of the Metropolis-Hastings [181] algorithm.
Samples are obtained from the full conditional distributions of the model
parameters. A generic example of a Gibbs sampling algorithm is defined
through the following steps, given a vector of model parameters θ [22]:
1) Initial values are assigned to the components of the parameter vector
θ
(0)
1 , θ
(0)
2 , ..., θK∗.
2) Samples are drawn repeatedly from the full conditional distribution
θ
(1)
1 is drawn from P (θ1|θ(0)2 , θ(0)3 , ..., θ(0)K∗ , data)
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θ
(1)
2 is drawn from P (θ2|θ(1)1 , θ(0)3 , ..., θ(0)K∗ , data)
...
θ
(1)
K∗ is drawn from P (θK∗|θ(1)1 , θ(1)2 , ..., θ(1)K∗−1, data).
3) Sampling according to 2) is conducted until the Markov chain converges
to the stationary distribution which corresponds to the posterior distri-
bution.
4) A sample is then taken from the posterior distribution P (θ|data).
3.2.1 Forward sampling and updating priors through data
Bayesian tools can be used in several ways to propagate parameter un-
certainty through models. One approach is to exclusively conduct “forward
sampling” by means of a random number generator. An alternative is to con-
duct Bayesian inference by updating prior distributions by means of data.
Information available in the literature or expert opinion can be included di-
rectly into the prior distributions (so-called prior elicitation). In that case,
these are termed “informative” priors and can (but do not necessarily have
to) be updated by available data. If a model includes exclusively informative
prior distributions which are not updated by any data, the prior and posterior
distributions are basically identical; the calculation of convergence statistics
and an assessment of autocorrelation is thus not necessary. This approach
is termed “forward sampling” and conducted in Section 3.3.2 of this PhD
thesis. The Gibbs samplers in JAGS and WinBUGS as well as the software
Stan [4] (running the “fixed parameter” algorithm) can be used to conduct
forward sampling.
In contrast, in Section 3.5, individual-level and aggregate data are used
to update informative and minimally-informative prior distributions into the
corresponding posteriors. If a model includes at least one prior distribu-
tion which is updated by data, the remaining priors which are not updated
by data can result in posterior distributions considerably differing from the
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corresponding priors. This might occur in model parameters which are not
independent, for example i) if a transition parameter of moving to a certain
state is calculated as a function of a combination of model parameters (as
for the force of infection), or ii) if transition parameters are based on hierar-
chical models. Thus, the assessment of convergence (through the Gelman
and Rubin statistic) and autocorrelation is essential in this respect.
3.2.2 The Gelman and Rubin statistic
The Gelman and Rubin statistic (also referred to as GR statistic or Potential
Scale Reduction) compares the between-chains to the within-chain variation
of two or more chains which are run in parallel [151]. We use a similar
notation as in [22]. For each θ(s∗) of the parameter vector θ = (θ(1), ..., θ(S∗)),
the posterior variance is calculated as [22]
V̂ ar(θ(s∗)|data) = nsims − 1
nsims
W (θ(s∗)) +
1
nsims
B(θ(s∗)).
The within-chain and between-chains variance are represented by W (θ(s∗))
and B(θ(s∗)), respectively, and nsims represents the overall number of simu-
lations conducted. As a next step, the Gelman and Rubin statistic can be
calculated as
Rˆ =
√
V̂ ar(θ(s∗)|data)
W (θ(s∗))
.
The Gelman and Rubin statistic Rˆ is an estimate of the reduction factor of
the scale of the posterior distribution of θ(s∗). If Rˆ ≤ 1.1, the corresponding
posterior distribution is assumed to have converged properly. Larger val-
ues of Rˆ require additional measures to improve convergence, e.g. through
changes in the corresponding statistical model, or a higher number of simu-
lations [22].
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3.2.3 Autocorrelation
Due to the Markov assumption described in Sections 2.2.2 and 3.2, consec-
utive iterations are by definition correlated. As a consequence, the sample
of the posterior distribution obtained is not comparable to collected data of
the same sample size, and thinning often is required [22]. Thinning implies
that consecutive iterations are not considered in the sample of the posterior
distribution, and only every xth iteration is included, where x is a predefined
number. The higher the amount of autocorrelation, the larger the value of
x needs to be defined. We adopt the notation from [22]. The term effec-
tive sample size neff refers to the number of simulations out of the overall
number of simulations conducted which are comparable to a sample of iid
observations and is estimated as
neff =
nsims
1 + 2
∑∞
l=1 corrt
.
The correlation between two iterations is indicated by corrt, where t rep-
resents the time step of the simulation. If the effective sample size neff is
not considerably smaller than the overall number of iterations nsims, this in-
dicates that there are no issues with autocorrelation. The posterior can still
converge properly even in case of high autocorrelation. However, if neff is
considerably small, this could induce an issue in the estimation of the ex-
treme quantiles of the corresponding posterior [196].
3.3 Model assumptions
In the three approaches compared, we distinguish between sexes as well
as high- and low-risk sexual behaviour. The duration of the follow up is set
at 100 years. We consider an arbitrary population size of 1,000,000 and
initially assume that 600 people are infected, whereas the remainder are
susceptible. Males amount to 50% and the high-risk group to 20% of the
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population; the sex ratio in the two risk groups is equal. The proportion of
infecteds in both sexes and risk groups is identical; this is to ensure equal
conditions in the beginning of follow-up. We account for sex-specific dif-
ferences in sexual behaviour, assuming higher partner acquisition rates in
males. The population size changes due to births and deaths.
We conduct our analysis for two fictional competing health-care interven-
tions. We assume that in the status-quo, screening takes place at intervals
of five years at a pre-defined rate to enable an early detection of the STI.
For simplicity, we assume that under the vaccination scenario no screen-
ing takes place. However, in real life, screening and vaccination are often
combined; screening has commonly already been conducted before the in-
troduction of vaccination, and the combination of both interventions results
in maximal protection. We assume that the vaccine is only effective before
initial STI infection occurs; thus, susceptibles are vaccinated at a specified
vaccine uptake rate. The vaccine is given at intervals of five years, based on
the assumption that vaccine-induced immunity lasts for five years. Following
STI diagnosis, treatment is provided in both interventions.
All rates of change in the ODE systems differ according to the two char-
acteristics considered. We refer to these using the indices v, v′ = (Male,
Female) to indicate the respective sex and its opposite. For example, a
male is represented through the index M ; the index of his female mixing
partner is F . The sexual behaviour group is indicated through the index
b = (Low, H igh). In the ODE model, the transition rate ρv,b,1,2(t) from the
state Susceptible to the state Infected is calculated similarly to Equation 2.3;
however, it additionally depends on the covariates sex and behaviour as de-
scribed in the next section. In the BMM, the sex- and behavioural specific
transition probability piv,b,1,2,t is estimated by transforming ρv,b,1,2(t) according
to Equation 2.4. As a consequence of the definition of the transition prob-
abilities for movements from a certain state which must sum up to 1, the
estimation of piv,b,1,2,t affects the transition probability pi1,1 of remaining in the
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state Susceptible.
Since disease progression in the chronic STI is a very slow process,
we assume a yearly Markov cycle length to be sufficient. To reduce the
shortcomings induced by the discrete-time approach, we conduct a half-cyle
correction which is based on the assumption of uniformity within a Markov
cycle [51,264,327]. The correction is calculated by averaging the number of
people who are in the same state at two consecutive cycles and assigning
the result to the latter cycle.
3.3.1 The force of infection
For simplicity, we exclusively account for random mixing and heterosexual
relationships; members of the population of sex v randomly select sexual
partners of the opposite sex v′. The advantage of random mixing is that it is
a realistic assumption in sexual partnership formation. Effects of saturation
(infectious people mix with infectious people and thus do no longer spread
the infection) are less likely. In contrast, in assortative mixing (where people
are more likely to mix with members of their own risk group), the effects of
saturation would affect members of the high-risk group. In addition, those in
the low-risk group would preferably mix with low-risk people and thus reduce
their risk of infection. Overall, STI prevalence would thus decrease, possibly
resulting in lower cost-effectiveness of the STI vaccine.
Because of the impact of the covariates, the estimation of the overall
prevalence in the sexual partners of sex v′ is a weighted average of the
prevalence in both behaviour groups of sex v′. We show the corresponding
equations for the continuous-time approach as functions of t; for a discrete-
time approach, these are similar. The time-specific probability of selecting a
partner from the high-risk group, which we indicate as gv′H(t), depends on
the partner acquisition rates ωv′H and ωv′L as well as on the population sizes
Nv′H(t) and Nv′L(t). The probability of selecting a partner from the low-risk
45
CHAPTER 3. CASE STUDY FOR MODEL COMPARISON
group is represented by gv′L(t). The corresponding equations adapted from
[371] only account for two sexual behaviour groups and are thus extended
for heterosexual mixing, to give
gv′H(t) =
ωv′HNv′H(t)
ωv′HNv′H(t) + ωv′LNv′L(t)
gv′L(t) = 1− gv′H(t).
We estimate the sex-, behavioural- and time-specific force of infection as
ρv,b,1,2(t) = βωvbψv′(t), (3.1)
where
ψv′(t) =
(
gv′H(t)
Iv′H(t)
Nv′H(t)
+ gv′L(t)
Iv′L(t)
Nv′L(t)
)
is the weighted average of the STI population prevalence. This in turn is
estimated as a function of the probabilities gv′b(t) of selecting a partner of
the opposite sex from one of the two sexual behaviour groups and the time-,
sex- and behavioural-specific population prevalence Iv′b(t)
Nv′b(t)
. The number of
infectious people Iv′b(t) is estimated as those in the state Infected of the
respective sex and behaviour group.
In line with (2.3), the force of infection ρv,b,1,2(t) is a function of the STI
transmission probability per partnership β, the partner acquisition rates ωvb,
and the population prevalence ψv′(t).
3.3.2 Model parameters and prior elicitation
In addition to the probability of STI transmission β and the partner acqui-
sition rates ωvb, the model contains a variety of parameters such as those
determining the screening and vaccine coverage, the unit costs of STI diag-
nostics and treatment and the health utilities, which are relevant in context
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of the cost-effectiveness analysis.
To conduct the first analysis, we assume not to have access to individual-
level, prevalence and time series data on the natural history of the STI.
We thus specify the distributional assumptions of the informative priors so
that both the outputs of the prevalence estimation and the health economic
evaluation are within realistic ranges. In contrast, the second analysis in
Section 3.5 includes simulated data.
Table 3.1 shows an overview of the assumptions about the model pa-
rameters θ∗ = {ωvb, χ, β, pir,s, η, σ, α, γ, c, us}. The means and 95% credible
intervals are rounded to two decimal places. However, the 95% CI of the
parameter χ is in fact defined as [0.009420;0.010596]. The 95% credible
intervals of several parameters are considerably narrow; however, the case
study is fictional and despite these assumptions, the amount of uncertainty
in the model outcome is realistic as shown in Figures 3.1, 3.2 and 3.3.
The distributional assumptions differ between the two models as follows.
Since the BMM is based on a discrete-time approach, the corresponding
transition probabilities are modelled using Beta distributions (constrained
between 0 and 1). In contrast, the transition rates of the continuous-time
BODE are modelled using Gamma distributions (defined on R+). The tran-
sition rate ρv,b,1,2 is estimated according to Equation 3.1 and transformed
into the transition probability piv,b,1,2 according to Equation 2.4. The transition
probabilities for movements between the other states are estimated through
informative priors, and those for movements from the states Susceptible, In-
fected and Asymptomatic to Dead are assumed as identical; thus, only pi1,5
is shown. Competing risks (i.e. the fact that people in a state can move to
more than one target state to account for deaths) are accounted for through
the transition probability matrix shown in Equation 2.2.2. Apart from the
force of infection and the transition probability of remaining susceptible, we
assume for simplicity that transition parameters in the three models do not
differ between the sexes and behaviour groups.
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Table 3.1: Overview of the distributional assumptions for the high variability sce-
nario. The values are fictional and were chosen so as to produce most
realistic prevalence outcome and cost-effectiveness results.
Parameter Description Distribution BMM Distribution BODE Mean 95% interval
ωMH Partner acquisi-
tion rate (high-
risk males)
Gamma(2070.25, 227.5) equivalent to BMM 9.10 [8.70;9.50]
ωML Partner acquisi-
tion rate (low-risk
males)
Gamma(8100, 4500) equivalent to BMM 1.80 [1.76;1.84]
ωFH Partner acquisi-
tion rate (high-
risk females)
Gamma(1406.25, 187.5) equivalent to BMM 7.50 [7.11;7.90]
ωFL Partner acquisi-
tion rate (low-risk
females)
Gamma(3025, 2750) equivalent to BMM 1.10 [1.06;1.14]
χ Proliferation pa-
rameter
Beta(1099.99, 108899) Gamma(1111.1,111111.1) 0.01 [0.01;0.01]
β STI transmission
probability per
partnership
Beta(764.85, 4334.15) equivalent to BMM 0.15 [0.14;0.16]
pi2,3 Transition pa-
rameter from
state 2 to state 3
Beta(5119.2, 1279.8) Gamma(25600,32000) 0.80 [0.79;0.81]
pi3,4 Transition pa-
rameter from
state 3 to state 4
Beta(1842.66, 18631.34) Gamma(2025,22500) 0.09 [0.09;0.09]
pi4,5 Transition pa-
rameter from
state 4 to state 5
Beta(1535.96, 36863.04) Gamma(1600,40000) 0.04 [0.04;0.04]
pi1,5 Transition pa-
rameter from
state 1 to state 5
Beta(156.171, 312186.6) Gamma(156.25,312500) <0.01 [<0.01;<0.01]
η Probability of STI
diagnosis
Uniform(0.8, 1) equivalent to BMM 0.90 [0.81;0.99]
σ Screening prob-
ability
Uniform(0.8, 1) equivalent to BMM 0.90 [0.80;1]
α Vaccine cover-
age parameter
Beta(809.1, 89.9) Gamma(8100,9000) 0.90 [0.88;0.92]
γ Vaccine efficacy
parameter
Beta(809.1, 89.9) Gamma(8100,9000) 0.90 [0.88;0.92]
cscreen Unit cost of
screening in £
Lognormal(2.996, 0.693) equivalent to BMM 25.39 [5.19;77.53]
cvac Unit cost of vac-
cination in £
Lognormal(5.011, 0.01) equivalent to BMM 150.02 [147.14;152.98]
ctest Unit cost of STI
test in £
Lognormal(2.996, 0.03) equivalent to BMM 20.01 [18.83;21.19]
cblood Unit cost of blood
test in £
Lognormal(3.401, 0.03) equivalent to BMM 30 [28.26;31.79]
ctreat Unit cost of treat-
ment in £
Lognormal(8.517, 0.015) equivalent to BMM 4999.78 [4853.56;5149.24]
cdis Unit cost of dis-
ease treatment
in £
Lognormal(9.210, 0.01) equivalent to BMM 9999.95 [9802.97;10198.10]
cgp Unit cost of visit
to general practi-
tioner in £
Lognormal(3.912, 0.02) equivalent to BMM 50.01 [48.08;52.01]
u2 Health utility of
infected (min=0,
max=1)
Beta(1469.3, 629.7) equivalent to BMM 0.70 [0.68;0.72]
u3 Health utility of
asymptomatic
(min=0, max=1)
Beta(1439.4, 959.6) equivalent to BMM 0.60 [0.58;0.62]
u4 Health utility of
morbid (min=0,
max=1)
Beta(629.7, 1469.3) equivalent to BMM 0.30 [0.28;0.32]
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We do not implement a set of different model structures and only consider
in theory which effects of structural uncertainty could have an impact on
the results of the case study. For example, the asymptomatic state could
be removed and joined with the infectious state; however, this would com-
plicate considering the lower quality of life and higher costs in those with
changes in the blood count as a consequence of STI infection. The corre-
sponding parameters could be estimated as (weighted) average parameters
of the two states, resulting in a loss of information. This could have a high
impact on the health economic outcomes. In addition, it would be possible
to account for the intervention of regular condom use, possibly reducing the
cost-effectiveness of STI vaccination due to lower STI prevalence. Possible
adverse events of vaccination and indirect costs induced by absence from
work in those in the state morbid could also be included in the model. The
first would decrease the cost-effectiveness of vaccination, whereas the latter
would increase it.
Parameters of deterministic models are commonly informed through max-
imum likelihood estimates or summary statistics, e.g. mean, median or
mode. For a deterministic ODE system, the parameter on the probability
of screening (σ) could for example be estimated as follows. If data on the
sample size Nσ and the number of screened people Rσ were available, σ
could be informed through a maximum likelihood approach with a binomial
likelihood, obtaining an estimator of the mean as σ¯ = Rσ
Nσ
.
As a consequence of ignoring the impact of parameter uncertainty, mod-
els including fixed values (e.g. point estimates) for parameters are prone to
result in incorrect outcome. Therefore, if computationally feasible, including
suitable probability distributions for each model parameter is preferable. In
theory, these can be included both into deterministic (e.g. ODE systems)
and stochastic (e.g. SDE or Markov) models.
According to simulation studies conducted in [176] and a review pub-
lished in [302], outputs of deterministic models are comparable to the mean
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outputs of stochastic models if the following criteria are fulfilled: i) the mod-
els are linear, ii) the number of people in a state cannot become negative,
iii) the follow-up period is predefined, and iv) the initial number of infect-
eds and the basic reproduction number R0 (the number of new infections
induced by one infectious person) are high enough to prevent the disease
from going extinct during follow-up [302]. In the case study, criteria ii)-iv) are
fulfilled. However, the models are not linear as a consequence of multiplying
the force of infection ρ1,2 (or pi1,2 in the BMM) with the number of susceptibles
n1 as shown in Equations 2.1 and 2.2. The function of the force of infection
includes the number of infecteds n2; the term n1n2 introduces nonlinearity
into the ODE systems and the BMM [191].
An incorrect output of models including fixed parameter values can be
avoided if Bayesian estimators obtained through loss functions are used to
inform the corresponding parameter values. Loss functions quantify the loss
induced through the difference between realised and estimated parameter
values. In health economic evaluations, the loss corresponds to an incorrect
model outcome, resulting in an overestimation of costs or underestimation
of benefits of interventions. In the literature, the loss is often considered
to be symmetric. A symmetric loss implies that the consequences of over-
and underestimation of specific model output are identical. In that case,
the point estimate to inform the parameter values of deterministic models
is commonly the mean. However, in the case study, this is an unsuitable
estimator for two reasons: i) the distributions of specific parameters are
highly skewed (e.g. Gamma distributed partner acquisition rates), and ii) the
consequences of an under- or overestimation of infection prevalence are not
comparable, resulting in a non-symmetric loss.
An underestimation of STI prevalence influences the results of the corre-
sponding cost-effectiveness analysis. The higher the prevalence, the higher
the probability that preventive interventions and treatments are considered
cost-effective; this is induced by the higher proportion of the population
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in need of the intervention. The worst consequence of prevalence under-
estimation could be that highly effective and affordable interventions were
withheld from the population since these were considered not to be cost-
effective. In that case, people were subject to unnecessary suffering and
possibly death. In contrast, an overestimation of prevalence could result
in wasting scarce resources for possibly ineffective and highly costly treat-
ments. These resoures were no longer available to fund other (possibly
life-saving) treatments, causing suffering in patients affected by other health
conditions.
Due to the reasons listed above, withholding highly effective treatments
from the population is considered slightly worse than wasting scarce re-
sources. Thus, the loss is not symmetric. A piecewise linear loss function
can be used to inform the parameter values of the dODE through specific
quantiles of the parameters of the BODE, obtained through Bayesian esti-
mators. The piecewise linear loss is given by [301]
Lk1,k2(ψ, ψˆ)
k2(ψ − ψˆ) if ψ > ψˆk1(ψˆ − ψ) otherwise,
where k2 is the impact of a decision depending on underestimated preva-
lence ψˆ in comparison to the realised prevalence ψ, and k1 is the impact
of prevalence overestimation. These parameters represent the slopes of
the loss function; the higher the slope, the higher the corresponding loss
induced. A Bayesian estimator for the quantiles of the parameters of the
BODE to inform the parameters of the dODE is then given by [301]
P (ψ < ψˆ | data) = k2
k1 + k2
=
1.2
0.8 + 1.2
= 0.6. (3.2)
The values of k2 and k1 are determined by comparing the prevalence output
of the dODE to the prevalence output of the gold standard of the BODE.
If the parameters of the dODE are informed by the 60% quantiles of the
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parameters of the BODE, the two prevalence outputs are almost identical.
Since underestimating prevalence is considered slightly worse than an over-
estimation, k2 should be slightly higher than k1. To obtain a result of 0.6 in
(3.2), we define k2 = 1.2 and k1 = 0.8. To result in correct prevalence out-
come of the dODE, the parameters of the dODE are thus informed by the
60% quantiles of the parameters of the BODE.
Scenarios evaluated and software used
To investigate the impact of different levels of parameter uncertainty on the
model outcome, we evaluate three scenarios. In a perfect knowledge sce-
nario, we assume no variability in any of the parameters of the three models
compared. However, this scenario is not relevant, as we never have perfect
knowledge in reality. In a scenario with low variability, each model parameter
in the BMM and BODE is assigned a prior distribution that is tightly centered
around its mean. In a scenario with high variability, we increase the amount
of parameter uncertainty in the BMM and the BODE. This scenario is the
most realistic since infectious disease modelling is commonly associated
with a large amount of parameter (and possibly structural) uncertainty; this
is likely to have a major impact on the economic analysis.
The dODE is estimated using the R package EpiModel [199] which uses
ODE solvers provided by the R package deSolve [326]. For the BMM and
BODE, we estimate the parameters using forward sampling as described
in Section 3.2.1, running two chains with a total of 10,000 simulations and
discarding the first 500. We run the simpler BMM in JAGS [293], while the
BODE is fitted in Stan to deal more efficiently with the ODE system.
In the perfect knowledge scenario, running the dODE for a follow-up pe-
riod of 100 years on a Dell Latitude E6320 (Intel Core i5-2520M, 2x4GB
DDR3 RAM, 500GB SATA HDD (2.5", 7200rpm)) takes 0.22 seconds, where-
as the BODE and the BMM take 0.64 seconds and 0.09 seconds, respec-
tively. In the scenarios including variability the BMM runs in 95.96 seconds,
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whereas the BODE runs in 188.50 seconds.
3.3.3 Prevalence estimation
We first estimate the prevalence outcome of the three models as follows.
In the ODE-based models, we estimate the proportion of the population
which are infectious by dividing the overall number of those in the state
of infection Ivb(t) by the corresponding population size Nvb(t), resulting in
the time-specific STI prevalence. Although in the BMM time is represented
by intervals, the prevalence estimation is comparable to the ODE-based
models. As described in the beginning of Section 3.3, a half-cycle correction
is commonly conducted in discrete-time models to adjust for incorrect results
induced by a cycle length which might be too large. In our case study,
assumptions on discrete time in the BMM do not seem to have an impact
on the results since we found the STI prevalence outcome with and without
half-cycle correction to be identical in all scenarios evaluated.
In all three scenarios, we estimate STI prevalence for the overall popu-
lation. Obviously, prevalence is higher in males than in females as a con-
sequence of differences in partner acquisition rates; on average, females
tend to have lower partner acquisition rates than males, whereas a very
small number of females have an extremely high number of partners. Thus,
the distributions on partner acquisition rates considerably differ between the
sexes. Furthermore, due to a higher number of partners, the high-risk sexual
behaviour group results in a considerably higher STI prevalence. However,
the main focus of our analysis is to compare the three models rather than
accounting for differences in prevalence outcomes in the subgroups of the
population. Thus, we only present the overall prevalence outcomes and dis-
play these graphically for the two scenarios including parameter uncertainty.
In addition to the mean prevalence output, we show 95% confidence
bands for the BMM and BODE. As for the dODE, we display the range of
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Figure 3.1: Deterministic ODE-based model, mean Bayesian ODE-based model
and mean Bayesian Markov model output comparison of the chronic
STI prevalence. The left panel shows the scenario with lower vari-
ability, whereas the scenario with higher variability is displayed on the
right panel. The results of the deterministic ODE-based model are dis-
played by black dashed lines, whereas the mean prevalence output of
the Bayesian Markov and ODE-based models are drawn by grey solid
and red dotted lines, respectively. Scenario analysis of the determinis-
tic ODE-based model is shown by black dotted lines for the 2.5% and
97.5% quantiles, respectively. Uncertainty in the probabilistic Bayesian
Markov and ODE-based models is displayed by grey and red 95% con-
fidence bands, which mainly overlap.
values at the extremes through a scenario analysis. In a scenario analysis,
predefined quantiles are estimated from the parameter distributions. These
quantiles are summary statistics and do therefore not account for the whole
amount of parameter uncertainty characterised in the distributions. By con-
trast, in a Bayesian setting, the whole distributions and potential correlation
across the parameters is considered. To conduct the analysis for the 2.5%
quantile, we use the lower limits of the 95% CIs of the BMM parameters
as input to inform the parameters of the dODE. The scenario analysis for
the 97.5% quantile is performed accordingly, using the upper limits of the
95% CIs.
Unsurprisingly, in the perfect knowledge scenario, the outcome of the
dODE, BMM and BODE is virtually identical and thus the corresponding re-
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sults are not presented. Figure 3.1 shows the mean prevalence outcome
for the scenarios incorporating a lower and higher amount of parameter un-
certainty in the panels on the left and right, respectively. In the scenario
with a low amount of parameter uncertainty, the mean prevalence of the
three models is very similar, although the ranges of the confidence bands
for the probabilistic models are slightly wider than those of the deterministic
sensitivity analyses. The confidence bands for the probabilistic models are
approximately identical.
In the scenario with higher variability, the outcomes of the BMM, BODE
and dODE are comparable; however, the dODE slightly overestimates STI
prevalence from year 80 of follow-up. The comparable outcomes are a con-
sequence of estimating the parameters of the dODE through the 60% quan-
tiles of the parameters of the BODE as described in the previous section.
The scenario analysis of the dODE shows the wider range of the param-
eters. The bounds of the confidence bands of the BMM and BODE are
lower than the extremes of the scenario analysis. The model outputs of
the mean STI prevalence and the lower bound of the 95% CIs in the BMM
and the BODE are approximately identical. In contrast, the upper bound of
the 95% CI of the BODE is slightly wider in the beginning of the follow-up,
and from year 60, the situation is reversed. Nevertheless, these differences
are minor. Our results clearly show that the BMM approximates the BODE
very closely.
3.3.4 Cost-effectiveness analysis
In cost-effectiveness analysis, costs generated by the interventions are com-
pared to their induced benefits, e.g. an improvement in the quality of life. The
quality of life of members of the population in certain states is described
by so-called utilities, typically ranging between 0 and 1, representing death
and perfect health, respectively. These are used to compute the Quality-
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Adjusted Life Years (QALYs). We denote the unit costs and utilities as csti
and us, with indices s, t and i representing states s ∈ {1, ..., S}, observation
time points t and interventions i = 1 (status quo) and i = 2 (vaccination). We
assume decreasing utility values for more severe states. Costs are induced
by screening, vaccination, a visit at the general practitioner and diagnostic
tests. Following a positive STI diagnosis, further diagnostic tests and treat-
ment are necessary. For all these quantities, the distributional assumptions
are presented in Table 3.1.
The overall costs per intervention are calculated as
Ci =
T∑
t=1
S∑
s=1
cstinsti
(1 + z)t−1
,
where nsti is the number of people in state s at time t when intervention
i is applied and z is the yearly discount rate. In both the continuous- and
discrete-time approaches, the model output on the natural history of dis-
ease infection and progression is evaluated at pre-specified time points
t ∈ {1, ..., T}, where T represents the end of follow-up. Costs and bene-
fits induced in the distant future have a lower impact on the results since
they include a higher amount of uncertainty due to unknown future events;
furthermore, patients gain most from an instant improvement of their health
condition. Therefore, we discount both costs and benefits at a fixed yearly
rate z = 0.03, following ISPOR recommendations [192]. Similarly, the overall
utilities are computed as
Ui =
T∑
t=1
S∑
s=1
usnsti
(1 + z)t−1
.
The overall costs and benefits can be re-scaled to compute the population
averages
µFci =
Ci
Ni
and µFei =
Ui
Ni
,
where Ni =
∑
t
∑
s nsti is the total number of people in the virtual cohort.
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These can be used to define the monetary net benefit NBi(θF) = kFµ
F
ei −
µFci . This quantifies the utility of intervention i as a function of a parameter
of willingness to pay kF, which determines the amount of money that the
decision-maker is willing to invest to increase the benefits by one QALY. The
economic evaluation is performed by calculating suitable summaries such
as the increment in mean cost ∆c = µ
F
c2 − µFc1 and the increment in mean
effectiveness ∆e = µ
F
e2− µFe1 between vaccination and the status-quo, or the
incremental cost-effectiveness ratio
ICER =
E[∆c]
E[∆e]
.
In the BMM and BODE, these quantities are estimated directly as functions
of the parameters, while in the dODE, we conduct a scenario analysis in-
cluding the 2.5% and 97.5% quantiles of the ICER to evaluate the range
of “plausible” results. A cut-off point of a willingness-to-pay kF of approxi-
mately £20,000 – £30,000 per QALY gained, adopted by NICE [298], is used
as the benchmark of value for money.
As for PSA, it is usually based on: (i) the analysis of the cost-effective-
ness plane, depicting the joint probability distribution of (∆e,∆c); (ii) the
cost-effectiveness acceptability curve CEAC = Pr(kF∆e − ∆c > 0 | data),
which shows the probability that the reference intervention is cost-effective
as a function of the willingness to pay kF; and (iii) the expected value of
“perfect” information
EVPI = Eθ∗
[
max
i
NBi (θ∗)
]
−max
i
Eθ∗ [NBi (θ∗)] ,
which quantifies the maximum amount of money that the decision-maker
should be willing to invest (e.g. in a new study) in order to resolve parameter
uncertainty and thus make a “better” decision. The probabilistic models can
perform these analyses in a straightforward way, since these quantities are
all functions of the model parameters and thus a full posterior distribution
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can be directly obtained.
The BODE and dODE result in identical ICERs of £ 13,774, whereas the
ICER of the BMM is slightly higher at £ 13,854. These differences do not
have a significant impact on the decision-making process. Accounting for
a higher amount of parameter uncertainty in the BMM and the BODE, the
ICERs of the three models are considerably lower, resulting in £ 6,702 in
the dODE, £ 6,800 in the BODE and £ 7,084 in the BMM. In comparison
to the “perfect knowledge” scenario, population prevalence results in higher
values. The higher the estimated prevalence, the lower the ICER; if an inter-
vention such as vaccination can prevent more disease cases in a population
and therefore show its full potential, it will result in a more cost-effective out-
come.
For the dODE, we conduct a scenario analysis to estimate the 2.5% and
97.5% quantiles of the ICER, resulting in £−13,660 and £ 133,620, respec-
tively. The ICER is defined in R, where negative values indicate that the new
intervention dominates the status quo or vice versa. Uncertainty in cost- and
effectiveness differentials ∆e and ∆c is displayed in the cost-effectiveness
plane through the joint distribution P (∆e,∆c). However, when calculating
the ICER as a ratio of expectations of the posteriors of ∆c and ∆e, uncer-
tainty is averaged out. In contrast to ∆c and ∆e, the ICER does not have
a probability distribution. In terms of a scenario analysis, ranges for ICERs
can be presented; however, it would not be possible to estimate credible
intervals of an ICER. Furthermore, we point out that results at the extremes
commonly only occur with low probability. This is a consequence of the cor-
responding distributions which often have long tails. An exception would be
a Uniform distribution which is not used in our models. If these aspects are
ignored, the interpretation of results at the extremes could be falsified.
To estimate the 2.5% quantile of the ICER, the 97.5% quantile of the
prevalence outcome is used since a high prevalence results in a low ICER.
This effect is reinforced by using the 97.5% quantiles of screening cover-
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age, 2.5% quantiles of vaccine coverage, 2.5% quantiles of costs induced
by vaccination, 97.5% quantiles of costs induced by screening and the STI,
and 2.5% quantiles of the utilities of the states. The scenario analysis of
the 2.5% quantile of the ICER is conducted accordingly; however, the as-
sumptions on the prevalence calculation, coverage rates, costs and utilities
are reversed.
This analysis clearly shows that the three models result in comparable
outcome. However, the quantiles to inform the parameters values of the
dODE have to be estimated following careful considerations. If the mean
or median is used due to simplicity, infection prevalence might be under-
estimated, and thus the cost-effectiveness potential of certain interventions
might not be recognised. As a consequence, effective and affordable in-
terventions might be withheld from the population, resulting in a significant
deterioration of overall population health.
Figure 3.2 displays the cost-effectiveness plane for the BMM and BODE
in grey and black, respectively, showing the effectiveness-differential in QALY
on the x−axis and the cost-differential in £ on the y−axis. The vast major-
ity of points in both models lie within the sustainability area or close to its
border, indicating that vaccination is cost-effective at a threshold of £ 25,000
when compared to screening.
Figure 3.3 shows the outputs of the CEACs and the EVPI analyses. The
CEACs reach values of only around 30% cost-effectiveness at the break-
even points of £ 7,084 and £ 6,800, respectively, and a value of 80% is
reached at a willingness-to-pay of around £ 40,000 in both models. The
EVPI analyses result in values of around £ 23 per individual in the BMM
and BODE, which is considerably low. The results indicate that the amount
of uncertainty in the BMM and the BODE is basically identical which is in
accordance with the confidence bands shown in Figure 3.1.
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Figure 3.2: The cost-effectiveness plane indicates that vaccination is less expen-
sive and more effective than the status-quo of STI screening. Most
points are within the sustainability area, showing that vaccination is
cost-effective. The results of the Bayesian Markov model are displayed
in grey, whereas those of the Bayesian ODE-based model are shown
in black. Additionally, the Incremental Cost-Effectiveness Ratios are
displayed as a red and blue dot for the Bayesian Markov model and
the Bayesian ODE-based model, respectively. The joint distributions of
cost- and effectiveness differentials of both models are comparable.
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3.4 Modelling observed data
In the analysis described in the previous sections, we assumed to have
no access to individual-level data. Therefore, the prior distributions were
informed through aggregate data and expert opinion as shown in Table 3.1.
However, available individual-level (and aggregate) data are commonly used
to update the priors in a Bayesian framework. In models including a high
number of parameters, data to infer each individual parameter are rarely
available. We therefore include simulated individual-level and aggregate
data on a selection of parameters; these are partner acquisition rates, STI
transmission probability per partnership, vaccine coverage, vaccine efficacy,
probability of diagnosis and probability of screening. Minimally-informative
and informative priors are specified; in case of minimally-informative priors,
the data speak for themselves and the prior does not influence the result of
the posterior. In the informative priors, prior knowledge is incorporated and
then updated through individual-level data.
We assume to have access to individual-level data Yvb obtained through
a survey on the yearly number of sexual partners of altogether 2,000 individ-
uals. This corresponds to 500 individuals in each of the two sexes and risk
groups. The data Yvb are simulated through random number generators;
the parameters of the corresponding Gamma distributions are estimated
through means and standard deviations which are comparable to those re-
ported in the literature on sexual mixing [206, 360]. To infer the partner ac-
quisition rates ωvb, we assume to have observed Yvb and use these data to
update informative Gamma priors into the corresponding posteriors through
Poisson-Gamma models as
Yvb ∼ Poisson(ωvb)
ωvb ∼ Gamma(0.1, 0.1).
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Table 3.2: Overview of the posterior means and 95% credible intervals of the pa-
rameters of the BMM which are updated by simulated data. The poste-
rior results of the BODE are comparable.
Parameter Description Model Mean 95% interval
ωMH Partner acquisition rate (high-
risk males)
Poisson-Gamma 9.10 [8.77;9.29]
ωML Partner acquisition rate (low-risk
males)
Poisson-Gamma 2.98 [2.82;3.12]
ωFH Partner acquisition rate (high-
risk females)
Poisson-Gamma 9.00 [8.71;9.26]
ωFL Partner acquisition rate (low-risk
females)
Poisson-Gamma 1.96 [1.86;2.09]
β STI transmission probability per
partnership
Beta-Binomial 0.16 [0.15;0.16]
η Probability of STI diagnosis Beta-Binomial 0.90 [0.88;0.92]
σ Screening probability Beta-Binomial 0.90 [0.87;0.92]
α Vaccine coverage parameter Beta-Binomial 0.90 [0.87;0.92]
γ Vaccine efficacy parameter Beta-Binomial 0.90 [0.87;0.92]
The approaches for the other parameters are similar; however, since these
parameters are probabilities, the corresponding models are Beta-Binomial.
As an illustrative example, we show the model for the STI transmission prob-
ability β which is specified as
Rβ ∼ Binomial(β,Nβ)
β ∼ Beta(0.5, 0.5).
The data are given by Rβ and Nβ which represent the number of people
who become infected by the STI and the overall number of people observed,
respectively. The corresponding prior is the reference prior. The reference
prior ensures that the information given by the data has a maximal impact
on the result of the posterior [389].
The means and 95% credible intervals of the resulting posteriors of the
BMM are shown in Table 3.2. The remaining parameters are not updated by
data and thus identical to those displayed in Table 3.1. The posterior results
of the BODE are similar to the BMM and therefore not reported.
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As described in Section 3.3.2, the BMM is run in JAGS. In R, Bayesian
ODE-based models can be run through Stan or WinBUGS [355], using the
interface WBDiff [247]. We intended to compare the two alternatives. In
the previous analysis, the BODE was run in Stan; therefore, in the second
analysis, we switch to WinBUGS. In most applications, however, Stan is more
computationally efficient. An ODE solver for stiff regions of ODEs is provided
in the newest release (2.14).
Both models are run for 1,000 simulations to achieve good convergence
of each parameter and the output. Furthermore, issues with autocorrela-
tion are avoided. Compared to the analysis described in Section 3.3.2, the
number of simulations is reduced by around factor ten. The computation
times are 146.23 seconds and 81.34 seconds for the BMM and BODE, re-
spectively. In comparison to the first analysis, the computation time of the
BMM is longer as a consequence of data inclusion, whereas the BODE runs
faster in WinBUGS when compared to Stan. This is most likely a consequence
of the lower number of simulations. We assess convergence and potential
issues with autocorrelation using standard tools such as the Potential Scale
Reduction Rˆ and the effective sample size [151]. Further details on Rˆ and
autocorrelation are described in Sections 3.2.2 and 3.2.3. Convergence is
sufficiently achieved with Rˆ < 1.1 in all model parameters. We can conclude
that there are no issues with autocorrelation since the effective sample size
is almost as high as the overall number of simulations in all model parame-
ters. The relevant model code is presented in Appendix A.
3.5 Model calibration
Model calibration is an essential part of infectious disease modelling for two
reasons. The first is that not all model parameters can always be informed
directly; sometimes, reliable data cannot be collected (e.g. due to ethical
reasons as for the probability of infection transmission described in Sec-
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tion 1.3). In this case, a common approach is to calibrate the corresponding
model outcome to high quality data, e.g. obtained from a large registry. The
parameter values resulting in outcome which is most comparable to these
registry data are then assumed to be most realistic and used to inform the
model [366]. The second reason to calibrate model outcome is to ensure
that the results are in line with high quality data, even if the model parame-
ters can be informed by data directly. If the model outcome is not compara-
ble to the high quality data, the corresponding model parameters have to be
adjusted, either through direct or indirect calibration approaches.
In the second analysis of the case study, simulated data are thus in-
cluded as follows. In the Bayesian models, individual-level and aggregate
data are included to update the priors into the corresponding posteriors as
described in the previous section. In addition to posterior sampling, simu-
lated data are included to calibrate the model outcome to time series data
on the number of people in each state. In the dODE, simulated data are
included to determine the parameter values which result in most realistic
model outcome. Since the literature on infectious disease modelling in-
cludes a large variety of calibration approaches (which are often not pre-
sented in sufficient detail), we conduct the three approaches which are
most commonly applied. These are visual calibration as well as frequen-
tist probabilistic and Bayesian calibration. A visual calibration approach is
also conducted for the HPV model in Section 6.3. Further details on the
three approaches are described in the following.
In a visual calibration approach, the model output and data are displayed
graphically and compared visually. Key model parameters are adjusted re-
peatedly until the model output shows reasonable fit to the data. However,
this approach is quite crude and prone to induce incorrect results; thus,
the application of more systematic calibration approaches (e.g. probabilistic
calibration in a frequentist or Bayesian setting) is often advisable.
In a frequentist probabilistic calibration approach, large numbers of sets
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of input parameter combinations are created through random sampling, e.g.
forward sampling (as described in Section 3.2.1) or Latin Hypercube Sam-
pling. A range of model outputs corresponding to each input parameter set
is then compared to data [209]. The procedure involves the calculation of
goodness-of-fit (GOF) statistics. Depending on the GOF statistic, lowest
(sum of mean squared errors, χ2 statistics, log-likelihood) or highest (maxi-
mum likelihood) values indicate best model fit [366].
In the Bayesian calibration approach, model parameters are inferred by
fitting the model to data directly (in one step). The updating of the model
output takes place by assigning suitable distributions to the data. For exam-
ple, if the model output corresponds to count data (e.g. on the number of
people in certain states at a specific period of follow-up), a Poisson distribu-
tion could be assigned. The event rate λ∗ is then directly represented by the
expectation on the model output.
In addition to Bayesian calibraton approaches, direct frequentist likelihood-
based approaches exist; however, these are less flexible since parame-
ter uncertainty cannot be propagated through the model. For example,
Bretó et al. [50] fit models based on stochastic processes to time series data
through frequentist likelihood-based approaches. The authors present so-
called “plug and play” models, meaning that simulations of sample paths
are made by repeatedly plugging random input parameters into a “black
box” of “equation-free” models. Thus, transition probabilities do not have
to be available in closed form, and sample paths are not predefined but
simulated. Likelihood-based inference is then conducted to inform the cor-
responding model parameters. A variety of both frequentist and Bayesian
likelihood-based methods of inference for “plug and play” models is imple-
mented in the R-package POMP (Partially observed Markov process) [224].
The procedures in this package are very extensive and account for specific
data, e.g. including measurement error, unobserved variables, covariates,
irregular sampling intervals, as well as properties such as non-stationarity
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and nonlinearity [77,190,223]. An important limitation of the package is the
related computational effort which increases considerably the more states
and parameters are included into a model. Thus, at present, POMP is not
suitable to fit more complex models to data [182].
Another direct frequentist calibration approach based on the Ramsay
method is presented by Koulis et al. [230]; this is applied to an experiment
in psychoacoustics, where participants’ reaction to specific sound is mea-
sured. Observations vary between as well as within participants. Thus,
hierarchical data are obtained, with observations nested within participants.
In mixed-effects models, calibration takes place through centering of the
regressors towards the origin. This is conducted to break the correlation
between the intercept and the slope in the regression models.
3.5.1 Visual comparison of model output to data
Before we conduct systematic calibration approaches, we describe the pro-
cess of parameter adjustment through visual calibration due to the following
reasons. In the health economic literature on interventions against infec-
tious diseases, the outcome of the corresponding models is often compared
visually to data. In addition, we conduct a visual calibration approach for the
HPV model in Section 6.3 since time series data on HPV-induced diseases
are not available; for consistency, we show this approach for the case study
as well.
To conduct a visual calibration approach, we simulate data on the preva-
lence of the chronic STI for an observation time period of 100 years. Data
simulation is conducted by running the dODE for different inital and param-
eter values; this dODE is termed prevSim. We initialize prevSim with a very
large virtual population of 100,000,000 people, comparable to the size of
a data registry. As described in Section 3.3, we assume 20% of the pop-
ulation to be in the high-risk group and 50% to be male. Initially, 20,000
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people in each of the four subgroups (high- and low-risk female and male,
respectively) are assumed to be infected. The output of prevSim on STI
prevalence (including an average dataset of the proportion of the population
in the states infected, asymptomatic and morbid) is then used to calibrate
the dODE, BODE and BMM.
The key parameters which need to be adjusted in the visual calibration
process are the STI transmission probability β and the transition rate and
probability of moving from the state morbid to the state death (ρ4,5 and pi4,5,
respectively). In the Bayesian models, β, ρ4,5 and pi4,5 are modified by shift-
ing the corresponding distributions so that the means of the distributions be-
fore calibration correspond to the 97.5% quantiles of the distributions after
calibration. In the dODE, the vast majority of parameter values corresponds
to the mean values of the BODE; however, β and ρ4,5 are informed by the
15% quantile and the minimum of the corresponding parameter distributions
of the BODE, respectively.
Figure 3.4 shows the model outcome on STI prevalence after calibra-
tion. The two Bayesian models fit the simulated data well, with a slight STI
prevalence overestimation in the BMM between years 30 and 40 of the ob-
servation time period, and a slight underestimation in the BODE between
years 60 and 100. The fit of the dODE is not as good, including an under-
estimation before year 50, and an overestimation afterwards. These differ-
ences might be a consequence of including a much larger population into
prevsim than into the dODE and of informing the corresponding parameters
by slightly different values when compared to the dODE. These results show
that visual comparison as a single calibration method is insufficient to further
improve model fit to data, and the application of a more systematic calibra-
tion approach is necessary. The amount of uncertainty in the two Bayesian
models is comparable. The ranges of the scenario analysis of the dODE
are considerably smaller than the bounds of the 95% credible intervals of
the BMM and BODE.
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Figure 3.4: The prevalence outcome of the three models following a visual calibra-
tion approach. Prevalence of the calibrated BODE and BMM is com-
parable to the simulated data, whereas the calibrated dODE underesti-
mates STI prevalence during the first 50 years of the observation time
period, and overestimates it afterwards.
Following visual calibration, we conduct a cost-effectiveness analysis as
described in Section 3.3.4. The ICER of the dODE results in £ 8,095.48
(ranging from £ 1,953.48 to £ 18,374.71 in the scenario analysis), whereas
the ICERs of the BODE and BMM are considerably higher at £ 12,343.95
and £ 11,691.11, respectively. The ICERs of the three models are well below
the threshold of cost-effectiveness of £ 25,000.
PSA on the outcome of the two Bayesian models is conducted as part
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of the health economic evaluation. The CEACs and EVPIs of the two mod-
els are comparable. The joint distribution of cost- and effectiveness differ-
entials is right-skewed. Thus, the values of the CEACs are considerably
low and never reach values above 40% for a willingness-to-pay ranging be-
tween £ 0 and £ 50,000. Further details on skewed distributions of cost-
and effectiveness differentials and their impact on the values of the CEAC
are described in Section 6.6.1. The population EVPIs result in values of
around £ 4,000,000,000.
As described, the ICER estimated through the dODE differs from those
of the BODE and BMM despite visual calibration to simulated data on popu-
lation prevalence. These differences are a consequence of the considerably
high amount of uncertainty in the simulated prevalence data; prevalence is
a summary statistic and does not include details on the number of people in
each of the states over follow-up. Thus, following calibration, the model out-
puts on the number of people in the states can still be substantially different.
Furthermore, despite repeated parameter adjustment, the model fit of the
dODE to the simulated data is not ideal. To result in comparable outcome
of the cost-effectiveness analysis, more systematic calibration approaches
are conducted in the following.
3.5.2 Probabilistic calibration approaches
In addition to visual calibration, the literature includes probabilistic calibra-
tion approaches which can be conducted in a frequentist or Bayesian set-
ting. The dODE is calibrated through a frequentist probabilistic calibra-
tion approach, whereas the BODE and the BMM are calibrated through
Bayesian calibration approaches. Simulated time series data on the num-
ber of high-risk people in the states Susceptible, Infected, Asymptomatic
and Morbid in the first five years of follow-up are used for calibration. A
short observation time horizon of only a couple of years (five years in this
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case) is common in available time series data. These data are simulated by
running the dODE for a follow-up period of five years; the input parameter
values are informed through the means of the parameters of the BODE.
The computation times are 149.81 seconds and 6,587.67 seconds
(around 1 hour 50 minutes) for the BMM and BODE, respectively. When
compared to the previous analysis, the number of simulations is reduced
from 10,000 to 1,000. The computation time of the BMM is only 3 seconds
longer. The considerably increased computation time of the BODE is a con-
sequence of the Bayesian calibration approach which is conducted in the
WinBUGS interface WBDiff. In addition, the computation time of the dODE
considerably increases from 0.22 seconds to 4,480.19 seconds (around 1
hour 15 minutes) since the model is run for a high number of parameter sets
in context of frequentist probabilistic calibration.
The comparison of computation times clearly shows that the BMM is
highly efficient when time series data are included to calibrate the model
outcome. In the BMM, model calibration almost makes no difference in com-
putation time if the BMM is run for a reduced number of simulations. At the
same time, the BMM results in model outcome comparable to the gold stan-
dard of the BODE. In contrast to the BMM, computation time increases by
factor 35 and 20,365 in the BODE and dODE, respectively, when the mod-
els are calibrated. However, it is questionable to compare the computation
times of the BODE with and without calibration to data since software and
number of simulations differ.
Frequentist calibration of the deterministic ODE-based model
We calibrate the dODE through a frequentist probabilistic calibration ap-
proach as shown in [205, 358, 366]. Suitable probability distributions are
assigned to the model parameters which play a role in natural history of dis-
ease. The parameters of the distributions are estimated through means and
standard deviations obtained through expert opinion. For the STI transmis-
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sion probability, transition rates and reproduction rate, these are identical
to the means and standard deviations used to inform the corresponding
informative priors shown in Table 3.1. For the partner acquisition rates,
we calculate means and standard deviations of the simulated individual-
level data which are used to update the non-informative priors as described
in Section 3.4.
As a next step, sets of 50,000 parameter combinations are sampled
from the predefined parameter distributions through Monte Carlo sampling.
We calculate the sum of squared errors between the outputs of the 50,000
model runs (for each parameter set combination) and simulated data (which
are described in Section 3.5.2) on number of high-risk people for the first
five years of follow-up in four states as
Q(θ∗) =
5∑
t=1
4∑
s=1
(ys(t)− fs(t | θ∗))2 .
The dODE is based on a continuous-time approach; however, in order to
result in outcome which is comparable to the BMM in discrete time, the
corresponding output is evaluated at yearly time points t ∈ {1, ..., 5}. This
cycle length is deemed appropriate since the natural history of disease of
the chronic STI is considerably slow; a progression to a disease state fol-
lowing infection often takes several years to decades. The simulated data
on the number of high-risk people in state s at time point t are indicated by
ys(t), and fs(t | θ∗) is the model output on high-risk people in state s at time t
given the input parameter set θ∗. As a final step of the calibration, the set θ∗
corresponding to the model output which results in the least sum of squares
is selected; it is displayed in Table 3.3. The fit of the calibrated model output
to the simulated data is assessed visually as shown in Figure 3.5.
The natural history of the disease is evaluated through the calibrated
model outcome, and cost-effectiveness analysis is also conducted. Due to
the fact that the model outcome of the dODE does not include distributions,
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Table 3.3: Point estimates of the parameters of the deterministic ODE-based model
obtained through a frequentist probabilistic calibration approach. The
parameter set θ∗ with the best fit to simulated data minimises the sum of
squared errors.
Parameter Description Point estimate
ωMH Partner acquisition rate (high-risk males) 8.3515
ωML Partner acquisition rate (low-risk males) 2.4526
ωFH Partner acquisition rate (high-risk females) 8.3836
ωFL Partner acquisition rate (low-risk females) 1.6085
χ Proliferation parameter 0.0100
β STI transmission probability per partnership 0.1639
pi2,3 Transition parameter from state 2 to state 3 0.7957
pi3,4 Transition parameter from state 3 to state 4 0.0891
pi4,5 Transition parameter from state 4 to state 5 0.0232
pi1,5 Transition parameter from state 1 to state 5 0.0005
PSA is not performed; yet, scenario analysis of the ICER is conducted. The
results are shown in the following sections.
Bayesian calibration of the BODE and BMM
We calibrate the Bayesian models through a Bayesian calibration approach
as conducted in [106, 170, 377, 379]. Both Bayesian and frequentist proba-
bilistic model calibration are systematic approaches. Therefore, in compar-
ison to visual calibration, we expect the differences in results of the BODE,
BMM and dODE to decrease.
In the BODE, the model output on the number of people in the states
over the follow-up period corresponds to the solutions of the ODEs (see
Equation 2.1). In the BMM, the model output corresponds to the solutions
of the state allocation algorithm; in the state allocation algorithm, members
of the population are allocated to the states in each year of follow-up (see
Equation 2.2). Both the solutions of the ODEs and the state allocation algo-
rithm are constantly updated through simulated time series data on high-risk
people. The procedure of data simulation and nature of data is described at
the beginning of this section. The updating takes place by assigning Pois-
son distributions to the simulated data; the event rate λ∗ is then represented
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by the solutions of the ODEs and the state allocation algorithm, respectively.
As a consequence, the resulting model outcome is already calibrated, and
no further steps such as the calculation of GOF statistics are necessary.
The evaluation of the natural history of disease and the cost-effectiveness
analysis including PSA can be conducted straightforwardly.
Natural history of disease
Figure 3.5 shows the outcome on the natural history of disease of the fic-
tional chronic STI following calibration. In contrast to Sections 3.3.3 and
3.5.1, the number of people in four of the states rather than prevalence are
shown. Only the results on high-risk females are displayed; those on high-
risk males are comparable.
The results of the two Bayesian models are similar. The model outcome
on the states Susceptible and Morbid is basically identical, whereas the
outcome of the BODE shows higher estimates on the number of infected
and asymptomatic females. The outcome on the number of susceptible and
morbid females is higher in the dODE; in contrast, the outcome on those
in the states Infected and Asymptomatic is lower when compared to the
two Bayesian models. This is a consequence of the differences in model
parameter estimation (whole distributions of values in the BMM and BODE
and fixed parameter values in the dODE) as well as differences in calibration
approaches (Bayesian calibration in the BMM and BODE and frequentist
probabilistic calibration in the dODE).
The ranges of the 95% credible intervals of the BODE and BMM are sim-
ilar, showing wider ranges in the BMM. The 97.5% quantiles of the scenario
analysis of the dODE are lower than the upper bounds of the 95% CIs in the
states Infected and Asymptomatic and higher in the states Susceptible and
Morbid, whereas the 2.5% quantiles are considerably lower than the lower
bounds of the CIs (apart from the state Susceptible).
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Figure 3.5: Calibration results on the number of high-risk females in the states
Susceptible, Infected, Asymptomatic and Morbid. The results of the
Bayesian models are similar, with a higher number of high-risk females
in the states Infected and Asymptomatic estimated by the Bayesian
ODE-based model. In contrast, the deterministic ODE-based model
results in a lower estimate on the number of high-risk females in the
states Infected and Asymptomatic; however, the outcome on the states
Susceptible and Morbid is reversed.
Cost-effectiveness analysis
Details on common measures of cost-effectiveness analysis are explained
in Section 3.3.4. The CEA results of the visual calibration approach are
reported in Section 3.5.1. Following a frequentist probabilistic calibration
approach, the ICER of the dODE results in £ 7,203.416, ranging between
£ 2,592.44 and £ 469,906 in the scenario analysis at the 2.5% and 97.5%
quantiles. The ICERs of the probabilistic models are comparable to the
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dODE, resulting in £ 6,054.82 and £ 6,287.62 in the BODE and BMM, re-
spectively.
In contrast to a visual calibration approach, systematic probabilistic cali-
bration results in comparable outcome of cost-effectiveness analysis of de-
terministic and Bayesian models. In comparison to the cost-effectiveness
analysis based on the visual calibration approach, the ICERs of the Bayesi-
an models are considerably reduced, whereas the ICER of the dODE only
shows a slight decrease.
PSA is conducted on the outcome of the BMM and the BODE. Figure 3.6
displays the cost-effectiveness plane which is not comparable to the one
shown in Figure 3.2 since the corresponding models are informed through
additional information obtained from simulated data. The joint distributions
of cost and effectiveness differentials of the BODE and the BMM are sym-
metrical. Each point of the MCMC simulation lies within the grey sustain-
ability area, indicating that STI vaccination is cost-effective at a threshold of
£ 25,000 when compared to STI screening. STI vaccination is deemed to be
both more expensive and more effective than STI screening since all points
are located in the upper right quadrant of the graph. The ICERs of the BMM
and BODE are displayed as red and blue dots, respectively.
Figure 3.7 shows the results of the CEACs and the population EVPIs of
the two Bayesian models. The amount of uncertainty in the BMM is slightly
larger than in the BODE; however, 80% cost-effectiveness is clearly reached
at the break-even points of the ICERs of both models. The population EVPI
of the BMM at around £ 500,000,000 is higher than in the BODE, where it
reaches a value of around £ 400,000,000. The higher EVPI value of the
BMM is a consequence of the slightly larger amount of uncertainty. Thus,
the value of additional research is higher in the BMM.
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Figure 3.6: In comparison to the cost-effectiveness analysis based on visual cal-
ibration, the joint distribution of cost- and effectiveness differentials is
no longer skewed. The ICERs of £ 6,054.82 (blue dot, BODE) and
£ 6,287.62 (red dot, BMM) indicate cost-effectiveness of STI vaccina-
tion in comparison to STI screening at a threshold of £ 25,000. All
points lie within the sustainability area of cost-effectiveness.
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3.6 Conclusions
In this chapter, the dynamic Bayesian MM was compared to a determin-
istic and a Bayesian ODE-based model. The terms “deterministic” and
“Bayesian” refer to the nature of the parameters and the inference con-
ducted, respectively. The main purpose of this comparison was to evalu-
ate whether the approach of the dynamic BMM produced similar outcome
as the “gold standard” of the BODE. In addition, methodological uncertainty
was investigated, especially focussing on the implications of models includ-
ing parameters with fixed values and thus ignoring the effects of parameter
uncertainty. The comparison was made through the case study of the hypo-
thetical chronic sexually transmitted infection (STI) which was introduced in
Chapter 2; the study was described in further detail in this chapter. For the
three approaches compared, STI prevalence predictions were conducted.
Furthermore, the outcome of the cost-effectiveness analyis of a hypothet-
ical vaccine against the chronic STI was evaluated, including PSA on the
outcomes of the Bayesian models.
In the first part of the analysis, exclusively informative priors were in-
cluded, and no data were used to update the priors. Thus, prior elicitation
and forward sampling were conducted. When compared to the BODE, we
could clearly show that the dynamic BMM resulted in similar prevalence and
outcome of the CEA while at the same time considerably reducing the com-
putational effort. The parameter values of the dODE were estimated by
comparing the corresponding outcome to the outcome of the gold-standard
of the BODE. The loss induced by prevalence under- and overestimation
was non-symmetric, and thus 60% quantiles of the parameters of the BODE
(instead of the mean or median) were used to inform the parameters of the
dODE. If the proportion of the population under risk of infection was un-
derestimated, this would result in the false assumption of limited vaccine
requirement. As a consequence, the benefits of vaccination were under-
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estimated, and the cost-effective vaccine was withheld from the population.
This induced unnecessary suffering and possibly death. The non-symmetric
loss could be accounted for by informing the parameter values of the dODE
through the 60% quantiles of the BODE. As a consequence, the correspond-
ing results of prevalence and the CEA were comparable to the two Bayesian
models. However, a non-symmetric loss is usually not considered in deter-
ministic models in the literature. Therefore, it is essential to calibrate model
outcome to empirical data to avoid incorrect results.
In the second part of the analysis, we included simulated data into the
models for two reasons. First of all, Bayesian inference was conducted by
updating minimally-informative and informative priors through data into the
corresponding posteriors. Furthermore, data were used to calibrate the out-
puts of the two Bayesian models and the dODE. A systematic calibration
approach resulted in comparable outcome of natural history of disease and
cost-effectiveness analysis. The differences in ICER results were consider-
ably reduced, and benefits of vaccination were no longer underestimated by
the dODE. The computational effort of the BMM was around 44 times lower
when compared to the BODE and is thus still manageable even in highly
complex BMMs.
Therefore, we can conclude that the dynamic BMM is especially suitable
in CEAs of interventions against infectious diseases which require a high
number of states and separate compartments for covariates such as age,
sex and behaviour. The corresponding outcome is comparable to the “gold
standard” of a BODE at reduced computation time; this is even the case
if the model output is not calibrated to simulated data. One example of
a complex infectious disease is human papillomavirus (HPV). A literature
review on CEAs of HPV vaccination as well as the specification of the BMM
to an HPV context including the corresponding results are described in the
second part of this PhD thesis.
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Cost-effectiveness analysis of
human papillomavirus
vaccination

Chapter 4
Literature review
4.1 Introduction
This chapter includes an extensive literature review on methodology and re-
sults of health economic evaluations of female-only and universal (including
both sexes) human papillomavirus (HPV) vaccination strategies.
Since the early 2000s, several teams of researchers have considered the
inclusion of males to existing HPV vaccination programmes. HPV is sexu-
ally transmitted; the virus can also cause diseases in males, and males are
possible vectors in the virus transmission to females. As a consequence,
both sexes would experience a health benefit from non-sex-specific vaccine
recommendations. However, the question is whether universal HPV vacci-
nation is cost-effective.
The main purposes of the literature review are i) to ensure that our con-
tribution of the dynamic Bayesian MM is innovative in the context of HPV
transmission modelling; ii) to investigate the differences in methodologies
applied to compare universal to female-only vaccination; and iii) to evaluate
the reasons for contradictory results of the cost-effectiveness of universal
HPV vaccination.
First of all, we describe the databases searched and search word com-
binations applied. As a next step, we introduce the checklist on essential
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aspects of methodology, model assumptions and research outcome we use
to evaluate the retrieved publications. This checklist is especially helpful to
identify reasons for varying results of cost-effectiveness analysis (CEA). Re-
search outcomes in terms of ICERs per QALY (see Section 3.3.4) below a
willingness-to-pay value of e25,000 - e40,000 per QALY gained [135,256]
are deemed to be cost-effective. This benchmark of value for money roughly
corresponds to the value of £ 20,000 - £ 30,000 adopted by NICE [298].
In the end of the chapter, we discuss the results of the health economic
evaluations, structured separately for publications including universal and
female-only vaccination, respectively. Furthermore, we discuss the differ-
ences in methodology and model assumptions which explain contradictory
cost-effectiveness outcome. Finally, we compare the approaches presented
to our contribution of a dynamic Bayesian MM.
4.2 Databases and search word combinations
We perform the literature review through the databases Scopus, Pubmed,
The Cochrane Library, Web of Science and the Centre for Review and Dis-
semination (CRD) of the National Institute for Health Research. The CRD
combines the databases DARE (Database of Abstracts of Reviews of Ef-
fects), NHS EED (NHS Economic Evaluation Database) and HTA (Health
Technology Assessment).
The following search word combinations are used to identify literature on
the cost-effectiveness of HPV vaccination strategies:
((cost-effectiveness) OR (cost-utility) OR (cost-benefit))
AND ((HPV vaccine) OR (human papillomavirus vaccine)
OR HPV OR (human papillomavirus))
To focus specifically on male HPV vaccination, the search term is ex-
tended by
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AND (boys OR male).
Possible synonyms are considered and combined with the search word
OR, whereas obligatory search word combinations are linked with the search
word AND.
The above search identifies 110 studies including female-only vaccina-
tion and 34 studies including universal vaccination, focussing on CEA and/or
changes in natural history of HPV, such as reductions in HPV prevalence
and incidence or lifetime risk of cervical cancer.
4.3 Checklist for methodology and model assump-
tions
Each publication retrieved is evaluated thoroughly according to a checklist in
order to provide a systematized overview on methodology, model assump-
tions and aim of research. The checklist includes the following criteria:
• methodology: static vs. dynamic, deterministic vs. probabilistic;
– population-based: ordinary or partial differential equation (ODE/
PDE)-based vs. Markov vs. hybrid model;
– individual-based: microsimulation vs. network vs. hybrid model;
• model assumptions: country-specific context, HPV types consid-
ered, HPV-induced diseases included, vaccine coverage rate, vac-
cine efficacy, vaccination age, male vaccination, duration of vaccine-
induced immunity, booster application, levels of sexual activity, sexual
mixing strategy, cervical screening conducted, duration of follow-up,
vaccine price, discount rate;
• aim of research: CEA, prevalence/incidence reduction of HPV or
HPV-induced diseases following vaccination.
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All publications are summarized in Tables B.1 and B.2 in Appendix B.1,
which are structured separately for universal and female-only vaccination
strategies. The most important findings are discussed in the following. Pub-
lications on HPV prevalence predictions are only reported in Appendix B.1.
4.4 Methodology
We investigate six approaches presented in the literature on HPV trans-
mission and HPV-induced disease progression modelling, including i) differ-
ential equation models, ii) Markov models (MMs), iii) microsimulation mod-
els, iv) network models and v) hybrid models. Differential equation models
and MMs are population-based, implying that the population as a whole
is observed. As a consequence, proportions of the population in each
state at each time point or time interval of follow-up are evaluated. In con-
trast, in individual-based models such as microsimulation or network mod-
els, each individual is observed separately; thus, patient disease history is
accounted for.
A variety of dynamic transmission models based on differential equa-
tions are evaluated; these primarily predict the impact of universal vacci-
nation strategies. In context of female-only vaccination, the vast majority
of authors present static MMs; however, a static methodology commonly re-
sults in falsified prevalence and CEA outcome since effects of herd immunity
cannot be considered. Individual-based models are presented in dynamic or
static settings. Both static individual- and population-based models can be
linked to dynamic transmission models, resulting in so-called hybrid mod-
els. All methodologies are summarized in the following; additional details
are presented in Appendices B.2 – B.5.
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4.4.1 Differential equation models
In the literature on HPV vaccination, differential equation models are usually
stratified according to age, sex and sexual behaviour. Apart from [240], all
differential equation models reviewed estimate HPV transmission dynam-
ically through the force of infection, incorporating age-, sex- and behavi-
oural-specific sexual mixing matrices. Ten are based on ordinary differential
equations (ODEs) [63,131–133,187,204,229,240,349,392], whereas three
incorporate partial differential equations (PDEs) [26, 38, 368]. In contrast
to ODEs which are functions of time of follow-up, PDEs are functions of
both age and time. The vast majority of the ODE- and PDE-based mod-
els presented inform their parameters through fixed values, e.g. point es-
timates [26, 131–133, 187, 204, 240, 349, 392]. Bayesian approaches are
introduced for three models including a smaller number of states; how-
ever, not every model parameter is assigned a distribution, and fixed val-
ues are incorporated for certain model parameters [38, 229, 368]. Ten au-
thors [26,63,131–133,187,204,229,368,392] include universal vaccination
strategies; yet, only five [131–133,204,392] conduct CEAs, whereof only El-
basha et al. [131] come to the conclusion that universal vaccination is cost-
effective. In addition, two models [38, 349] exclusively account for female-
only vaccination, with [349] conducting a CEA and resulting in cost-effective
outcome. The most interesting models are described in Appendix B.2.
4.4.2 Markov models
Altogether, 30 newly developed Markov models [17, 34, 79, 83, 96, 99, 109,
111,153,162,173,225,241,245,248,263,270,274,294,311,321,328,330,
342, 344, 345, 358, 365, 370, 388] are presented, including eleven which as-
sign distributions to model parameters [34,81,96,136,153,225,241,245,294,
328,358], whereof three [81,136,358] are based on a Bayesian framework.
Nine of the newly developed Markov models [34, 79, 83, 109, 162, 263, 294,
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358, 365] are modified as follows: Five publications [57, 82, 232, 289, 364]
extend the original aim of research (e.g. including CEA), whereas 26 [9,16,
30, 87, 113–116, 130, 164, 169, 172, 183, 226, 228, 231, 257, 273, 300, 303,
304, 333, 337, 373, 382, 383] are adjusted to settings in different countries.
Three authors [83,274,365] use the term “Markov model” exclusively if only
one cohort of individuals is incorporated; however, in the health economic
literature, multi-cohort models are alternatively referred to as MMs.
Five authors [16,82,83,365,370] indirectly account for herd immunity in
static methodology. This approach is not comparable to a dynamic method-
ology since dynamic changes in population prevalence cannot be consid-
ered. The corresponding implications and disadvantages are discussed in
Section 1.2. Anonychuk et al. [16] follow an approach introduced by Bauch
et al. [27] to reduce HPV prevalence in unvaccinated individuals through
herd immunity. Chesson et al. [82, 83] multiply prevalence of HPV-induced
diseases by adjustment factors to estimate indirect protection of unvacci-
nated individuals. Vanagas et al. [365] consider a reduced risk of exposure
to HPV due to decreasing HPV prevalence in females after vaccine intro-
duction. Voko et al. [370] lower the transition probability to the state of HPV
infection, proportionally on vaccine coverage and vaccine efficacy.
Apart from [82, 173, 289, 330], all MMs exclusively account for female-
only vaccination. Stratton et al., Chesson et al. and Pearson et al. [82,289,
330] compare universal vaccination to screening-only and female-only vac-
cination, respectively, whereas Graham et al. [173] investigate the impact of
male HPV vaccination on oropharyngeal cancer incidence. All Markov mod-
els result in cost-effective outcome for female-only vaccination, and apart
from [289], universal vaccination is deemed to be cost-effective. We sum-
marize specific characteristics of the Markov models in Appendix B.3.
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4.4.3 Individual-based models
Two versions of individual-based models are given by network and microsim-
ulation models. In network models, each individual is represented by a
node, and interactions between individuals are enabled through links. Net-
work models are especially useful if the sources of infection or the impact
of quarantine measures are investigated. In contrast, in microsimulation
models, each individual is assigned an own function. Transitions between
the states are defined as events, and the probability of event occurrence
depends on individual-specific covariates, estimated through the functions
assigned.
Microsimulation models are an appropriate methodology if i) disease his-
tory of individuals has to be accounted for, or ii) multimorbidities are com-
mon [237]. If disease history is not considered, and the inclusion of mul-
timorbidities is not allowed in a microsimulation model, a comparable MM
can be seen as a limit of the respective microsimulation model.
In chronic health conditions such as diabetes, the history of blood glu-
cose levels in each individual has an important impact on the risk of devel-
oping long-term health effects such as kidney failure. A Markov model on
disease progression of diabetes would assume that the risk to move to a
state of diabetes related complication was independent of the individual his-
tory of blood glucose level; this would result in falsified outcome. In contrast
to diabetes, in context of HPV, individual disease history does not necessar-
ily have to be accounted for; HPV-induced cancer can develop both a couple
of years after first HPV infection and decades later.
Another aspect is that a microsimulation model enables the occurrence
of several health conditions simultaneously, whereas in a Markov model,
states are mutually exlusive and exhaustive. In subgroups of the population
such as the elderly, multimorbidities are common. These are often not inde-
pendent; if one condition worsens, this could have an effect on the other con-
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dition(s). This mechanism is thus considered appropriately by a microsimu-
lation model. However, as for HPV-induced diseases, a combination of con-
ditions is rather rare and therefore not relevant. Due to these two aspects
and the increased effort on implementation, microsimulation models are
quite rare in the literature on the cost-effectiveness of HPV vaccination; only
six authors [7, 108, 159, 220, 360, 367] present this approach. Out of these,
four models [7,108,159,220] are static as a consequence of exclusively in-
corporating a female model population, two are deterministic [7, 108], four
are stochastic [159, 220, 360, 367], and five are linked to dynamic trans-
mission models, resulting in hybrid models [161, 167, 168, 217, 219]. A se-
lection of newly developed models is modified to different country-specific
context or to extend the aim of research, resulting in 15 additional publica-
tions [55, 59, 70, 119, 122, 125, 160, 163, 166, 214, 221, 236, 243, 316, 359].
Four models [55, 59, 122, 236] investigate the impact of universal vaccina-
tion, presenting cost-effective [55, 59] and not cost-effective results [236],
whereas 18 models [7, 54, 56, 57, 70, 108, 119, 125, 159, 160, 163, 166, 214,
221, 243, 316, 359, 367] exclusively account for female-only vaccination. All
models apart from [108] result in cost-effective female-only vaccination. Fur-
ther details on the models are described in Appendix B.4.
4.4.4 Hybrid models
In a hybrid approach, the output of dynamic disease transmission models
is incorporated into static disease progression models. In the literature,
ten hybrid models [37,161,167,168,185,215,217–219,339] are presented.
Two include MMs [185,339], whereas eight [37,161,167,168,215,217–219]
estimate disease progression through a microsimulation model [160, 220].
Four models [185, 215, 218, 339] consider universal vaccination, whereas
six [37,161,167,168,217,219] exclusively account for female-only vaccina-
tion. Universal vaccination is not cost-effective (apart from [215]), whereas
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female-only vaccination is cost-effective in all settings. Further details are
presented in Appendix B.5.
4.5 Results of cost-effectiveness analysis
Apart from [108], all publications reviewed come to the conclusion that female-
only vaccination is cost-effective, whereas CEA results of universal vaccina-
tion are contradictory. Different methodological approaches do not seem to
play an important role with respect to the outcome of health economic evalu-
ations. Dynamic models based on differential equations, microsimulation or
hybrid approaches lead to both cost-effective and not cost-effective results
of universal vaccination. The results of the MMs (apart from [289]) and the
network models are cost-effective.
Differences in results occur mainly due to varying model assumptions.
Commonly, results become more cost-effective i) the more diseases in both
sexes are included, ii) the lower the vaccine coverage rate, iii) the higher
the vaccine efficacy, iv) the longer the duration of vaccine-induced immu-
nity, v) the higher the sexual activity, vi) the more disassortative the sexual
mixing, vii) the less frequent the cervical screening, viii) the longer the ob-
servation time period, ix) the lower the discount rate, and x) the lower the
unit cost of vaccination. In summary, all aspects which increase HPV preva-
lence in the population increase the necessity of vaccine protection; the
more individuals are exposed to the virus and under risk of infection, the
more HPV-induced diseases can be prevented by the vaccine. As a conse-
quence, the vaccine can show its full potential, which is prone to result in
cost-effective model outcome.
The model assumptions listed above can have a major impact on the
outcome of CEAs. These assumptions can also vary considerably between
different countries. If a pharmaceutical company would like to introduce
HPV vaccination to more than one country, country-specific information has
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thus to be considered. The most straightforward and least expensive way is
to adapt a model which was already implemented for a specific country to
one or more additional countries. This is a common approach in practice.
Elbasha et al.’s ODE-based model was for example adapted to a variety
of international settings [49,100–103,188,211,314,357,387], incorporating
country-specific information.
Usually, the model parameters which differ most between countries are
related to costs, including cost of the intervention, diagnostic measures,
hospitalisation, treatment of disease and adverse events. In addition, util-
ities might vary since people from different cultures have different coping
mechanisms with disease. Country-specific discount rates usually range
between 1.5% to 10% for benefits and 0% to 10% for costs [381] as de-
scribed in Section 6.5.2. Other crucial parameters are country-specific HPV
prevalence and mixing behaviour between susceptible and infected people.
Furthermore, the threshold of cost-effectiveness is country-specific and de-
pends on the gross domestic product (GDP) [280]. Differences between
countries are often minor if GDP, pricing, public health insurance systems,
cultural background and disease prevalence are comparable (such as for
Germany and France). However, these can also be considerably high if
low-resource settings of developing countries are compared to Europe or
the US.
4.5.1 Universal vaccination
Altogether, 34 publications including universal vaccination [26,39,49,55,59,
63,67,82,85,107,122,131–133,140,143,185,187,188,204,215,218,236,
277, 278, 289, 311, 317, 324, 330, 339, 360, 368, 392] are evaluated. Out of
those, eleven [49,55,63,82,131,140,215,277,278,317,330] report that uni-
versal HPV vaccination deems to be cost-effective, whereas eleven [67,85,
132,133,188,204,218,236,289,339,392] conclude that exclusively female-
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only vaccination is cost-effective. The remaining twelve publications do
not evaluate the cost-effectiveness and report predictions on natural history
of HPV.
The majority of methodology applied to evaluate the cost-effectiveness
of universal vaccination is based on differential equations; nine publica-
tions [49,63,85,131–133,188,204,392] use this methodology. All differential
equation models include fixed parameter values, inducing limitations in the
interpretability of results. Elbasha et al. [131], Bresse et al. [49], and Brown
et al. [63] present cost-effective outcome. A possible explanation for vary-
ing results might be that Zechmeister et al. [392] only account for cervical
cancer, whereas Bresse et al. [49] and Elbasha et al. [132, 133] addition-
ally account for CIN-stages, genital warts and in [131] for a great variety
of HPV-induced diseases. Elbasha et al. can only show that universal vac-
cination is cost-effective if all HPV-induced diseases are considered [131];
otherwise, female-only dominates universal vaccination [132, 133]. Jit et
al. [85,204] account for genital warts, CIN-stages and non-cervical cancers
as well; however, details on the dynamic transmission model are not re-
ported in sufficient detail. Therefore, we are unable to evaluate the reasons
for contradictory results to [131]. Accounting for different HPV types does
not seem to influence the outcome; Elbasha et al., Bresse et al. and Jit et
al. account for HPV 6, 11, 16 and 18, whereas Brown does not distinguish
between HPV types. Zechmeister accounts for HPV 16 and 18, but not for
HPV 6 and 11.
Only three MMs [82, 289, 330] are presented to investigate the cost-
effectiveness of universal vaccination; due to their static nature, standard
Markov models are not suitable to account for dynamic interactions between
individuals. To reduce this shortcoming, Chesson et al. [82] indirectly ac-
count for the effects of herd immunity as described in Appendix B.3. Both
Stratton et al. [330] and Chesson et al. [82] result in cost-effective outcome,
whereas Pearson et al. [289] conclude that universal vaccination is not cost-
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effective. Pearson et al.’s result could be induced by ignoring the effects of
herd immunity and assuming a duration of vaccine-induced immunity of only
20 years, in contrast to lifelong immunity in [82,330].
In contrast to standard Markov models, microsimulation models are of-
ten constructed in a dynamic way; van de Velde et al. [58,360] present a dy-
namic microsimulation model which is modified in two publications [55,236]
to conduct a CEA on universal vaccination. Laprise et al. [236] compare
universal to female-only vaccination strategies, concluding universal vacci-
nation not to be cost-effective. In contrast, Brisson et al. [55] find nonava-
lent in comparison to quadrivalent universal vaccination cost-saving, and
quadrivalent universal vaccination in comparison to screening-only cost-
effective. Other versions of individual-based models – three network mod-
els [140, 277, 278] – come to the conclusion that universal vaccination is
cost-effective.
Five authors [67, 215, 218, 317, 339] present combinations of static and
dynamic methodologies, so-called hybrid models; two [215, 317] result in
cost-effective outcome. A possible explanation for Taira et al.’s [339] results
could be that the authors only account for cervical cancer. Kim et al. [218]
and Burger et al. [67] account for a large variety of HPV-induced diseases;
however, despite these assumptions, universal vaccination is not deemed to
be cost-effective.
4.5.2 Female-only vaccination
The number of publications exclusively accounting for female-only vaccina-
tion is considerably higher with 110 [7,9,16,17,30,31,34,36,37,54,56,57,
68,70,72,75,81,83,87,96,99–103,108,109,111,113–116,119,120,125,130,
134,136,153,159–164,166–169,172,180,183,201–203,211,213,214,216,
217,219–222,225,226,228,229,231,232,234,241,243,245,248,257,263,
270,273,274,294,300,303,304,311,314,316,321,328,333,337,342,344,
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345,348–350,356–359,364,365,367,370,373,382,383,387,388] compared
to 34 focussing on universal vaccination.
All but one [108] publications come to the conclusion that female-only
vaccination is cost-effective or even cost-saving; as a consequence, we do
not face the challenge of inconclusive results as for universal HPV vaccina-
tion. Further details are presented in Appendix B.6.
4.6 Conclusion
Altogether, we reviewed 144 publications. To the best of our knowledge, we
did not find a methodology in the health economic literature on HPV vacci-
nation which is plainly comparable to our approach of a dynamic Bayesian
MM. However, several authors present dynamic models based on stochastic
processes [20,92,141,155,156]; yet, these are implemented in the context
of other pathogens and do not include health economic evaluations.
As described in Section 4.4.2, the literature presents five MMs which es-
timate the effects of herd immunity in an indirect way. Most of these models
incorporate exclusively female cohorts, and HPV prevalence is decreased
following vaccine introduction by means of adjustment factors. Thus, HPV
prevalence is a function of vaccine coverage, vaccine efficacy, and indirect
vaccine protection. These approaches of indirect herd immunity adjustment
only result in reliable model outcome when combined to extensive calibra-
tion approaches on HPV prevalence following vaccination. However, this
might not be possible at the current stage of research since long-term data
on HPV prevalence after the introduction of female-only vaccination do not
exist yet. In context of universal vaccination, data are not available yet since
the status quo in most Western countries (apart from Australia, Canada,
USA, Israel, Switzerland, Austria) is female-only vaccination [295]. The six
countries which recommended universal vaccination did so only recently. As
a consequence, indirect adjustment for the effects of herd immunity is not
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advisable at present.
In addition to indirect estimation of herd immunity, hybrid approaches
are presented; these integrate the prevalence predictions of dynamic ODE-
based or difference equation models into static Markov or microsimulation
models as described in Section 2.2.3. In contrast to hybrid models, our ap-
proach consists of only one model; we do not estimate HPV transmission
through an ODE system, and HPV prevalence is estimated dynamically di-
rectly by means of the Markov model. Thus, the related effort on implemen-
tation and computation is considerably reduced.
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Model specification
5.1 Introduction
In this chapter, we apply the methodology of the dynamic Markov model with
Bayesian inference (BMM) described in Section 2.3 to estimate the cost-
effectiveness of different HPV vaccination strategies in an Italian setting.
We published the methodology and the corresponding findings in the journal
Value in Health [178].
In contrast to the case study introduced in Chapter 3, the model incor-
porates a high variety of states, several age cohorts of both sexes and an
age-specific structure. Both the case study and the HPV model include an
open model structure; however, the difference is that the case study ac-
counts for births of newborns, whereas the HPV model enables the entering
of new cohorts of healthy individuals at puberty.
The chapter is structured as follows: The model specification is explained
in a detailed way, including i) the reference population, ii) interventions con-
ducted, iii) model parameters on transition probabilities, unit costs and util-
ities, iv) evidence synthesis to inform a selection of model parameters, v)
the age-, sex- and behavioural-specific force of infection, and vi) a selection
of transition probabilities in females. The remaining transition probabilities
in females, the transition probabilities in males, the sources of prior infor-
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mation and the posterior results are presented in Appendices D, E.2 and F,
respectively.
5.2 Reference population
The BMM considers a “virtual” population, comprising of both males and
females. We use official data on the population composition by age and sex
from the Italian Office for National Statistics (www.istat.it) and derived
from the 2011 census. These are used to define the population size. The
model is implemented in discrete time, including yearly Markov cycles.
Initially, 14 cohorts aged twelve-25 years are considered. During the
first ten years of observation, every year a new cohort of twelve year old
individuals enters the model. This dynamic process results in 24 cohorts
of individuals aged twelve-35, in the eleventh year of follow-up. The follow-
up period is set to 55 years. At the end of observation, members of the
youngest cohort that are still alive reach the age of 57; similarly, the eldest,
still alive individuals, reach the age of 80 years.
We use official data from the Italian Office for National Statistics to es-
timate the number of new twelve year old individuals in the first ten years
of follow up. In other words, those who enter the population at time interval
It = 1 are the individuals who were eleven years old at It = 0 and are still
alive; similarly, those who enter the population at It = 2 are the individuals
who were ten at It = 0 and are still alive; and so on. Uncertainty is not ac-
counted for in these demographic data; however, the observables included
are based on a large sample size and thus provide realistic information.
It is essential to notice that, because of the much more complex structure
of the comprehensive HPV model, it is not meaningful to assume a life-
time follow up, which would imply extrapolation to population dynamics that
could not be supported by empirical evidence and would inevitably rely on
untestable assumptions. A life-time follow up is also not required since most
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HPV-induced cancers commonly occur at earlier age. At the end of the
follow-up period of 55 years, the cohorts are aged between 57 and 80 years.
Peak prevalence of cervical cancer (the most frequent HPV-induced cancer)
is already reached at age 40, and of head/neck and anal cancer at age 70.
In older ages, prevalence does no longer increase and remains constant.
Thus, the age ranges considered in the model are sufficient.
The input data for the first year of follow-up, It = 0, are taken from the
BEST I study1 [136]. In BEST I, there is only one cohort of twelve year
old individuals, healthy in the beginning, who is observed for ninety years.
HPV incidence is initialized through data obtained by Myers et al. [263]. In
contrast, we initialize the states of the model using the output of the BEST I,
run for a follow-up of 14 years and accounting for the numbers of individuals
in every state in every year. The results of the first year of simulation for
BEST I are then used as input data for the youngest cohort of twelve year
old individuals in the BEST II; the results of the second year of follow-up
as input data for the cohort of 13 year olds and similarly, until we finish
the initialization process with the results of the 14th year for the cohort of
25 year old individuals. No distinction between the interventions has to be
made since vaccination does not take place during initialization.
5.3 Interventions
We consider the following intervention strategies:
1) screening in females, no intervention in males (which we term “screen-
ing-only” );
2) screening and vaccination in twelve year old females, no intervention
in males (“female-only vaccination” );
1Bayesian modelling assessing the Effectiveness of a vaccination Strategy To prevent
HPV-related diseases
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3) screening and vaccination in twelve year old females, vaccination in
twelve year old males (“universal vaccination” ).
The health economic evaluation is performed comparing the cost-effective-
ness of the two active strategies 2) and 3) against screening-only, as well as
universal against female-only vaccination in an Italian context. Italian data
are used to inform unit costs and utilities in order to provide results for Italian
authorities such as public health insurances, comparable to the NHS in the
UK. Details of cervical screening and vaccination strategies are reported in
the following two sections.
Cervical screening
In every scenario, we assume that cervical screening is available for fe-
males. On the basis of the European Commission Guidelines on Quality
Assurance in Cervical Cancer Screening, in Italy women aged between 25
and 64 years are recommended to undergo cervical cancer screening every
three years. This is useful for early detection and treatment of pre-cancerous
cervical lesions and to prevent the onset of invasive cervical cancer [88].
The level of access to screening is not consistent across the country. Con-
sequently, more than 30% of the eligible female Italian population has never
been screened during their lifetime [195]. Due to consistency, we do not
include age-specific cervical cancer screening probabilities here; however,
we refer to Table F.1 in Appendix F.
When a cervical lesion is diagnosed, a further Pap test (including a col-
poscopy and a biopsy) is performed twice in the first year [158]. We con-
servatively assume that screening is performed each year in a three-year
period after the treatment of a precancerous cervical lesion.
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Vaccination
For scenarios 2) and 3) in which vaccination is present we assume that
individuals aged twelve are eligible to receive it. We account for the quadri-
valent HPV vaccine, including genotypes 16, 18, 6 and 11. HPV 16 and 18
are high-risk types which can induce cancers, whereas HPV 6 and 11 can
lead to benign lesions such as genital warts. We assume lifelong vaccine-
induced immunity; therefore, we do not consider a vaccine booster.
Table 5.1 shows graphically the dynamics underlying the process by
which the cohorts enter the observation and the availability of vaccination.
Every row in the table represents one of the 24 cohorts eventually populat-
ing the model. For simplicity, we listed the cohorts in a descending order,
i.e. with the oldest individuals in the top rows of the table. The columns of
the table represent the years of follow-up, from It = 0 (when the observation
starts) to It = 55, when it finishes. Empty cells indicate the fact that, for a
given year of follow-up, a given cohort has not yet entered the observation.
For example, cohorts 15-24 are not observed at It = 0 (because none of
them have reached twelve years of age).
At the time of follow-up coincinding with the year of their twelfth birth-
day, the cohorts successively enter the population. Depending on the vac-
cination strategy being tested, the subjects are given the opportunity to be
vaccinated against HPV. The vaccine coverage rate of twelve year olds who
are vaccinated in interventions 2 and 3 are as follows: for both females
and males, we model the probability of actually receiving the vaccine us-
ing an informative Beta(7.2,0.8) distribution, resulting in a mean coverage
of 90.48% and 95% credible interval of [65.97%;99.92%]. In the literature,
vaccine coverage rates usually vary between 60% and 100%. A coverage
rate of around 90% is thus considerably high. We based our probabilistic
estimation on information given by [63,82,215,339] and expert opinion.
These percentages represent the proportion of individuals who receive at
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Table 5.1: Description of the dynamics in the model. Each row represents one of
the cohorts sequentially populating the model. The columns represent
the time intervals (years) of the virtual follow-up. The entries in the cells
represent the age of each cohort at each time interval of follow-up. Cells
typeset in italics indicate the moments in time when a vaccination strat-
egy is made available for a given cohort. The label of the cohorts that
directly benefit from vaccination are typeset in italics.
Time interval of follow-up
Cohort 0 1 2 3 4 5 6 7 8 9 10 ... 55
1 25 26 27 28 29 30 31 32 33 34 35 ... 80
2 24 25 26 27 28 29 30 31 32 33 34 79
3 23 24 25 26 27 28 29 30 31 32 33 78
4 22 23 24 25 26 27 28 29 30 31 32 77
5 21 22 23 24 25 26 27 28 29 30 31 76
6 20 21 22 23 24 25 26 27 28 29 30 75
7 19 20 21 22 23 24 25 26 27 28 29 74
8 18 19 20 21 22 23 24 25 26 27 28 73
9 17 18 19 20 21 22 23 24 25 26 27 72
10 16 17 18 19 20 21 22 23 24 25 26 71
11 15 16 17 18 19 20 21 22 23 24 25 70
12 14 15 16 17 18 19 20 21 22 23 24 ... 69
13 13 14 15 16 17 18 19 20 21 22 23 68
14 12 13 14 15 16 17 18 19 20 21 22 67
15 12 13 14 15 16 17 18 19 20 21 66
16 12 13 14 15 16 17 18 19 20 65
17 12 13 14 15 16 17 18 19 64
18 12 13 14 15 16 17 18 63
19 12 13 14 15 16 17 62
20 12 13 14 15 16 61
21 12 13 14 15 60
22 12 13 14 59
23 12 13 58
24 12 ... 57
least one shot. The actual number of fully protected and compliant individu-
als is thus lower, so that, in addition to the coverage rate, the vaccine compli-
ance is also considered. Individuals who receive three shots of the vaccine
are fully compliant. New research results indicate that two shots might al-
ready be sufficient for protection [236]; however, we acknowledge that our
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model is based on the conservative estimate of three shots being necessary
for full protection. According to the Istituto Superiore die Sanita [193], we
assume a compliance rate of 93.79% for females and males. Similarly to
BEST I, we assume that individuals who are not fully compliant reduce their
vaccine efficacy by 50% on average. Vaccine efficacy is defined in a way
that infection by HPV is prevented and as a consequence the development
of HPV-induced diseases; we do not account for “leaky” vaccines which do
not prevent infection with the pathogen yet pathogen related disease devel-
opment [296,299].
As described in Section 3.3.2 for the case study, we do not implement a
set of models to account for structural uncertainty in practice; however, we
consider the implications of structural uncertainty in the HPV model in the-
ory. An important aspect of accounting for structural uncertainty is that all
possible interventions and their implications are considered. We acknowl-
edge that we do not compare all HPV vaccines which are currently available
and only focus on the quadrivalent vaccine (containing HPV genotypes 6,
11, 16, 18). A comparison of the quadrivalent to the bivalent2 and nonava-
lent3 vaccines is increasingly often conducted in the literature and provides
valuable information. However, due to the complexity of our model, we do
not include separate states for HPV genotypes. This would be a straightfor-
ward approach in order to compare the different vaccines.
For the health economic analysis, the whole population will be consid-
ered: this includes cohorts directly benefiting from the vaccination (twelve
year old females or twelve year old females and males) as well as cohorts
indirectly benefiting from the effects of herd immunity.
2containing HPV genotypes 16 and 18
3containing HPV genotypes 6, 11, 16, 18, 31, 33, 45, 52, 58 as described in [80]
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5.4 Model structure
Altogether, the dynamic BMM includes SF = 36 states in females4 and
SM = 22 in males5. Figure 5.1 gives an overview of the HPV-induced dis-
eases in females and males. The model includes separate compartments
for the two sexes. Both compartments include the states healthy, exposure,
infection, clearance, reinfection, death, and non-sex-specific HPV-induced
diseases, whereas sex-specific diseases are exclusively considered in the
corresponding female or male compartment.
The female compartment expands on the BEST I structure [136], which
accounts for genital warts, cervical intraepithelial neoplasia (CIN) stages I-III
and cervical cancer, by additionally including anal, head/neck, vaginal and
vulvar cancer as well as their associated pre-cancerous stages6. The male
module considers the diseases which affect non-sex-specific organs, as well
as penile cancer and its precancerous stage7.
Individuals in each state can die, with an increased probability after can-
cer diagnosis. In both sexes, survival post cancer diagnosis is modelled
through a sequence of three tunnel states; individuals surviving for four
years are deemed to be cured.
Nodes drawn in an ellipse shape display a single state, whereas rectan-
gles (so-called boxes) are a combination of states related to the respective
organ. For example, Figure 5.2 shows the box Cervical cancer which in-
cludes the states CIN I-III, cervical cancer, and the states of one, two and
three years post cervical cancer diagnosis. Further details on the HPV-
induced disease boxes are displayed graphically in Appendix C.
4These are described in Table D.1 in Appendix D
5These are described in Table E.1 in Appendix E.1
6The pre-cancerous stages of anal cancer are low-grade squamous intraepithelial le-
sions (LSIL) and high-grade squamous intraepithelial lesions (HSIL). In head/neck cancer,
it is assumed that no pre-cancerous stage can be diagnosed before cancer outbreak. In
vaginal cancer, three precancerous stages similar to cervical neoplasms are considered;
these are vaginal intraepithelial neoplasms stage I–III (VaIN I–III). As for vulvar cancer, we
assume that there is only one pre-cancerous stage (vulvar intraepithelial neoplasm, VIN).
7penile intraepithelial neoplasm (PeIN)
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Infection Clearance Reinfection
Cervical
cancer
CIN I CIN II
CIN III
Year 3Year 2Year 1
Figure 5.2: The rectangle Cervical cancer consists of the precancerous stages
CIN I-III, cervical cancer and the three tunnel states post cancer diag-
nosis. After initial HPV infection, females move in between the CIN-
stages and can either clear their infection or progress to cervical can-
cer. Having survived for four years after cancer diagnosis, we assume
females to be cured. After clearance, they can be reinfected and the
whole process will start from new, possibly in another organ.
All states are mutually exclusive and exhaustive. The arrows linking the
states represent possible transitions from one state to another. Individuals
move in between these states according to pre-specified transition proba-
bilities, based on equations described for females in Section 5.8 and Ap-
pendix D and for males in Appendix E.2. The overview Tables D.1 and
E.1 present detailed information on the states, including the corresponding
numbering, which is used in the equations of the transition probabilities.
In terms of structural uncertainty, the most important point is clearly the
number of HPV-induced disease states included in the model. For example,
Elbasha et al. [131] could show that universal HPV vaccination only be-
comes cost-effective if HPV-induced diseases of the cervix, vulva, vagina,
anus, head/neck as well as recurrent respiratory papillomatosis and anogen-
ital warts are considered. Therefore, if we only included cervical cancer
in our model, it was extremely unlikely that universal vaccination would be
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deemed to be cost-effective.
We do not include separate states for different HPV genotypes in our
model. The overall number of states is already considerably high with alto-
gether 58 states and would double or even quadruple if we accounted for
HPV 16 and 18 or HPV 6, 11, 16 and 18, respectively. As a consequence,
the computational effort would no longer be manageable. In the literature,
the vast majority of models account for HPV 16 and 18 (either separately or
pooled), and some also for HPV 6 and 11. Models accounting for a higher
number of genotypes are rare exceptions as described in Appendix B.4 for
the individual-based model of Brisson et al. [58].
We acknowledge that not modelling HPV genotypes separately is a limi-
tation since there are possible differences in the probability of HPV trans-
mission per partnership, risk of reinfection following HPV clearance and
cancer development. Bogaards et al. [38] model transmissibility and wan-
ing of natural immunity of 14 HPV genotypes. They find the yearly rate of
waning resistance to reinfection to be lowest for HPV 68 (0.014, 95% CI of
(0.01,0.039)) and highest for HPV 56 (0.047, 95% CI of (0.03, 0.079)). HPV
66 seems to be highly transmissible (0.94, 95% CI of (0.74, 1)), whereas
HPV 68 is transmitted in fewest partnerships (0.43, 95% CI of (0.33, 0.51)).
In contrast to Bogaards et al., Burchell et al. [64] report that the differences
in per-partnership transmissibility among genotypes are minor as described
in Section 5.7.1.
In addition, HPV-induced cancer risk differs between genotypes; around
74–77% of invasive cervical cancer in the Western world is caused by HPV
16 or 18, and mainly HPV 31, 33, 35, 45, 52 and 58 are responsible for the
development of the remaining cases [325]. In our model, vaccine efficacy in
the cervix is estimated in a way to consider vaccine-specific genotypes (HPV
6, 11, 16, 18) as well as a an effect of cross-protection against the remaining
genotypes [136], in accordance with expert opinion. This is described for the
parameter χF in the next section.
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5.5 Model parameters
A set of relevant model parameters are used to generate the transition prob-
abilities and run the BMM. The vector of model parameters is
θ = (α,µ,γ, δ, ζ, η,β,ω, ι, ξ(z) , υ,ρF ,σ, τ ,φ♦(z) , χF, ν , c,u,ψ(z) , d,w),
which is comparable to the parameter vector of the case study shown in
Section 3.3.2. The last three components are observable variables. All pa-
rameters are briefly described in the following. The corresponding posterior
results (means and 95% credible intervals), distributional assumptions and
sources used to inform these parameters are displayed in Appendix F.
The parameters are defined as follows:
• α is the vaccine coverage rate which expresses the proportion of indi-
viduals who take up the vaccination programme;
• µ(z)j with z = cerv (cervix), z = an (anus), z = hn (head and neck),
z = vag (vagina), z = vulv (vulva), z = pen (penis) (representing the
location in the respective organ), and j = 1, 2, 3, 4 (the cancer stages),
are the probabilities of being diagnosed with the respective cancer at
a particular stage;
• γ = (γ1, γ2, γ3) are the vaccine efficacies against cervical, anal and
head/neck associated neoplasiae, respectively, expressed as the re-
duction in the occurrence of HPV due to vaccination. Vaccine efficacy
against initial HPV infection or diseases which affect body areas other
than the anus or head and neck are assumed to take the same value
as against cervical diseases (γ1). Individuals who are vaccinated fully
experience a rate of occurence of HPV that is (1 − γh) times that of
those who are not vaccinated, with h = 1, 2, 3;
• δ = (δ0a, δ1, δ2, δ3, δ4, δ5, δ6) are the probabilities for the age-specific re-
gression from infection towards exposure, and the progression towards
CIN I, CIN II, anal LSIL, anal HSIL, VaIN I/II, or PeIN, respectively. For
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the transition to VIN, we assume the same value as for VaIN I/II (δ5).
The probabilities to develop anal LSIL and anal HSIL are taken from
data on homosexual males or HIV positive females and therefore have
to be adjusted; see the description of ρF and Appendix G.1 for further
details on the adjustment parameters ρF2 and ρ
F
3 , respectively;
• ζ is the proportion of subjects at increased risk of reinfection, due to
the presence of risk factors;
• η = (η1, η2, η3, η4, η5) are the probabilities of being diagnosed with CIN II,
CIN III (without screening), anal LSIL, anal HSIL, VaIN I/II or VIN, re-
spectively;
• β = (β1, β2) are the HPV transmission probabilities per sexual partner-
ship with average and high-risk sexual behaviour, respectively;
• ω = (ωF1, ωF2, ωM1, ωM2) are the partner acquisition rates in females
and males with average and high-risk sexual behaviour, respectively;
• ι is the decrease in vaccine efficacy due to incomplete compliance; we
assume individuals who receive three shots of the vaccine to be fully
protected;
• ξ(z) = ξ(z)x,y with z = cerv (cervix), z = an (anus), z = hn (head and
neck), z = vag (vagina), z = vulv (vulva) and z = pen (penis), the or-
gan involved, x = 1, 2, 3 (representing first, second and third degree in-
traepithelial neoplasiae), y = 0, 1, 2, 3, 4 (representing exposure, differ-
ent degrees of precancerous stages and cancer) are the probabilities
to acquire HPV-induced diseases. These are defined according to the
possible paths described in Figures 5.1, 5.2, and C.1 – C.5. The corre-
sponding transition probabilities are explained in Section 5.8 and Ap-
pendix D for females and Appendix E.2 for males. In case of diseases
related to the cervix, the exponent is two dimensional (z = (z1, z2)),
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with the first dimension z1 representing the organ (cervix), whereas
in the second dimension, z2 = 1 represents conization and z2 = 2
no conization. Conization is a medical expression for the removal of
abnormal cervical tissue as treatment of a CIN stage;
• υ = (υF , υM) is the recurrence rate of genital warts in females and
males, respectively;
• ρF = (ρF1 , ρ
F
2 , ρ
F
3 ) are the changes in risk of HPV infection in indi-
viduals who present particular risk factors or are at decreased infec-
tion risk. The parameter ρF1 represents a risk increase, e.g. induced
through smoking or early first sexual intercourse. In contrast, ρF3 is the
risk decrease in developing anal LSIL or anal HSIL in heterosexual
males and females when compared to homosexual males. Since het-
erosexual females are at a higher risk of anal cancer than heterosex-
ual males, their risk is first decreased by factor ρF3 and then increased
by ρF2 8;
• σ = (σ1, ..., σA) are the three-yearly screening probabilities, which vary
by age;
• τ = (τ1, τ2) are the probabilities in CIN I patients of undergoing an
immediate or delayed conization;
• φ♦(z) = φ♦(z)q,j are the survival probabilities of HPV-induced cancers,
with z = cerv (cervix), z = an (anus), z = hn (head and neck), z = vag
(vagina), z = vulv (vulva) and z = pen (penis) representing the body
area affected, and q = 1, ..., 4 and j = 1, ..., 4 representing the years of
survival and cancer stage, respectively;
8Technically, ρF3 and ρ
F
2 are assumed to be associated with suitable Gamma distri-
butions; for heterosexual males we consider a mean risk reduction ρF3 of 17.1880 (95%
CI [0.8714; 53.5615]) in comparison to homosexual males. For females, we assume an
increased risk ρF2 of 1.6975 (95% CI [1.5055; 1.9026]) when compared to heterosexual
males.
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• χF is the reduction in the occurrence of HPV-related events due to
the effect of cross-protection. This effect implies a protection against
additional genotypes of the infectious agent which are not included in
the vaccine. Commonly, the level of cross-protection is considerably
lower than the vaccine efficacy. In the model, we account for cross-
protection against HPV high-risk types different from HPV 16 and 18
only in context of diseases related to the cervix;
• ν = (ν1, ν2, ν3) are the probabilities that vaccinated subjects have re-
spectively one, two or three doses, which represent increasing levels
of compliance with the vaccination programme;
• c = (cacq, cadm, ccinl , c
cerv
r , c
lsil, chsil, canr , c
hn
r , c
vain, cvagr , c
vin, cvulvr , c
gw, ccol,
canbiop, ccyt, cdna, cpap) is the vector of relevant one-year unit costs for the
acquisition and administration of the vaccine, the management and
treatment of HPV-induced cancers and their precancerous stages of
grade x, and anogenital warts, the performance of colposcopy, ano-
scopy and biopsy, anal cytology, HPV DNA testing, and the Pap smear
test, respectively;
• u = (ugwv , uascus, ucinl , u
cerv
r∗ , u
lsil, uhsil, uanr∗,v, u
hn
r∗,v, u
vag
r∗ , u
vulv
r∗ , u
pen) is the vec-
tor of utilities defined in terms of qualities of life (QoL) for the states of
anogenital warts, precancerous stages and HPV-induced cancers. A
further description of utilities and their assessment is given in Sec-
tion 3.3.4. The utilities for the states in health, exposure, infection,
clearance, reinfection, as well as two and three years after diagnosis
of cancer are set to 1. The utility for death is set to 0. The indices v,
l and r∗ represent sex, precancerous stage and cancer stage, respec-
tively, for diseases where sex- and stage-specific utilites are available
in the literature. In case we did not find any information, we used ex-
pert opinion to inform these parameters;
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• ψ(z) = (ψ(z)1v , ..., ψ
(z)
Av) is the vector of age- and sex-specific prevalence
of anogenital warts (z = gw) and head/neck cancer (z = hn), respec-
tively;
• d = (d1v, ..., dAv) is the vector of age- and sex-specific mortality rates;
• w = (w1, ..., wA) is the vector of age-specific probabilities of sexual
activity. We assume every individual to be sexually active after having
had the first sexual relationship.
When data for the model parameters are available directly, we impose min-
imally informative prior distributions and use the data to inform the ensuing
posteriors. When data are not available directly, we encode the informa-
tion obtained by literature review or assumptions based on the elicitation of
opinions from clinical specialists in suitable informative prior distributions. All
distributional assumptions for the priors and their corresponding sources are
described in a number of tables in Appendix F, where additionally, the mean
and corresponding 95% credible intervals for all parameters are displayed.
We found a medical publication to inform the age- and sex-specific inci-
dence of anogenital warts (ψ(gw)a,v ). Marra et al. [252] estimate the incidence
rates of genital warts in females and males according to the respective age
groups. We estimate head and neck cancer incidence ψ(hn)a,v , separately for
age groups and sex, according to the data given for oral cancer on the Can-
cer Research UK website [352]. Since these cancers are not necessarily
a consequence of a HPV infection, but can be alcohol- or tobacco-induced,
we multiply the given incidence rates by 1.8, the odds ratio for developing
head and neck cancer caused by HPV [322]. We will conduct our cost-
effectiveness analysis specifically for Italy; therefore, whenever possible, we
integrate Italian data into our model to create a most realistic situation. Ac-
cording to expert opinion, data from the UK are comparable to an Italian set-
ting since public health insurance systems in both countries work in a similar
way. Finally, we use official data from registry or population databases, such
112
5.5. Model parameters
as the Italian Office for National Statistics (www.istat.it), to obtain infor-
mation on the age- and sex-specific mortality rates (da,v), and probability of
sexual activity (wa). Given that these are all population data, we consider
them to be deterministic information, without substantial uncertainties.
5.5.1 Economic parameters
We use cost and utility information that is available from BEST I, which is
updated by considering the information given by Baio et al. [23], Mennini et
al. [256] and Marcellusi et al. [249]. For the extra parameters, we performed
an extensive literature review and found information for the cost of anal [47,
98, 165], vaginal [179] and vulvar [179] pre-cancerous lesions, as well as
for anal [340], head and neck [110, 308, 385], vaginal [149], vulvar [149]
and penile [315, 362] cancer. Information from more than one source is
combined through evidence synthesis as described in Section 5.6.
As for penile intraepithelial lesions, despite our attempt to identify suit-
able evidence from the relevant literature, we were unable to find data that
could be used to inform this parameter. Thus, we consider the treatment
cost for PeIN to be equivalent to the first stage of penile cancer. Addition-
ally, according to expert opinion, we assume the cost of penile cancer stage
I to be eligible to inform the corresponding cost parameters for penile cancer
stages II-IV.
The utility values were found in the literature for anal LSIL and HSIL
[210] and four stages of anal [341] and head/neck [110, 137, 308] cancer.
Information about utilities for penile and vulvar cancer was found only for
the first cancer stage [91]. For vaginal cancer, the information was given
for the first and second cancer stage [91]. For the pre-cancerous lesions of
rare diseases, no utility values were found. Consequently, we assume that
utility values for low-grade VaIN are equal to anal LSIL utilities; similarly,
we set the utilities for high-grade VaIN to the same value as those for anal
113
CHAPTER 5. MODEL SPECIFICATION
HSIL. For the pre-cancerous stage of vulvar cancer, the same utility value
as for anal LSIL is assumed. Finally, we consider the same utility value
as for penile cancer stage I for the pre-cancerous stage of penile cancer.
For vaginal and vulvar cancer, we assume the same utility values as for
cervical cancer. Part of the Italian utilities are drawn from the HPV Italian
Collaborative Study group [249].
In case information from several literature sources and expert opinion is
available on specific model parameters, this is combined through evidence
synthesis as described in the next section.
5.6 Evidence synthesis
Before the 1960ies, the selection of medical treatments was purely based
on experience of clinicians [335]. Nowadays, so-called “evidence-based
medicine” becomes increasingly important in medical decision making. Evi-
dence-based medicine relies on scientific evidence on the efficacy and safety
of treatments investigated through randomised clinical trials. Outcome of dif-
ferent trials is often combined through evidence synthesis, resulting in a so-
called meta-analysis which commonly reports a pooled estimate on a treat-
ment effect. A meta-analysis is usually based on a larger sample size than a
single clinical trial, involves thorough investigation of the quality of included
studies, and thus contributes scientific evidence at highest level [380]. Fre-
quentist [43,90] and Bayesian [336,380] approaches to evidence synthesis
are possible.
A meta-analysis can either be conducted through a fixed or a random
effects model. A fixed effects model is based on the assumption of one true
treatment effect in all studies included, whereas in a random effects model,
the treatment effect has a distribution and thus allows for differences be-
tween studies. Each study included is assigned a weight, either correspond-
ing to its sample size (with larger studies contributing more information), or
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to its inverse variance. However, the inverse variance is approximately pro-
portional to the sample size. In a fixed effects model, the variance corre-
sponds to the within-study variance. In contrast to a fixed effects model, in a
random effects model, the variance is calculated as the sum of within-study
and between-studies variance. Therefore, in random effects models, stud-
ies with smaller sample size are able to contribute more information than in
fixed effects models [43].
Meta-analysis can also be conducted through information reweighting,
which has to be distinguished from the weighting approaches to account for
differences in the impact of studies discussed above. Information reweight-
ing is conducted in a Bayesian context and a convenient approach if addi-
tional studies are included in a meta-analysis sequentially, meaning at later
stages. The additional information is assigned a distribution, and the initial
priors are then updated by this distribution. This process results in reweight-
ing the posterior. The MCMC does not have to be rerun, which saves a
considerable amount of time, yet could come at the cost of bias, especially
if a large number of studies are included at several later stages [374].
Another technique to combine evidence from several sources is given
by meta-regression. Similar to regression analysis, the impact of explana-
tory covariates on the dependent variable, the treatment effect, is investi-
gated. However, in contrast to regression analysis, no individual-level data
but aggregate data obtained through studies are included. Both potential
categorical and continuous treatment effect modifiers can be included in
a meta-regression model. In addition, so-called subgroup analyses can
be conducted for categorical covariates. In a subgroup analysis, separate
meta-analyses are conducted for each category of the respective covariate.
In the literature, meta-regression models are often presented as an alterna-
tive to meta-analysis if a large amount of heterogeneity between the studies
could be confirmed, e.g. through the I2 statistic [90]. However, by the very
nature of evidence synthesis, heterogeneity is always present since each
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study included differs from the others, and statistics to detect heterogeneity
have low power. Therefore, if the number of studies is high enough (more
than ten), and covariates which are possible treatment effect modifiers are
known, conducting meta-regression is recommended, for example to gener-
ate hypotheses for future research [283,346].
Model parameters can be informed following a similar principle as meta-
analysis and meta-regression; several literature sources from a number
of clinical trials and observational studies as well as expert opinion can
be combined. In a Bayesian framework, this process is commonly imple-
mented through hierarchical models. In a hierarchical model, both within-
and between-study heterogeneity is considered [336]. We use similar nota-
tion as in [22].
Figure 5.3 shows an example structure of a hierarchical model for evi-
dence synthesis, including J studies, each including data of sample size nj
with outcome yhj; h indicates an individual study participant. The parame-
ters θ♦1 , θ
♦
2 , ..., θ
♦
J are study-specific and thus represent the underlying study
heterogeneity. In a hierarchical model, the parameter vector θ♦ is defined to
have one common probability distribution; the parameters θ♦1 , θ
♦
2 , ..., θ
♦
J are
thus exchangeable. The corresponding hyperparameters of this common
distribution are indicated as φF [22].
One advantage of this pooling approach is that the conclusions drawn
from studies including a small sample size can be improved by other stud-
ies from the same area of research with a large sample size [22]. It is even
possible to compare treatments in an indirect way as for a so-called “‘net-
work meta-analysis”. For example, if treatment A and B are compared in a
number of studies, and treatment B and C in several other studies, a net-
work meta-analysis would be able to compare treatments A and C even if no
study included compared those directly [117]. Several example models of
Bayesian network meta-analysis are reported in the NICE Decision Support
Unit Series [118].
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φF
θ♦1 θ
♦
2 θ
♦
J
y11 y21 ... yn11 y12 y22 ... yn22 ... y1J y2J ... ynJJ
Figure 5.3: Example structure of a hierarchical model for Bayesian evidence syn-
thesis. The data from each study of size n are indicated by yhj , where
h defines an individual study participant, and j the number of the study.
The study-specific parameters θ♦j represent within-study heterogene-
ity. The hyperparameter φF enables pooling study-specific estimates
through one common distribution.
In the dynamic Bayesian HPV model, several parameters are informed
through evidence synthesis; these are probabilities of stage-specific HPV-
induced cancer survival, stage-specific probabilities of diagnosis, and sev-
eral unit costs of diagnosis and treatment. As described above, the evidence
synthesis is based on hierarchical models. As an example, we introduce the
model for the pooled probability φF of two-year survival in head/neck cancer
stage II as
Rq ∼ Binomial(pi◦q , Nq)
logit(pi◦q ) = α
F
q
αFq ∼ Normal(µ◦, τF)
µ◦ ∼ Normal(0, 0.0000001)
σF ∼ Uniform(0, 100)
τF = 1/σ
2
F.
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The overall number of head/neck cancer patients in stage II is represented
by Nq, where the index q indicates the respective study. The number of
patients who survive is given by Rq. The data are obtained by [86,126,310];
if Rq is not directly stated in above format, it is derived from given sample
size, survival probabilities or Kaplan-Meier survival curves. The number of
events regarding survival are assumed to follow a Binomial distribution.
The parameter pi◦q represents the two-year head/neck cancer survival
probability in stage II. To account for study heterogeneity, each pi◦q is esti-
mated to be a realisation of a Normal distribution on the logit scale. The
minimally informative prior distribution for αFq has µ◦ and τF as hyperparam-
eters for the mean and precision, respectively. The software JAGS expects
the precision rather than the variance as an input parameter of the Normal
distribution; therefore, σF is transformed into the precision τF. These priors
are updated by the data given by the three studies. The parameter µ◦ is
then transformed by
φF =
eµ◦
1 + eµ◦
to result in the pooled probability of head/neck cancer survival φF.
5.7 The force of infection
In this section, we specify the force of infection for the HPV model. In con-
trast to the general case of any infectious disease described in Section 2.3,
the force of infection depends on sex and sexual behaviour. This was pre-
viously explained for the case study in Section 3.3.1. Furthermore, in the
HPV model, partner acquisition rates are age-specific, which is considered
in Section 5.7.5 through the corresponding equation. As a consequence of
the inclusion of the force of infection into the state allocation algorithm, the
transitions from the state of exposure to the state of infection are dependent
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on age-, sex- and behavioural-specific sexual mixing.
To specify the force of infection, first of all we make assumptions on the
probability of HPV transmission per partnership. In addition, we report age-,
sex- and behavioural-specific sexual mixing matrices as well as partner ac-
quisition rates which are included in the model to simulate the process of
partnership formation.
5.7.1 HPV transmission probability per partnership
This is a crucial parameter since there is very limited information and knowl-
edge on HPV transmission in single sex acts and partnerships. In accor-
dance to the notation of the case study, we indicate it as β . We found ev-
idence describing HPV transmission probabilities in heterosexual couples:
for example, Burchell et al. [65] estimate the probability of HPV transmis-
sion within the first four months of a partnership as 0.42 with a 95% CI of
[0.36;0.47]. They consider 36 HPV genotypes (including high-risk, interme-
diate and low-risk types) and find that probability of transmission does not
seem to differ considerably between types [64]. Furthermore, in an earlier
publication including 27 HPV genotypes, Burchell et al. [66] report the me-
dian probability of transmission per sex act to be around 40% with a range
of 5-100%. These findings, however, are far from definitive and suggest the
likely possibility of both much lower and higher values, in different scenarios.
Another challenge is that the per partnership and per sex act estimation of
HPV transmission is not directly comparable. In a stable partnership, a high
number of sex acts is conducted, increasing the probability of transmission
when compared to a single sex act.
Korostil et al. [229] have modelled this using a Uniform distribution in the
interval [0;1], which essentially amounts to allowing any value (between 0
and 100%) as equally possible.
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Sexual behaviour
We define two different groups of sexual behaviour: individuals with two -
ten lifetime partners are considered to be at “average-risk” in terms of their
sexual behaviour, whereas those with eleven or more lifetime partners are
at “high-risk”. We assume that individuals who change their partners more
frequently are generally at higher risk of sexually transmitted diseases and
therefore to become infected by HPV. This seems quite reasonable, since it
is likely that there is a substantial degree of correlation between high partner
turn-over rates and other risk factors.
In particular, smoking, a low education level, sexual intercourse before
the age of 18 and five or more lifetime partners are observed to increase
the risk of acquiring an HPV infection. Marcellusi et al. [249] classify 26.3%
of the population in the high-risk group. Based on these data and also ac-
counting for van de Velde et al.’s [360] assumptions of 22% high-risk indi-
viduals and evidence based on the National Survey of Sexual Attitudes and
Lifestyles (Natsal 2000) [206] with 34.6% of men and 19.4% of women un-
der high risk, we assume that 20% of the population could be classified in
the high-risk sexual behaviour group.
Finally, we assume the chance of being transmitted the virus to be lower
in the average-risk group and modify the information given by Burchell et al.
[65,66] for the two different risk groups. We assume the yearly probability of
HPV acquisition to be between 17% and 35% for individuals in the average-
risk group (β1), whereas we expect β2 to be higher and between 30% and
74% for those in the high-risk group. These assumptions are consistent with
those reported by Burchell et al. [66], who assume a 40% HPV transmission
probability, ranging from 5% to 100%.
The risk factors which contribute to a higher HPV transmission prob-
ability also account for a higher probability of reinfection after HPV clear-
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ance. Additionally, using oral contraceptives for five or more years9, multi-
parity and previous occurrence of sexually transmitted infections, especially
Chlamydia trachomatis and Herpes simplex type 2, play a role in risk in-
crease [44,76,256,319,323,324].
Another source of structural uncertainty is how risk factors are incorpo-
rated into the model. We assume that those impact the probability of HPV
infection and reinfection; however, another possible assumption would be to
consider those in the transition probabilities of moving to infection clearance.
People in the high-risk group would then require a longer amount of time to
clear their infection, increasing HPV prevalence.
5.7.2 Age-dependent partnership formation probabilities
For each sex, we define the probability of a sexual partnership to vary with
the age of the partner. We incorporate whole distributions of values into the
model and report the mean age-, sex- and behavioural-specific probabilities
in Tables 5.2–5.5.
Table 5.2: Sexual partnership probability matrix for females in the average-risk
group. The entries in the table identify the mean probability that a fe-
male in the age group presented in the rows of the table chooses a male
sexual partner in the age group along the columns within one Markov
cycle of length one year.
Age 12-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-80
12-19 1 26 58 15 1 0 0 0 0 0 0 0
20-24 0 0 36 49 12 2 0 0 0 0 0 0
25-29 0 0 14 47 28 9 2 0 0 0 0 0
30-34 0 0 1 16 38 30 12 3 1 0 0 0
35-39 0 0 0 0 8 36 34 16 5 1 0 0
40-44 0 0 0 0 0 18 44 23 9 3 1 0
45-49 0 0 0 0 0 0 24 55 17 3 0 0
50-54 0 0 0 0 0 0 0 24 55 17 3 1
55-59 0 0 0 0 0 0 0 0 14 43 26 17
60-64 0 0 0 0 0 0 0 0 0 14 43 43
65-80 0 0 0 0 0 0 0 0 0 0 14 86
9Long-term use of oral contraceptives increases the probability of HPV persistence in
the cervix [251]; in addition, females who use these are less likely to have safer sex in-
cluding barrier methods such as condoms. Condoms considerably reduce the risk of HPV
transmission [174].
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Table 5.3: Sexual partnership probability matrix for males in the average-risk group.
The entries in the table identify the mean probabilities that a male in the
age group presented in the rows of the table chooses a female sexual
partner in the age group along the columns within one Markov cycle of
length one year
Age 12-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-80
12-19 58 26 15 1 1 0 0 0 0 0 0 0
20-24 0 49 36 12 2 0 0 0 0 0 0 0
25-29 0 14 47 28 9 2 0 0 0 0 0 0
30-34 0 1 16 38 30 12 3 1 0 0 0 0
35-39 0 0 0 8 36 34 16 5 1 0 0 0
40-44 0 0 0 0 18 44 23 9 3 1 0 0
45-49 0 0 0 0 0 24 55 17 3 0 0 0
50-54 0 0 0 0 0 24 55 17 3 1 0 0
55-59 0 0 0 0 0 0 14 43 26 17 0 0
60-64 0 0 0 0 0 0 0 0 0 57 38 5
65-80 0 0 0 0 0 0 0 0 0 38 57 5
As a general rule, we assume that males tend to have sexual partners who
are in the same age group or younger, while females tend to have sex with
partners who are in the same age group or older. However, notice that we
still allow for the possibility of different behaviours (e.g. a male choosing an
older female partner): these circumstances may happen, but with a lower
chance. Also, notice that we only consider a heterosexual population.
Tables 5.2 – 5.5 are based on the data presented by van de Velde et
al. [360] which were collected through PISCES (Psychological Impact of
cervical Screening and Condylomas: an Epidemiological Study ), a Cana-
dian prospective multicentre clinical study [123, 124]. The tables show the
assumptions for the partnership probabilities for females and males, for both
the average- and high-risk groups. The data are self-reported, therefore, it
is essential to account for parameter uncertainty by assigning suitable prob-
ability distributions to these values. Thus, the entries in the tables identify
the mean probability that a random individual of a given sex v and age a
(presented in the rows of the tables) mixes with a random individual of the
opposite sex v′ (i.e. if v indicates “female”, v′ indicates “male” and vice versa)
and of age a′ (along the columns of the tables).
As an example, consider a 20 year old female; given the estimations
122
5.7. The force of infection
Table 5.4: Sexual partnership probability matrix for females in the high-risk group.
The entries in the table identify the mean probabilities that a female in
the age group presented in the rows of the table chooses a male sexual
partner in the age group along the columns within one Markov cycle of
length one year
Age 12-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-80
12-19 0 37 50 11 2 0 0 0 0 0 0 0
20-24 0 0 37 50 11 2 0 0 0 0 0 0
25-29 0 0 14 47 28 9 2 0 0 0 0 0
30-34 0 0 0 28 45 18 6 2 1 0 0 0
35-39 0 0 0 0 20 39 22 11 5 2 1 1
40-44 0 0 0 0 0 20 39 22 11 5 2 2
45-49 0 0 0 0 0 0 20 39 22 11 5 4
50-54 0 0 0 0 0 0 0 20 39 22 11 9
55-59 0 0 0 0 0 0 0 0 20 39 22 19
60-64 0 0 0 0 0 0 0 0 0 20 39 41
65-80 0 0 0 0 0 0 0 0 0 0 20 80
Table 5.5: Sexual partnership probability matrix for males in the high-risk group.
The entries in the table identify the mean probabilities that a male in the
age group presented in the rows of the table chooses a female sexual
partner in the age group along the columns within one Markov cycle of
length one year
Age 12-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-80
12-19 50 37 11 2 0 0 0 0 0 0 0 0
20-24 0 50 37 11 2 0 0 0 0 0 0 0
25-29 0 14 47 28 9 2 0 0 0 0 0 0
30-34 0 0 28 45 18 6 2 1 0 0 0 0
35-39 0 0 0 20 39 22 11 5 2 1 1 0
40-44 0 0 0 0 20 39 22 11 5 2 2 0
45-49 0 0 0 0 0 20 39 22 11 5 4 0
50-54 0 0 0 0 0 20 39 22 11 9 0 0
55-59 0 0 0 0 0 0 20 39 22 19 0 0
60-64 0 0 0 0 0 0 0 0 41 20 34 5
65-80 0 0 0 0 0 0 0 0 10 80 5 5
produced in Table 5.2, we assume that she has on average a 36% chance
of selecting a sexual partner who is a 20-24 year old male; on average a
49% chance of selecting a sexual partner who is a 25-29 year old male; on
average a 12% chance of selecting a sexual partner who is a 30-34 year old
male; and on average only a 2% chance of selecting a sexual partner who
is a 35-39 year old male. Any other age group for potential sexual partners
is ruled out under the assumptions of Table 5.2 and therefore irrelevant.
The results of the health economic evaluation are highly sensitive to the
choice of these matrices; therefore, sensitivity analysis is performed to this
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aspect. Model calibration as described in Section 6.3 ensures that the re-
sulting age-dependent HPV prevalence estimates are realistic.
5.7.3 Partner acquisition rates
Van de Velde et al. [360] also present summary statistics on the rate of part-
ner acquisition for four different levels (` ∈ 0, 1, 2, 3) of sexual activity: indi-
viduals who have zero - one life-time partners are defined in the ` = 0 group;
individuals with two - ten life-time partners are grouped in level ` = 1 (notice
that the combination of these two groups is what we define as the average-
risk group); individuals with eleven - 39 life-time partners are grouped in level
` = 2. Finally, individuals with 40 or more life-time partners are grouped in
level ` = 3. By combining ` = 2 and ` = 3, we define our high-risk group.
We combine the information presented in van de Velde et al. [360] and use
the matrices to model the mixing process for the individuals in our average-
and high-risk groups.
Tables 5.6 and 5.7 show the annual minimum, mean and maximum part-
ner acquisition rates for both sexes in the groups of average and high-risk
sexual behaviour. The partner acquisition rates are displayed for nine differ-
ent age groups, ranging from the age of twelve to the age of 60. We assign
Table 5.6: Annual minimum, mean and maximum partner acquisition rates for fe-
males and males in nine different age groups for the average-risk group,
defined as two - ten life-time partners
Females Males
Age Minimum Mean Maximum Minimum Mean Maximum
12-19 0.74 1.26 1.78 0.90 1.92 2.94
20-24 0.54 0.96 1.38 0.68 1.38 2.09
25-29 0.40 0.73 1.07 0.48 1.05 1.63
30-34 0.30 0.56 0.83 0.35 0.85 1.35
35-39 0.23 0.43 0.64 0.27 0.69 1.11
40-44 0.18 0.34 0.50 0.21 0.51 0.81
45-49 0.14 0.26 0.39 0.10 0.27 0.45
50-59 0.11 0.20 0.30 0.08 0.21 0.35
60 0.05 0.10 0.15 0.04 0.11 0.18
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Table 5.7: Annual minimum, mean and maximum partner acquisition rates for fe-
males and males in nine different age groups for the high-risk group,
defined as eleven or more life-time partners
Females Males
Age Minimum Mean Maximum Minimum Mean Maximum
12-19 4.29 6.515 8.74 5.21 9.810 14.41
20-24 4.90 6.330 7.76 6.24 8.995 11.75
25-29 2.92 3.825 4.73 3.50 5.365 7.23
30-34 1.46 2.050 2.64 1.70 3.000 4.30
35-39 0.67 1.040 1.41 0.79 1.610 2.43
40-44 0.29 0.510 0.73 0.35 0.775 1.20
45-49 0.12 0.250 0.38 0.09 0.265 0.44
50-59 0.05 0.120 0.19 0.04 0.130 0.22
60-69 0.03 0.065 0.10 0.02 0.065 0.11
70-80 0.01 0.030 0.05 0.01 0.035 0.06
suitable probability distributions and incorporate probabilistic partner acqui-
sition rates into our model. As an example, we can expect a female in the
average-risk group aged 20-24 to have on average 0.96 sexual partners per
year, with minimum and maximum values of 0.54 and 1.38, respectively.
As described for the case study in Section 3.3.3, on average, males
tend to have a higher number of partners than females; the distributions on
partner acquisition rates are thus different in the two sexes, also accounting
for the fact that a small number of females have an extremely high number
of male partners (e.g. prostitutes).
A correct estimation of both partner acquisition rates and the probabil-
ity of HPV transmission per partnership play an extremely important role
in the dynamic HPV model. Intuitively, the higher the number of partners,
the higher the benefits of HPV vaccination. With low partner acquisition
rates, the population is under lower risk of acquiring an HPV infection. If
the HPV prevalence in the population is large, the vaccine obviously can
prevent more diseases. Vaccination is still expensive because of the acqui-
sition cost, but due to its preventive effect on many diseases, its benefits
compensate for the amount of money spent.
On the other hand, if we assume that couples stay together for a long
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time and remain faithful, HPV prevalence decreases and there are fewer
disease cases in the population. Therefore, the vaccine cannot show its full
benefits; however, it is still necessary due to other ways of disease transmis-
sion, even in faithful couples and individuals with low sexual activity. HPV
can be transmitted by fomites such as public saunas or shared towels and
it can remain in reservoirs within the female and male body after infection
for a lifetime without causing any symptoms. Even a digital transmission is
possible [242].
5.7.4 Sexual mixing matrices
We can now combine the values considered in Section 5.7.2 and Sec-
tion 5.7.3 into the sexual mixing matrices, which are needed to fully describe
the interaction between the two sexes. These represent the per capita an-
nual rates at which an individual of sex v from sexual behaviour group b
and of age a acquires a sexual partner of the opposite sex v′ from sexual
behaviour group b′ and of age a′.
Following Korostil [229], we define suitable sexual mixing matrices whose
elements mv,b,b′,a,a′ are given by the product of the age-dependent partner-
ship formation probabilities and partner acquisition rates. Back to the previ-
ous example of a 20 year old female in the average-risk group (i.e. if we set
v = Female, b = 1 and age group a = 20), we can obtain the mean values
of mF,1,b′,20,a′ for all the possible age groups a′ of the male partner with the
following calculation:
• mF,1,b′,20,a′ = 36%× 1.38 = 0.4968, for a′ = 20-24;
• mF,1,b′,20,a′ = 49%× 1.38 = 0.6762, for a′ = 25-29;
• mF,1,b′,20,a′ = 12%× 1.38 = 0.1656, for a′ = 30-34;
• mF,1,b′,20,a′ = 2%× 1.38 = 0.0276, for a′ = 35-39;
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• mF,1,b′,20,a′ = 0, for any other age group a′.
Notice the differences between the sexual mixing matrixm of the HPV model
and the partner acquisition rate ω in the general case described in Sec-
tion 2.3; in contrast to ω, m is age-, sex-, and behavioural-specific. As for
ω, the partner acquisition rates of the case study, ωv,b, are not age-specific
either, yet depend on sex and behaviour as explained in Section 3.3.1.
5.7.5 The equation of the force of infection
Finally, we use the HPV transmission probabilities of Section 5.7.1 and the
sexual mixing matrices of Section 5.7.4 to determine the force of infection,
which now depends on age, sex and sexual behaviour. As described in Sec-
tion 2.3, we first define the rate of infection ρ♦v,b,a(It). This quantity measures
the time-dependent overall force of HPV infection for a random member of
the population of sex v, sexual behaviour b and age a and is defined as:
ρ♦v,b,a(It) = βb
∑
b′,a′
mv,b,b′,a,a′ψv′,b′,a′(It), (5.1)
where, in summary:
• βb represents the HPV transmission probability per sexual partnership,
depending on sexual behaviour b and described in Section 5.7.1;
• mv,b,b′,a,a′ represents the sex-, behavioural- and age-specific sexual
mixing matrix, containing yearly partner acquisition rates as described
in Section 5.7.4;
• ψv′,b′,a′(It) =
(
Iv′,b′,a′ (It)
Nv′,b′,a′ (It)
)
represents the HPV prevalence in the sexual
partner of sex v′, sexual behaviour b′ and age a′ at time interval It;
Iv′,b′,a′(It) and Nv′,b′,a′(It) indicate the number of infected individuals
and the overall population size, respectively.
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In practice, Equation 5.1 implies that at each time interval of the follow up,
the probability of HPV infection depends on the pool of potential partners of
the opposite sex who are:
• available for mating; this depends on the age and sex of the individual
being considered, as well as on their sexual behaviour;
• currently infected by HPV. As vaccination is likely to reduce the num-
ber of individuals who originally become infected, the probability of
HPV infection will become smaller and will be affected by the impact
of vaccination, thus mimicking the mechanism underlying herd immu-
nity.
We can use the argument presented in Section 2.3 to obtain the correspond-
ing probabilities of infection piFv,b,a(It), which represent the sex-, behavioural-
and age-dependent transition probabilities to the state of HPV infection.
These can be obtained by transforming the rates ρ♦v,b,a(It) into probabilities,
using Equation 2.4.
We assume that individuals in the states infection, CIN I-III, LSIL/HSIL,
VaIN I-II, VIN, PeIN, head/neck cancer and reinfection contribute to virus
spreading. Individuals in all cancer states except from head/neck cancer
and those in the recovery phase of one year post cancer as well as individ-
uals with the visible condition of genital warts are excluded from the pool of
infectious subjects.
5.8 Transition probabilities in females
The transition probabilities of moving across the states are constructed us-
ing a set of clinical data, demographic statistics, expert opinion and time-
dependent characteristics of HPV infection and induced diseases. They are
indicated by piFi,a,r,s in females and piMi,a,r,s in males, where
• i indexes the intervention (see Section 5.3);
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• a indexes the population member’s age according to the corresponding
age cohort (see Table 5.1 in Section 5.3);
• r indexes the original state;
• s indexes the target state.
In sex-specific model parameters, v indexes the individual’s sex, where
v = F represents females and v = M males. The female model com-
partment includes 36 states. To show the general principle of estimating
transition probabilities, those for females in the states Healthy (r = 1) and
Exposure (r = 2) are described in a detailed way in this section. In addition,
the transition probabilities corresponding to the remaining 34 states are de-
scribed in Appendix D. Table D.1 in Appendix D presents an overview to
enable the reader an easy allocation of each of the 36 states to the cor-
responding number. The numbering of the relevant states r and s in the
transition probabilities described in this section is 1=Healthy, 2=Exposure,
3=Infection and 9=Dead.
In contrast to the female model compartment, the male compartment
only includes 22 states. Accordingly, the numbering is different when com-
pared to females. A list of the states in males with the corresponding num-
bering as well as all male transition probabilites are displayed in Appen-
dices E.1 and E.2.
Due to the constraint of probabilities, the sum of transition probabilities of
moving from one original state to all target states has to be 1. However, due
to competing risks (e.g. a high probability of dying in older ages in combina-
tion with a high probability of developing a certain HPV-induced cancer), in
rare cases, this sum can be higher than 1. To ensure that the constraint of
probabilities is never validated, we re-proportion the transition probabilities
(we divide these by the sum of transition probabilities corresponding to the
same original state).
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From the state Healthy
Once people enter the population, they are assumed to be in the state of
perfect health (r = 1). Within every Markov cycle, they can either have sex
and move to the state of exposure (s = 2), with the corresponding age-
dependent probability wa, die (s = 9) with age- and sex-specific probability
da,F , or remain in the state of perfect health (s = 1). Transitions to other
states are impossible. To ensure all transition probabilities sum up to one,
remaining in health is calculated as a function of the other two transitions
possible. These assumptions are represented by
piFi,a,1,s = 0∀ s /∈ {1, 2, 9}
piFi,a,1,2 = wa
piFi,a,1,9 = da,F
piFi,a,1,1 = 1−
∑
s 6=1
piFi,a,1,s.
From the state Exposure
A dynamic process of sexual mixing is accounted for, represented by the
force of infection piFF,b,a(It), which is described in detail in Section 5.7.5.
This parameter depends on sex, sexual behaviour, age and time interval
of follow-up.
The corresponding transition probability of moving from the state expo-
sure to the state infection varies for the interventions evaluated, since we
assume a protective effect of the vaccine, resulting in a lower infection prob-
ability.
For intervention i = 1
According to the scheme described above, individuals who were exposed to
HPV can only remain in this condition (s = 2), progress to infection (s = 3), or
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die (s = 9). Consequently, we set all transition probabilities for s 6= 2, 3, 9 to
zero. Remaining in the state of exposure is represented by the sum-to-one
constraint. In intervention i = 1, no vaccine is applied, therefore, there is no
reduction in the probability of infection piFF,b,a(It). The transition probabilities
are given as
piF1,a,2,s = 0∀ s /∈ {2, 3, 9}
piF1,a,2,3 = pi
F
F,b,a(It) (see Section 5.7.5)
piF1,a,2,9 = da,F
piF1,a,2,2 = 1−
∑
s 6=2
piF1,a,2,s.
For intervention i = 2 and i = 3
Individuals who take up the vaccination scheme (in a proportion α) expe-
rience a reduction in the chance of moving towards the state of infection
(expressed by piFF,b,a(It)). In contrast, the transition probability of moving to
the state of death (s = 9) is independent of the intervention i.
The value of this reduction depends on the level of compliance with vac-
cination: the proportion ν3 of patients who complete the vaccination pro-
gramme by receiving the required three doses benefit from a full reduc-
tion, which is expressed by (1 − γ1). Conversely, individuals who take up
vaccination but receive only one or two doses instead of the three doses
necessary to complete the vaccination programme have a lower level of re-
duction, which we model using the parameter ζ. However, we acknowledge
that latest research indicates that two doses of the vaccine are sufficient for
protection [236].
Subjects without complete coverage miss out partially on the benefits of
vaccination and thus have an intermediate risk. We assume that vaccinees
who receive fewer than three doses experience approximately 50–60% of
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the full expected efficacy of the quadrivalent vaccine (on the basis of the
combined effect observed in an unrestricted susceptible population and an
intention-to-treat population10). The reduction in efficacy refers to the direct
protection against HPV infection. This has to be distinguished from “leaky”
vaccines, which do not prevent infection with the pathogen, yet pathogen-
induced disease development [296,299].
Those people who do not take up the vaccination programme (in a pop-
ulation proportion of 1− α) have the same chance of being infected by HPV
as in the scenario i = 1, where vaccination is not available. Equation 5.2
displays the indices i = 2; however, these are equivalent to indices of i = 3
and can therefore be used interchangeably.
Individuals can only move to the states s = 2, 3, 9, whereas all other tran-
sition probabilities are set to zero. Finally, applying the usual constraint, we
define the probability to remain in the state s = 2, and present the transition
probabilities as
piF2,a,2,s = 0∀ s /∈ {2, 3, 9}
piF2,a,2,3 = α[ν3(1− γ1)piFF,b,a(It) + (1− ν3)(1− ζγ1)piFF,b,a(It)] + (1− α)piFF,b,a(It)
piF2,a,2,9 = da,F
piF2,a,2,2 = 1−
∑
s 6=2
piF2,a,2,s.
(5.2)
As mentioned above, the transition probabilities of moving to the remaining
states are described in Appendix D.
10Estimated on the basis of the combined effect observed in an unrestricted susceptible
population and an ITT (intention-to-treat) population. The unrestricted susceptible popula-
tion is a population of young women who are initiating sexual debut; it includes all women
who were seronegative and PCR-negative to HPV-16, HPV-18 or both, including those who
received incomplete vaccination regimens, were exposed to HPV 16/18 before receiving
three doses, or had major protocol violations. The ITT population is a population that in-
cludes all women, regardless of HPV DNA findings, serostatus, or the presence of CIN at
the time of vaccination [19].
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5.9 Summary
In this chapter, the dynamic BMM introduced in Section 2.3 was specified
for the cost-effectiveness analysis of HPV vaccination. Model assumptions
such as interventions conducted, the model structure, the process of sexual
mixing and the calculation of the force of infection as well as a selection of
transition probabilities in females were described in detail.
The next chapter will show the corresponding results, including diag-
nostic checks on convergence and autocorrelation, the model calibration to
data, the natural history of HPV and induced diseases and the health eco-
nomic evaluation.
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Chapter 6
Results
6.1 Introduction
In this chapter, the results of the health economic evaluation on universal
vaccination in comparison to screening-only and female-only vaccination
are presented. Furthermore, the model output on the natural history of HPV,
so-called Markov traces, is evaluated in the intervention screening-only.
To obtain the results, several steps are conducted. The Markov Chain
Monte Carlo (MCMC) simulations are run to estimate the posterior distribu-
tions of all model parameters, followed by diagnostic checks on convergence
and autocorrelation as described in Section 3.2. The transition probabilities
are computed according to the equations specified in Section 5.8 and Ap-
pendices D and E.2; these are functions of the model parameters and as
a consequence random variables. The state allocation algorithm is run, in-
cluding the force of infection as described in Section 5.7.5, and all people
in all age cohorts are assigned to their target states over the full observa-
tion time horizon. The Markov traces are calibrated to data obtained from
cancer registries and the literature. Since time series data on the number
of people in HPV-induced health states are not available, we use a visual
calibration approach as described in Section 3.5.1. Following calibration,
several transition probabilities are adjusted.
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To conduct the health economic evaluation, first of all, overall costs and
utilities are calculated. As a next step, a cost-effectiveness analysis through
the Incremental Cost-Effectiveness Ratio (ICER) is performed. In addition,
probabilistic sensitivity analysis is conducted through the cost-effectiveness
plane, cost-effectiveness acceptability curve (CEAC), expected value of per-
fect information (EVPI) and the expected value of perfect partial informa-
tion (EVPPI) as described in Section 3.3.4.
6.2 MCMC simulation and diagnostics
As for the BMM of the case study described in Section 3.3.2, we use the
software JAGS, which is integrated into R by means of the package R2jags.
We run two parallel chains, for which we set different starting points. To re-
duce the amount of autocorrelation, thinning is required. We run a very high
number of simulations and just use every 360th simulation. Since results
of successive iterations are not considered, the issue of autocorrelation is
avoided, while at the same time the overall number of simulations is still
sufficiently high. Further details on autocorrelation are described in Sec-
tion 3.2.3.
We define altogether niter = 200, 000 simulations and assume a burn-in of
nburn = 20, 000, with a thinning nthin = 360. Altogether, this finally results in a
number of nsims = 1, 000 simulations, which are calculated as
nsims = nchains
(niter − nburn)
nthin
= 2
(200, 000− 20, 000)
360
= 1, 000.
We assume 1,000 simulations to be sufficient for our analysis; essential
diagnostics of MCMC sampling as described in Sections 3.2.2 and 3.2.3
confirm good convergence and no issues with autocorrelation under these
assumptions. If we run the model without thinning, the effective sample
size shows that the amount of autocorrelation is then higher; therefore, this
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Figure 6.1: The convergence statistics Rˆ for the model parameters θ are shown
graphically to give an overview of their values. No parameters show
convergence problems, and Rˆ is always below 1.1.
approach is not recommended.
Figure 6.1 shows the Gelman-Rubin statistic Rˆ for all parameters in-
cluded in the model. Convergence is sufficiently reached for all model pa-
rameters, resulting in values of Rˆ ranging from 1.0 to 1.045. Therefore, we
can conclude that 1,000 simulations are sufficient to enable all model pa-
rameters to converge. In addition, convergence diagnostics are conducted
through trace plots which confirm good convergence of all model parame-
ters in accordance to Rˆ.
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6.3 Model calibration
Calibration of the model output to data is essential in order to prevent a falsi-
fied estimation of the natural history of HPV infection and imprecise results
of the corresponding health economic evaluation. Data for calibration are
commonly obtained from large databases such as cancer registries, or from
the literature. Several calibration approaches are described in Section 3.5.
Due to the complexity of the HPV model and the availability of age-specific
prevalence and incidence data rather than time series data, we conduct a
visual calibration approach as shown for the case study in Section 3.5.1. In
the following, we describe the data used for calibration, the visual calibra-
tion approach and the results on HPV prevalence as well as cervix-related
diseases in detail. The calibration results on genital warts, precancerous
stages and cancers in the other body regions are reported in Appendix G.
6.3.1 Data on prevalence and incidence
We visually calibrate the model through data on prevalence and incidence
of HPV infection and HPV-induced diseases. By definition, the term “preva-
lence” describes the number of individuals out of a specific population, e.g.
a country, which are affected by a certain health condition at a specific
time point (point prevalence) or a specific time interval (interval prevalence).
Prevalence is also often reported as a proportion of the population at risk of
disease acquisition.
In contrast, the term “incidence” describes the rate of individuals who
have newly acquired a specific health condition in a predefined time inter-
val. It is usually reported as a proportion of the population at risk, e.g. per
100,000 of the population. Incidence is often calculated for specific covari-
ates such as sex and age. If a disease is not curable and not deadly, in-
cidence contributes to constantly increasing prevalence; prevalence is then
only reduced by cases of deaths.
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We acknowledge that the data on prevalence and incidence used for cal-
ibration are only taken from one selected source per state; therefore, uncer-
tainty in these data is not considered. However, for the calibration of HPV-
induced cancer states, these are high quality data from cancer registries
with large sample size. In contrast, precancerous stages are calibrated to
data obtained from clinical trials with smaller sample size since there are no
registries for precancerous lesions.
In the model, people affected by genital warts and precancerous intraep-
ithelial neoplasiae can remain in the corresponding states over a consider-
able amount of time, and disease history is not accounted for. Therefore,
prevalence data are suitable to calibrate these states. In contrast, the model
outcome on HPV-induced cancers is calibrated to yearly incidence rates.
Our model structure is defined in a way that individuals remain in the can-
cer states for one year as described in Section 5.4; this corresponds to the
definition of yearly cancer incidence. Afterwards, individuals either die or
move to the first post-cancer tunnel state; however, the three tunnel states
following cancer diagnosis are not considered in the model calibration due
to non-existing data.
We conduct an extensive literature review in order to find most suitable
age- and sex-specific data on prevalence and incidence. If possible, we
use Italian data on cancer incidence; however, in most organs affected by
HPV-induced cancer, these are not available, and instead, we use data from
the UK. We assume those to be comparable to Italian data; both countries
offer related cervical screening programmes to their female population, and
in both countries, the public health insurance systems are similar.
6.3.2 Visual calibration approach
The visual calibration approach conducted is similar to the one of the case
study described in Section 3.5.1. We calibrate HPV prevalence and HPV-
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induced diseases in the female and male model compartments through ad-
justments of several transition probabilities by age- and sex-specific vari-
ables λv,a,r,s, where the indices v, a, r and s indicate sex, age cohort, origi-
nal and target states, respectively. The numbering of the states is described
in Appendices D and E.1. We acknowledge that this approach is quite
crude; however, due to unavailable time series data on the number of in-
dividuals affected by HPV-induced diseases as well as model complexity,
a more systematic calibration approach is not feasible. Also, the literature
shows that visual calibration approaches are quite common and generally
well accepted.
As a first step, we estimate the transition probabilities through informa-
tive priors, informed by the literature. We incorporate the mean and ranges
reported. Having run the model, we visually compare the results obtained
to data. Therefore, we evaluate data and model outcome in graphical dis-
play. If those are not comparable, we shift the mean of the corresponding
informative prior towards the upper or lower bounds of the ranges reported,
including a large variance. In addition, we multiply the corresponding tran-
sition probabilities by λv,a,r,s. The final values of the variables λv,a,r,s are es-
timated by rerunning the model until the results are comparable to the data.
As a consequence of the adjustments, the transition probabilities become
age- and sex-specific. This is reasonable since commonly, the chance of
infection clearance is considerably reduced in older age cohorts, whereas
the risk of progressing to more severe precancerous stages and cancer is
considerably lower in younger age cohorts.
We calibrate the model output of all states in the three interventions
screening-only, female-only and universal vaccination, separately for females
and males. Data used for calibration are based on population prevalence
and incidence of HPV-induced diseases prior to the introduction of HPV
vaccination. Therefore, we assume that only the results of the intervention
screening-only are comparable to the data; in the interventions including
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vaccination, the model output on incidence and prevalence is considerably
reduced. When compared to screening-only, the size of the reduction is
approximately by factor 1.4 in female-only vaccination and 1.65 in univer-
sal vaccination.
6.3.3 HPV prevalence
The age-specific HPV prevalence data used for calibration are reported by
Baussano et al. [28]. These are available for females only. At the current
stage of research, no HPV tests for males are available [2]; therefore, data
on male HPV prevalence are not routinely collected. As a consequence, we
assume that male and female HPV population prevalence are identical.
In the Italian age-specific prevalence data, age is grouped into intervals
of ten years, and reporting starts in females as young as 15 years. The
oldest age group includes females aged 55 years and older. We interpolate
the starting age to twelve years, assuming the same values as for 15 year
olds. For the oldest age group, we consider constant prevalence results until
the age of 80 years, representing the oldest people in our population. We
assume people in all states apart from Healthy, Exposure and Clearance
to be infected by HPV and as a consequence contribute to the overall HPV
population prevalence. Following prevalence calibration, the HPV transmis-
sion probabilities per partnership are adjusted to on average 25.52% with a
95% credible interval of [16.7%;35.48%], and to 52.74% [29.84%;74.45%]
in the average- and high-risk groups, respectively.
Figure 6.2 presents the calibration results. For screening-only, our model
estimates HPV prevalence in a realistic way; the predictions show a good
approximation to the data, with peak HPV prevalence in the youngest, de-
creasing in older people. Younger people are mainly affected by HPV due
to i) commonly higher sexual activity, ii) non-existing natural immunity to
HPV infection which is usually acquired following first virus exposure, and
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iii) low cervical screening rates and thus infrequent intervention against pre-
cancerous lesions [38]. Male HPV prevalence is higher than female as a
consequence of more frequent partner change in males [360].
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Figure 6.2: Visual calibration of the HPV prevalence model output to data taken
from Baussano et al. [28]. The age- and sex- specific prevalence es-
timates are displayed separately for the three interventions screening-
only, female-only, and universal vaccination. The figure shows that the
model realistically predicts HPV prevalence, peaking in the youngest
age groups.
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6.3.4 Cervix-related diseases
As for the prevalence data, data on yearly cervical cancer incidence are
specific to Italy, obtained from an Italian cancer registry [275]. These are
used to calibrate the model output on cervical cancer. In contrast to data
on cervical cancer incidence, Italian data on the age-specific prevalence of
the cervical precancerous stages CIN I-III are not available. Brazilian data
are available [121]; however, these differ from Italian data as described be-
low and are thus not used for transition probability estimation through visual
calibration. Instead, we only compare the model output on CIN prevalence
to these data to evaluate whether the age-specific trend on CIN prevalence
is estimated correctly by our model; we assume that Italian and Brazilian
CIN prevalence follow similar age trends. We acknowledge that this ap-
proach is not ideal and has limitations since the real differences between
CIN prevalence in the two countries are unknown and cannot be estimated
straightforwardly. The actual model output on the age-specific proportion of
females in the CIN-stages is thus not validated.
The corresponding transition probabilities are estimated through evidence
synthesis on Italian data on CIN progression, regression, cervical screen-
ing and conization as described in Appendix D. In addition, we model the
transition probability to move from CIN II to CIN III, as well as regressing
from CIN III to CIN I or CIN II in an age-specific way according to [71], indi-
cated by adjustments through λF,a,5,6, λF,a,6,4, and λF,a,6,5. Furthermore, we
assume that the transition probabilities of clearing the HPV infection or de-
veloping cervical cancer for those in CIN III highly depend on age, adjusted
through λF,a,6,13 and λF,a,6,8, respectively. Consequently, older individuals in
CIN III have a higher risk of progressing to cervical cancer, whereas the
younger are more likely to move to the state of Clearance. As a result, we
successively increase cervical cancer incidence in older individuals since
the older are both more likely to be affected by CIN III, and to progress from
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CIN III to cervical cancer. This results in a shift of peak cervical cancer
incidence to the oldest females, comparable to the Italian cervical cancer
registry data [275].
Brazilian cervical cancer incidence is around two times higher in females
up to age 29 and more than six times higher in those over 75 when com-
pared to Italian incidence [121, 275]. Therefore, one could assume that the
corresponding CIN prevalence is also increased by similar factors. How-
ever, this is not the case due to issues with Pap smears of low sensitivity
in Brazil. CIN prevalence is thus considerably underestimated in Brazil as
described in [94]. The positivity index (the proportion of females with a pos-
itive CIN diagnosis of all females tested) in Brazil would be expected to
be considerably higher than in a developed country due to the higher cer-
vical cancer incidence. However, the opposite is the case, resulting in a
positivity index of only 2.72% in Brazil [94] when compared to developed
countries which show positivity indices of 3.7% (Italy) [287], 6.5% (United
Kingdom) [186] and 6.8% (USA) [104] despite considerably lower cervical
cancer incidence. However, these values are only an indicator of low sen-
sitivity of Pap smears and highly depend on tools such as laboratory equip-
ment used for Pap smear evaluation as well as unknown true prevalence.
An adjustment of Brazilian data on CIN prevalence to an Italian context by
these values would thus rely on unreported or untestable assumptions and
is therefore not conducted.
In Figure 6.3, we present the model outcome on the CIN stages and cer-
vical cancer; the model outcome seems reasonable; however, conclusions
have to be made with care due to the Brazilian data used. The trends of
peak CIN I-II prevalence in the youngest and lower prevalence in older fe-
males seem to be estimated in a realistic way. Furthermore, the reverse
trend in CIN III with a peak incidence in older females is well portrayed. Our
model outcome results in peak cervical cancer incidence in middle-aged
females which is a good approximation to reality. However, cervical can-
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(a) The coloured curves show that the age-specific
trend in CIN I with a peak prevalence in the youngest
is reasonably well approximated by our model.
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(b) As for CIN I, in CIN II, the model output shows
a good approximation to the age-specific trend in
prevalence.
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(c) The trend of a peak prevalence of CIN III in middle-
aged women is reasonably represented by our
model output.
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(d) The calibration result of cervical cancer clearly fol-
lows the trend of increasing incidence by age.
Figure 6.3: Visual calibration of the model outcome on cervial cancer to data on
incidence. In addition, we show the age-specific trend in prevalence
of the precancerous stages CIN I-III. The coloured curves display the
model outcome in the three interventions screening-only, female-only
and universal vaccination, whereas the black line indicates the data.
We focus on the red lines representing screening-only since our data
on CIN prevalence and cervical cancer incidence are based on the era
pre HPV vaccine.
cer incidence in the oldest is underestimated; yet, this is not relevant since
only a few age cohorts in our model reach such a high age. In addition, fu-
ture events are highly discounted and have a very low impact on the results
of the cost-effectiveness analysis. Therefore, the calculation of the overall
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costs and QALYs is still conducted in a realistic way. As mentioned in the
beginning of the section, calibration results for the other states are reported
in Appendix G.
6.4 Markov traces
Following model calibration, Markov traces are evaluated to assess the
model predictions on the proportions of the population in the states through-
out the observation time horizon. We display the Markov traces graphically
through bar charts on the natural history of HPV infection in the intervention
screening-only.
Figure 6.4 shows the cumulative proportions of individuals in the states
over the observation period, separately for the two sexes and diseased
and unaffected people, respectively. The vast majority remains unaffected
by HPV-induced diseases. However, a small proportion (up to 4% of fe-
males and 2.5% of males) acquires a disease at a particular time point of
the follow-up. Anogenital warts and early precancerous stages mainly af-
fect younger people, whereas more severe precancerous lesions and HPV-
induced cancers commonly occur at a later stage in life. We do not display
extremely rare cases of cancers of the anus, vulva, vagina, and penis.
6.5 Cost-effectiveness analysis
The economic evaluation is performed using the incremental cost-effective-
ness ratio (ICER), accounting for the amount of money spent per quality-
adjusted life-year (QALY) gained. Utilities (as described in Section 3.3.4)
are used to compute the Quality-Adjusted Life Years (QALYs); therefore, the
utility of a given state is multiplied with the amount of time spent within [22].
Costs averted by the implementation of vaccination as well as QALYs gained
are additionally estimated. In the absence of an Italian official cost-effecti-
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Figure 6.4: Model outcome of the natural history of HPV infection and disease pro-
gression. Cumulative proportions of unaffected and diseased people
are displayed separately for the two sexes. The vast majority of peo-
ple remain unaffected by the virus, whereas a small age-dependent
proportion (up to 4% of females and 2.5% of males) develop an HPV-
induced disease.
veness threshold, the same assumptions as described in Section 4.1 are
applied to specify the willingness-to-pay of the decision maker.
6.5.1 Overall costs and utilities
Since we include 36 states in females and 22 states in males in the model,
the calculations of overall costs and utilities are quite extensive. Further-
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more, we consider that according to expert opinion, patients in states related
to the cervix and anus do not only induce treatment expenses; additionally,
the costs of diagnostic procedures have to be accounted for.
In cervical diseases, costs are induced by two Pap smears and two col-
poscopies in all females affected by cervical neoplasiae, and by a HPV DNA
test in patients suffering from CIN III or cervical cancer. For diseases lo-
cated in the anus, we assume that all patients receive an anoscopy with
biopsy as well as a cytology. We assume that the information on expenses
of precancerous stages and cancers of the vulva, vagina and penis as well
as head/neck obtained from the literature incorporates both diagnostic and
treatment costs. To result in the overall costs, we multiply the unit costs
of each state with the number of people within the state, respectively. The
overall costs are calculated as
Ci,t = C
scr
i,t + C
vac
i + C
gw
i,t + C
cin
1,i,t + C
cin
2,i,t + C
cin
3,i,t + C
cerv
i,t + C
lsil
i,t
+ Chsili,t + C
an
i,t + C
hn
i,t + C
vin
i,t + C
vulv
i,t + C
vain
1,i,t + C
vain
2,i,t
+ Cvain3,i,t + C
pein
i,t + C
pen
i,t ,
including cervical screening as well as both diagnostic and treatment costs
induced by people in all states at time t of follow-up in intervention i. For
simplicity, time t indicates the time interval It of the discrete-time approach.
In interventions i = 2, 3 where vaccination takes place, the costs of vaccine
administration and the vaccine also have to be considered.
As an illustrative example, we report the calculation of the overall costs
of genital warts in intervention i at time t, which is described as
Cgwi,t = Gi,tcgw.
The number of people in intervention i at time t affected by genital warts,
Gi,t, is multiplied by the corresponding unit cost cgw. The overall costs of the
148
6.5. Cost-effectiveness analysis
remaining states are calculated accordingly; however, in contrast to the visi-
ble and symptomatic health condition of genital warts, precancerous lesions
and cancer only result in costs after their diagnosis. Therefore, the actual
costs of the respective diseases are multiplied with the corresponding prob-
abilities of diagnosis.
The calculation of the overall utilities is straightforward; the actual num-
ber of people in each state in intervention i at time t is multiplied by the
corresponding utility value, resulting in
Ui,t = U
health
i,t + U
inf
i,t + U
gw
i,t + U
cin
1,i,t + U
cin
2,i,t + U
cin
3,i,t + U
cerv
r,i,t + U
lsil
i,t
+ Uhsili,t + U
an
r,i,t + U
hn
r,i,t + U
vin
i,t + U
vulv
r,i,t + U
vain
1,i,t + U
vain
2,i,t + U
vain
3,i,t
+ U vagr,i,t + U
pein
i,t + U
pen
r,i,t.
For all HPV-induced precancerous stages and cancer states, the overall
utilities are multiplied by the respective probabilities of diagnosis.
6.5.2 The present value of cost and the present value of
utility
The overall costs and utilities Ci,t and Ui,t are summed up for the whole
observation time period to result in the present value of cost (PVC) and the
present value of utility (PVU).
Because of the model’s long-term horizon, it is necessary to discount
overall costs and utilities. Approaches to this differ [42]: In an Italian con-
text, ISPOR guidelines [74] suggest discounting both costs and benefits at
a 3% rate, although NICE [268] recommend a slightly higher value of 3.5%,
with a 0-6% range for sensitivity analysis. Rates actually applied vary be-
tween countries, ranging from 1.5% to 10% for benefits and 0% to 10% for
costs [381]. In line with [74], the annual discount rates zc for costs and zu for
utilities are set at 3%.
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The PVC and the PVU for a follow-up period of t = 55 years are calcu-
lated as
PVCi =
55∑
t=1
Ci,t
(1 + zc)t−1
and
PVUi =
55∑
t=1
Ui,t
(1 + zu)t−1
.
6.5.3 Population sizes, overall costs and QALYs
Costs and QALYs are reported for the population as a whole. Table 6.1
shows the mean population size and mean QALYs per intervention over the
whole observation time period along with the corresponding 95% credible
intervals. With screening-only, population size is the lowest since more indi-
viduals die due to the higher incidence of HPV-induced cancers.
Table 6.1: Population size and overall QALYs in the three interventions over total
follow-up.
Population size Overall QALY
Intervention Mean Mean 95% CI
Screening-only 149,652,365 127,935,994 [127,884,948;127,987,040]
Female-only 149,727,525 128,409,504 [128,399,222;128,419,785]
Universal 149,736,770 128,449,826 [128,444,388;128,455,264]
The mean and median costs are shown in Table 6.2. The cost distribution in
the screening-only scenario is highly right-skewed, resulting in a median that
is ten times lower than the mean. In contrast, the costs in the interventions
female-only and universal vaccination are symmetrically distributed; as a
consequence, their mean and median are similar.
Mean overall costs differ by a factor of five between screening-only and
universal vaccination, reflecting the larger population to which the vaccine
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is made available in the latter case. Interestingly, QALYs are also highest
under universal vaccination.
Table 6.2: Overall costs in e in the three interventions over total follow-up.
Overall cost
Intervention Mean 95% CI Median 95% CI
Screening-only 187,189,634 [169,986,589;204,392,679] 18,279,665 [13,007,644;28,495,706]
Female-only 484,357,417 [478,212,474; 490,502,360] 478,135,234 [469,493,395;487,530,520]
Universal 948,732,541 [937,699,221; 959,765,861] 941,748,716 [929,302,951;951,984,667]
6.5.4 The Incremental Cost-Effectiveness Ratio
The Incremental Cost-Effectiveness Ratio (ICER) is described in further de-
tail in Section 3.3.4. To compare the cost-effectiveness of universal (i = 3)
and female-only (i = 2) vaccination, as a first step, the cost- and effective-
ness differentials ∆c = PVC3−PVC2 and ∆e = PVU3−PVU2 are calculated.
As described in Section 5.5, all model parameters are included in the param-
eter vector θ = (θ3, θ2), with θ3 referring to the parameters in the reference
intervention i = 3 and θ2 to those of the comparator, i = 2. The ICER is then
calculated as
ICER =
E[PVC | θ3]− E[PVC | θ2]
E[PVU | θ3]− E[PVU | θ2] =
E[∆c]
E[∆e]
.
The calculation of the ICER for the comparison of universal vaccination to
screening-only is conducted accordingly. When comparing universal vacci-
nation to the other two alternatives, the ICER is about e1,500 in comparison
to screening-only and about e11,600 in comparison to female-only vacci-
nation.
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6.6 Probabilistic sensitivity analysis
The uncertainty around the cost-effectiveness estimates is analysed by means
of the cost-effectiveness plane, the cost-effectiveness acceptability curve
(CEAC), the expected value of perfect information (EVPI) analysis and the
expected value of perfect partial information (EVPPI) analysis. The cost-
effectiveness plane, CEAC and EVPI are described in further detail in Sec-
tion 3.3.4.
6.6.1 Universal versus female-only vaccination
Figure 6.5 shows a cost-effectiveness plane comparing universal to female-
only vaccination, with the effectiveness differential on the x-axis and the
cost-differential on the y-axis. The majority of points lie at the limit of the
sustainability area, with low CEAC values as a consequence. However,
mean cost- and effectiveness differentials do indicate cost-effectiveness, re-
sulting in an ICER of around e11,600 (displayed as a red dot), well below
the cost-effectiveness thresholds set in Section 4.1. This is substantially due
to herd immunity. As a consequence, the higher overall cost of the universal
vaccination strategy is clearly compensated by the gain in utilities.
Figure 6.6 presents a graphical summary of PSA. The left panel contains
the CEAC. Typically, low values of the CEAC indicate the presence of a large
amount of parameter uncertainty [22]. In Figure 6.6, the values are below
80% for the whole range of choices for the willingness-to-pay displayed. Yet,
the CEAC only measures the probability of cost-effectiveness, but fails to
reflect the impact of uncertainty on the consequences of a “wrong” decision.
The panel on the right shows the EVPI, again as a function of willingness-
to-pay. In the present case, EVPI is at most e 320,030,305 for the overall
population and e 2.1 per subject, representing the extremely low future fi-
nancial investment necessary to resolve parameter uncertainty. These val-
ues indicate that the impact of parameter uncertainty on the results of the
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model is extremely low, despite the low CEAC values, which are induced by
a markedly skewed distribution for the underlying cost- and effectiveness-
differentials. Under these circumstances, the results of the cost-effectiveness
analysis are rather stable, despite the underlying parameter uncertainty.
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Figure 6.5: Cost-effectiveness plane comparing universal to female-only vaccina-
tion. The x-axis shows ∆e and the y-axis ∆c. Points lying within
the grey sustainability area are cost-effective under the threshold of
£ 25,000, defined by the NHS. The red dot represents the ICER; its
actual value is displayed in red.
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6.6.2 Universal vaccination versus screening-only
The incremental cost of applying universal vaccination compared to screen-
ing-only is higher than in the preceding section, since fewer individuals were
potentially vaccinated. However, incremental QALYs are higher, too, as a
consequence of the reduced effects of herd immunity. Figure 6.7 shows the
corresponding cost-effectiveness plane.
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Figure 6.7: Cost-effectiveness plane for a comparison of universal vaccination to
screening-only. In comparison to Figure 6.5, the joint distribution of
cost and effectiveness differentials is less skewed to the right, resulting
in a cost-effectiveness acceptability curve nearly reaching values of
60% cost-effectiveness.
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In comparison to the former analysis, a higher number of points lie within
the sustainability area, and the joint distribution of cost- and effectiveness
differentials is less right-skewed. Thus, the CEAC exhibited in the left panel
of Figure 6.8 has higher values, nearly reaching 60%. Additionally, EVPI
indicates a higher value of further research amounting to up to e 3.7 per in-
dividual and e 553,291,173 for the whole population. However, this is still a
comparatively low value, suggesting a low impact of parameter uncertainty.
Therefore, one can conclude that despite the low CEAC, universal vaccina-
tion is a highly cost-effective alternative when compared to screening-only.
6.6.3 The Expected Value of Perfect Partial Information
The global EVPI is a measure of the overall value of future financial in-
vestment necessary to resolve uncertainty in the model parameters θ as
described in Section 3.3.4. In contrast to the global EVPI, the Expected
Value of Perfect Partial Information (EVPPI) identifies the exact sources of
parameter uncertainty. In an EVPPI analysis, as a first step, the EVPPI
is calculated separately for each model parameter of interest. Afterwards,
model parameters resulting in an EVPPI greater than zero are grouped ac-
cording to the medical context in order to identify the areas with the largest
value for future research.
Thus, θ is split into φ∗ and ψ∗ ; φ∗ represents the parameters of inter-
est, whereas ψ∗ are the remainder. A single parameter or a combination
of parameters can be included in φ∗ . Following parameter specification, the
EVPPI is calculated as
EVPPI(φ∗) = E(φ∗)
[
max
i
E(ψ∗ |φ∗){NB(i,φ∗ ,ψ∗)}
]
︸ ︷︷ ︸
perfect information on φ∗
−max
i
E(θ){NB(i, θ)}.︸ ︷︷ ︸
current information on θ
(6.1)
The first term of the expression represents a scenario with perfect infor-
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mation on φ∗ ; thus, the conditional expectation E(ψ∗ |φ∗) on the net benefit
NB(i,φ∗ ,ψ∗) is estimated per intervention i, and the maximum is calculated.
The net benefit is defined in Section 3.3.4. Finally, since φ∗ is unknown,
the maximum is averaged over the current information available on φ∗ . The
scenario with current information on θ is represented by the maximum over
the expectations of the net benefits (E(θ){NB(i, θ)}). The larger the EVPPI,
the higher the financial investment necessary to resolve uncertainty in φ∗ .
As for the EVPI, the EVPPI can be estimated through Monte Carlo simu-
lation. However, in contrast to an EVPI analysis, an EVPPI analysis induces
a considerably higher computational effort, especially in more complex mod-
els: the first expression of Equation 6.1, including perfect information on φ∗ ,
is estimated by running an inner loop to calculate the conditional expecta-
tion, followed by an outer loop to average over φ∗ . To simplify computation,
Strong et al. [331] introduce two innovative approaches on EVPPI analysis.
The first is a nonparametric regression approach based on a Gener-
alised Additive Model (GAM). The conditional expectation
E(ψ∗ |φ∗){NB(i,φ∗ ,ψ∗)}
is a function of φ∗ since it takes a different value for each φ∗ . Thus, it can
be approximated by an unknown function f(i,φ∗) which consists of a set of
smoothing functions, representing some form of spline.
The GAM regression is suitable for a first screening of each individual
model parameter to evaluate the corresponding amount of uncertainty. How-
ever, if more than six model parameters are included in the vector of param-
eters of interest φ∗ , GAM regression becomes unstable. As an alternative,
the authors introduce a second approach of EVPPI estimation by means of
Gaussian Process (GP) regression. As for the GAM regression, the con-
ditional expectation is approximated by a function f(i,φ∗). The unknown
values of the input parameters of the function are represented through a
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multivariate normal distribution. The smoothness of the function f(i,φ∗) is
given by a correlation matrix with respect to the parameters in φ∗ . For further
details on GAM and GP regression, see [331].
In the online appendix to [331], R functions for both methods are avail-
able. The function inputs consist of the distribution of the net benefits of the
two interventions compared. In addition, the parameters of interest φ∗ and
the overall input parameters θ have to be specified.
We conduct the EVPPI analysis for universal vaccination in compari-
son to female-only vaccination and to screening-only. For a first parameter
screening, we run both the GAM as well as the GP regression for every sin-
gle model parameter. The results of the two approaches are approximately
identical. As a next step, we group parameters with an EVPPI greater than
zero according to the medical context, and apply GP regression.
Table 6.3 shows the results per individual for the comparison of universal
to female-only vaccination at the break-even point of e11,600. In addition,
the standard errors and the upward biases of the GP regression are dis-
played. The upward biases are a consequence of the maximisation step in
the first term of Equation 6.1, which can be reduced through an increased
number of simulations. For 500 simulations, the upward bias is consider-
ably low and never reaches a value above 0.43. Furthermore, the standard
errors are close to zero; therefore, we can conclude that all values of the
EVPPI are estimated with precision.
Unsurprisingly, as for the low global EVPI, all grouped EVPPIs indicate a
low future financial investment to resolve parameter uncertainty. The highest
amount of uncertainty is found in some of the transition probabilities and the
parameters related to age-, sex- and behavioural-specific sexual mixing and
cervical screening, whereas the uncertainty in parameters related to costs
and utilities seems to play a minor role. As for the transition probabilities,
regressing to the state of exposure, progressing to head/neck cancer and to
diseases related to the penis include the highest amount of uncertainty.
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Table 6.3: Results of the EVPPI-analysis of universal in comparison to female-only
vaccination. Model parameters are grouped according to the medical
context, and the analysis is conducted via Gaussian Process regression.
Parameter group EVPPI Standard Error Upward bias
Probabilities of screening 1.1564 0.0472 0.3107
Probabilities of diagnosis 0.4661 0.0808 0.3264
Probabilities of survival 0.6549 0.0687 0.3629
Vaccine-related parameters 0.1940 0.0699 0.0764
Transition probabilities
Regression from HPV infection 1.0931 0.0468 0.3419
Risk of reinfection 0 0.0177 0.0075
Head/neck 1.0810 0.0525 0.3436
Genital warts 0.9564 0.0589 0.3983
Cervix 0.1971 0.0759 0.1672
Anus 0.1144 0.0644 0.0404
Vulva 0.9499 0.0605 0.4303
Vagina 0.0049 0.0148 0.0089
Penis 1.1192 0.0475 0.3233
Sexual mixing
Average-risk female 1.0767 0.0491 0.3530
Average-risk male 1.1171 0.0486 0.3560
High-risk female 1.0262 0.0508 0.3621
High-risk male 1.0955 0.0476 0.3342
Health economic parameters
Costs 0.4703 0.0835 0.2719
Utilities 0.0555 0.0554 0.0489
Table 6.4 shows the results of the EVPPI analysis for the comparison of
universal vaccination to screening-only at the break-even point of e 1,500.
Compared to the previous analysis, the overall amount of uncertainty is
slightly higher; however, it is still considerably low. As for the previous anal-
ysis, the distributions of the highest amount of uncertainty are located in
the parameters related to sexual mixing and in the transition probabilities
of regression to the state of exposure, as well as progression to head/neck
cancer and genital warts. Again, uncertainty in the distributions on costs
and utilities seems to play a minor role. The standard errors and upward
biases are higher when compared to Table 6.3.
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Table 6.4: Results of the EVPPI-analysis of universal vaccination in comparison
to screening-only. As for the previous analysis, model parameters are
grouped according to the medical context, and the analysis is conducted
via Gaussian Process regression.
Parameter group EVPPI Standard Error Upward bias
Probabilities of screening 1.5375 0.0995 0.5566
Probabilities of diagnosis 0.4817 0.1150 0.2985
Probabilities of survival 1.9224 0.0869 0.4313
Vaccine-related parameters 0.1559 0.1082 0.0926
Transition probabilities
Regression from HPV infection 2.0288 0.0725 0.3735
Risk of reinfection 0.0106 0.0573 0.0248
Head/neck 2.3214 0.0697 0.2657
Genital warts 2.1619 0.0743 0.3416
Cervix 0.2541 0.1176 0.1427
Anus 0.3400 0.1160 0.2273
Vulva 1.9320 0.0827 0.4198
Vagina 0.0468 0.0650 0.0708
Penis 1.6285 0.0977 0.5132
Sexual mixing
Average-risk female 2.1550 0.0735 0.3435
Average-risk male 2.1433 0.0728 0.3539
High-risk female 2.1550 0.0735 0.3435
High-risk male 2.2223 0.0745 0.3143
Health economic parameters
Costs 0.5374 0.1240 0.2710
Utilities 0.1705 0.1027 0.1220
6.7 Conclusion
Universal HPV vaccination is found to be a cost-effective choice when com-
pared to either cervical cancer screening or female-only vaccination within
the Italian context. These results are based on Markov traces which were
calibrated to data. Extensive probabilistic sensitivity analysis was conducted
in order to assess the amount of parameter uncertainty. The low values of
the global EVPI and the EVPPI show that further expenses to resolve pa-
rameter uncertainty are not necessary.
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Chapter 7
Summary and conclusions
7.1 Summary of the research
Standard Markov models (MMs) are static by definition of the Markov prop-
erty. Thus, when applied in the context of infectious disease, changes in
population prevalence over time are commonly not considered. In this PhD
thesis, the standard framework of MMs is extended by directly incorporating
the dynamic force of infection into the transition probabilities to the state of
Infection, accounting for the effects of herd immunity. As a consequence,
the probability of infection is modified according to the proportion of peo-
ple who at any given time are infected and exposed to the infectious agent.
The corresponding inference is conducted in a Bayesian context. The thesis
starts with a motivation for the research in Chapter 1. Chapter 2 presents a
general introduction into compartmental methodology and our approach of
the dynamic Bayesian Markov model, termed as BMM.
The “gold standard” applied to perform epidemiological and economic
evaluations of infectious diseases is based on systems of ordinary differ-
ential equations (ODEs) [291]. While particularly effective in modelling the
dynamic transmission of infectious diseases, these are usually too complex
for assigning a suitable probability distribution to each model parameter, lim-
iting the possibility of performing extensive probabilistic sensitivity analysis
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(PSA). As a consequence, PSA can only be conducted when applying ad-
ditional retrospective simulation procedures such as the Latin Hypercube
Sampling (LHS) [255].
However, PSA is fundamental in any health economic evaluation [22,51,
329] and particularly so in the case of infectious disease modelling, where
uncertainty surrounding the parameters and assumptions of the model may
impact dramatically on cost-effectiveness results. In contrast to most ODE-
based models, the BMM developed in this thesis is implemented in a Bayesian
framework. Therefore, the model parameters are assigned distributions,
permitting to accommodate PSA in a straightforward way. At the same
time, by using discrete time rather than continuous time for modelling the
Markov cycle, we are able to include the dynamics of infection and popula-
tion characteristics. Regulatory bodies such as NICE may benefit from our
methodology since it produces a full economic evaluation based on a tool
they are familiar with; also, PSA can be directly embedded in the model.
In addition to the advantages previously discussed, it considerably reduces
the effort on implementation and computation when compared to standard
ODE-based methodology.
The use of a Bayesian approach is particularly relevant in the case of
infectious disease modelling, since it is likely that many of the fundamental
parameters are informed by a combination of evidence, some of which may
be based on expert opinion. Thus, it is important to fully account for the
underlying uncertainty - failure to do so may result in an under- or overesti-
mation of the economic performance of the interventions being investigated.
A full Bayesian analysis also has the advantage of making the conduct of
the all-important PSA relatively straightforward, as the uncertainty in the
model parameters is directly accounted for in the main model computations.
Using tools such as the R package BCEA [3] or the SAVI webapp [1], it is
fairly straightforward to systematically compute the relevant summary as-
sessments such as CEAC, EVPI and EVPPI analysis.
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In Chapter 3, we apply our approach to a case study on a fictional chronic
sexually transmitted infection (STI), including a small number of states. We
perform two different analyses; in the first analysis, we assume not to have
access to individual-level data. Thus, we include exclusively informative
priors into the models. Depending on data availability of the pathogen un-
der investigation, this could be a realistic scenario. In contrast, in the sec-
ond analysis, the priors are updated by fictional aggregate and simulated
individual-level data. The individual-level data are simulated through ran-
dom number generators as described in Section 3.4. In addition, the model
outcome is calibrated to data on STI prevalence as well as time series data
on the number of people in the states. In both analyses, we compare the
output of our dynamic Bayesian MM to the outputs of a deterministic (in-
cluding fixed parameter values) and a Bayesian ODE-based model. Fur-
thermore, we conduct a health economic evaluation, comparing a fictional
vaccine against the STI to screening-only.
The second part of the thesis focusses on the application of our method-
ology to human papillomavirus (HPV) transmission and disease progression
modelling, followed by a cost-effectiveness analysis of universal vaccina-
tion in comparison to female-only vaccination and screening-only. To gain
insight into this area of research, an extensive literature review on health
economic evaluations of different HPV vaccination strategies is presented
in Chapter 4.
As shown in the literature, conclusive HPV models incorporate a high
number of states; this is necessary to account for HPV-induced neoplasiae
in a large number of body regions. If these are not considered, the model
predictions might be falsified. Furthermore, HPV prevalence and thus the
force of infection is age- and sex-specific. Therefore, in order to produce re-
liable results, models on HPV transmission and disease progression usually
induce a considerably high level of complexity.
The specification of our BMM to an HPV context is described in Chap-
165
CHAPTER 7. SUMMARY AND CONCLUSIONS
ter 5. In contrast to Bayesian ODE-based models, our methodology is es-
pecially suitable to incorporate a large number of age cohorts and states
without considerably increasing the computational effort. Altogether, 24 age
cohorts, 58 states and two sexual behaviour groups are included in an open
model structure, enabling healthy twelve year old individuals to enter the
model. The force of infection is age-, sex- and behavioural-specific. In con-
trast to the ODE-based models in the literature on HPV modelling, all of
our model parameters are assigned distributions, and thus we are able to
conduct PSA as an essential part of a full health economic evaluation in a
straightforward way.
Having run the model, we investigate convergence and the amount of
autocorrelation in the model parameters. We calibrate the vast majority of
states to available data, taken from cancer registries and the literature. The
results of MCMC diagnostics, model calibration, natural history of HPV and
induced diseases as well as the health economic evaluation are presented
in Chapter 6.
7.2 Summary of the results
7.2.1 Comparison of the BMM to the “gold standard” BODE
In Chapter 3, we compare the outcome of the BMM to a deterministic (in-
cluding fixed parameter values) and a Bayesian ODE-based model. The
prevalence outcome and the results of the cost-effectiveness analysis of
the “gold standard” of the BODE and the BMM are approximately identical.
Therefore, we can clearly show that population dynamics, mixing patterns
between people, and time-dependent changes in population prevalence are
accounted for in a realistic way by our BMM.
The loss induced by an over- or underestimation of STI prevalence is not
symmetric. The lower the prevalence, the higher the ICERs of the interven-
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tions under investigation. As a result, prevalence underestimation results
in too high ICERs. In the worst case, the cost-effectiveness of the corre-
sponding interventions is not recognised, and highly effective treatments
are withheld from the population. In contrast, an overestimation of preva-
lence could result in wasting scarce resources for highly costly or inefficient
interventions. In the first analysis, the model outcome is not calibrated to
simulated data. To avoid falsified outcome of the dODE, the corresponding
model parameters are informed through 60% quantiles of the parameters
of the BODE which are estimated through a multilinear loss function. This
function accounts for asymmetry in losses. As a consequence of consid-
ering the non-symmetric loss, prevalence outcome and results of the cost-
effectiveness analysis of the dODE are comparable to the Bayesian models,
resulting in ICERs of £ 6,702, £ 6,800 and £ 7,084 in the dODE, BODE and
BMM, respectively.
In the second analysis, the outcome of the three models is calibrated
to simulated data which are obtained by running the dODE for i) different
initial values as well as for ii) a short observation time period of only five
years. In a visual calibration approach, data on STI prevalence are used.
The outcome of the BMM and BODE fit the data well. However, despite
calibration, the dODE results in an underestimation of STI prevalence in the
beginning of follow-up, and an overestimation at a later stage. Thus, the
values of the ICERs differ, resulting in £ 8,095, £ 12,344 and £ 11,691 in the
dODE, BODE and BMM.
In contrast, systematic calibration approaches result in comparable ICERs.
The Bayesian models are calibrated through Bayesian calibration approa-
ches, whereas the dODE is calibrated through a frequentist probabilistic
calibration approach. When Bayesian calibration is conducted, an impor-
tant advantage of the BMM is that the model runs 44 times faster than the
BODE. Time series data on the number of people in the states in the first
five years of follow-up are used for calibration. The corresponding outcomes
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fit the data well; the ICERs result in values of £ 7,203, £ 6,055 and £ 6,288 in
the dODE, BODE and BMM. The ICERs obtained through direct calibration
approaches are very similar to those of the first analysis which is conducted
without simulated data. The ICERs of the visual (not systematic) calibration
approach differ considerably. Finally, we can conclude that the predictions of
deterministic models including fixed parameter values can be considerably
improved if the corresponding parameters are informed in a proper way (e.g.
through multilinear loss functions), or if the model outcome is calibrated to
time series data using a systematic calibration approach.
An important difference between the BMM and ODE-based models is
the specification of time. If the Markov cycle length (the interval length of the
follow-up) is specified properly considering the medical context, a discrete-
time approach does not seem to impact the results since the model outcome
with and without half-cycle correction is identical in all scenarios conducted.
Furthermore, the results of the BMM and the BODE, which are based on
discrete- and continous-time approaches, respectively, are basically identi-
cal.
7.2.2 Cost-effectiveness analysis of human papillomavirus
vaccination
As shown in Chapter 6, our results indicate universal vaccination targeting
the same age group (twelve years) to be an extremely cost-effective strategy
in comparison to screening-only or to a single cohort of females vaccinated
at the age of twelve years. The discounted costs per QALY gained corre-
spond to e1,500 (EVPI = e3.7 per subject) and e11,600 (EVPI = e2.2 per
subject), respectively. These values are well below the monetary threshold
of sustainability for health interventions.
Moreover, recent research indicates that vaccinating individuals with only
two doses of the HPV vaccine is sufficient to prevent HPV infection [236],
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thus reducing vaccination expenses. The conservative vaccination schedule
includes three doses for full protection; it therefore strengthens the evidence
that universal vaccination can be a cost-effective intervention.
The HPV model differs from previous studies in six ways: i) incorpora-
tion of the full set of HPV-induced diseases (apart from recurrent respiratory
papillomatosis (RRP)); ii) a lifelong duration of vaccine-induced immunity
without booster application; iii) a comparatively low unit cost of vaccination;
iv) a very high vaccine coverage rate; v) a comparatively low vaccine effi-
cacy; and vi) a shorter follow-up of 55 years. Points i) - iii) contribute to lower
ICER values, whereas points iv) - vi) tend to increase them.
The following four aspects seem to drive the results of the health eco-
nomic evaluation [200,254]:
• the dynamic force of infection, incorporating sexual mixing between
females and males, thus automatically considering changes in mixing
patterns and population prevalence over time. In contrast, a static
force of infection in standard MMs only depends on covariates such
as age;
• the inclusion of a high variety of HPV-induced diseases compared to
other health economic evaluations which only account for cervical can-
cer [140,339,392];
• the assumption of lifelong immunity following initial HPV-vaccination
with three doses, without the necessity of a booster application, in
contrast to [140,187,277,339,392];
• the considerably low unit cost of vaccination compared to the official
list price of the vaccine on the Italian market.
In the future, the benefits of HPV vaccination will be further increased since
a nonavalent vaccine including genotypes 16, 18, 31, 33, 45, 52, 58, 6 and
11 is being developed. The preliminary results of the corresponding clinical
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trials are promising [80]. Therefore, the cost-effectiveness of universal HPV
vaccination is likely to further improve, creating added potential to optimise
the control of HPV-induced diseases.
7.3 Conclusions
The BMM is a highly suitable approach for infectious disease modelling in
a health economic context for a variety of reasons. Decision makers are
commonly familiar with MMs. At the same time, the shortcoming of stan-
dard MMs which are static by definition is avoided; including the effects of
herd immunity is essential when pathogens transmissible between humans
are modelled to obtain realistic results. In the Bayesian setting, parameter
uncertainty is accounted for, and PSA can be conducted straightforwardly
by means of the probabilistic model output. Furthermore, in the BMM, the
disadvantages of ODE-based models such as the commonly fixed param-
eter values (often informed through point estimates), the related difficulties
in conducting PSA, the necessity of numerical approximations to solutions
and the corresponding errors do not play a role. Through the case study,
we clearly show that our methodology realistically accounts for population
dynamics and changes in population prevalence over time; the prevalence
outcome of the BODE and the BMM are basically identical.
Our methodology is especially suitable to conduct a cost-effectiveness
analysis of HPV vaccination. Due to the nature of HPV, the model specifi-
cation is considerably complex. In our HPV model, 58 states, 24 age co-
horts, two sexual behaviour groups and the entering of new individuals are
incorporated. In addition, parameter uncertainty is accounted for which is
essential since several key parameters cannot be estimated with precision.
For example, the probability of HPV transmission between sexual partners
cannot be investigated in clinical trials due to ethical restrictions, and only
observational studies can be conducted. The Bayesian framework enables
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the inclusion of probability distributions. Under these conditions, the compu-
tational effort of the BMM is still manageable. In contrast to the BMM, at the
current stage of research, a Bayesian ODE-based model including the same
number of states and age cohorts would increase the computational effort
to an extreme level. Even for programmers experienced in the language C++
this would not be manageable [33].
In addition to the high number of advantages, our Bayesian methodology
shows several limitations. The amount of parameter uncertainty is subject to
the availability and quality of the literature to inform the model parameters;
if no information is available, it depends on the knowledge of the medical
experts consulted. A particular challenge is the estimation of measures re-
lated to quality of life, so-called utilities, especially in rare diseases. Data to
inform utilities are commonly sparce or not available at all; if covariates such
as sex have to be considered, expert opinion is often necessary. Another
limitation is that it might be inevitable to include observable variables to esti-
mate demographic data; these could be for example birth rates of newborns
or age- and sex-specific death rates. As a consequence, no distributional
assumptions on these parameters can be made, and they remain determin-
istic.
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Appendix A
R code of the case study
In this appendix, we present the R code of the dODE, BODE and BMM for the
systematic, direct calibration approaches described in Section 3.5.2. The
dODE is implemented through one single R file. In contrast, the Bayesian
models each consist of two files; these are R files to run the models, and text
files containing the model codes in WinBUGS and JAGS, respectively. The text
files are called from within R.
In the following, we present summary tables of the input parameters,
data included, and outcome of the three models. Table A.1 is an extension
of Table 3.1 and presents the names of the input parameters in the model
code. These were chosen as self-explanatory as possible, in accordance
with the notation presented in Table 3.1.
To update non-informative priors into the corresponding posteriors and
to calibrate the model outcome, simulated data are included into the models.
These are summarized in Table A.2 and consist of individual-level data on
the yearly numbers of partners as well as the numbers of observed people
and people with events. The former are included in the Poisson-Gamma
models, whereas the latter are used in the Beta-Binomial models. In addi-
tion, time series data on the numbers of people in the states over follow-up
are relevant for the probabilistic calibration approaches. More specific infor-
mation on these data is given in Section 3.4.
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Table A.1: Overview of the names of the input parameters in the programme
codes of the deterministic and probabilistic ODE systems as well as
the Bayesian Markov model
Parameter Description Name in code Parameter Description Name in code
ωMH Partner acquisi-
tion rate (high-
risk males)
rmalH α Vaccine cover-
age parameter
pi
ωML Partner acquisi-
tion rate (low-
risk males)
rmalL γ Vaccine efficacy
parameter
eff
ωFH Partner acquisi-
tion rate (high-
risk females)
rfemH cscreen Unit cost of
screening in £
c.screen
ωFL Partner acquisi-
tion rate (low-
risk females)
rfemL cvac Unit cost of vac-
cination in £
c.vac
χ Proliferation pa-
rameter
chi ctest Unit cost of STI
test in £
c.test.sti
β STI transmis-
sion probability
per partnership
beta cblood Unit cost of
blood test in £
c.test.blood
pi2,3 and ρ2,3 Transition pa-
rameter from
state 2 to state
3
piia and rhoia ctreat Unit cost of
treatment in £
c.trt
pi3,4 and ρ3,4 Transition pa-
rameter from
state 3 to state
4
piam and rhoam cdis Unit cost of dis-
ease treatment
in £
c.trt.dis
pi4,5 and ρ4,5 Transition pa-
rameter from
state 4 to state
5
pimd and rhomd cgp Unit cost of visit
to general prac-
titioner in £
c.gp
pi1,5 and ρ1,5 Transition pa-
rameter from
state 1 to state
5
pisd and rhosd u2 Health utility of
infected
u.inf
η Probability of
STI diagnosis
diag u3 Health utility of
asymptomatic
u.asym
σ Screening prob-
ability
screen u4 Health utility of
morbid
u.morb
The outputs of the three models consist of the number of people in the
states over follow-up, separately for the two sexes and behaviour groups.
These are given in array form, including three dimensions. The correspond-
ing numbering of the states in the dODE (shown in Table A.3) differs from
the BODE and BMM (shown in Table A.4).
In the dODE, the first dimension consists of the number of parameter
sets created (50,000), whereas the second dimension includes the year t
of observation (100). The third dimension includes the states per sex and
behaviour group, the overall sample size per sex and behaviour group as
well as the respective year of follow-up, resulting in a value of 25. Thus, the
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Table A.2: Overview of the data included in the models; only the time series data
are included in the deterministic ODE system.
Data set Description
datfemH Individual-level data on yearly numbers of partners in high-risk females
datmalH Individual-level data on yearly numbers of partners in high-risk males
datfemL Individual-level data on yearly numbers of partners in low-risk females
datmalL Individual-level data on yearly numbers of partners in low-risk males
popsize Sample size in individual-level data on yearly numbers of partners
r.beta Number of successes in STI transmission
n.beta Number observed in terms of STI transmission
r.eff Number of successes in vaccine efficacy
n.eff Number observed in terms of vaccine efficacy
r.pi Number covered by STI vaccine
n.pi Number observed in terms of vaccine application
r.screen Number of successes in screening
n.screen Number observed in terms of screening
r.diag Number of successes in diagnosis
n.diag Number observed in terms of diagnosis
dat.sus.femH Time series data on numbers of high-risk susceptible females
dat.inf.femH Time series data on numbers of high-risk infected females
dat.asy.femH Time series data on numbers of high-risk asymptomatic females
dat.mor.femH Time series data on numbers of high-risk morbid females
dat.sus.malH Time series data on numbers of high-risk susceptible males
dat.inf.malH Time series data on numbers of high-risk infected males
dat.asy.malH Time series data on numbers of high-risk asymptomatic males
dat.mor.malH Time series data on numbers of high-risk morbid males
overall size of the array output_dode is 50, 000 × 100 × 25. The parameter
set with best fit is selected through model calibration and corresponds to the
least sum of squared errors. This is indicated by the index gof in the first
dimension of the array. For example, the number of high-risk susceptible fe-
males per year of follow-up is given by output_dode[gof,t,2]. The numbering
of all states (in the third dimension) is shown in Table A.3. The array out-
put_dode only includes the results of the intervention screening; the results
of the intervention vaccination are stored in the data frame dode_vac with
rows representing year t and columns representing the states; the number-
ing of the states is identical to output_dode.
The arrays solution and y contain the output of the BODE and BMM, re-
spectively. Their dimensions differ from output_dode; solution and y include
the years of follow-up t (100) and the states per sex and behaviour group
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Table A.3: Overview of the numbering of the states in the output of the determinis-
tic ODE system
Deterministic ODE-based model
Output Description Output Description
output_dode[gof,t,2] High-risk susceptible females output_dode[gof,t,12] Low-risk susceptible females
output_dode[gof,t,3] High-risk infected females output_dode[gof,t,13] Low-risk infected females
output_dode[gof,t,4] High-risk asympt. females output_dode[gof,t,14] Low-risk asympt. females
output_dode[gof,t,5] High-risk morbid females output_dode[gof,t,15] Low-risk morbid females
output_dode[gof,t,6] High-risk dead females output_dode[gof,t,16] Low-risk dead females
output_dode[gof,t,7] High-risk susceptible males output_dode[gof,t,17] Low-risk susceptible males
output_dode[gof,t,8] High-risk infected males output_dode[gof,t,18] Low-risk infected males
output_dode[gof,t,9] High-risk asympt. males output_dode[gof,t,19] Low-risk asympt. males
output_dode[gof,t,10] High-risk morbid males output_dode[gof,t,20] Low-risk morbid males
output_dode[gof,t,11] High-risk dead males output_dode[gof,t,21] Low-risk dead males
Table A.4: Overview of the numbering of the states in the output of the probabilistic
ODE system and the Bayesian Markov model
Bayesian ODE-based and Bayesian Markov model
Output Description Output Description
solution[t,1,i] and y[t,1,i] Low-risk susceptible females solution[t,11,i] and y[t,11,i] Low-risk susceptible males
solution[t,2,i] and y[t,2,i] Low-risk infected females solution[t,12,i] and y[t,12,i] Low-risk infected males
solution[t,3,i] and y[t,3,i] Low-risk asymptomatic females solution[t,13,i] and y[t,13,i] Low-risk asymptomatic males
solution[t,4,i] and y[t,4,i] Low-risk morbid females solution[t,14,i] and y[t,14,i] Low-risk morbid males
solution[t,5,i] and y[t,5,i] Low-risk dead females solution[t,15,i] and y[t,15,i] Low-risk dead males
solution[t,6,i] and y[t,6,i] High-risk susceptible females solution[t,16,i] and y[t,16,i] High-risk susceptible males
solution[t,7,i] and y[t,7,i] High-risk infected females solution[t,17,i] and y[t,17,i] High-risk infected males
solution[t,8,i] and y[t,8,i] High-risk asymptomatic females solution[t,18,i] and y[t,18,i] High-risk asymptomatic males
solution[t,9,i] and y[t,9,i] High-risk morbid females solution[t,19,i] and y[t,19,i] High-risk morbid males
solution[t,10,i] and y[t,10,i] High-risk dead females solution[t,20,i] and y[t,20,i] High-risk dead males
(20) per intervention i (2). Thus, the overall array size is 100 × 20 × 2. The
second dimension represents the numbering of the states. For example, the
number of low-risk susceptible females in year t in intervention i (1=screen-
ing, 2=vaccination) is given by solution[t,1,i] and y[t,1,i] in the BODE and
BMM, respectively. The numbering of all states is listed in Table A.4.
A.1 The deterministic ODE-based model
The dODE is implemented by means of the R-package EpiModel. In order to
select a parameter set with best fit to the time series data, 50,000 parame-
ter sets are created through forward sampling. In the intervention screening,
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the model is run for each parameter set, and the parameter set correspond-
ing to the least sum of squared errors is identified as described in Section
3.5.2. In the intervention vaccination, the model is only run once since we
assume that no data are available for calibration.
1 #save s t a r t o f run t ime
2 ptm <− proc . t ime ( )
3 #set seed
4 set . seed (2188)
5 #set working d i r e c t o r y
6 setwd ( "C: / Users / k a t r i n / Dropbox / TestModel /R code and CE r e s u l t s /
Comparison MSM and ODE/ F ina l code / ThesisAppendix / " )
7 # f u n c t i o n to est imate shape and ra te parameters o f the gamma
d i s t r i b u t i o n when mean and standard d e v ia t i o n are known
8 gammaPar <− f u n c t i o n (m, s ) {
9 a <− (m^2) / ( s ^2)
10 b <− m/ ( s ^2)
11 l i s t ( a=a , b=b )
12 }
13 # es t ima t ing shape and ra te o f gamma d i s t r i b u t i o n o f pa r tne r
a c q u i s i t i o n ra te i n high−r i s k females
14 mean . datfemH=9
15 sd . datfemH=1.026698
16 alpha . datfemH=gammaPar (mean . datfemH , sd . datfemH ) $a
17 beta . datfemH=gammaPar (mean . datfemH , sd . datfemH ) $b
18 # par tne r a c q u i s i t i o n ra te i n low−r i s k females
19 mean . datfemL =1.958
20 sd . datfemL=0.7857932
21 alpha . datfemL=gammaPar (mean . datfemL , sd . datfemL ) $a
22 beta . datfemL=gammaPar (mean . datfemL , sd . datfemL ) $b
23 # par tne r a c q u i s i t i o n ra te i n high−r i s k males
24 mean . datmalH=9.058
25 sd . datmalH=1.075616
26 alpha . datmalH=gammaPar (mean . datmalH , sd . datmalH ) $a
27 beta . datmalH=gammaPar (mean . datmalH , sd . datmalH ) $b
28 # par tne r a c q u i s i t i o n ra te i n low−r i s k males
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29 mean . datmalL =2.976
30 sd . datmalL =0.7158554
31 alpha . datmalL=gammaPar (mean . datmalL , sd . datmalL ) $a
32 beta . datmalL=gammaPar (mean . datmalL , sd . datmalL ) $b
33 #### c rea t i on o f 50 ,000 parameter sets
34 nsets=50000
35 # ar ray f o r r e s u l t s o f outputs o f dODE
36 output_dode=ar ray (0 , c ( nsets ,100 ,25) )
37 # d i s t r i b u t i o n s o f pa r tne r a c q u i s i t i o n ra tes
38 rfemH . dode=rgamma( nsets , alpha . datfemH , beta . datfemH )
39 rfemL . dode=rgamma( nsets , alpha . datfemL , beta . datfemL )
40 rmalH . dode=rgamma( nsets , alpha . datmalH , beta . datmalH )
41 rmalL . dode=rgamma( nsets , alpha . datmalL , beta . datmalL )
42 # d i s t r i b u t i o n o f reproduc t ion ra te
43 ch i . dode=rgamma( nsets ,1111.1 ,111111.1)
44 # d i s t r i b u t i o n s o f t r a n s i t i o n ra tes
45 rho ia . dode=rgamma( nsets ,25600 ,32000)
46 rhoam . dode=rgamma( nsets ,2025 ,22500)
47 rhomd . dode=rgamma( nsets ,0.6944444 ,69.44444)
48 rhosd . dode=rgamma( nsets ,156.25 ,312500)
49 # d i s t r i b u t i o n o f STI t ransmiss ion p r o b a b i l i t i e s
50 beta . dode=rbeta ( nsets ,16.20667 ,108.46)
51 # d i s t r i b u t i o n o f p r o b a b i l i t i e s o f d iagnos is
52 diag . dode=rbeta ( nsets ,809 .1 ,89 .9 )
53 # d i s t r i b u t i o n o f screening p r o b a b i l i t i e s
54 screen . dode=rbeta ( nsets ,809 .1 ,89 .9 )
55 # d i s t r i b u t i o n o f vaccine coverage p r o b a b i l i t y
56 p i . dode=rbeta ( nsets ,809 .1 ,89 .9 )
57 #sets o f vaccine e f f i c a c y
58 e f f . dode=rbeta ( nsets ,809 .1 ,89 .9 )
59 # d i s t r i b u t i o n s o f costs
60 c . screen . dode=r lnorm ( nsets ,2 .996 ,0 .693)
61 c . vac . dode=r lnorm ( nsets ,5.518352 ,0.07986607)
62 c . t e s t . s t i . dode=r lnorm ( nsets ,2 .996 ,0 .03 )
63 c . t e s t . blood . dode=r lnorm ( nsets ,3 .401 ,0 .03 )
64 c . t r t . dode=r lnorm ( nsets ,4.258597 ,0.8325546)
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65 c . t r t . d i s . dode=r lnorm ( nsets ,6.194998 ,0.1980422)
66 c . gp . dode=r lnorm ( nsets ,3 .912 ,0 .02 )
67 # d i s t r i b u t i o n s o f hea l th u t i l i t i e s
68 u . i n f . dode=rbeta ( nsets ,1469.3 ,629.7)
69 u . asym . dode=rbeta ( nsets ,1439.4 ,959 .6)
70 u . morb . dode=rbeta ( nsets ,629 .7 ,1469.3)
71 ###dODE implemented through R package EpiModel
72 # load ing package i n c l u d i n g ODE so lve r
73 l i b r a r y ( deSolve )
74 # load ing package to implement ODE system
75 l i b r a r y ( EpiModel )
76 #Funct ion con ta in ing the ODEs; t and t0 are def ined by f u n c t i o n
c a l l o f c o n t r o l . dcm; parms are def ined by params i n f u n c t i o n
c a l l o f dcm; f u n c t i o n i s c a l l e d separa te ly f o r both
i n t e r v e n t i o n s
77 Qmod <− f u n c t i o n ( t , t0 , parms ) {
78 # t0 and parms def ined as l i s t
79 wi th ( as . l i s t ( c ( t0 , parms ) ) , {
80 #Dynamic Ca lcu la t i ons
81 #Sample s ize i n high−r i s k females , high−r i s k males , low−r i s k
females and low−r i s k males : those who are a l i v e ( a l l s ta tes
apar t from Death )
82 nfemH = sfemH+ifemH+afemH+mfemH
83 nmalH = smalH+imalH+amalH+mmalH
84 nfemL = sfemL+ifemL+afemL+mfemL
85 nmalL = smalL+imalL+amalL+mmalL
86 # p r o b a b i l i t y to s e l e c t a female par tne r from the high−r i s k
group
87 gfemH = ( rfemH . dode *nfemH ) / ( ( rfemH . dode *nfemH ) +( rfemL . dode *
nfemL ) )
88 # p r o b a b i l i t y to s e l e c t a female par tne r from the low−r i s k
group
89 gfemL = 1−gfemH
90 # p r o b a b i l i t y to s e l e c t a male par tne r from the high−r i s k group
91 gmalH = ( rmalH . dode *nmalH ) / ( ( rmalH . dode *nmalH ) +( rmalL . dode *
nmalL ) )
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92 # p r o b a b i l i t y to s e l e c t a male par tne r from the low−r i s k group
93 gmalL = 1−gmalH
94 #prevalence i n females : weighted average of i n f ec t e d s i n the
high− and low−r i s k groups
95 pfem = gfemH* ( ifemH / nfemH ) +gfemL * ( i femL / nfemL )
96 #prevalence i n males : weighted average of i n f e c t e d males i n
the high− and low−r i s k groups
97 pmal = gmalH* ( imalH / nmalH ) +gmalL * ( imalL / nmalL )
98 # Force of i n f e c t i o n according to sex and r i s k group . In
i n t e r v e n t i o n STI screening , p i . ode=1 and e f f . dode=0; the re fo re ,
on ly f i r s t term of sum i s considered .
99 # In i n t e r v e n t i o n vacc ina t ion , fo rce o f i n f e c t i o n i s reduced
by those who are covered ( p i . dode ) by (1− e f f . dode ) .
100 lambdafemH <− ( p i . dode * (1− e f f . dode ) * ( beta . dode * rfemH . dode * pmal
) ) +((1− p i . dode ) * ( beta . dode * rfemH . dode * pmal ) )
101 lambdafemL <− ( p i . dode * (1− e f f . dode ) * ( beta . dode * rfemL . dode * pmal
) ) +((1− p i . dode ) * ( beta . dode * rfemL . dode * pmal ) )
102 lambdamalH <− ( p i . dode * (1− e f f . dode ) * ( beta . dode * rmalH . dode * pfem
) ) +((1− p i . dode ) * ( beta . dode * rmalH . dode * pfem ) )
103 lambdamalL <− ( p i . dode * (1− e f f . dode ) * ( beta . dode * rmalL . dode * pfem
) ) +((1− p i . dode ) * ( beta . dode * rmalL . dode * pfem ) )
104 # D i f f e r e n t i a l Equations
105 #High−r i s k females
106 dSfemH = ch i . dode *nfemH−lambdafemH*sfemH−rhosd . dode *sfemH
107 dIfemH = lambdafemH*sfemH−rho ia . dode * ifemH−rhosd . dode * ifemH
108 dAfemH = rho ia . dode * ifemH−rhoam . dode *afemH−rhosd . dode *afemH
109 dMfemH = rhoam . dode *afemH−rhomd . dode *mfemH−rhosd . dode *mfemH
110 dDfemH = rhomd . dode *mfemH+rhosd . dode *nfemH
111 #Low−r i s k females
112 dSfemL = ch i . dode *nfemL−lambdafemL * sfemL−rhosd . dode * sfemL
113 dIfemL = lambdafemL * sfemL−rho ia . dode * ifemL−rhosd . dode * ifemL
114 dAfemL = rho ia . dode * ifemL−rhoam . dode *afemL−rhosd . dode * afemL
115 dMfemL = rhoam . dode *afemL−rhomd . dode *mfemL−rhosd . dode *mfemL
116 dDfemL = rhomd . dode *mfemL+rhosd . dode * nfemL
117 #High−r i s k males
118 dSmalH = ch i . dode *nmalH−lambdamalH *smalH−rhosd . dode *smalH
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119 dImalH = lambdamalH *smalH−rho ia . dode * imalH−rhosd . dode * imalH
120 dAmalH = rho ia . dode * imalH−rhoam . dode *amalH−rhosd . dode *amalH
121 dMmalH = rhoam . dode *amalH−rhomd . dode *mmalH−rhosd . dode *mmalH
122 dDmalH = rhomd . dode *mmalH+rhosd . dode *nmalH
123 #Low−r i s k males
124 dSmalL = ch i . dode * nmalL−lambdamalL * smalL−rhosd . dode * smalL
125 dImalL = lambdamalL * smalL−rho ia . dode * imalL−rhosd . dode * imalL
126 dAmalL = rho ia . dode * imalL−rhoam . dode * amalL−rhosd . dode * amalL
127 dMmalL = rhoam . dode * amalL−rhomd . dode *mmalL−rhosd . dode *mmalL
128 dDmalL = rhomd . dode *mmalL+rhosd . dode * nmalL
129 #Output : number o f i n d i v i d u a l s i n the s ta tes per covar ia te ,
sample s ize per covar ia te , f o r the whole observa t ion t ime
per iod
130 l i s t ( c (dSfemH , dIfemH , dAfemH , dMfemH, dDfemH ,
131 dSmalH , dImalH , dAmalH , dMmalH , dDmalH ,
132 dSfemL , dIfemL , dAfemL , dMfemL , dDfemL ,
133 dSmalL , dImalL , dAmalL , dMmalL , dDmalL ) ,
134 nfemH = nfemH , nfemL = nfemL , nmalH = nmalH ,
135 nmalL = nmalL )
136 } )
137 }
138 # i n i t i a l i z a t i o n through f u n c t i o n c a l l i n i t . dcm:
139 i n i t <− i n i t . dcm( sfemH=100000−60, ifemH=60 , afemH=0 , mfemH=0 ,
dfemH=0 , smalH=100000−60, imalH =60 , amalH=0 , mmalH=0 , dmalH=0 ,
sfemL=400000−240, i femL =240 , afemL=0 , mfemL=0 , dfemL=0 , smalL
=400000−240, imalL =240 , amalL=0 , mmalL=0 , dmalL=0)
140 #Funct ion c a l l o f c o n t r o l . dcm: nsteps : number o f t ime steps the
model i s solved f o r (100) , new .mod: s ince no b u i l t −i n model i s
run , f u n c t i o n Qmod con ta in ing the model i s s p e c i f i e d
141 c o n t r o l <− c o n t r o l . dcm( nsteps = 100 , new .mod = Qmod)
142 # c a l l i n g f u n c t i o n Qmod f o r each of the 50 ,000 parameter sets
143 f o r ( s i n 1 : nsets ) {
144 param <− param .dcm( rfemH . dode = rfemH . dode [ s ] , rfemL . dode= rfemL .
dode [ s ] , rmalH . dode = rmalH . dode [ s ] , rmalL . dode = rmalL . dode [ s
] , ch i . dode = ch i . dode [ s ] , beta . dode=beta . dode [ s ] , rho ia . dode=
rho ia . dode [ s ] , rhoam . dode=rhoam . dode [ s ] , rhomd . dode=rhomd . dode [
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s ] , rhosd . dode=rhosd . dode [ s ] , e f f . dode=0 , p i . dode=1)
145 #parameter t r a n s f e r , i n i t i a l i z a t i o n , s p e c i f i c a t i o n o f observa t ion
t ime hor izon and model through c a l l o f dcm f u n c t i o n
146 mod <− dcm( param , i n i t , c o n t r o l )
147 #output i s saved i n data frame dode
148 dode = as . data . frame (mod)
149 # t rans fo rma t i on o f data frame to mat r i x
150 dode2=as . mat r i x ( dode )
151 #outputs o f a l l 50 ,000 model runs are saved i n output_dode
152 output_dode [ s , , ] = dode2
153 }
154 ###GOF c a l c u l a t i o n
155 #sum of squared e r r o r s o f model outcome i n f i r s t 5 years o f
observa t ion t ime and t ime se r i es data dat
156 #dat . sus . femH [ t ] : number o f suscep t i b l e high−r i s k females a t t ime
t
157 #dat . i n f . femH [ t ] : number o f i n f e c t e d high−r i s k females a t t ime t
158 #dat . asy . femH [ t ] : number o f asymptomatic high−r i s k females a t t ime
t
159 #dat . mor . femH [ t ] : number o f morbid high−r i s k females a t t ime t
160 # no ta t i on f o r males i s equ iva len t
161 gof = ( ( dat . sus . femH [ 1 ] − output_dode [ , 1 , 2 ] ) ^2 + ( dat . sus . femH [ 2 ]
162 − output_dode [ , 2 , 2 ] ) ^2 + ( dat . sus . femH [ 3 ] − output_dode [ , 3 , 2 ] ) ^2
163 + ( dat . sus . femH [ 4 ] − output_dode [ , 4 , 2 ] ) ^2 + ( dat . sus . femH [ 5 ]
164 − output_dode [ , 5 , 2 ] ) ^2 + ( dat . i n f . femH [ 1 ] − output_dode [ , 1 , 3 ] ) ^2
165 + ( dat . i n f . femH [ 2 ] − output_dode [ , 2 , 3 ] ) ^2 + ( dat . i n f . femH [ 3 ]
166 − output_dode [ , 3 , 3 ] ) ^2 + ( dat . i n f . femH [ 4 ] − output_dode [ , 4 , 3 ] ) ^2
167 + ( dat . i n f . femH [ 5 ] − output_dode [ , 5 , 3 ] ) ^2 + ( dat . asy . femH [ 1 ]
168 − output_dode [ , 1 , 4 ] ) ^2 + ( dat . asy . femH [ 2 ] − output_dode [ , 2 , 4 ] ) ^2
169 + ( dat . asy . femH [ 3 ] − output_dode [ , 3 , 4 ] ) ^2 + ( dat . asy . femH [ 4 ]
170 − output_dode [ , 4 , 4 ] ) ^2 + ( dat . asy . femH [ 5 ] − output_dode [ , 5 , 4 ] ) ^2
171 + ( dat . mor . femH [ 1 ] − output_dode [ , 1 , 5 ] ) ^2 + ( dat . mor . femH [ 2 ]
172 − output_dode [ , 2 , 5 ] ) ^2 + ( dat . mor . femH [ 3 ] − output_dode [ , 3 , 5 ] ) ^2
173 + ( dat . mor . femH [ 4 ] − output_dode [ , 4 , 5 ] ) ^2 + ( dat . mor . femH [ 5 ]
174 − output_dode [ , 5 , 5 ] ) ^2 + ( dat . sus . malH [ 1 ] − output_dode [ , 1 , 7 ] ) ^2
175 + ( dat . sus . malH [ 2 ] − output_dode [ , 2 , 7 ] ) ^2 + ( dat . sus . malH [ 3 ]
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176 − output_dode [ , 3 , 7 ] ) ^2 + ( dat . sus . malH [ 4 ] − output_dode [ , 4 , 7 ] ) ^2
177 + ( dat . sus . malH [ 5 ] − output_dode [ , 5 , 7 ] ) ^2 + ( dat . i n f . malH [ 1 ]
178 − output_dode [ , 1 , 8 ] ) ^2 + ( dat . i n f . malH [ 2 ] − output_dode [ , 2 , 8 ] ) ^2
179 + ( dat . i n f . malH [ 3 ] − output_dode [ , 3 , 8 ] ) ^2 + ( dat . i n f . malH [ 4 ]
180 − output_dode [ , 4 , 8 ] ) ^2 + ( dat . i n f . malH [ 5 ] − output_dode [ , 5 , 8 ] ) ^2
181 + ( dat . asy . malH [ 1 ] − output_dode [ , 1 , 9 ] ) ^2 + ( dat . asy . malH [ 2 ]
182 − output_dode [ , 2 , 9 ] ) ^2 + ( dat . asy . malH [ 3 ] − output_dode [ , 3 , 9 ] ) ^2
183 + ( dat . asy . malH [ 4 ] − output_dode [ , 4 , 9 ] ) ^2 + ( dat . asy . malH [ 5 ]
184 − output_dode [ , 5 , 9 ] ) ^2 + ( dat . mor . malH [ 1 ] − output_dode [ , 1 , 1 0 ] )
185 ^2 + ( dat . mor . malH [ 2 ] − output_dode [ , 2 , 1 0 ] ) ^2 + ( dat . mor . malH [ 3 ]
186 − output_dode [ , 3 , 1 0 ] ) ^2 + ( dat . mor . malH [ 4 ] − output_dode [ , 4 , 1 0 ] )
187 ^2 + ( dat . mor . malH [ 5 ] − output_dode [ , 5 , 1 0 ] ) ^2)
188 # s e l e c t i n g the parameter set w i th the l e a s t sum of squared e r r o r s
189 index=which ( gof == min ( gof ) )
190 #save the end of model run t ime
191 t ime=proc . t ime ( )−ptm
192 #save the outputs o f the 50 ,000 model runs , the GOF−s t a t i s t i c s ,
and the index wi th the l e a s t sum of squared e r r o r s
193 save ( output_dode , gof , index , f i l e = " dode . RData " )
194 #### vacc ina t i on
195 #No t ime se r i es data are a v a i l a b l e f o r the vacc ina t i on scenar io ;
thus , the parameters are not se lec ted through c a l i b r a t i o n , and
informed by the means of the d i s t r i b u t i o n s .
196 param_vac <− param .dcm( rfemH . dode = mean( rfemH . dode ) , rfemL . dode=
mean( rfemL . dode ) , rmalH . dode = mean( rmalH . dode ) ,
197 rmalL . dode = mean( rmalL . dode ) , ch i . dode = mean( ch i . dode ) , beta .
dode=mean( beta . dode ) , rho ia . dode = mean( rho ia . dode ) , rhoam . dode
= mean( rhoam . dode ) , rhomd . dode=mean( rhomd . dode ) , rhosd . dode =
mean( rhosd . dode ) , e f f . dode=mean( e f f . dode ) , p i . dode=mean( p i . dode
) )
198 # f u n c t i o n c a l l o f Qmod
199 mod_vac <− dcm( param_vac , i n i t , c o n t r o l )
200 #saving outcome as data frame
201 dode_vac = as . data . frame (mod_vac )
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A.2 The Bayesian ODE-based model
The Bayesian ODE-based model is implemented in the WinBUGS interface
WBDiff and linked to R through the package R2WinBUGS. Bayesian calibra-
tion takes place directly in the model by assigning Poisson distributions to
time series data. The event rates correspond to the model outcome on the
number of high-risk people in the states as described in Section 3.5.2. The
code of the BODE consists of two files; these include an R script and a text
file containing the WinBUGS model which is called from inside R. The text file
is called Model_BODE.txt and has to be saved in a separate file in order to
run the model.
1 #save s t a r t o f computat ion t ime
2 ptm=proc . t ime ( )
3 #set working d i r e c t o r y
4 setwd ( "C : / Users / k a t r i n / Dropbox / TestModel /R code and CE r e s u l t s /
Comparison MSM and ODE/ F ina l code / ThesisAppendix / " )
5 # I n t e r f a c e connect ing R to WinBUGS
6 l i b r a r y (R2WinBUGS)
7 # load workspace i n c l u d i n g i n d i v i d u a l− l e v e l data to update p r i o r s
8 load ( "WS. RData " )
9 # load workspace i n c l u d i n g t ime se r i es data f o r Bayesian model
c a l i b r a t i o n
10 load ( " States_Data_New2 . RData " )
11 # t e x t f i l e i n c l u d i n g the WinBUGS code
12 model . f i l e = "Model_BODE . t x t "
13 #data input , n . g r i d : number o f t ime po in t s est imated , dim : number
o f s ta tes , o r i g i n : observa t ion s t a r t a t t =1 , t o l = to le rance
leve l , g r i d = observa t ion t ime hor izon , datfemH= i n d i v i d u a l− l e v e l
data on yea r l y numbers o f par tne rs i n high−r i s k females (
s i m i l a r f o r the o ther sex and r i s k group ) , popsize=sample s ize
i n data on par tne r a c q u i s i t i o n rates , r . beta=number o f people
who became in fec ted , n . beta=number o f people observed ( s i m i l a r
f o r vaccine coverage , e f f i c a c y , screening , and d iagnos is ) , dat .
sus . femH=t ime se r i es data on number o f high−r i s k suscep t i b l e
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females ( s i m i l a r f o r o ther s ta tes and high−r i s k males )
14 dataWin <− l i s t ( n . g r i d = 100 , dim = 20 , o r i g i n = 1 , t o l = 0.001 ,
g r i d = seq (1 ,100 ,1) , datfemH = datfemH , datmalH = datmalH ,
datfemL = datfemL , datmalL = datmalL , popsize = popsize , r . beta
= r . beta , n . beta = n . beta , r . e f f = r . e f f , n . e f f = n . e f f , r . p i
= r . p i , n . p i = n . p i , r . screen = r . screen , n . screen = n . screen ,
r . d iag = r . diag , n . diag = n . diag , dat . sus . femH = dat . sus . femH ,
dat . i n f . femH = dat . i n f . femH , dat . asy . femH = dat . asy . femH , dat .
mor . femH = dat . mor . femH , dat . sus . malH = dat . sus . malH , dat . i n f .
malH = dat . i n f . malH , dat . asy . malH = dat . asy . malH , dat . mor . malH
= dat . mor . malH )
15 #parameter i n i t i a l i z a t i o n
16 i n i t s <− f u n c t i o n ( ) { l i s t ( rfemH= r u n i f ( 1 ) , rfemL= r u n i f ( 1 ) , rmalL=
r u n i f ( 1 ) , ch i= r u n i f ( 1 ) , beta= r u n i f ( 1 ) , e f f = r u n i f ( 1 ) , p i = r u n i f
( 1 ) , screen= r u n i f ( 1 ) , d iag= r u n i f ( 1 ) )
17 }
18 #parameters , s o l u t i o n : outcome on the number o f people i n the
s ta tes over fo l l ow−up f o r both sexes and r i s k groups , r :
pa r tne r a c q u i s i t i o n rates , ch i : rep roduc t ion rate , rho :
t r a n s i t i o n rates , beta : p r o b a b i l i t y o f STI t ransmiss ion , p i :
vaccine coverage , e f f : vaccine e f f i c a c y , screen : p r o b a b i l i t y o f
screening , diag : p r o b a b i l i t y o f d iagnosis , c : costs , u :
u t i l i t i e s
19 parameters <− c ( " s o l u t i o n " , " rfemH " , " rfemL " , " rmalH " , " rmalL " , "
ch i " , " rho ia " , " rhoam " , " rhomd " , " rhosd " , " beta " , " p i " , " e f f " ,
" screen " , " d iag " , " c . screen " , " c . vac " , " c . t e s t . s t i " , " c . t e s t .
blood " , " c . t r t " , " c . t r t . d i s " , " c . gp " , " u . i n f " , " u . asym" , " u .
morb " )
20 #run the model f o r 2 chains , 1000 s imu la t ions , w i thou t t h i n n i n g
21 simODE <− bugs ( data=dataWin , i n i t s = i n i t s , parameters . to . save=
parameters , model . f i l e =model . f i l e , n . chains =2 , n . i t e r =1000 , n .
t h i n =1 , DIC=F , debug=F , bugs . d i r e c t o r y =" c : / Program F i l e s /
winbugs14 /WinBUGS14 / " )
22 # at tach output to R
23 at tach . bugs (simODE)
24 #save end of computat ion t ime
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25 t ime=proc . t ime ( )−ptm
26
27 ###WinBUGS model f i l e Model_BODE . t x t −−> has to be saved i n
separate t e x t f i l e
28 model {
29 # def ine ODEs i n WBDiff syntax
30 s o l u t i o n [ 1 : n . g r id , 1 : dim ,1:2] <−ode ( i n i t [ 1 : dim , 1 : 2 ] , g r i d [ 1 : n . g r i d ] ,D
( y [ 1 : dim , 1 : 2 ] , t ) , o r i g i n , t o l )
31 # f o r i n t e r v e n t i o n s i =1 ( screening only ) and i =2 ( vacc ina t i on )
32 f o r ( i i n 1 :2 ) {
33 #ODEs f o r low−r i s k females
34 # Suscept ib le
35 D( y [1 , i ] , t ) <−ch i * nfemL [ i ]− lambdafemL [ i ] * y [ 1 , i ]− rhosd * y [1 , i ]
36 # In fec ted
37 D( y [2 , i ] , t ) <−lambdafemL [ i ] * y [ 1 , i ]− rho ia * y [2 , i ]− rhosd * y [2 , i ]
38 #Asymptomatic
39 D( y [3 , i ] , t ) <−rho ia * y [2 , i ]−rhoam* y [3 , i ]− rhosd * y [3 , i ]
40 #Morbid
41 D( y [4 , i ] , t ) <−rhoam* y [3 , i ]−rhomd* y [4 , i ]− rhosd * y [4 , i ]
42 #Dead
43 D( y [5 , i ] , t ) <−rhosd * nfemL [ i ]+ rhomd* y [4 , i ]
44 #ODEs f o r high−r i s k females
45 # Suscept ib le
46 D( y [6 , i ] , t ) <−ch i *nfemH [ i ]−lambdafemH [ i ] * y [ 6 , i ]− rhosd * y [6 , i ]
47 # In fec ted
48 D( y [7 , i ] , t ) <−lambdafemH [ i ] * y [ 6 , i ]− rho ia * y [7 , i ]− rhosd * y [7 , i ]
49 #Asymptomatic
50 D( y [8 , i ] , t ) <−rho ia * y [7 , i ]−rhoam* y [8 , i ]− rhosd * y [8 , i ]
51 #Morbid
52 D( y [9 , i ] , t ) <−rhoam* y [8 , i ]−rhomd* y [9 , i ]− rhosd * y [9 , i ]
53 #Dead
54 D( y [10 , i ] , t ) <−rhosd *nfemH [ i ]+ rhomd* y [9 , i ]
55 #ODEs f o r low−r i s k males
56 # Suscept ib le
57 D( y [11 , i ] , t ) <−ch i * nmalL [ i ]− lambdamalL [ i ] * y [11 , i ]− rhosd * y [11 , i ]
58 # In fec ted
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59 D( y [12 , i ] , t ) <−lambdamalL [ i ] * y [11 , i ]− rho ia * y [12 , i ]− rhosd * y [12 , i ]
60 #Asymptomatic
61 D( y [13 , i ] , t ) <−rho ia * y [12 , i ]−rhoam* y [13 , i ]− rhosd * y [13 , i ]
62 #Morbid
63 D( y [14 , i ] , t ) <−rhoam* y [13 , i ]−rhomd* y [14 , i ]− rhosd * y [14 , i ]
64 #Dead
65 D( y [15 , i ] , t ) <−rhosd * nmalL [ i ]+ rhomd* y [14 , i ]
66 #ODEs f o r high−r i s k males
67 # Suscept ib le
68 D( y [16 , i ] , t ) <−ch i *nmalH [ i ]− lambdamalH [ i ] * y [16 , i ]− rhosd * y [16 , i ]
69 # In fec ted
70 D( y [17 , i ] , t ) <−lambdamalH [ i ] * y [16 , i ]− rho ia * y [17 , i ]− rhosd * y [17 , i ]
71 #Asymptomatic
72 D( y [18 , i ] , t ) <−rho ia * y [17 , i ]−rhoam* y [18 , i ]− rhosd * y [18 , i ]
73 #Morbid
74 D( y [19 , i ] , t ) <−rhoam* y [18 , i ]−rhomd* y [19 , i ]− rhosd * y [19 , i ]
75 #Dead
76 D( y [20 , i ] , t ) <−rhosd *nmalH [ i ]+ rhomd* y [19 , i ]
77 #number o f low−r i s k females a l i v e
78 nfemL [ i ] <− y [1 , i ]+ y [2 , i ]+ y [3 , i ]+ y [4 , i ]
79 #number o f high−r i s k females a l i v e
80 nfemH [ i ] <− y [6 , i ]+ y [7 , i ]+ y [8 , i ]+ y [9 , i ]
81 #number o f low−r i s k males a l i v e
82 nmalL [ i ]<−y [11 , i ]+ y [12 , i ]+ y [13 , i ]+ y [14 , i ]
83 #number o f high−r i s k males a l i v e
84 nmalH [ i ]<−y [16 , i ]+ y [17 , i ]+ y [18 , i ]+ y [19 , i ]
85 # p r o b a b i l i t y o f s e l e c t i n g a high−r i s k male par tne r
86 gmalH [ i ] <− ( rmalH *nmalH [ i ] ) / ( rmalH *nmalH [ i ]+ rmalL * nmalL [ i ] )
87 # p r o b a b i l i t y o f s e l e c t i n g a low−r i s k male par tne r
88 gmalL [ i ] <− 1−gmalH [ i ]
89 # p r o b a b i l i t y o f s e l e c t i n g a high−r i s k female par tne r
90 gfemH [ i ] <− ( rfemH *nfemH [ i ] ) / ( rfemH *nfemH [ i ]+ rfemL * nfemL [ i ] )
91 # p r o b a b i l i t y o f s e l e c t i n g a low−r i s k female par tne r
92 gfemL [ i ] <− 1−gfemH [ i ]
93 #prevalence i n males
94 pmal [ i ] <− gmalH [ i ] * ( y [17 , i ] / nmalH [ i ] ) +gmalL [ i ] * ( y [12 , i ] / nmalL [ i ] )
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95 #prevalence i n females
96 pfem [ i ] <− gfemH [ i ] * ( y [ 7 , i ] / nfemH [ i ] ) +gfemL [ i ] * ( y [ 2 , i ] / nfemL [ i ] )
97 # i n t e r v e n t i o n screening : vaccine coverage ( p i2 =1) , vaccine
e f f i c a c y ( e f f 2 =0) , i n t e r v e n t i o n vacc ina t i on : vaccine coverage (
p i2= p i ) , vaccine e f f i c a c y ( e f f 2 = e f f )
98 pi2 [ i ]<− p i * step ( i −1.1)+(1−step ( i −1.1) )
99 e f f 2 [ i ]<− e f f * step ( i −1.1)
100 # fo rce o f i n f e c t i o n i n the two r i s k groups and sexes
101 lambdafemL [ i ] <−p i2 [ i ] * (1− e f f 2 [ i ] ) * beta * rfemL * pmal [ i ]+(1− pi2 [ i ] ) *
beta * rfemL * pmal [ i ]
102 lambdafemH [ i ] <−p i2 [ i ] * (1− e f f 2 [ i ] ) * beta * rfemH * pmal [ i ]+(1− pi2 [ i ] ) *
beta * rfemH * pmal [ i ]
103 lambdamalL [ i ] <−p i2 [ i ] * (1− e f f 2 [ i ] ) * beta * rmalL * pfem [ i ]+(1− pi2 [ i ] ) *
beta * rmalL * pfem [ i ]
104 lambdamalH [ i ] <−p i2 [ i ] * (1− e f f 2 [ i ] ) * beta * rmalH * pfem [ i ]+(1− pi2 [ i ] ) *
beta * rmalH * pfem [ i ]
105 }
106 # I n i t i a l cond i t i ons i n t e r v e n t i o n screening−only :
107 i n i t [ 1 , 1 ] <− 399760; i n i t [ 2 , 1 ] <− 240; i n i t [ 3 , 1 ] <− 0; i n i t [ 4 , 1 ]
<− 0; i n i t [ 5 , 1 ] <− 0; i n i t [ 6 , 1 ] <− 99940; i n i t [ 7 , 1 ] <− 60; i n i t
[ 8 , 1 ] <− 0; i n i t [ 9 , 1 ] <− 0; i n i t [ 10 ,1 ] <− 0; i n i t [ 11 ,1 ] <−
399760; i n i t [ 12 ,1 ] <− 240; i n i t [ 13 ,1 ] <− 0; i n i t [ 14 ,1 ] <− 0;
i n i t [ 15 ,1 ] <− 0; i n i t [ 16 ,1 ] <− 99940; i n i t [ 17 ,1 ] <− 60; i n i t
[18 ,1] <− 0; i n i t [ 19 ,1 ] <− 0; i n i t [ 20 ,1 ] <− 0
108 # i n i t i a l cond i t i ons i n t e r v e n t i o n vacc ina t i on are equ iva len t
109 i n i t [1 ,2] <− i n i t [ 1 , 1 ] ; i n i t [2 ,2] <− i n i t [ 2 , 1 ] ; i n i t [3 ,2] <− i n i t [ 3 , 1 ] ;
i n i t [4 ,2] <− i n i t [ 4 , 1 ] ; i n i t [5 ,2] <− i n i t [ 5 , 1 ] ; i n i t [6 ,2] <− i n i t
[ 6 , 1 ] ; i n i t [7 ,2] <− i n i t [ 7 , 1 ] ; i n i t [8 ,2] <− i n i t [ 8 , 1 ] ; i n i t [9 ,2] <−
i n i t [ 9 , 1 ] ; i n i t [10 ,2] <− i n i t [ 1 0 , 1 ] ; i n i t [11 ,2] <− i n i t [ 1 1 , 1 ] ; i n i t
[12 ,2] <− i n i t [ 1 2 , 1 ] ; i n i t [13 ,2] <− i n i t [ 1 3 , 1 ] ; i n i t [14 ,2] <− i n i t
[ 1 4 , 1 ] ; i n i t [15 ,2] <− i n i t [ 1 5 , 1 ] ; i n i t [16 ,2] <− i n i t [ 1 6 , 1 ] ; i n i t
[17 ,2] <− i n i t [ 1 7 , 1 ] ; i n i t [18 ,2] <− i n i t [ 1 8 , 1 ] ;
110 i n i t [19 ,2] <− i n i t [ 1 9 , 1 ] ; i n i t [20 ,2] <− i n i t [ 20 ,1 ]
111 #Poisson−gamma model on par tne r a c q u i s i t i o n ra tes
112 f o r ( i i n 1 : popsize ) {
113 datfemH [ i ] ~ dpois ( rfemH )
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114 datfemL [ i ] ~ dpois ( rfemL )
115 datmalH [ i ] ~ dpois ( rmalH )
116 datmalL [ i ] ~ dpois ( rmalL )
117 }
118 #non−i n f o r m a t i v e p r i o r s on par tne r a c q u i s i t i o n ra tes
119 rfemH ~ dgamma( 0 . 1 , 0 . 1 )
120 rfemL ~ dgamma( 0 . 1 , 0 . 1 )
121 rmalH ~ dgamma( 0 . 1 , 0 . 1 )
122 rmalL ~ dgamma( 0 . 1 , 0 . 1 )
123 # i n f o r m a t i v e p r i o r on reproduc t ion ra te
124 ch i~dgamma(1111.1 ,111111.1)
125 # i n f o r m a t i v e p r i o r on t r a n s i t i o n ra te i n f e c t e d −−> asymptomatic
126 rho ia~dgamma(25600 ,32000)
127 # i n f o r m a t i v e p r i o r on t r a n s i t i o n ra te asymptomatic −−> morbid
128 rhoam~dgamma(2025 ,22500)
129 # i n f o r m a t i v e p r i o r on t r a n s i t i o n ra te morbid −−> dead
130 rhomd~dgamma(1600 ,40000)
131 # i n f o r m a t i v e p r i o r on t r a n s i t i o n ra te suscep t i b l e −−> dead
132 rhosd~dgamma(156.25 ,312500)
133 #beta−b inomia l model on HPV t ransmiss ion p r o b a b i l i t y per
pa r tne rsh ip
134 r . beta ~ dbin ( beta , n . beta )
135 beta ~ dbeta ( 0 . 5 , 0 . 5 )
136 #beta−b inomia l model on vaccine coverage
137 r . p i ~ dbin ( p i , n . p i )
138 p i ~ dbeta ( 0 . 5 , 0 . 5 )
139 #beta−b inomia l model on vaccine e f f i c a c y
140 r . e f f ~ dbin ( e f f , n . e f f )
141 e f f ~ dbeta ( 0 . 5 , 0 . 5 )
142 #beta−b inomia l model on p r o b a b i l i t y o f d iagnos is
143 r . d iag ~ dbin ( diag , n . diag )
144 diag ~ dbeta ( 0 . 5 , 0 . 5 )
145 #beta−b inomia l model on p r o b a b i l i t y o f screening . r . screen : number
o f events , n . screen : sample s ize
146 r . screen ~ dbin ( screen , n . screen )
147 screen ~ dbeta ( 0 . 5 , 0 . 5 )
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148 #Bayesian model c a l i b r a t i o n through data on the number o f
suscept ib les , in fec teds , asymptomatics , and morbids i n high−
r i s k females and males . These are count data and t h e re f o r e
modelled through poisson d i s t r i b u t i o n s . This i s done f o r the
f i r s t t ime po in t o f fo l l ow−up .
149 dat . sus . femH [ 1 ] ~ dpois ( i n i t [ 6 , 1 ] )
150 dat . i n f . femH [ 1 ] ~ dpois ( i n i t [ 7 , 1 ] )
151 dat . asy . femH [ 1 ] ~ dpois ( i n i t [ 8 , 1 ] )
152 dat . mor . femH [ 1 ] ~ dpois ( i n i t [ 9 , 1 ] )
153 dat . sus . malH [ 1 ] ~ dpois ( i n i t [ 1 6 , 1 ] )
154 dat . i n f . malH [ 1 ] ~ dpois ( i n i t [ 1 7 , 1 ] )
155 dat . asy . malH [ 1 ] ~ dpois ( i n i t [ 1 8 , 1 ] )
156 dat . mor . malH [ 1 ] ~ dpois ( i n i t [ 1 9 , 1 ] )
157 #Data f o r t ime po in t s 2−5 are a lso a v a i l a b l e and used to c a l i b r a t e
high−r i s k i n d i v i d u a l s i n fou r o f the s ta tes . The c o n s t r a i n t (
maximum) was inc luded due to a computat iona l issue , i s not
re l evan t and can be omi t ted .
158 f o r ( n i n 2 :5 ) {
159 conssusfemH [ n ] <− max( 0 . 1 , s o l u t i o n [ n , 6 , 1 ] )
160 dat . sus . femH [ n ] ~ dpois ( conssusfemH [ n ] )
161 consinffemH [ n ] <− max( 0 . 1 , s o l u t i o n [ n , 7 , 1 ] )
162 dat . i n f . femH [ n ] ~ dpois ( consinffemH [ n ] )
163 consasyfemH [ n ] <− max( 0 . 1 , s o l u t i o n [ n , 8 , 1 ] )
164 dat . asy . femH [ n ] ~ dpois ( consasyfemH [ n ] )
165 consmorfemH [ n ] <− max( 0 . 1 , s o l u t i o n [ n , 9 , 1 ] )
166 dat . mor . femH [ n ] ~ dpois ( consmorfemH [ n ] )
167 conssusmalH [ n ] <− max( 0 . 1 , s o l u t i o n [ n , 1 6 , 1 ] )
168 dat . sus . malH [ n ] ~ dpois ( conssusmalH [ n ] )
169 consinfmalH [ n ] <− max( 0 . 1 , s o l u t i o n [ n , 1 7 , 1 ] )
170 dat . i n f . malH [ n ] ~ dpois ( consinfmalH [ n ] )
171 consasymalH [ n ] <− max( 0 . 1 , s o l u t i o n [ n , 1 8 , 1 ] )
172 dat . asy . malH [ n ] ~ dpois ( consasymalH [ n ] )
173 consmormalH [ n ] <− max( 0 . 1 , s o l u t i o n [ n , 1 9 , 1 ] )
174 dat . mor . malH [ n ] ~ dpois ( consmormalH [ n ] )
175 }
176 ### i n f o r m a t i v e p r i o r s on costs and u t i l i t i e s
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177 tau . screen <−1/pow(0 .693 ,2 )
178 c . screen ~ dlnorm (2 .996 , tau . screen )
179 tau . vac<−1/pow(0.07986607 ,2)
180 c . vac ~ dlnorm (5.518352 , tau . vac )
181 tau . t e s t . s t i <−1/pow(0 .03 ,2 )
182 c . t e s t . s t i ~ dlnorm (2 .996 , tau . t e s t . s t i )
183 tau . t e s t . blood <−1/pow(0 .03 ,2 )
184 c . t e s t . blood ~ dlnorm (3 .401 , tau . t e s t . blood )
185 tau . t r t <−1/pow(0.8325546 ,2)
186 c . t r t ~ dlnorm (4.258597 , tau . t r t )
187 tau . t r t . d is <−1/pow(0.1980422 ,2)
188 c . t r t . d i s ~ dlnorm (6.194998 , tau . t r t . d i s )
189 tau . gp<−1/pow(0 .02 ,2 )
190 c . gp ~ dlnorm (3 .912 , tau . gp )
191 u . i n f ~ dbeta (1469.3 ,629.7)
192 u . asym ~ dbeta (1439.4 ,959.6)
193 u . morb ~ dbeta (629.7 ,1469.3)
194 }
A.3 The Bayesian Markov model
In contrast to the BODE, the BMM is implemented JAGS, an alternative soft-
ware to WinBUGS. JAGS is linked to R through the package R2jags. As for the
BODE, Bayesian calibration takes place directly in the model by assigning
Poisson distributions to time series data with event rates corresponding to
the model outcome on the number of high-risk people in the states. As for
the BODE, the code of the BMM consists of two files; these correspond to an
R script and a text file containing the JAGS model which is called from inside
R. The text file is called Model_BMM.txt and has to be saved in a separate
file in order to run the model.
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1 #saving the s t a r t t ime i n ptm
2 ptm <− proc . t ime ( )
3 #set the seed f o r reproducable r e s u l t s
4 set . seed (2188)
5 # def ine working d i r e c t o r y
6 working . d i r = "C : / Users / k a t r i n / Dropbox / TestModel /R code and CE
r e s u l t s / Comparison MSM and ODE/ F ina l code / ThesisAppendix / "
7 #change path o f working d i r e c t o r y
8 setwd ( "C : / Users / k a t r i n / Dropbox / TestModel /R code and CE r e s u l t s /
Comparison MSM and ODE/ F ina l code / ThesisAppendix / " )
9 # load i n d i v i d u a l− l e v e l data on par tne r a c q u i s i t i o n ra tes and data
to in form the beta−b inomia l models
10 load ( "WS. RData " )
11 # load workspace i n c l u d i n g t ime se r i es data on number o f people i n
s ta tes f o r c a l i b r a t i o n
12 load ( " States_Data_New2 . RData " )
13 # load l i b r a r y R2jags to connect R wi th JAGS
14 l i b r a r y ( R2jags )
15 dataJags = l i s t ( "A" , " datfemH " , " datfemL " , " datmalH " , " datmalL " , "
popsize " , " r . beta " , " n . beta " , " r . d iag " , " n . diag " , " r . screen " , "
n . screen " , " r . p i " , " n . p i " , " r . e f f " , " n . e f f " , " dat . sus . femH" , "
dat . i n f . femH" , " dat . asy . femH" , " dat . mor . femH" , " dat . sus . malH" ,
" dat . i n f . malH" , " dat . asy . malH" , " dat . mor . malH" )
16 # t e x t f i l e con ta in ing the model , expected as i npu t parameter when
c a l l i n g the f u n c t i o n jags ( )
17 f i l e i n <− paste ( working . d i r , "Model_BMM . t x t " , sep=" " )
18 # i n i t i a l i z i n g the parameters to prevent JAGS from ass ign ing random
values
19 i n i t s <− f u n c t i o n ( ) { l i s t ( rfemH= r u n i f ( 1 ) , rfemL= r u n i f ( 1 ) , rmalL=
r u n i f ( 1 ) , ch i= r u n i f ( 1 ) , p i i a = r u n i f ( 1 ) , piam= r u n i f ( 1 ) , pimd=
r u n i f ( 1 ) , p isd= r u n i f ( 1 ) , beta= r u n i f ( 1 ) , d iag= r u n i f ( 1 ) , screen=
r u n i f ( 1 ) , p i = r u n i f ( 1 ) , e f f = r u n i f ( 1 ) , c . screen= r u n i f ( 1 ) , c . vac=
r u n i f ( 1 ) , c . t e s t . s t i = r u n i f ( 1 ) , c . t e s t . blood= r u n i f ( 1 ) , c . t r t =
r u n i f ( 1 ) , c . t r t . d i s= r u n i f ( 1 ) , c . gp= r u n i f ( 1 ) , u . i n f = r u n i f ( 1 ) , u .
asym= r u n i f ( 1 ) , u . morb= r u n i f ( 1 ) ) }
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20 #the parameters monitored
21 params = c ( " y " , " rfemH " , " rfemL " , " rmalH " , " rmalL " , " ch i " , " p i i a " ,
" piam " , " pimd " , " p isd " , " beta " , " d iag " , " screen " , " p i " , " e f f " ,
" c . screen " , " c . vac " , " c . t e s t . s t i " , " c . t e s t . blood " , " c . t r t " , " c
. t r t . d i s " , " c . gp " , " u . i n f " , " u . asym" , " u . morb " )
22 #number o f i t e r a t i o n s
23 n . i t e r <− 600
24 #number o f s imu la t i ons discarded dur ing the burn−i n
25 n . burn in <− 100
26 # t h i n n i n g step : no t h i n n i n g i s conducted
27 n . t h i n <− 1
28 # c a l l i n g the f u n c t i o n jags ( ) , running 2 chains i n p a r a l l e l
29 sim <− jags ( dataJags , i n i t s , params , model . f i l e = f i l e i n , n . chains
=2 , n . i t e r , n . burnin , n . th in ,
30 DIC=T , working . d i r e c t o r y =working . d i r , progress . bar= " t e x t " , jags .
module=" d i c " )
31 #making the ob jec t sim a v a i l a b l e i n R, con ta in ing the p o s t e r i o r
d i s t r i b u t i o n s o f the parameters
32 at tach . jags ( sim )
33 #saving the end of model run t ime
34 t ime=proc . t ime ( )−ptm
35
36 ###JAGS model f i l e Model_BMM . t x t −−> has to be saved i n separate
t e x t f i l e
37 model {
38 #y : ar ray i n c l u d i n g the number o f i n d i v i d u a l s per year i n the
s ta tes . The f i r s t dimension i s the year o f fo l l ow−up , whereas
the second dimension i s the s ta te w i th 1= suscep t i b l e low−r i s k
females , 2= i n f e c t e d low−r i s k females , 3=asymptomatic low−r i s k
females , 4=morbid low−r i s k females , 5=dead low−r i s k females , 6=
suscep t i b l e high−r i s k females , 7= i n f e c t e d high−r i s k females , 8=
asymptomatic high−r i s k females , 9=morbid high−r i s k females , 10=
dead high−r i s k females , 11= suscep t i b l e low−r i s k males , 12=
i n f e c t e d low−r i s k males , 13=asymptomatic low−r i s k males , 14=
morbid low−r i s k males , 15=dead low−r i s k males , 16= suscep t i b l e
high−r i s k males , 17= i n f e c t e d high−r i s k males , 18=asymptomatic
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high−r i s k males , 19=morbid high−r i s k males , 20=dead high−r i s k
males . The t h i r d dimension i s the i n t e r v e n t i o n (1= screening , 2=
vacc ina t i on ) .
39 # i n i t i a l i z a t i o n o f s ta tes (5 s ta tes * 2 sexes * 2 r i s k groups = 20
e n t r i e s ) f o r year 1 o f fo l l ow−up ( f i r s t dimension o f y )
40 y [ 1 , 1 , 1 ] <− 399760; y [ 1 , 2 , 1 ] <− 240; y [ 1 , 3 , 1 ] <− 0; y [ 1 , 4 , 1 ] <− 0;
y [ 1 , 5 , 1 ] <− 0; y [ 1 , 6 , 1 ] <− 99940; y [ 1 , 7 , 1 ] <− 60; y [ 1 , 8 , 1 ] <−
0; y [ 1 , 9 , 1 ] <− 0; y [1 ,10 ,1 ] <− 0; y [1 ,11 ,1 ] <− 399760; y
[1 ,12 ,1 ] <− 240; y [1 ,13 ,1 ] <− 0; y [1 ,14 ,1 ] <− 0; y [1 ,15 ,1 ] <−
0; y [1 ,16 ,1 ] <− 99940; y [1 ,17 ,1 ] <− 60; y [1 ,18 ,1 ] <− 0; y
[1 ,19 ,1 ] <− 0; y [1 ,20 ,1 ] <−0; y [ 1 , 1 , 2 ] <− y [ 1 , 1 , 1 ] ; y [ 1 , 2 , 2 ] <−
y [ 1 , 2 , 1 ] ; y [ 1 , 3 , 2 ] <− y [ 1 , 3 , 1 ] ; y [ 1 , 4 , 2 ] <− y [ 1 , 4 , 1 ] ; y [ 1 , 5 , 2 ]
<− y [ 1 , 5 , 1 ] ; y [ 1 , 6 , 2 ] <− y [ 1 , 6 , 1 ] ; y [ 1 , 7 , 2 ] <− y [ 1 , 7 , 1 ] ; y
[ 1 , 8 , 2 ] <− y [ 1 , 8 , 1 ] ; y [ 1 , 9 , 2 ] <− y [ 1 , 9 , 1 ] ; y [1 ,10 ,2 ] <− y
[ 1 , 1 0 , 1 ] ; y [1 ,11 ,2 ] <− y [ 1 , 1 1 , 1 ] ; y [1 ,12 ,2 ] <− y [ 1 , 1 2 , 1 ] ; y
[1 ,13 ,2 ] <− y [ 1 , 1 3 , 1 ] ; y [1 ,14 ,2 ] <− y [ 1 , 1 4 , 1 ] ; y [1 ,15 ,2 ] <− y
[ 1 , 1 5 , 1 ] ; y [1 ,16 ,2 ] <− y [ 1 , 1 6 , 1 ] ; y [1 ,17 ,2 ] <− y [ 1 , 1 7 , 1 ] ; y
[1 ,18 ,2 ] <− y [ 1 , 1 8 , 1 ] ; y [1 ,19 ,2 ] <− y [ 1 , 1 9 , 1 ] ; y [1 ,20 ,2 ] <−y
[ 1 , 2 0 , 1 ] ;
41 # c a l c u l a t i o n o f sample s ize according to r i s k−group and sex f o r
year 1 o f fo l l ow−up ; on ly those a l i v e are considered exc lud ing
those i n the s ta te o f death w i th i nd i ces 5 , 10 , 15 , 20)
42 nfemL [ 1 , 1 ] <− y [1 ,1 ,1 ]+ y [1 ,2 ,1 ]+ y [1 ,3 ,1 ]+ y [ 1 , 4 , 1 ]
43 nfemH [ 1 , 1 ] <− y [1 ,6 ,1 ]+ y [1 ,7 ,1 ]+ y [1 ,8 ,1 ]+ y [ 1 , 9 , 1 ]
44 nmalL [ 1 , 1 ] <− y [1 ,11 ,1 ]+ y [1 ,12 ,1 ]+ y [1 ,13 ,1 ]+ y [1 ,14 ,1 ]
45 nmalH [ 1 , 1 ] <− y [1 ,16 ,1 ]+ y [1 ,17 ,1 ]+ y [1 ,18 ,1 ]+ y [1 ,19 ,1 ]
46 nfemL[1 ,2] <−nfemL [ 1 , 1 ]
47 nfemH[1 ,2] <−nfemH [ 1 , 1 ]
48 nmalL [1 ,2] <−nmalL [ 1 , 1 ]
49 nmalH[1 ,2] <−nmalH [ 1 , 1 ]
50 #the p r o b a b i l i t i e s o f s e l e c t i n g a male / female par tne r from the
high− or low−r i s k group , respec t i ve l y , i n year 1 o f fo l l ow−up
51 gmalH [ 1 , 1 ] <− ( rmalH *nmalH [ 1 , 1 ] ) / ( rmalH *nmalH [1 ,1 ]+ rmalL * nmalL
[ 1 , 1 ] )
52 gmalL [ 1 , 1 ] <− 1−gmalH [ 1 , 1 ]
53 gfemH [ 1 , 1 ] <− ( rfemH *nfemH [ 1 , 1 ] ) / ( rfemH *nfemH [1 ,1 ]+ rfemL * nfemL
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[ 1 , 1 ] )
54 gfemL [ 1 , 1 ] <− 1−gfemH [ 1 , 1 ]
55 gmalH[1 ,2] <−gmalH [ 1 , 1 ]
56 gmalL [1 ,2] <−gmalL [ 1 , 1 ]
57 gfemH[1 ,2] <−gfemH [ 1 , 1 ]
58 gfemL[1 ,2] <−gfemL [ 1 , 1 ]
59 #weighted average of STI prevalence i n males i n year 1 o f fo l l ow−
up
60 pmal [ 1 , 1 ] <− gmalH [ 1 , 1 ] * ( y [ 1 , 1 7 , 1 ] / nmalH [ 1 , 1 ] ) +gmalL [ 1 , 1 ] * ( y
[ 1 , 1 2 , 1 ] / nmalL [ 1 , 1 ] )
61 #weighted average of STI prevalence i n females i n year 1 o f fo l l ow
−up
62 pfem [ 1 , 1 ] <− gfemH [ 1 , 1 ] * ( y [ 1 , 7 , 1 ] / nfemH [ 1 , 1 ] ) +gfemL [ 1 , 1 ] * ( y
[ 1 , 2 , 1 ] / nfemL [ 1 , 1 ] )
63 pmal [1 ,2] <−pmal [ 1 , 1 ]
64 pfem[1 ,2] <−pfem [ 1 , 1 ]
65 # fo rce o f i n f e c t i o n : f u n c t i o n o f STI t ransmiss ion p r o b a b i l i t y beta
, pa r tne r a c q u i s i t i o n ra tes i n low−r i s k females rfemL (
accord ing ly f o r the other sex and r i s k group ) , and sex−s p e c i f i c
popu la t ion prevalence pmal and pfem , i n year 1 o f fo l l ow−up )
66 lambdafemL [ 1 , 1 ] <−1−exp(−beta * rfemL * pmal [ 1 , 1 ] )
67 lambdafemH [ 1 , 1 ] <−1−exp(−beta * rfemH * pmal [ 1 , 1 ] )
68 lambdamalL [ 1 , 1 ] <−1−exp(−beta * rmalL * pfem [ 1 , 1 ] )
69 lambdamalH [ 1 , 1 ] <−1−exp(−beta * rmalH * pfem [ 1 , 1 ] )
70 lambdafemL [ 1 , 2 ] <−1−exp(−( p i * (1− e f f ) * beta * rfemL * pmal [1 ,2]+(1− p i ) *
beta * rfemL * pmal [ 1 , 2 ] ) )
71 lambdafemH [ 1 , 2 ] <−1−exp(−( p i * (1− e f f ) * beta * rfemH * pmal [1 ,2]+(1− p i ) *
beta * rfemH * pmal [ 1 , 2 ] ) )
72 lambdamalL [ 1 , 2 ] <−1−exp(−( p i * (1− e f f ) * beta * rmalL * pfem[1 ,2]+(1− p i ) *
beta * rmalL * pfem [ 1 , 2 ] ) )
73 lambdamalH [ 1 , 2 ] <−1−exp(−( p i * (1− e f f ) * beta * rmalH * pfem[1 ,2]+(1− p i ) *
beta * rmalH * pfem [ 1 , 2 ] ) )
74 #dat . sus . femH : s imulated data on suscep t i b l e high−r i s k females ,
used f o r c a l i b r a t i o n i n year 1 . The parameter y [ 1 , 6 , 1 ] conta ins
the number o f suscep t i b l e high−r i s k females i n year 1 and i s
c a l i b r a t e d by the data f o r year 1 . The approach f o r high−r i s k
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females i n the s ta tes in fec ted , asymptomatic and morbid as we l l
as f o r high−r i s k males i n the same s ta tes i s conducted
accord ing ly .
75 dat . sus . femH [ 1 ] ~ dpois ( y [ 1 , 6 , 1 ] )
76 dat . i n f . femH [ 1 ] ~ dpois ( y [ 1 , 7 , 1 ] )
77 dat . asy . femH [ 1 ] ~ dpois ( y [ 1 , 8 , 1 ] )
78 dat . mor . femH [ 1 ] ~ dpois ( y [ 1 , 9 , 1 ] )
79 dat . sus . malH [ 1 ] ~ dpois ( y [ 1 , 1 6 , 1 ] )
80 dat . i n f . malH [ 1 ] ~ dpois ( y [ 1 , 1 7 , 1 ] )
81 dat . asy . malH [ 1 ] ~ dpois ( y [ 1 , 1 8 , 1 ] )
82 dat . mor . malH [ 1 ] ~ dpois ( y [ 1 , 1 9 , 1 ] )
83 # c a l i b r a t i o n i n years 2−5
84 f o r ( a i n 2 :5 ) {
85 dat . sus . femH [ a ] ~ dpois (max( 0 . 1 , y [ a , 6 , 1 ] ) )
86 dat . i n f . femH [ a ] ~ dpois (max( 0 . 1 , y [ a , 7 , 1 ] ) )
87 dat . asy . femH [ a ] ~ dpois (max( 0 . 1 , y [ a , 8 , 1 ] ) )
88 dat . mor . femH [ a ] ~ dpois (max( 0 . 1 , y [ a , 9 , 1 ] ) )
89 dat . sus . malH [ a ] ~ dpois (max( 0 . 1 , y [ a , 1 6 , 1 ] ) )
90 dat . i n f . malH [ a ] ~ dpois (max( 0 . 1 , y [ a , 1 7 , 1 ] ) )
91 dat . asy . malH [ a ] ~ dpois (max( 0 . 1 , y [ a , 1 8 , 1 ] ) )
92 dat . mor . malH [ a ] ~ dpois (max( 0 . 1 , y [ a , 1 9 , 1 ] ) )
93 }
94 f o r ( i i n 1 :2 ) {
95 # i n t e r v e n t i o n screening−only : p i2 =1 , e lse : p i2= p i
96 pi2 [ i ]<− i f e l s e ( i ==1 ,1 , p i )
97 # i n t e r v e n t i o n screening−only : e f f 2 =0 ( no vaccine e f f i c a c y ) , e lse :
e f f 2 = e f f
98 e f f 2 [ i ]<− i f e l s e ( i ==1 ,0 , e f f )
99 ### s ta te a l l o c a t i o n a lgo r i thm
100 f o r ( a i n 2 :A) {
101 # ch i i s the reproduc t ion ra te
102 #nfemL and lambdafemL were expla ined at an e a r l i e r stage
103 #pisd i s the p r o b a b i l i t y o f death from any cause
104 # p i i a i s the t r a n s i t i o n p r o b a b i l i t y i n f e c t i o n −−> asymptomatic
105 #piam i s the t r a n s i t i o n p r o b a b i l i t y asymptomatic −−> morbid
106 #pimd i s the t r a n s i t i o n p r o b a b i l i t y morbid −−> dead
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107 # s ta te a l l o c a t i o n o f low−r i s k females i n year a ; y [ , 1 ] = suscept ib le
, y [ , 2 ] = in fec ted , y [ , 3 ] = asymptomatic , y [ , 4 ] = morbid , y [ , 5 ] = dead
108 y [ a ,1 , i ] <− y [ a−1 ,1 , i ]+ ch i * nfemL [ a−1, i ]− lambdafemL [ a−1, i ] * y [ a−1 ,1 ,
i ]−pisd * y [ a−1 ,1 , i ]
109 y [ a ,2 , i ] <− y [ a−1 ,2 , i ]+ lambdafemL [ a−1, i ] * y [ a−1 ,1 , i ]− p i i a * y [ a−1 ,2 , i
]−pisd * y [ a−1 ,2 , i ]
110 y [ a ,3 , i ] <− y [ a−1 ,3 , i ]+ p i i a * y [ a−1 ,2 , i ]−piam * y [ a−1 ,3 , i ]−pisd * y [ a
−1 ,3 , i ]
111 y [ a ,4 , i ] <− y [ a−1 ,4 , i ]+ piam * y [ a−1 ,3 , i ]−pimd * y [ a−1 ,4 , i ]−pisd * y [ a
−1 ,4 , i ]
112 y [ a ,5 , i ] <− y [ a−1 ,5 , i ]+ p isd * nfemL [ a−1, i ]+ pimd * y [ a−1 ,4 , i ]
113 # s ta te a l l o c a t i o n o f high−r i s k females i n year a ; y [ , 6 ] =
suscept ib le , y [ , 7 ] = in fec ted , y [ , 8 ] = asymptomatic , y [ , 9 ] = morbid ,
y [ , 10 ]= dead
114 y [ a ,6 , i ] <− y [ a−1 ,6 , i ]+ ch i *nfemH [ a−1, i ]−lambdafemH [ a−1, i ] * y [ a−1 ,6 ,
i ]−pisd * y [ a−1 ,6 , i ]
115 y [ a ,7 , i ] <− y [ a−1 ,7 , i ]+ lambdafemH [ a−1, i ] * y [ a−1 ,6 , i ]− p i i a * y [ a−1 ,7 , i
]−pisd * y [ a−1 ,7 , i ]
116 y [ a ,8 , i ] <− y [ a−1 ,8 , i ]+ p i i a * y [ a−1 ,7 , i ]−piam * y [ a−1 ,8 , i ]−pisd * y [ a
−1 ,8 , i ]
117 y [ a ,9 , i ] <− y [ a−1 ,9 , i ]+ piam * y [ a−1 ,8 , i ]−pimd * y [ a−1 ,9 , i ]−pisd * y [ a
−1 ,9 , i ]
118 y [ a ,10 , i ] <− y [ a−1 ,10 , i ]+ p isd *nfemH [ a−1, i ]+ pimd * y [ a−1 ,9 , i ]
119 # s ta te a l l o c a t i o n o f low−r i s k males i n year a ; y [ , 11 ]= suscept ib le ,
y [ , 12 ]= in fec ted , y [ , 13 ]= asymptomatic , y [ , 14 ]= morbid , y [ , 15 ]=
dead
120 y [ a ,11 , i ] <− y [ a−1 ,11 , i ]+ ch i * nmalL [ a−1, i ]− lambdamalL [ a−1, i ] * y [ a
−1 ,11 , i ]−pisd * y [ a−1 ,11 , i ]
121 y [ a ,12 , i ] <− y [ a−1 ,12 , i ]+ lambdamalL [ a−1, i ] * y [ a−1 ,11 , i ]− p i i a * y [ a
−1 ,12 , i ]−pisd * y [ a−1 ,12 , i ]
122 y [ a ,13 , i ] <− y [ a−1 ,13 , i ]+ p i i a * y [ a−1 ,12 , i ]−piam * y [ a−1 ,13 , i ]−pisd * y [
a−1 ,13 , i ]
123 y [ a ,14 , i ] <− y [ a−1 ,14 , i ]+ piam * y [ a−1 ,13 , i ]−pimd * y [ a−1 ,14 , i ]−pisd * y [
a−1 ,14 , i ]
124 y [ a ,15 , i ] <− y [ a−1 ,15 , i ]+ p isd * nmalL [ a−1, i ]+ pimd * y [ a−1 ,14 , i ]
125 # s ta te a l l o c a t i o n o f high−r i s k males i n year a ; y [ , 16 ]= suscept ib le
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, y [ , 17 ]= in fec ted , y [ , 18 ]= asymptomatic , y [ , 19 ]= morbid , y [ , 20 ]=
dead
126 y [ a ,16 , i ] <− y [ a−1 ,16 , i ]+ ch i *nmalH [ a−1, i ]− lambdamalH [ a−1, i ] * y [ a
−1 ,16 , i ]−pisd * y [ a−1 ,16 , i ]
127 y [ a ,17 , i ] <− y [ a−1 ,17 , i ]+ lambdamalH [ a−1, i ] * y [ a−1 ,16 , i ]− p i i a * y [ a
−1 ,17 , i ]−pisd * y [ a−1 ,17 , i ]
128 y [ a ,18 , i ] <− y [ a−1 ,18 , i ]+ p i i a * y [ a−1 ,17 , i ]−piam * y [ a−1 ,18 , i ]−pisd * y [
a−1 ,18 , i ]
129 y [ a ,19 , i ] <− y [ a−1 ,19 , i ]+ piam * y [ a−1 ,18 , i ]−pimd * y [ a−1 ,19 , i ]−pisd * y [
a−1 ,19 , i ]
130 y [ a ,20 , i ] <− y [ a−1 ,20 , i ]+ p isd *nmalH [ a−1, i ]+ pimd * y [ a−1 ,20 , i ]
131 # c a l c u l a t i o n o f sample s ize according to r i s k−group and sex f o r
year a o f fo l l ow−up ; on ly those a l i v e are considered exc lud ing
those i n the s ta te o f death w i th i nd i ces 5 , 10 , 15 , 20)
132 nfemL [ a , i ] <− y [ a ,1 , i ]+ y [ a ,2 , i ]+ y [ a ,3 , i ]+ y [ a ,4 , i ]
133 nfemH [ a , i ] <− y [ a ,6 , i ]+ y [ a ,7 , i ]+ y [ a ,8 , i ]+ y [ a ,9 , i ]
134 nmalL [ a , i ] <− y [ a ,11 , i ]+ y [ a ,12 , i ]+ y [ a ,13 , i ]+ y [ a ,14 , i ]
135 nmalH [ a , i ] <− y [ a ,16 , i ]+ y [ a ,17 , i ]+ y [ a ,18 , i ]+ y [ a ,19 , i ]
136 #the p r o b a b i l i t i e s o f s e l e c t i n g a male / female par tne r from the
high− or low−r i s k group , respec t i ve l y , i n year a o f fo l l ow−up
137 gmalH [ a , i ] <− ( rmalH *nmalH [ a , i ] ) / ( rmalH *nmalH [ a , i ]+ rmalL * nmalL [ a , i
] )
138 gmalL [ a , i ] <− 1−gmalH [ a , i ]
139 gfemH [ a , i ] <− ( rfemH *nfemH [ a , i ] ) / ( rfemH *nfemH [ a , i ]+ rfemL * nfemL [ a , i
] )
140 gfemL [ a , i ] <− 1−gfemH [ a , i ]
141 #weighted average of STI prevalence i n males i n year a o f fo l l ow−
up
142 pmal [ a , i ] <− gmalH [ a , i ] * ( y [ a ,17 , i ] / nmalH [ a , i ] ) +gmalL [ a , i ] * ( y [ a ,12 ,
i ] / nmalL [ a , i ] )
143 #weighted average of STI prevalence i n females i n year a o f fo l l ow
−up
144 pfem [ a , i ] <− gfemH [ a , i ] * ( y [ a ,7 , i ] / nfemH [ a , i ] ) +gfemL [ a , i ] * ( y [ a ,2 , i
] / nfemL [ a , i ] )
145 # fo rce o f i n f e c t i o n : f u n c t i o n o f STI t ransmiss ion p r o b a b i l i t y beta
, pa r tne r a c q u i s i t i o n ra tes i n low−r i s k females rfemL (
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accord ing ly f o r the other sex and r i s k group ) , and sex−s p e c i f i c
popu la t ion prevalence pmal and pfem , i n year a o f fo l l ow−up )
146 lambdafemL [ a , i ] <−1−exp(−( p i2 [ i ] * (1− e f f 2 [ i ] ) * beta * rfemL * pmal [ a , i
]+(1− p i2 [ i ] ) * beta * rfemL * pmal [ a , i ] ) )
147 lambdafemH [ a , i ] <−1−exp(−( p i2 [ i ] * (1− e f f 2 [ i ] ) * beta * rfemH * pmal [ a , i
]+(1− p i2 [ i ] ) * beta * rfemH * pmal [ a , i ] ) )
148 lambdamalL [ a , i ] <−1−exp(−( p i2 [ i ] * (1− e f f 2 [ i ] ) * beta * rmalL * pfem [ a , i
]+(1− p i2 [ i ] ) * beta * rmalL * pfem [ a , i ] ) )
149 lambdamalH [ a , i ] <−1−exp(−( p i2 [ i ] * (1− e f f 2 [ i ] ) * beta * rmalH * pfem [ a , i
]+(1− p i2 [ i ] ) * beta * rmalH * pfem [ a , i ] ) )
150 }
151 }
152 #poisson−gamma model to update non−i n f o r m a t i v e p r i o r s on par tne r
a c q u i s i t i o n ra tes by data
153 #datfemH : number o f yea r l y par tne rs i n high−r i s k females ,
accord ing ly f o r the other sex and r i s k−group
154 #rfemH : par tne r a c q u i s i t i o n ra te i n high−r i s k females , acco rd ing ly
f o r the other sex and r i s k−group
155 #popsize : popu la t ion s ize o f the s imulated data on yea r l y par tne rs
; we assume t h a t 500 i n d i v i d u a l s were in te rv iewed on t h e i r
156 # yea r l y number o f par tners , t h e r e f o r e popsize =500.
157 f o r ( i i n 1 : popsize ) {
158 datfemH [ i ] ~ dpois ( rfemH )
159 datfemL [ i ] ~ dpois ( rfemL )
160 datmalH [ i ] ~ dpois ( rmalH )
161 datmalL [ i ] ~ dpois ( rmalL ) }
162 #non−i n f o r m a t i v e p r i o r s on par tne r a c q u i s i t i o n ra tes
163 rfemH ~ dgamma( 0 . 1 , 0 . 1 )
164 rfemL ~ dgamma( 0 . 1 , 0 . 1 )
165 rmalH ~ dgamma( 0 . 1 , 0 . 1 )
166 rmalL ~ dgamma( 0 . 1 , 0 . 1 )
167 # i n f o r m a t i v e p r i o r on reproduc t ion ra te ch i .
168 ch i~dgamma(1111.1 ,111111.1)
169 # i n f o r m a t i v e p r i o r on t r a n s i t i o n p r o b a b i l i t y i n f e c t e d −−>
asymptomatic .
170 p i i a ~dbeta (5119.2 , 1279.8)
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171 # i n f o r m a t i v e p r i o r on t r a n s i t i o n p r o b a b i l i t y asymptomatic −−>
morbid .
172 piam~dbeta (1842.66 ,18631.34)
173 # i n f o r m a t i v e p r i o r on t r a n s i t i o n p r o b a b i l i t y morbid −−> dead .
174 pimd~dbeta (1535.96 ,36863.04)
175 # i n f o r m a t i v e p r i o r on t r a n s i t i o n p r o b a b i l i t y suscep t i b l e −−> dead .
176 pisd~dbeta (156.1714 ,312186.6)
177 #beta−b inomia l model on p r o b a b i l i t y o f STI t ransmiss ion . r . beta :
number o f events , n . beta : sample s ize
178 r . beta ~ dbin ( beta , n . beta )
179 #non−i n f o r m a t i v e p r i o r on beta
180 beta ~ dbeta ( 0 . 5 , 0 . 5 )
181 #beta−b inomia l model on p r o b a b i l i t y o f d iagnos is . r . d iag : number
o f events , n . diag : sample s ize
182 r . d iag ~ dbin ( diag , n . diag )
183 #non−i n f o r m a t i v e p r i o r on diag
184 diag ~ dbeta ( 0 . 5 , 0 . 5 )
185 #beta−b inomia l model on p r o b a b i l i t y o f screening . r . screen : number
o f events , n . screen : sample s ize
186 r . screen ~ dbin ( screen , n . screen )
187 #non−i n f o r m a t i v e p r i o r on screen
188 screen ~ dbeta ( 0 . 5 , 0 . 5 )
189 #beta−b inomia l model on vaccine coverage . r . p i : number o f events ,
n . p i : sample s ize
190 r . p i ~ dbin ( p i , n . p i )
191 #non−i n f o r m a t i v e p r i o r on p i
192 p i ~ dbeta ( 0 . 5 , 0 . 5 )
193 #beta−b inomia l model on vaccine e f f i c a c y . r . e f f : number o f events ,
n . e f f : sample s ize
194 r . e f f ~ dbin ( e f f , n . e f f )
195 #non−i n f o r m a t i v e p r i o r on e f f
196 e f f ~ dbeta ( 0 . 5 , 0 . 5 )
197 ### i n f o r m a t i v e p r i o r s on costs and u t i l i t i e s
198 tau . screen <−1/pow(0 .693 ,2 )
199 c . screen ~ dlnorm (2 .996 , tau . screen )
200 tau . vac<−1/pow(0.07986607 ,2)
200
A.3. The Bayesian Markov model
201 c . vac ~ dlnorm (5.518352 , tau . vac )
202 tau . t e s t . s t i <−1/pow(0 .03 ,2 )
203 c . t e s t . s t i ~ dlnorm (2 .996 , tau . t e s t . s t i )
204 tau . t e s t . blood <−1/pow(0 .03 ,2 )
205 c . t e s t . blood ~ dlnorm (3 .401 , tau . t e s t . blood )
206 tau . t r t <−1/pow(0.8325546 ,2)
207 c . t r t ~ dlnorm (4.258597 , tau . t r t )
208 tau . t r t . d is <−1/pow(0.1980422 ,2)
209 c . t r t . d i s ~ dlnorm (6.194998 , tau . t r t . d i s )
210 tau . gp<−1/pow(0 .02 ,2 )
211 c . gp ~ dlnorm (3 .912 , tau . gp )
212 # u t i l i t y o f i n f e c t e d
213 u . i n f ~ dbeta (1469.3 ,629.7)
214 # u t i l i t y o f asymptomatic
215 u . asym ~ dbeta (1439.4 ,959.6)
216 # u t i l i t y o f morbid
217 u . morb ~ dbeta (629.7 ,1469.3) }
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Appendix B
Further details on the literature
review
In this appendix, the results of the literature review are reported in tabu-
lar way, separately for universal and female-only vaccination. In contrast to
Chapter 4, which gives a brief summary, the methodology, model assump-
tions and outcomes of all publications reviewed are reported in full detail.
In addition to the summary tables, most interesting publications are eval-
uated, separately according to the methodology used and the vaccination
strategies incorporated.
B.1 Summary tables of the literature review
We present two extensive summary tables. The first one focusses on the
results of the literature review on universal vaccination, whereas the second
table incorporates those of female-only vaccination. Each table is struc-
tured according to the checklist of the search criteria, which is displayed in
Section 4.3.
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B.1.1 Universal vaccination
Table B.1 summarizes the results of the literature review on universal vacci-
nation. For each publication found, we present the corresponding authors,
the year of publication, the statistical methodology and the model assump-
tions. Furthermore, we describe the outcome of research in a detailed way,
separately for cost-effectiveness results reported in terms of ICERs and
medical parameters such as HPV prevalence or cervical cancer prevalence
reduction.
Table B.1: Summary table of publications estimating the cost-effectiveness and/or
HPV (or cervical cancer) prevalence reduction of universal vaccination.
The most important aspects of the methodology, model assumptions
and outcomes are summarized and displayed to explain possible varia-
tions in results of the research.
Authors Year Methodology Model assumptions ICER Prevalence reduc-
tion
Institute of Medicine [330] 2000 Static Markov model USA, 100% vaccine coverage
and efficacy, e 74.11 vaccine
price
e 4,474.94
(vs. screen)
—
Hughes et al. [187] 2002 Deterministic ODE-based, 2
models, 1 adapted from An-
derson and May [13]
USA, HPV 16, CIN, cervical
cancer, 90% vaccine coverage,
75% vaccine efficacy, vaccina-
tion age not reported, 10 years
duration of immunity, no booster,
3 levels of sexual activity, cervi-
cal screening, observation hori-
zon not reported, vaccine price
not reported, discounting not re-
ported
— universal vacci-
nation 44% HPV
prevalence reduc-
tion (female only
30%)
Taira et al. [339] 2004 Hybrid, population-based:
dynamic deterministic HPV
transmission model based
on difference equations,
combined with static Markov
model for natural history of
HPV infection [311]
USA, HPV 16 and 18, cervical
cancer, 70% vaccine coverage,
90% vaccine efficacy, vaccina-
tion of infants, 12 year olds and
18 year olds, lifelong immunity,
immunity of 10 years, booster, 4
levels of sexual activity, assor-
tative mixing, cervical screen-
ing, observation horizon not re-
ported, vaccine price e 74.11,
discounting not reported
e 10,851.25
(female vs.
screen),
e 329,682.85
(uni vs. female)
64% (17–46%) re-
duction in cervical
cancer
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Barnabas et al. [26] 2006 Deterministic PDE-based Finland, HPV 16, CIN, cervical
cancer, 10-90% vaccine cover-
age, 100% vaccine efficacy, vac-
cination at ages 15-30, lifelong
duration of immunity, no booster,
4 levels of sexual activity, mixing
strategy not reported, cervical
screening, observation horizon
85 years, vaccine price not re-
ported, discounting not reported
— Cervical cancer re-
duction 32–98%
DACEHTA [140] 2007 Dynamic probabilistic
individual-based network
Denmark, HPV 16, 18, CIN I,
CIN II/III, cervical cancer, vac-
cine coverage 70% and 85%,
vaccine efficacy not reported,
vaccination of 12 year old indi-
viduals (catch-up to 19 years),
lifelong immunity, 10 years im-
munity, booster, 2 sexual activ-
ity levels, age-dependent mix-
ing, cervical screening, observa-
tion time period of 70 years, vac-
cine price e 156 (e 80.44 – e
123.94), 3% (0%, 5%) discount-
ing
e 11,414.79 –
e 18,508.60
per LYG
(female vs.
screen),
e 31,239.36 –
e 47,052.63
per LYG (uni vs.
screen)
70% reduction of
cervical cancer,
25% of CIN I, 60%
of CIN II
Elbasha et al. [132] 2007 Deterministic ODE-based USA, HPV 6, 11, 16, 18, CIN,
cervical cancer, genital warts in
both sexes, 90% vaccine cover-
age (0%–75% in the catch-up),
90% vaccine efficacy, vaccina-
tion of 12 year olds with catch-
up in 12-24 year olds, lifelong
immunity, waning immunity af-
ter 10 years, no booster, 3 lev-
els of sexual activity, assortative
and proportionate mixing, cervi-
cal screening, observation hori-
zon 100 years, vaccine price e
88.93 (e 74.11 – e 123.51) (incl.
admin. cost), 3% discounting
e 2,201.92
(female vs.
screen), female
only dominates
universal,
dominated –e
39,383
(universal
strategies)
genital warts 97%,
CIN 2/3 91%, cervi-
cal cancer 91%
French et al. [143] 2007 see Barnabas et al. [26] Finland, HPV 16, cervical can-
cer, vaccine coverage 10-90%,
100% vaccine efficacy, vaccina-
tion of 12 year olds, vaccina-
tion of 12 yo, 15 yo, 12-18 yo
or 15-18 yo, lifelong immunity,
no booster, 4 levels of sexual
activity, mixing strategy not re-
ported, cervical screening, ob-
servation horizon of 100 years,
vaccine price not reported, dis-
counting not reported
— 67% (females aged
15 years) – 87%
(universal) reduc-
tion of cervical
cancer after 60
years
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Insinga et al. [188] 2007 see Elbasha et al. [132] Mexico, 0-70% vaccine cover-
age, 90% vaccine efficacy, as-
sortative mixing according to
age and sexual activity level,
other assumptions according to
[132], vaccine price e 151.25,
3% discounting
e 1,693.04
(female vs.
screen), female
dominates
universal,
e 1,898.27 – e
10,400.95
(different
catch-up
strategies)
Incidence reduc-
tion 93% in genital
warts, 39% in CIN
II/III and 4% in
cervical cancer
Kim et al. [215] 2007 Hybrid: Deterministic ODE-
based [26], probabilistic mi-
crosimulation
Brazil, low resource setting,
HPV 16 and 18, CIN, cervical
cancer, 0-90% vaccine cover-
age, high vaccine efficacy, vac-
cination before the age of 12,
lifetime vaccine protection, no
booster, 4 levels of sexual ac-
tivity, proportionate and assorta-
tive mixing, no cervical screen-
ing, lifelong observation, vac-
cine price e 6.18 – e 98.82 (incl.
admin. cost), 3% discounting
cost-saving – e
3,108.04 per
LYS (female vs.
screen),
e 81.79 –
e 101,799.43
per LYS
(universal vs.
female)
14-67% cervical
cancer reduction
Elbasha et al. [133] 2008 Deterministic ODE-based USA, HPV 6/11, 16/18, CIN, cer-
vical cancer, genital warts, 0-
70% vaccine coverage, 90% ef-
ficacy, vaccination before age 12
with a catch-up in 12-24 year
olds, lifelong protection, waning
after 10 years, no booster, 3 sex-
ual activity groups, assortative
and proportionate mixing, cervi-
cal screening, observation hori-
zon length not reported, vaccine
price e 88.94, discounting takes
place, actual rates not reported
e 2,193.77
(female vs.
screen), female
dominates
universal,
e 33,347.66
(universal vs.
univer-
sal+female
catch-up)
—
Jit et al. [204] 2008 Dynamic deterministic trans-
mission model
UK, HPV types 6, 11, 16, 18 and
third group of high-risk types,
CIN, cervical cancer, squamous
cell carcinomas, adenocarcino-
mas, non-cervical cancers, gen-
ital warts, 70% and 90% vac-
cine coverage, 100% vaccine ef-
ficacy, vaccination at the age of
12 or 13 and 14 or 12, 16, 18
and 25, vaccine protection be-
tween 10 years and lifelong, no
booster, number of sexual ac-
tivity levels not reported, mixing
strategies not reported, cervical
screening, 100 years observa-
tion time, vaccine price e 71.53
– e 95.97, 3.5% discounting
e 18,099.17 –
e 40,611.02
(female vs.
screen),
e 136,512.40 –
e 623,836.21
(universal vs.
female 12-25
yo)
—
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Kim and Goldie [218] 2009 Hybrid: see Kim et al. [215] USA, anal, oral cancers, RRP,
vaccination at age 12, 75% vac-
cine coverage, 90-100% vaccine
efficacy, vaccine price e 88.94,
other assumptions identical to
[215]
e 15,535.50 –
e 29,834.96
(female vs.
screen),
e 84,753.20 –
e 214,854.66
(universal vs.
female)
—
Zechmeister et al. [392] 2009 Deterministic ODE-based
[150]
Austria, HPV 16 and 18, CIN,
cervical cancer, 65% vaccine
coverage, 90% vaccine efficacy,
vaccination age 12 years, nat-
ural immunity lost at constant
rate, booster after 10 years, 3
levels of sexual activity, mixing
strategies not reported, cervical
screening, observation time 52
years, vaccine price e 110, 5%
(0–5%) discounting
e 64,000 per
LYG (female vs.
screen), e
311,000 per
LYG (universal
vs. female)
—
Choi et al. [85] 2010 see Jit et al. [204] UK, CIN, cervical cancer, gen-
ital warts, 88% vaccine cover-
age, 100% vaccine efficacy, vac-
cination of 12 year old or 13
and 14 or 14, 16, 18, 20 and
25 year old individuals, dura-
tion of immunity of 20 years, no
booster, number of sexual ac-
tivity levels not reported, mix-
ing between completely assor-
tative and completely propor-
tionate, cervical screening, 60
years observation time horizon,
vaccine price not reported, dis-
counting not reported
see Jit [204] 72% (32–78%) re-
duction in cervical
cancer incidence
Elbasha et al. [131] 2010 see Elbasha et al. [133] USA, CIN, RRP, genital warts,
cervical, vaginal, vulvar, anal,
penile, head and neck cancer,
vaccination ages 9-26 years,
vaccine price e 98.82 (incl. ad-
min. cost), 3% discounting,
other model assumptions equiv-
alent to [133]
e 2,429.13 – e
16,366.67
(female vs.
screen),
e 18,994.90– e
144,565.23
(universal vs.
female)
35% (female only)
and 52% (univer-
sal) reduction in
female GW, male
GW reduction
slightly higher
Olsen et al. [277] 2010 Dynamic probabilistic network
model [140]
Denmark, HPV 6, 11, 16, 18,
cervical cancer, genital warts,
70% and 85% vaccine coverage,
100% vaccine efficacy (93.5%,
99.8%), vaccination of 12 or
12 and 15 or 12-26 year olds,
waning immunity after 15 years,
booster after 15 and 25 years,
cervical screening, 62 years ob-
servation time, vaccine price e
138.33 (incl. admin. cost), 3%
discounting
e1,917 –
e 8,727 (female
interventions),
e 18,677
(universal vs.
female)
complete elim-
ination of HPV
6/ 11/ 16/ 18 after
50 years
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van de Velde et al. [360] 2010 Dynamic probabilistic mi-
crosimulation
Canada, 18 HPV types, no con-
sideration of HPV-induced dis-
eases, 100% vaccine coverage,
95% vaccine efficacy, vaccina-
tion age of 12 years with a possi-
ble catch-up until 18, waning im-
munity following normal distribu-
tion with mean of 20 years, no
booster, 4 levels of sexual activ-
ity, assortative mixing, cervical
screening, observation time of
120 years, vaccine price not re-
ported, discounting not reported
— 60% (female only)
and 95% (uni-
versal) reduction
in HPV 16/18
prevalence, 100%
reduction in HPV
6/11 prevalence
Bogaards et al. [39] 2011 Deterministic ODE-based Netherlands, HPV 16, no HPV-
induced diseases, 5%-95% cov-
erage, 100% vaccine efficacy,
vaccination age of 12 years, life-
long immunity, no booster, 3 lev-
els of sexual activity, propor-
tionate and assortative mixing,
no cervical screening, observa-
tion time period of 100 years,
vaccine price not reported, dis-
counting not reported
— single-sex vacci-
nation leads to a
faster HPV preva-
lence reduction
than universal
vaccination
Brisson et al. [59] 2011 see van de Velde et al. [360] Canada, vaccination age 12
years, 70% vaccine coverage,
time horizon of 70 years, vac-
cine price not reported, dis-
counting not reported, other as-
sumptions consistent with [360]
— prevalence reduc-
tion of HPV 16/18
62% (female only)
and 85% (univer-
sal) in both sexes
Brown et al. [63] 2011 Deterministic ODE-based to
evaluate best HPV vaccina-
tion strategy
UK, no distinction between HPV
types, no consideration of HPV-
induced diseases, 90% cover-
age, efficacy not reported, vac-
cination age not reported, dura-
tion of immunity between 5 and
100 years, no booster, no sexual
activity levels, assortative mix-
ing, cervical screening, obser-
vation time period of 20 years,
vaccine price not reported, dis-
counting not reported
Male
vaccination is
cost-effective,
no ICERs
calculated
—
Chesson et al. [82] 2011 see Chesson et al. [83] USA, HPV 6, 11, 16, 18, CIN,
genital warts, RRP, cervical,
vaginal, vulvar, anal, oropha-
ryngeal, penile cancer, 20%,
30% and 75% vaccine coverage,
100% efficacy and 75% versus
60% in females and males re-
spectively, vaccination age of
12 years, lifelong immunity, no
booster, 1 level of sexual activ-
ity, assortative mixing, cervical
screening, observation time of
100 years, vaccine pricee 74.11
– e 88.94 (incl. admin. cost),
discounting not reported
e 4,218.79 – e
21,019.92
(female vs.
screen),
e 17,467.26 –
e 548,664.30
(universal vs.
female)
—
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de Kok et al. [107] 2011 Mathematical formula, no
model
Netherlands, HPV 16, 18, cer-
vical, penile, vulvar, vaginal,
anal, oral, oropharyngeal can-
cer, 100% vaccine coverage,
vaccine efficacy not reported,
vaccination age of 12 years, life-
long duration of immunity, no
booster, sexual activity and mix-
ing do not play a role, obser-
vation time period not reported,
vaccine price e 133.33 (e 33.33
– e 166.67), 3% discounting (no
discounting)
— —
Smith et al. [324] 2011 see Barnabas et al. [26] Australia, HPV 16, cervical,
anal, penile, mouth, tongue, ton-
sils, oropharynx, hypopharynx
and larynx cancers, age-specific
coverage ranging from 40% to
78% in females and 35.5% to
78% in males, 90-100% and
80-100% vaccine efficacy in fe-
males and males respectively,
female vaccination age of 12-26
years, male vaccination age of
12 with catch-up in 13-15 year
olds, duration of immunity from
10 years to lifelong, no booster,
sexual activity levels and mix-
ing strategies see [26], no cervi-
cal screening, lifelong observa-
tion, vaccine price and discount-
ing not reported
— 73–99% (males)
and 89–99% (fe-
males) reduction in
HPV 16 prevalence
Drolet et al. [122] 2013 see van de Velde et al. [360] Canada, genital warts, cervi-
cal, vulvar, vaginal, penile, anal
and oral cancers, 70% vac-
cine coverage (<50% and >
70%), 100% vaccine efficacy
against vaccine-specific HPV
types, lower cross-protection
levels, vaccination of 12 year
olds, lifelong immunity, waning
immunity after 20 years and
waning cross-protection after 10
years, no booster, 4 levels of
sexual activity, mixing not re-
ported, cervical screening, ob-
servation time horizon of 80
years, vaccine price and dis-
counting not reported
— 60–75% cervical
cancer reduction
depending on vac-
cination strategy
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Horn et al. [185] 2013 Hybrid: deterministic ODE-
based [85, 132, 392], Markov
[313]
Germany, HPV 16, 18, CIN I-III,
cervical cancer, genital warts,
50% vaccine coverage (20%,
80%), 98% efficacy, vaccination
at the age of 12, waning im-
munity at a yearly rate of 10%,
no booster, 3 sexual activity
levels, assortative and propor-
tionate mixing, cervical screen-
ing, observation time period 100
years, vaccine price and dis-
counting not reported
— 36.8%, 43.8%
(bivalent without
and with cross-
protection) and
41.5% (quadri-
valent) cervical
cancer reduction
Vänskä et al. [368] 2013 Bayesian PDE-based Finland, 14 high-risk HPV types,
no HPV-induced diseases, 80%
vaccine coverage (40%-90%),
type-dependent efficacy from
0% to 95%, vaccination age of
12 years, waning immunity, no
booster, no sexual activity lev-
els, proportionate mixing, cervi-
cal screening, observation time
of 60 years, vaccine price and
discounting not reported
— HPV prevalence
reduction of 54.6%
Bresse et al. [49] 2014 see Elbasha et al. [131] Austria, genital warts, RRP, CIN,
VIN, VaIN, cervical, anal, head/-
neck, penile, vaginal, vulvar can-
cer, 65% vaccine coverage, 49-
100% vaccine efficacy, vaccina-
tion age of 9 years, lifetime (20
years) duration of protection, no
booster, 3 sexual activity groups,
sexual mixing not reported, cer-
vical screening, follow-up of 100
years, vaccine price e 110, 3%
(0-5%) discounting
e 10,033 – e
26,701
(universal vs.
screen-only)
55–87% preva-
lence reduction
Burger et al. [67] 2014 see Kim et al. [217,218] Norway, HPV 6, 11, 16, 18, gen-
ital warts, RRP, anal, cervical,
oropharyngeal, penile, vaginal,
vulvar cancer, 71% (90%) cov-
erage, 100% and 90% efficacy
in females and males, 80% effi-
cacy in sensitivity analysis, vac-
cination age of 12 years, life-
time duration of protection, no
booster, 4 sexual activity levels,
sexual mixing not reported, cer-
vical screening, lifelong follow-
up, vaccine price e 44.68 – e
134.05, 4% (0-3%) discounting
female-only: e
4468.47–e
18410.12,
universal: e
53711.07 – e
130032.62
41% (female-only)
and 51% (univer-
sal) reduction in
cervical cancer
cases
210
B.1. Summary tables of the literature review
Laprise et al. [236] 2015 see van de Velde et al. [360]
and HPV-Advise [58]
Canada, 2- and 3-dose vacci-
nation regimens, 18 HPV types,
genital warts, cervical, vulvar,
vaginal, anal, penile, oropharyn-
geal cancer, 80% (40-80%) cov-
erage, 95% (90%) efficacy, vac-
cination age 9 years, lifelong (10
years - lifelong) immunity, no
booster, sexual activity, mixing
and follow-up as in [58], cervi-
cal screening, vaccine price e
54.70 per dose, 3% discounting
2-dose
universal vs.
2-dose
female-only: e
55,476.23,
3-dose
universal vs.
best strategy: e
643,502.50
2-dose female-
only: 34.5%
cervical cancer
reduction, 2-dose
universal: addi-
tional 1.6%
Pearson et al. [289] 2014 see Blakely et al. [34] New Zealand, HPV 6/11, 16/18,
genital warts, CIN, cervical,
anal, oropharyngeal and vul-
var cancer, 45-73% coverage,
99% efficacy, vaccination at age
12, duration of protection 20
years, no booster, sexual activ-
ity and mixing as in [360], cervi-
cal screening, lifetime follow-up,
vaccine price not reported, 3%
(0-6%) discounting
female-only vs.
screening: e
11,234,45,
universal vs.
female-only: e
70,242.28
—
Graham et al. [173] 2015 Deterministic Markov Canada, oropharyngeal cancer
in males, no distinction between
HPV types, oropharyngeal can-
cer, 50% (30-70%) coverage,
83.8% (50-99.7%) efficacy, vac-
cination age of 12 years, lifelong
protection, no booster, sexual
activity and mixing not reported,
no cervical screening, lifetime
duration of follow-up, time-step
of follow-up 3 months, vaccine
price e 260.17, 5% discounting
cost-saving
ICER: - e
4975.09
—
Olsen et al. [278] 2015 see Olsen et al. [277] and
DACEHTA [140]
Denmark, HPV 6, 11, 16,
18, genital warts, CIN, cervi-
cal, anal, penile, vaginal, vul-
var, head/neck cancer, 85% cov-
erage, 100% efficacy, vaccina-
tion age 12 years, lifelong im-
munity, booster, sexual activity
and mixing not reported, cervi-
cal screening, follow-up of 62
years, vaccine price e 417, 3%
(0-5%) discounting
e 3,581
(female-only), e
41,636
(universal vs.
female-only), e
27,343 (uni. vs.
f-o., 2-dose
regime)
—
Sharma et al. [317] 2015 see Kim et al. [215] Southern Vietnam, HPV 16/18,
genital warts, cervical cancer,
25-90% coverage, 100% effi-
cacy, vaccination at age 12, life-
long duration of immunity, no
booster, sexual activity and mix-
ing as [26], cervical screening
in sensitivity analysis, lifetime
follow-up, vaccine price e 8.98 -
e 179.67, 3% discounting
female-only:
cost-saving - e
1686.4,
universal: e
114.10 - e
7025.06
cervical cancer
reduction: 20%
(female-only) and
22.7% (universal)
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Brisson et al. [55] 2016 see van de Velde et al. [360] US, comparison of 4- to 9-valent
vaccine, 18 HPV types, geni-
tal warts, CIN, cervical, anal,
oropharyngeal, penile, vaginal,
vulvar cancer, 46% and 25%
coverage in females and males,
95% efficacy, vaccination at 13-
17 years, lifelong (20 years) pro-
tection, no booster, 4 levels of
sexual activity, assortative and
disassortative mixing, cervical
screening, follow-up of 70 (30)
years
9-valent
universal:
cost-saving
when compared
to 4-valent
universal;
4-valent
universal: e
6518.8 when
compared to
screening-only
70% and 80% de-
crease in cervical
cancer incidence
through 4- and
9-valent universal
vaccination
B.1.2 Female-only vaccination
In contrast to Table B.1 which includes publications on universal vaccina-
tion, Table B.2 summarizes the results of the literature review for female-
only vaccination. The structure of the tables is identical and based on the
list of search criteria presented in Section 4.3. Similarly to Table B.1, Ta-
ble B.2 presents the authors, the year of publication, the statistical method-
ology, model assumptions and details about research outcomes. Research
outcomes are reported separately in terms of ICERs, the results of cost-
effectiveness analyses, and clinical parameters such as reductions in HPV
prevalence and/or cervical cancer.
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Table B.2: Summary table of publications estimating the cost-effectiveness and/or
HPV (or cervical cancer) prevalence reduction of female-only vaccina-
tion. The most important aspects of the methodology, model assump-
tions and outcomes are summarized to explain possible variations in
results.
Authors Year Methodology Model assumptions ICER Prevalence reduc-
tion
Myers et al. [263] 2000 Probabilistic Markov USA, no distinction of HPV
types, CIN, cervical cancer, no
HPV vaccination, only natural
history model, cervical screen-
ing, observation horizon of 70
years, no vaccine price, no dis-
counting
— —
Goldie et al. [162] 2003 Probabilistic Markov Cost Rica, HPV 16/18, low-risk,
CIN, cervical cancer, 25-100%
vaccine coverage, 50-98% vac-
cine efficacy, vaccination before
age 13, 25-100% waning immu-
nity after 10 years, no booster,
cervical screening, duration of
follow-up, vaccine price and dis-
counting not reported
— 25–65% incidence
reduction of cervi-
cal cancer
Kulasingam et
al. [232]
2003 see Myers et al. [263] USA, 50-100% vaccine cover-
age, 25-100% vaccine efficacy,
vaccination of 12 year olds (12-
19 yo), 10 years duration of pro-
tection (2-30 years), booster at
17 or 22 years, cervical screen-
ing, observation time period of
73 years, vaccine price e 49.41
(e 24.70 – e 148.23), 3% dis-
counting
e 335.84
(screen vs.
female) per
LYG – not
cost-effective
(vaccination
only or older
vaccination
ages)
Incidence reduc-
tion in cervical
cancer 16.8% –
93.2%
Sanders et al. [311] 2003 Probabilistic Markov USA, 13 high-risk HPV-types,
low-risk types, CIN, cervical
cancer, vaccine coverage 70%
(30-100%), vaccine efficay 75%
(0-100%), vaccination age 12
(15) years, duration of immunity
10 years, booster application ev-
ery 10 years, no cervical screen-
ing, lifetime observation period,
vaccine price e 74.11 (e24.7 –
e123.52) (incl. admin. costs)
e 17,000.37 19.87% reduction
in cervical cancer
cases
Goldie et al. [164] 2004 see Goldie et al. [162] USA, 90% (50-100%) vaccine
efficacy, vaccination age 12
years (12-15), lifelong immunity
(5, 10, 15, 20 years), boost-
ers, cervical screening, obser-
vation time horizon 100 years,
vaccine price e 93.13 (e 46.44
– e 139.58), 3% discounting
e 15,246.84 –
e 24,942.65
(female vs.
screen)
86.9 – 99.2% cer-
vical cancer reduc-
tion
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Brisson et al. [57] 2007 see van de Velde et al. [358],
comparison of bivalent and
quadrivalent vaccine
Canada, vaccination of 12 (15,
20, 25) year olds, vaccine price
e 94.61 (incl. admin. costs), 3%
discounting
e 21,765.33 –
e 80,478.45
(bivalent) and
e 14,373.80 –
e 45,257.30
(quadrivalent)
—
Goldhaber-Fiebert et
al. [159]
2007 Static probabilistic microsimu-
lation model
USA, HPV 16, 18, other high-
risk, low-risk, CIN I, CIN II/III,
cervical cancer, 100% coverage,
100% efficacy, vaccination be-
fore the age of 12, lifelong dura-
tion of immunity, no booster, cer-
vical screening, lifetime obser-
vation, time step 1 month, vac-
cine price and discounting not
reported
— Cervical cancer in-
cidence reduction
55% (screening ev-
ery 5 years) – 95%
(screening every 3
years+vaccination)
Goldie et al. [163] 2007 see Kim et al. [215,220] Brazil, 70% vaccine coverage
(10-100%), 100% vaccine effi-
cacy (70%), vaccination before
the age of 12, lifelong immu-
nity, booster after 10 years, sex-
ual activity levels and mixing
not reported, cervical screen-
ing, lifelong observation time pe-
riod, monthly time steps, vac-
cine price e 18.52 – e 111.09,
3% discounting
— 22% (screening)
– 62% (screen-
ing+HPV DNA
test+vaccine)
cervical cancer
reduction
Kim et al. [220] 2007 Probabilistic microsimulation
model
Brazil, HPV 16, 18, other high-
risk, low-risk, CIN I, CIN II/III,
cervical cancer, no vaccination,
cervical screening, lifetime ob-
servation period with monthly
time steps, vaccination cost and
discounting do not play a role
— —
Kohli et al. [225] 2007 Probabilistic Markov UK, HPV 16, 18, 31, 45, 52,
other high-risk, low-risk, CIN I-
III, cervical cancer, 80% and
100% coverage, 90% and 100%
efficacy, vaccination of 12 (10,
18) year olds, lifelong immunity,
waning of cross-protection after
10 years, booster application,
cervical screening, lifetime ob-
servation period, vaccine price
and discounting not reported
— Cervical cancer
reduction by 76%
(60.8% – 79.6%)
van de Velde et al.
[358]
2007 Bayesian Markov Canada, HPV 16, 18, other high-
risk, low-risk, CIN I, CIN II/III,
100% vaccine coverage, 95%
vaccine efficacy (85%), vacci-
nation age of 12 (15, 20, 30)
years, lifelong (30 years) immu-
nity, booster application, cervical
screening, observation time pe-
riod 90 years, vaccine price and
discounting not reported
— decrease in lifetime
cervical cancer risk
by 60% (45–70%)
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Chesson et al. [83] 2008 Deterministic multi- and
single-cohort model. Indi-
rect consideration of herd
immunity.
USA, bivalent vs. quadriva-
lent, HPV 16/18, 6/11, CIN I-
III, cervical, anal, vaginal, vulvar
and oropharyngeal cancer, gen-
ital warts, 70% coverage, 100%
(95%, 99%) efficacy, vaccination
of 12 year olds, lifelong immu-
nity, booster, cervical screening,
observation time period of 100
years, vaccine price e 88.88 (e
222.02 – e 362.64), discounting
at 3%
Quadrivalent: e
2,914.06 (herd
immunity, all
HPV-induced
diseases),
e 7,679.80 (no
herd immunity,
only CIN,
cervical cancer,
genital warts),
bivalent:
e 5,808.17,
e 10,896.24
—
Dasbach et al. [101] 2008 see Elbasha et al. [132] UK, vaccination of 12 year olds
with catch-up in 12-14, 12-17 or
12-24 yo, 80% coverage, catch-
up coverage in first year: 40%
in 12 - 14 yo, 30% in 15-17
yo, 25% in 19-24 yo, afterwards
twice as high, cervical screen-
ing, 100 years observation, vac-
cine price e 89.30, discounting
at 3.5%
12 year old
vaccination
dominates
screening only,
e 13,674.65
when 12–24 yo
vaccination is
compared to
12–17 yo
vaccination
86% reduction in
cervical cancer in-
cidence
Dasbach et al. [102] 2008 see Elbasha et al. [132] and
Dasbach et al. [101]
Norway, catch-up in 12-24 year
olds, vaccine price e 122.35
(incl. admin cost), discounting at
3.5%
e 6,400 (female
vs. screen),
e 7,662.56
(catch-up vs.
female)
92% cervical can-
cer reduction
Dasbach et al. [100] 2008 see Elbasha et al. [132] and
Dasbach et al. [101]
Taiwan, catch-up in 12-24 year
olds, vaccine price e 98.99 (incl.
admin cost), 3% discounting
vaccination
dominates
screening,
e 10,254.17
(catch-up vs.
female)
(e 10,254.17 –
e 61,640.81)
cervical cancer re-
duction 91%
Debicki et al. [109] 2008 Two probabilistic Markov UK, Canada, Taiwan, Italy,
model 1: HPV 16, 18 (95%
efficacy), 31 (53% efficacy), 45
(88% efficacy), 52, other high-
risk, low-risk, CIN I-III, cervical
cancer. Model 2: no distinction
between HPV types (correction
factors in efficacy according
to HPV type distribution), CIN
I, CIN II/III, cervical cancer.
100% coverage, vaccination
of 12 year olds, lifelong dura-
tion of protection, no booster,
cervical screening, lifelong ob-
servation time period, vaccine
price e 100.39 (UK), e 95.70
(Canada), e 99.92 (Taiwan),
e 120.91 (Italy), 3.5% (UK)
and 3% (Canada, Taiwan, Italy)
discounting
UK: model 1: e
21,608.13,
model 2:
e 28,440.26,
Canada: model
1:
e 15,795.72,
model 2:
e 19,643.00,
Taiwan: model
1:
e 15,802.02,
model 2:
e 13,920.67,
Italy:
model 1:
e 31,791,
model 2:
e 31,223
Cervical cancer re-
duction, UK: model
1: 76.1%, model
2: 76.9%, Canada:
model 1: 70.5%,
model 2: 71.5%,
Taiwan: model 1
and 2: 71.5%, Italy:
model 1: 76.2%,
model 2: 75.0%
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Diaz et al. [120] 2008 see Goldie et al. [163] India, HPV 16, 18, other high-
risk, low-risk, CIN I, CIN II/III,
cervical cancer, 10-90% cover-
age, 50-100% efficacy, vacci-
nation before age 12, waning
immunity, lifelong observation,
vaccine price e 1.23 – e 88.82
(incl. admin cost), 3% discount-
ing
When
compared to
screening only,
vaccination is
cost-saving at
the lowest
price.
Otherwise,
it is dominated.
e 44.40 –
e 61,081.91
(different
screening
strategies and
vaccination)
13–63% cervical
cancer reduction
Goldhaber-Fiebert et
al. [160]
2008 see Goldhaber et al. [159] USA, HPV 16, 18, other high-
risk, low-risk, CIN I, CIN II/III,
cervical cancer, 100% vaccine
coverage (25%, 75%), 100%
vaccine efficacy (75%), vaccina-
tion of 12 year olds, lifelong im-
munity (15 years), no booster,
cervical screening, lifelong ob-
servation, vaccine price e 99.19
(e 74.02 – e222.06), 3% dis-
counting
e 4,458.98
when compared
to no
intervention, e
5,180.20 – e
12,749,000 for
different
screening and
intervention
strategies
—
Goldie et al. [168] 2008 Hybrid: ODE-based [163], mi-
crosimulation [220]
USA, 4 HPV types, CIN, cervi-
cal cancer, 70% vaccine cover-
age, efficacy not reported, vac-
cination age before 12 years,
lifelong immunity, sexual activity
levels and mixing according to
[163], no cervical screening, life-
long observation, vaccine price
e 1.48 – e 3.70, 3% discounting
e 186.16 -
e 2,211.63
40-55% lifetime
cervical cancer risk
reduction
Goldie et al. [167] 2008 Hybrid [163,220] 72 developing countries, 70%
coverage, high efficacy, vaccina-
tion before the age of 12, lifelong
immunity, sexual activity and
mixing according to [163], cer-
vical screening according to the
respective country, lifelong ob-
servation period, vaccine price
e 7.40 – e 37 (incl. admin.
cost), discounting not reported
cost-saving – e
2,197.88 per
DALY
20.4–60.1% cervi-
cal cancer reduc-
tion
Goldie et al. [161] 2008 Hybrid [163,220] Carribean, Latin America, 70%
coverage, 100% efficacy, vac-
cination of 12 year olds, life-
long immunity, sexual activity
and mixing according to [163],
cervical screening, lifelong ob-
servation, vaccine price e 0.41
– e 88.82 (incl. admin. cost),
3% (6%) discounting
cost-saving – e
5,232.00
14.2–68.6% cervi-
cal cancer reduc-
tion
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Kim et al. [219] 2008 Hybrid [159,163,220] Vietnam, 70% coverage (0-
100%), 100% efficacy (50-
100%), vaccination before the
age of 12, lifelong immunity,
sexual activity and mixing
according to [163], cervical
screening, observation time
horizon 5 years, vaccine price e
1.48 – e 93.84, 3% discounting
cost-saving – e
49,382.07
cervical cancer re-
duction 20.4% –
76.1%
Kim et al. [217] 2008 Hybrid [218,220] USA, genital warts, cervical, vul-
var, vaginal, anal, oral, oropha-
ryngeal cancers, RRP, vaccina-
tion of 12 year olds with catch-
up in 18, 21 or 26 years, 25%
coverage rate within the first 5
years after vaccine introduction,
followed by 75% coverage rate,
100% vaccine efficacy, lifelong
(10 years) immunity, booster ap-
plication, sexual activity levels
and mixing strategies according
to [163], cervical screening, life-
long observation, vaccine price
e 88.67, 3% discounting
e 32,265.22 (e
25,826.98 –
e 113,002.28)
—
Kulasingam et
al. [231]
2008 see Myers et al. [263] UK, HPV 6, 11, 16, 18, geni-
tal warts, CIN I, CIN II/III, cer-
vical cancer, 100% vaccine cov-
erage (50%, 85%), 100% vac-
cine efficacy (85%), vaccina-
tion of 12 year olds, vaccine-
induced immunity for 20 (10)
years, booster application, cervi-
cal screening, observation time
horizon 73 years, vaccine price
e 89.39 (e 83.43 – e 95.35, 3%
(1.5%) discounting
e 25,199.83 (e
3,737.08 – e
101,623.80)
58.46% cervical
cancer reduction
Rogoza et al. [303] 2008 see Debicki et al. [109] and
Kohli et al. [225]
Canada, The Netherlands, Tai-
wan, UK, USA, HPV 16, 18, 31,
45, 52, other high-risk, low-risk,
CIN I–III, cervical cancer, 100%
vaccine coverage, 95% effi-
cacy against HPV 16/18 (53%
against HPV 31, 88% against
HPV 45), vaccination at the
age of 12, lifelong duration of
protection, no booster, cervical
screening, lifelong observa-
tion, vaccine price e 95.45
(Canada) – e 116.72 (USA),
discounting 4% costs, 1.5%
benefits (Netherlands), 3%
(Canada, Taiwan, USA), 3.5%
(UK)
e 5,792.94
(USA) –
e 21,573.69
(UK)
cervical cancer
reduction 70.5%
(Canada) – 76.1%
(UK)
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Suárez et al. [333] 2008 see Debicki et al. [109] Chile, Finland, Ireland, Poland
and Taiwan, HPV 16, 18, CIN I,
CIN II/III, cervical cancer, 100%
(80%) vaccine coverage, 95%
vaccine efficacy, vaccination at
the age of 11, 10 (25) years du-
ration of immunity, booster ap-
plication, cervical screening, life-
long observation, vaccine price
e 70 (Chile) – e 150 (Finland),
discounting 3% (Chile), 3.5%
(Ireland, Poland), 3% costs,
1.5% benefits (Finland, Taiwan)
e 6,879.10
(Chile) –
e 24,799
(Ireland)
20% reduction of
cervical cancer
cases
Szucs et al. [337] 2008 see Myers et al. [263] and Ku-
lasingam et al. [232]
Switzerland, HPV 6, 11, 16, 18,
CIN I-III, cervical cancer, geni-
tal warts, 80% coverage, 95%
(90-100%) efficacy, vaccination
of 11 year olds, lifelong immu-
nity, waning immunity after 10
years, booster application, cervi-
cal screening, lifelong observa-
tion, vaccine price e 192.21, dis-
counting 3% (costs) and 1.5%
(benefits)
e 21,044.31 (e
18,195.56 –
e 85,409.49)
62% cervical can-
cer reduction
Usher et al. [356] 2008 see DACEHTA et al. [140] Ireland, female-only vaccination,
HPV 16, 18, CIN I, CIN II/III, cer-
vical cancer, 80% (30%) vaccine
coverage, 95.2% (85-99%) vac-
cine efficacy, vaccination of 12
year olds with catch-up in 12-15,
12-17, 12-19 or 12-26 yo, life-
long immunity, waning after 10
years, booster application, sex-
ual activity and mixing according
to [140], cervical screening, ob-
servation time of 70 years, vac-
cine price e 100 (e 80 – e 120),
3.5% (0–6%) discounting
e 17,383
(e 18,893 –
e 24,534) per
LYG
—
Anonychuk et al. [16] 2009 see Debicki et al. [109] with
indirect consideration of herd
immunity [27]
Canada, HPV 16, 18, other
oncogenic, CIN I, CIN II/III, cer-
vical cancer, 75% vaccine cov-
erage, 98% vaccine efficacy
against HPV 16/18, 37% against
other oncogenic types, vaccina-
tion of 12 year olds (12-25 yo),
duration of immunity for 10 or 30
years, cervical screening, life-
long observation, vaccine price
e 99.84, 3% (0–5%) discounting
e 13,829.06 –
e 23,468.37
9–77% reduction
in cervical cancer
cases
218
B.1. Summary tables of the literature review
Colantonio et al. [87] 2009 see Debicki et al. [109] Latin America (Argentina, Brazil,
Chile, Mexico, Peru), HPV 16,
18, 31, 45, CIN I, CIN II/III,
cervical cancer, vaccine cover-
age not reported, vaccine ef-
ficacy 66.1% – 76.3%, vac-
cination of 12 year olds (12-
18), 20 years duration of immu-
nity, booster application, cervical
screening, lifelong observation,
vaccine price e 51.77 (incl. ad-
min cost), 3% discounting
e 3,314.74
(Peru) –
e 12,796.81
(Chile)
62.73% (Brazil)
– 70.09% (Ar-
gentina)cervical
cancer case reduc-
tion
Coupé et al. [96] 2009 Probabilistic Markov The Netherlands, HPV 16, 18,
31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66, 68, CIN I-III, cervi-
cal cancer, 85% coverage, 95%
efficacy, vaccination of 12 year
olds, lifelong immunity (10, 30
years), 3 sexual activity levels,
cervical screening, observation
time horizon of 88 years, vac-
cine price e 125 (e 75), dis-
counting 4% (cost) and 1.5%
(benefit) (0%)
e 19,429
(e 17,467 –
e 35,325)
86.66% reduction
of cervical cancer
(60.51% – 65.75%)
Dee et al. [111] 2009 Markov with fixed parameter
values
Ireland, comparison of 2- and
4-valent vaccine, no distinction
between HPV types, cervical
cancer, genital warts, 90% (60-
100%) coverage, 90% efficacy
against cervical cancer, 95% ef-
ficacy against genital warts, vac-
cination age of 12 years, lifelong
protection, no booster, cervical
screening, observation time pe-
riod of 88 years, vaccine price e
90, 4% (0–5%) discounting
e 30,460
(e 3,399 –
e 45,237,
bivalent),
e 25,349
(e 2,877 –
e 36,548,
quadrivalent)
51.28% cervical
cancer reduction
de Kok et al. [108] 2009 Static deterministic microsim-
ulation model [177]
The Netherlands, no distinc-
tion between HPV types, CIN
I-III, cervical cancer, 85% vac-
cine coverage, 70% vaccine ef-
ficacy against cervical cancer,
35% vaccine efficacy against
CIN, vaccination of 12 year olds,
lifelong immunity, booster appli-
cation, cervical screening, life-
long observation, vaccine price
e 118 (e 0 – e 120), 3% (0%)
discounting
e 53,500
(e 4,100 –
e 105,600)
61% reduction of
cervical cancer
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Elbasha et al. [134] 2009 see Elbasha et al. [132] USA, investigate proper age of
HPV vaccination, HPV 6, 11, 16,
18, CIN, cervical cancer, geni-
tal warts, 70% (50%, 90%)cov-
erage, 90% efficacy, vaccination
of 12 year olds (12-14, 12-17,
12-19, 12-24), lifelong (10 years)
immunity, no booster, three sex-
ual activity levels, age- and be-
havioural dependent sexual mix-
ing, cervical screening, obser-
vation time period of 100 years,
vaccine price e 88.74 (incl. ad-
min. costs), discounting 3%
Vaccination is
dominated by
screening only
(e 2,307.07 – e
8,136.57 for
catch-up)
6.9% (20.5%) re-
duction in cervical
cancer cases
Hillemanns et
al. [183]
2009 see Myers et al. [263] Germany, no distinction be-
tween HPV types, CIN I-III, cer-
vical cancer, genital warts, 80%
(100%) vaccine coverage, 100%
(90%) vaccine efficacy, vacci-
nation at age 12, lifelong (10
years) protection, booster appli-
cation, cervical screening, life-
long observation, vaccine price
e 143.8, discounting 4% (costs)
and 1.5% (benefits) (0–5%)
e 10,530
(e 3,049 –
e 42,493)
59.27% cervical
cancer reduction
Kim et al. [221] 2009 see Kim et al. [218] and
Goldhaber-Fiebert et al. [159]
USA, HPV 16, 18, other high-
risk, low-risk, CIN I, CIN II/III,
cervical cancer, 100% vaccine
coverage, 100% (70%) vac-
cine efficacy, vaccination of 35,
40 and 45 yo, lifelong (5, 10
years) protection, booster appli-
cation, sexual activity and mix-
ing according to [218], cervical
screening, lifelong observation,
vaccine price e 99.10, 3% dis-
counting
e 20,339.27 –
e 331,871.57
—
Mennini et al. [257] 2009 see Myers et al. [263] and Ku-
lasingam et al. [232]
Italy, no HPV type distinction,
CIN I-III, cervical cancer, genital
warts, 80% vaccine coverage,
100% vaccine efficacy, vaccina-
tion at the age of 12, lifelong (20
years) protection, booster appli-
cation, cervical screening, life-
time observation horizon, vac-
cine price e 106, discounting
3% (costs) and 1.5% (effects)
(0–5%)
e 9,569
(e 2,781 –
e 48,122)
63.3% cervical
cancer reduction
Oddsson et al. [274] 2009 Markov with fixed parameter
values
Iceland, no HPV type distinction,
CIN I, CIN II/III, cervical cancer,
90% coverage, 95% efficacy,
vaccination at the age of 12, life-
long immunity, no booster, cervi-
cal screening, lifelong observa-
tion, vaccine price e 107, dis-
counting at 3% (6%)
e 18,547
(e 14,000 –
e 86,000)
50% reduction of
cervical cancer
deaths
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Reynales-
Shigematsu et
al. [300]
2009 see Myers et al. [263] and Ku-
lasingam et al. [232]
Mexico, no distinction between
HPV types, CIN I-III, cervical
cancer, 100% (30%) vaccine
coverage, 95% vaccine efficacy,
vaccination of 12 (12-25) year
old females, duration of immu-
nity not reported, no booster,
cervical screening, observation
time 73 years, vaccine price e
11.09 (incl. admin. cost, e
33.28 – e 184.88), 3% (6%) dis-
counting
e 11,778.40
per LYG
(e 50.26 –
e 12,817.65)
13.49% – 77.27%
reduction in cervi-
cal cancer
Rogoza et al. [304] 2009 see Rogoza et al. [303] and
Kohli et al. [225]
The Netherlands, HPV 16, 18,
31, 45, 52, other high-risk, low-
risk, CIN I-III, cervical cancer,
100% vaccine coverage, vac-
cine efficacy 50-100%, lifelong
(20 years) duration of immunity,
cervical screening, lifelong ob-
servation, vaccine price e 100
(e 80 – e 120), discounting 4%
costs and 1.5% benefits (0–5%)
e 18,500
(e 5,800 –
e 103,800)
74% cervical can-
cer reduction
Sinanovic et al. [321] 2009 Markov with fixed parameter
values
South Africa, no distinction be-
tween HPV types, CIN I, CIN
II/III, cervical cancer, 80% cover-
age, 90% efficacy, vaccination of
12 year olds, lifelong (10 years)
duration of immunity, booster
application, cervical screening,
observation time period of 85
years, vaccine price e 88.74 (e
35.50, 4 doses necessary), 3%
(6%) discounting
e 796.81 –
e 1,079.16
—
Thiry et al. [345] 2009 Probabilistic Markov Belgium, no distinction between
HPV types, CIN II/III, cervical
cancer, 84% coverage, 60% (31-
80%) efficacy, vaccination of 12
(16) year olds, 10 year (life-
long) immunity, booster appli-
cation, cervical screening, life-
long observation, vaccine price
e 114.5, discounting 3% costs,
1.5% effects (0–5%)
e 32,665
(e 14,382 –
e 100,406)
50% reduction of
cervical cancer
Accetta et al. [7] 2010 Static deterministic microsim-
ulation
Italy, HPV 16/18, other high-risk,
low-risk, CIN I, CIN II/III, cervi-
cal cancer, 100% vaccine cov-
erage, 75.9% vaccine efficacy
(85%, 95%), vaccination age of
11 years, lifelong immunity, wan-
ing after 10 or 20 years, booster
application, cervical screening,
lifelong observation period, vac-
cine price e 90 (e 30, e 50, e
70), 3% discounting
Vaccination
dominated by
screening+DNA
test, e 2,537 –
e 270,943
76% (43.1% –
79.7%) cervi-
cal cancer risk
reduction
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Bergeron et al. [30] 2010 see Myers et al. [263] and Ku-
lasingam et al. [232]
France, no distinction between
HPV types, CIN I-III, cervical
cancer, genital warts, 80% cov-
erage, 80% (80-100%) efficacy,
vaccination of 14 year olds,
lifetime protection (10 years-
lifetime), booster application,
cervical screening, observation
time period of 71 years, vac-
cine price e 135.60, discounting
3.5% (costs) and 1.5% (effects)
(0–5%)
e 8,408
(e 2,019 –
e 37,228)
64.79% cervical
cancer reduction
Bogaards et al. [38] 2010 Deterministic PDE-based in-
cluding Bayesian approach
The Netherlands, HPV 16, 18,
31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, CIN 0-III, 3
sexual activity levels, assortative
mixing, cervical screening
— —
Dasbach et al. [103] 2010 see Elbasha et al. [132] Hungary, HPV 6, 11, 16, 18, CIN
I, CIN II/III, cervical cancer, gen-
ital warts, 50% and 70% cov-
erage, 95.2% efficacy against
CIN, 98.9% efficacy against
genital warts, vaccination of 12
year olds with catch-up in 12-
24 year olds, duration of im-
munity 10 years to lifelong, no
booster, sexual activity and mix-
ing according to [132], cervical
screening, observation time pe-
riod of 100 years, vaccine price
e 93 (incl. admin. cost), 5%
(0%) discounting
e 9,577
(e 7,356 –
e 16,880) for
12 yo
vaccination and
e 10,646
(e 2,435 –
e 40,083) for
catch-up
90% reduction of
cervical cancer
Demarteau et
al. [114]
2010 see Debicki et al. [109],
Suárez et al. [333], Anony-
chuk et al. [16], Colantonio et
al. [87]
Italy, France, Ireland, bivalent
vs. quadrivalent vaccine, low-
risk HPV, high-risk HPV, CIN
I, CIN II/III, cervical cancer,
genital warts, 100% coverage,
95% (90%, 100%) efficacy, life-
time and 10 year duration of
protection according to HPV
type, booster application, cer-
vical screening, lifetime obser-
vation period, vaccine price e
90 (France, Italy) and e 115
(Ireland), discounting 3%/1.5%
(France), 3.5% (Ireland) and
3%/3% (France)
Quadrivalent
dominates
bivalent vaccine
—
Diaz et al. [119] 2010 see Goldie et al. [163],
Goldhaber-Fiebert et al. [159],
Kim et al. [220]: dynamic
probabilistic microsimulation
Spain, HPV 16, 18, other
high-risk, low-risk, CIN I, CIN
II/III, cervical cancer, 90% (50-
100%) coverage, 70-100% ef-
ficacy, vaccination of 11 year
olds, 10 years to lifelong immu-
nity, no booster, sexual activity
and mixing according to Goldie
[163], cervical screening, life-
long observation time, vaccine
price e 104, discounting at 3%
e 24,350 per
LYG (screen +
HPV
test+vaccine vs.
no intervention)
(e 16,060 –
e 4,803,795)
61–98% reduction
in cervical cancer
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Konno et al. [228] 2010 see Debicki et al. [109] Japan, no distinction between
HPV types, CIN I, CIN II/III,
cervical cancer, 50% coverage,
61% to 81% efficacy, vaccina-
tion of 12 (10-45) year olds, du-
ration of immunity not reported,
no booster, cervical screening,
observation time horizon of 95
years, vaccine price e 266.50,
discounting 3% (0–5%)
e 13,585.54
(12 yo),
e 20,239.41
(10–45yo)
73% cervical can-
cer reduction
La Torre et al. [234] 2010 see Goldie et al. [164] Italy, HPV 16/18, other HPV,
CIN I-III, cervical cancer, 100%
vaccine coverage, 95.9% (HPV
16/18) or 27% (other HPV) ef-
ficacy, vaccination of 12 (11-
55) year olds, cervical screen-
ing, lifelong observation, vac-
cine price e 106, 3% discount-
ing
e 22,055
(e 3,566 –
e 91,397)
67% cervical can-
cer reduction
Liu et al. [245] 2010 Probabilistic Markov Taiwan, high-risk HPV, low-risk
HPV, CIN I, CIN II/III, cervi-
cal cancer, 100% (30-100%)
coverage, 75% efficacy (30-
100%), vaccination of 12 (12-
36) year olds, lifelong (10 years
to lifelong) duration of immu-
nity, booster application, cervical
screening, lifelong observation
period, vaccine price e 89.69 (e
67.27 – e 112.11), discounting
3% (0–5%)
e 10,124.39 (e
1,475.91 – e
27,304.26)
73.3% reduction of
cervical cancer
Obradovic et al. [273] 2010 see Myers et al. [263] Slovenia, CIN I-III, cervical can-
cer, 80% (50-100%) coverage,
98% (86–100%) efficacy, vacci-
nation of 12 year olds, lifelong
(10 years to lifelong) duration of
protection, booster application,
cervical screening, observation
time horizon of 73 years, vac-
cine price e 100 (e 80 – e 120),
5% (0–5%) discounting
e 23,178
(e 1,708 –
e 58,690)
89.69% (92.62%)
cervical cancer
reduction
Torvinen et al. [348] 2010 see Suárez et al. [333] Finland, no distinction of HPV
types, CIN I, CIN II/III, cervical
cancer, 90% vaccine coverage,
52%-77% efficacy depending on
HPV-induced disease, vaccina-
tion of 11 year olds, lifelong
protection, no booster, cervical
screening, observation time pe-
riod of 96 years, vaccine price e
77.24, discounting at 0% or 3%
e 17,294
(e 2,592)
71% cervical can-
cer reduction
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Vanagas et al. [365] 2010 Markov with fixed parameter
values, indirect consideration
of herd immunity
Lithuania, no distinction of HPV
types, CIN I-III, cervical cancer,
10-90% coverage, 90-100% effi-
cacy, vaccination of 12 (15) year
olds, lifelong (15, 20 years) du-
ration of immunity, booster ap-
plication, cervical screening, life-
long observation time horizon,
vaccine price not reported, 3%
discounting
e 2,999.74 per
LYG
(e 237.20 – e
395,801.38)
76.9% cervical
cancer reduction
Bogaards et al. [37] 2011 Hybrid: Deterministic PDE-
based [38], static probabilistic
microsimulation
The Netherlands, 14 HPV types,
CIN I, CIN II/III, cervical can-
cer, 90% and 50% (0-100%)
coverage, efficacy not reported,
vaccination of 12 (13-16) year
olds, lifelong protection, wan-
ing immunity after 10 years, no
booster application, sexual ac-
tivity and mixing according to
[38], cervical screening, lifelong
observation, vaccine price and
discounting not reported
— 69% (60–74%) cer-
vical cancer reduc-
tion
Bogaards et al. [36] 2011 see Bogaards et al. [37] The Netherlands, cost-
effectiveness analysis, 14
HPV types, CIN I, CIN II/III,
cervical cancer, 50% coverage,
efficacy 52-100% depending
on HPV type, vaccination of
17-25 (12-16) year olds, lifelong
immunity, waning immunity, no
booster, sexual activity levels
according to [38], assortative
mixing, cervical screening,
100 years observation period,
vaccine price e 125, e 65 or e
35, discounting at 4% (costs)
and 1.5% (effects) (0%, 3%)
e 22,526
(e 4,149 –
e 107,796)
53.85% (15.09%)
Campos et al. [70] 2011 see Goldie et al. [163] and Kim
et al. [220]
East Africa (Kenya, Mozam-
bique, Tanzania, Uganda, and
Zimbabwe), HPV 16, 18, other
high-risk, possible high-risk,
low-risk, CIN, cervical cancer,
70% (25%, 50%, 75%) cover-
age, 100% efficacy, vaccination
before the age of 12, lifelong
immunity, no booster, cervical
screening, lifelong observation,
vaccine price e 1.23 – e 49.28
(incl. admin. cost), discounting
not reported
Cost-saving – e
10,751.98 per
LYG
7.5–47% cervical
cancer reduction
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Canfell et al. [72] 2011 see Barnabas et al. [26],
Smith et al. [324], Canfell [71]
et al.
China, no distinction between
HPV types, CIN I-III, cervical
cancer, 70% (40%) coverage,
100% (70%) efficacy, vaccina-
tion of 15 (12-20) year olds, life-
long protection, waning immu-
nity after 10 years, no booster,
cervical screening, lifelong ob-
servation, vaccine price e 2.46
– e 14.78, 3% discounting
e 656.78 –
e 4,400.41 per
LYG
9.3–81.7% reduc-
tion in cervical can-
cer incidence
Capri et al. [75] 2011 Static deterministic
prevalence- and population-
based model
Italy, comparison of 2- and 4-
valent, HPV 16/18, other high-
risk, HPV 6/11, CIN I, CIN II/III,
cervical cancer, genital warts
(vaginal, vulvar cancer and the
corresponding precancerous le-
sions), 100% coverage, 48.5%–
86.5% efficacy depending on le-
sion and vaccine type, lifelong
(10–50 years) duration of immu-
nity, booster application, cervi-
cal screening, 1 year of follow-
up, vaccine price not reported,
no discounting
— 86.54% (biva-
lent) and 76.46%
(quadrivalent)
cervical cancer in-
cidence reduction
Chen et al. [81] 2011 Bayesian Markov Taiwan, HPV 16, 18, CIN I,
CIN II/III, cervical cancer, 100%
coverage, efficacy not reported,
vaccination age not reported,
lifetime duration of protection,
no booster, cervical screening,
lifetime observation period, vac-
cine price e 89.94 (incl. admin.
cost), 3% discounting
e 23,391.63 –
e 32,977.64
—
Demarteau et
al. [113]
2011 see Debicki [109] et al. France, no distinction between
HPV types, CIN I, CIN II/III, cer-
vical cancer, coverage not re-
ported, efficacy between 33.5%
and 98.0%, vaccination of 12
(12-56) year olds with catch-up
till 25 years, lifelong (15, 20
years) immunity, booster appli-
cation, cervical screening, ob-
servation time horizon of 96
years, vaccine price e 133.82 (e
107.06 – e 160.58), 3% (costs)
and 1.5% (effects) discounting
(0–5%)
e 9,706
(e 309)
85.5% cervical
cancer reduction
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Jit et al. [203] 2011 see Jit et al. [204], compari-
son of bivalent and quadriva-
lent vaccine
UK, HPV 6, 11, 16, 18, other
type, bivalent vaccine: cervi-
cal cancer, quadrivalent vac-
cine: cervical cancer, genital
warts, RRP, sensitivity analysis:
in addition cervical, vaginal, anal
and vulvar cancer, 80% cover-
age (30%–65% in the catch-up),
23.4-100% vaccine efficacy de-
pending on vaccine and HPV
type, duration of immunity for 10
or 20 years, no booster, sexual
activity and mixing according to
[204], cervical screening, obser-
vation time period of 100 years,
vaccine price e 100.88, 3.5%
(1.5% for benefits) discounting
bivalent:
e 17,863.86 –
e 47,636.96,
quadrivalent: e
14,291.09 – e
26,200.33
bivalent prevents
more cervical can-
cers, quadrivalent
more non-cervical
cancers and geni-
tal warts
Korostil et al. [229] 2011 Bayesian ODE-based, prob-
abilistic sexual mixing, other
model parameters determinis-
tic
Australia, HPV 6, 11, genital
warts, 80% coverage, 90% effi-
cacy, vaccination at the age of
15-19 years, duration of immu-
nity for 10-15, 20-25 and 40-45
years, no booster, 4 sexual ac-
tivity levels, assortative mixing,
no cervical screening, 120 years
follow-up, vaccine price and dis-
counting do not play a role
— 91.67% (males)
and 95.24% (fe-
males) decrease
in genital warts
incidence
Lee et al. [241] 2011 Probabilistic Markov Singapore, comparison of 2-
and 4-valent vaccine, no distinc-
tion between HPV types, CIN I,
CIN II/III, cervical cancer, geni-
tal warts, 100% (20-80%) cover-
age, efficacy: 88.3% for the bi-
valent, 79.4% for the quadriva-
lent, (70%, 90%), vaccination of
12 year olds, lifelong (5, 10, 20
years) immunity, booster appli-
cation, cervical screening, life-
long observation, vaccine price
e 79.24, 3% (0%) discounting
bivalent:
e 6,125.14
(e 490.98 –
e 41,545.67),
quadrivalent: e
5,346.53
(e 1,635.61 –
e 39,979.61)
86.03% (biva-
lent) and 76.86%
(quadrivalent)
cervical cancer
reduction
Praditsitthikorn et al.
[294]
2011 Probabilistic semi-Markov
(time of leaving state depends
on time spent)
Thailand, no distinction between
HPV types, CIN I, CIN II/III, cer-
vical cancer, 100% coverage,
79% efficacy, vaccination of 15
(16-25, 30, 40, 50, 60), lifelong
(5, 10 years) duration of immu-
nity, booster application, cervical
screening, lifetime observation
period, vaccine price e 116.66
(incl. admin. cost), 3% (0%, 5%,
10%) discounting
e 499.97 –
e 7,293.47
—
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Sopina et al. [328] 2011 Probabilistic Markov New Zealand, no distinction be-
tween HPV types, CIN I, CIN
II/III, cervical cancer, 90% (30%,
50%, 70%) coverage, 99% ef-
ficacy, vaccination of 12 year
olds, lifelong (10, 20 years) du-
ration of protection, booster ap-
plication, cervical screening, ob-
servation time horizon 73 years,
vaccine price e 92.23, 3% (1–
5%) discounting
e 2,152.34 – e
6,144.62
54.05–85.14% cer-
vical cancer reduc-
tion
Tay et al. [342] 2011 Markov with fixed parameter
values
Singapore, no distinction be-
tween HPV types, CIN, cervical
cancer, coverage not reported,
100% efficacy, vaccination of 12
(12–64) year olds, lifelong du-
ration of protection, no booster,
cervical screening, lifelong ob-
servation, vaccine price and dis-
counting do not play a role
— 6.5–76.5% cervical
cancer reduction
Westra et al. [382] 2011 see Rogoza et al. [303, 304],
Kohli et al. [225] (static
stochastic population-based
Markov model)
The Netherlands, HPV 16, 18,
31, 33, 45, other high-risk, low-
risk, CIN, cervical cancer, 100%
coverage, 95% efficacy against
HPV 16/18, 0% (0-78.7%) effi-
cacy against other types, vac-
cination at the age of 12 (12–
50), lifelong (20 years) duration
of immunity, booster application,
cervical screening, observation
time period 100 years, vaccine
price e 105 (e 45 – e 125), dis-
counting 4% (costs) and 1.5%
(effects)
e 19,900 –
e 52,000
50% reduction in
cervical cancer in-
cidence
Demarteau et
al. [115]
2012 see Debicki et al. [109] and
Suárez et al. [333] (static,
probabilistic, population-
based Markov model),
bivalent vs. quadrivalent
vaccine
Taiwan, no distinction between
HPV types, genital warts, CIN
I, CIN II/III, cervical cancer,
100% coverage, 98% efficacy
against HPV 16/18, bivalent:
79%, quadrivalent: 69.9% effec-
tiveness against cervical cancer,
vaccination of 12 year olds, life-
long (10 years for quadrivalent,
20 years for bivalent) duration
of immunity, booster applica-
tion, cervical screening, lifetime
observation, vaccine price e
100.31, discounting 3% (costs),
1.5% (effects) (0–5%)
Bivalent
vaccine
dominates
quadrivalent
29% less cervical
cancer cases for bi-
valent vs. quadri-
valent vaccine
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El Hasnaoui et al.
[130]
2012 see Debicki et al. [109] France, no distinction between
HPV types, CIN I, CIN II/III, cer-
vical cancer, 100% coverage,
98% and 89% vaccine efficacy
depending on previous expo-
sure, vaccination of 11-13, 14-
16 or 15-17 year olds (11–55
year olds), lifelong immunity, no
booster, cervical screening, 90
(20, 30, 60) years follow-up, vac-
cine price and discounting do
not play a role
— 63–86% cervical
cancer reduction
Favato et al. [136] 2012 Bayesian Markov Italy, no distinction between
HPV types, CIN I-III, cervical
cancer, genital warts, 84.7%
coverage, 78.3% efficacy, vacci-
nation of 12 and 15 (12,15,18 or
12,15,18,25) year olds, lifelong
duration of immunity, no booster,
cervical screening, observation
time period of 90 years, vac-
cine price e 69.13 (e 60.16 –
e 79.58), discounting 3% (costs)
and 1.5% (benefits)
e 12,013 –
e 15,890
55.79–67.54%
Goldie et al. [166] 2012 see Goldie et al. [161, 163,
168], Kim et al. [215, 217,
220], Goldhaber et al. [160]
and Diaz et al. [120] for dy-
namic stochastic individual-
based HPV transmission and
natural history model
Peru, HPV 16, 18, other high-
risk, low-risk, CIN I, CIN II/III,
cervical cancer, 82% (61–98%)
coverage, 100% (70%) efficacy,
vaccination of 11 year olds, life-
long immunity, no booster, sex-
ual activity levels and mixing
strategies according to Goldie
[163], cervical screening, life-
long observation, vaccine price
e 5.17 (e 3.69 – e 14.78), dis-
counting 3%
Cost-saving – e
957.43 per LYG
11.9–67.5% reduc-
tion in cervical can-
cer
Kawai et al. [211] 2012 see Elbasha et al. [131] Brazil, HPV 6, 11, 16, 18, CIN I,
CIN II/III, cervical cancer, genital
warts, 85% (50%) coverage in
12 year olds increasing to 95%
(60%) in 26 year olds, 90% ef-
ficacy, lifelong (20 years) immu-
nity, no booster, three sexual
activity levels, age- and sexual
activity specific mixing, cervical
screening, 100 years follow-up,
vaccine price e 11.19, 3% (0%,
5%) discounting
e 161.29 and e
331.42
(catch-up)
(cost-saving –
e 884.52)
94–98% incidence
reduction of cervi-
cal cancer
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Kohli et al. [226] 2012 see Debicki et al. [109] and
Anonychuk et al. [16]
Canada, bivalent vs. quadri-
valent vaccine, no distinction
between HPV types, CIN I,
CIN II/III, cervical cancer, geni-
tal warts, 100% coverage, 98%
efficacy, higher cross-protection
with bivalent vaccine (68.4% vs.
32.5% or lower), vaccination of
12 year olds, lifelong immu-
nity, no booster, cervical screen-
ing, observation time period 100
years, vaccine price e 73.88 (e
71.67, e 72.40 for quadrivalent),
3% (0%) discounting
Bivalent
dominates
quadrivalent (e
2,554.13 – e
107,359.63)
29.81% less cervi-
cal cancer with bi-
valent vaccine
Lee et al. [240] 2012 Static deterministic ODE-
based
USA, no vaccination, cervical
screening or sexual mixing, cal-
culation of R0 for treated and
untreated individuals to estimate
the number of infected individu-
als, vaccine price and discount-
ing do not play a role
— —
Schobert et al. [314] 2012 see Elbasha et al. [133] Germany, HPV 6, 11, 16, 18,
genital warts, CIN, cervical can-
cer, 6-38% coverage, 90-100%
efficacy, vaccination age 12-17
years, lifelong (20 years) du-
ration of immunity, no booster,
sexual activity and mixing not re-
ported, cervical screening, life-
time follow-up, vaccine price e
451.20, 3% (0-5%) discounting
e 5525 65% reduction in
cervical cancer in-
cidence
Sharma et al. [316] 2012 see Goldie et al. [163] and Kim
et al. [220]
Thailand, HPV 16, 18, other
high-risk, low-risk, CIN I, CIN
II/III, cervical cancer, 80% cover-
age, 100% (75%) efficacy, vac-
cination before the age of 12,
lifelong duration of immunity, no
booster, sexual activity and mix-
ing according to [163], cervical
screening, lifelong observation,
vaccine price e 2.46 – e 123.14
(incl. admin. cost), 3% discount-
ing
Cost-saving – e
14,670.78
4.7–70.1% reduc-
tion in cervical can-
cer
Termrungruanglert et
al. [344]
2012 Markov with fixed parameter
values
Thailand, no distinction be-
tween HPV types, CIN I, CIN
II/III, cervical cancer, genital
warts, 100% (80–100%) cover-
age, 97% (90–99.9%) efficacy,
vaccination at age 12, lifelong
immunity, no booster, no cervi-
cal screening, follow-up of 88
years, vaccine price e 48.13 (e
48.13 – e 96.26), discounting
3% (2–6%)
e 3,818.82 (no
inter- vention
vs. HPV
vaccination), (e
1,183.10 – e
23,020.45)
55.1% reduction of
cervical cancer in-
cidence
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Tully et al. [349] 2012 Deterministic ODE-based Canada, HPV 16/18, other HPV,
CIN I, CIN II/III, cervical cancer,
80%, 60% and 40% coverage,
90–100% efficacy against HPV
16/18, 5–19% against other
HPV, vaccination of 12 year olds,
catch-up in 18 (12-26) year olds,
lifelong (3% yearly waning) im-
munity, booster application, no
distinction of sexual activity lev-
els, cervical screening, follow-
up of 80 years, vaccine price e
63.60, 3% discounting
e 7,360.28
(e 4,436.54 – e
7,035.27)
Vanagas et al. [364] 2012 see Vanagas et al. [365] for
multi-cohort model
Lithuania, HPV 16, 18, CIN
I, CIN II/III, cervical cancer,
90% coverage, 90–100% effi-
cacy, vaccination of 12 year
olds, duration of protection not
reported, no booster, cervical
screening, observation for 90
years, vaccine price not re-
ported, 3% discounting
e 2,932.58
(e 3,468.20 – e
607,095.40)
77% reduction of
cervical cancer
van de Velde et al.
[359]
2012 see van de Velde et al. [360] Canada, bivalent vs. quadriva-
lent vs. nonavalent vaccine, 18
HPV types, CIN I-III, cervical,
anal, vulvar, vaginal, head and
neck cancer, genital warts, 70%
coverage, 100% efficacy against
vaccine types, 0–79% efficacy
against non-vaccine types, vac-
cination of 12 year olds, lifelong
(9, 15, 20 years) duration of im-
munity, no booster, four levels of
sexual activity, age-dependent
mixing, cervical screening, 70
(30, 50) years of follow-up, vac-
cine price and discounting do
not play a role
— Switching bivalent
(quadrivalent) to
nonavalent: 4.8%
(6.6%) additional
reduction of cervi-
cal cancer
Vanni et al. [367] 2012 Dynamic probabilistic mi-
crosimulation
Brazil, HPV 16, 18, 6/11, geni-
tal warts, CIN I-III, cervical can-
cer, 50%, 70% and 90% cover-
age, efficacy not reported, vac-
cination at 12 years, lifelong (10
years) immunity, booster appli-
cation, four sexual activity levels,
age- and sexual activity specific
mixing (see [26] [215]), cervical
screening, lifelong observation,
vaccine price e 6.16 – e 136.93,
discounting 5% (0%)
e 83.09 –
e 4 375.32
Prevalence of vac-
cine specific types
reaches zero 30
years after vaccine
introduction
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Vokó et al. [370] 2012 Markov with fixed parameter
values
Hungary, HPV 16, 18, CIN
I, CIN II/III, cervical cancer,
80% coverage, 45.1%–94.3%
efficacy, vaccination of 12 year
olds, lifelong (20 years) immu-
nity, booster application, cervi-
cal screening, observation pe-
riod 88 years, vaccine price e
56.89, 3.7% (5%) discounting
e 20,592.68 (e
18,523.42 –
e 40,897.85)
—
Yamamoto et al. [388] 2012 Markov with fixed parameter
values
Japan, HPV 16, 18, other high-
risk, low-risk, CIN I, CIN II/III,
cervical cancer, 100% cover-
age, 88% efficacy against HPV
16/18, 50% efficacy against
other HPV, vaccination of 11
year olds, lifelong immunity, no
booster, cervical screening, life-
long observation, vaccine price
e 142.99 (incl. admin. cost), 3%
discounting
Screening +
vaccination
dominates
screening only
(e 4.75 –
e 61,878.30)
66.1–86.8% cervi-
cal cancer reduc-
tion
Aponte-Gonzales et
al. [17]
2013 Markov with fixed parameter
values
Colombia, HPV 6, 11, 16, 18,
31, 45, 52, 58, genital warts,
CIN I, CIN II/III, cervical can-
cer, 80% (50-100%) vaccine
coverage, 90% (5-100%) effi-
cacy, vaccination age 12 years,
lifelong (30 or 70 years) pro-
tection, no booster, no distinc-
tion between sexual activity, sex-
ual mixing not reported, cervi-
cal screening, lifelong follow-up,
vaccine price e 168.02 and e
191.26 for quadrivalent and bi-
valent vaccine, 3% (0-6%) dis-
counting
e 21665.03
(quadrivalent)
and e 25708.29
(bivalent)
—
Berkhof et al. [31] 2013 see Bogaards et al. [37] Central, Eastern Europe and
central Asia, HPV type 16, 18,
31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66 and 68, cervi-
cal cancer, CIN II/III, 70% vac-
cine coverage, 100% vaccine ef-
ficacy, vaccination age 12 years,
lifelong duration of protection,
no booster, sexual activity lev-
els and sexual mixing not re-
ported, cervical screening, life-
time follow-up, bivalent vaccine
price e 44.69 – e 178.75, 3%
(0-5%) discounting
e 1475.56 – e
2865.31
75% reduction in
lifetime risk of cer-
vical cancer
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Brisson et al. [54] 2013 see van de Velde et al. [360] Canada, bivalent vs. quadri-
valent, 18 HPV types, cervi-
cal, vulvar, vaginal, anal, penile
and oropharyngial cancer, gen-
ital warts, 80% coverage, 95%
efficacy, vaccination of 10 yo
with last shot in 14 yo, catch-
up in 14 yo, duration of immu-
nity 20 years (lifetime), duration
of cross-protection 10 years, no
booster, 4 levels of sexual ac-
tivity, assortative, proportionate
and disassortative mixing, cervi-
cal screening, observation time
period 70 (30) years, vaccine
price e 67.34, 3% (0%, 5%) dis-
counting
Quadrivalent:
e 10,812.49
(e 3,627.42 –
e 29,856.42),
bivalent:
e 14,091.12
(e 2,581.05 –
e 52,388.26)
Quadrivalent:
41%, bivalent:
43% reduction of
cervical cancer
Brisson et al. [56] 2013 see van de Velde et al. [360] Canada, bivalent vs. quadriva-
lent, 18 HPV types, CIN, geni-
tal warts, cervical, vulvar, vagi-
nal, anal, penile and oropharyn-
gial cancer, 80% (50-70%) cov-
erage, 0-95% efficacy, vaccina-
tion of 10yo with last shot in 14
yo, catch-up in 14 yo, duration
of immunity 20 years (lifetime),
duration of cross-protection 10
years, no booster, sexual activity
and mixing not reported, cervi-
cal screening, observation time
period 70 (30) years, vaccine
price e 67.34, 3% (0%, 5%) dis-
counting
— quadrivalent: 67%
reduction in genital
warts, 40% in
CIN II/III, 35% in
cervical cancer.
bivalent: 0% re-
duction in genital
warts, 42% in
CIN II/III, 36% in
cervical cancer
da Fonseca et al. [99] 2013 Markov with fixed parameter
values
Brazilian Amazon region, CIN I,
CIN II/III, cervical cancer, 100%
(50%, 70%) coverage, 25–70%
efficacy, vaccination age 12
years, lifelong (10 years) immu-
nity, booster application, cervical
screening, lifelong observation,
vaccine price e 37.21 (incl. ad-
min. cost) (e 9.92 – e 124.02),
5% (0–10%) discounting
Vaccination
dominates no
vaccination (e
606.66 – e
937.57)
20–71% reduction
in cervical cancer
Demarteau et
al. [116]
2013 see Debicki et al. [109] Belgium, HPV 16/18, HPV 31/
33/ 35/ 39/ 45/ 51/ 52/ 56/ 58/ 59,
CIN I, CIN II/III, cervical cancer,
80% coverage, 98% efficacy,
vaccination of 12–40 year olds,
lifelong (10, 12 years) immu-
nity, no booster, cervical screen-
ing, 95 years of follow-up, vac-
cine price e 143.67 (e 115 –
e172.67) (incl. admin. cost), 3%
discounting (costs) and 1.5%
(benefits) (0%, 5%)
e 9,171
(e 9,164 –
e 49,028)
—
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Drolet et al. [125] 2013 see van de Velde et al. [360] Canada, comparison 4- to 9-
valent vaccine, 18 HPV types,
AGW, cervical, vulvar, vaginal,
anal, penile, oropharyngeal can-
cer, 80% coverage, 95% effi-
cacy (85% 9-valent in sensi-
tivity analysis), vaccination age
of 10 years, lifelong (20 year)
protection, no booster, 4 lev-
els of sexual activity, assortative
and disassortative mixing, cervi-
cal screening, lifelong follow-up,
vaccine price e 61.71, 3% dis-
counting
4-valent:
10087.22,
9-valent:
7927.25
—
Kim et al. [222] 2013 MS Excel-based model [168] Middle East, North Africa, HPV
16, 18, high-risk types, low-risk
types, CIN, cervical cancer, 70%
coverage, 100% efficacy, vacci-
nation age 12 years, lifelong im-
munity, booster, sexual activity
and mixing not reported, cervi-
cal screening, lifetime follow-up,
vaccine price e 4.48 - e 448.37,
3% (0-6%) discounting
cost-saving – e
103752.86
68-75.3% reduc-
tion in lifetime risk
of cervical cancer
Kim et al. [216] 2013 MS Excel-based model [161] Sub-Saharan Africa, HPV 16,
18, high-risk types, low-risk
types, CIN, cervical cancer, 70%
coverage, 100% efficacy, vacci-
nation age 12 years, lifelong im-
munity, booster, sexual activity
and mixing not reported, cervi-
cal screening, lifetime follow-up,
vaccine price e 4.48 - e 89.67,
3% (0-6%) discounting
e 269.02 – e
7532.62
59.7-63.7% reduc-
tion in lifetime risk
of cervical cancer
Luttjeboer et al. [248] 2013 Probabilistic Markov The Netherlands, HPV 16, 18,
31, 33, 45, 51, cervical, vul-
var, vaginal, anal, oropharyn-
geal cancer, 100% coverage,
44.8–92.9% efficacy, vaccina-
tion of 12 year olds, lifelong
immunity, no booster, cervical
screening, lifelong observation
horizon, vaccine price e 120 (e
30, 60, 90), 4% cost discount,
1.5% QALY discount
e 5,815
(e 6,471 –
e 11,431)
—
233
APPENDIX B. FURTHER DETAILS ON THE LITERATURE REVIEW
Turner et al. [350] 2013 see Jit et al. [204] Cost-effectiveness of bivalent
vaccine application in older
females, UK, HPV 16, 18, other
high-risk with cross-protection,
other high-risk without cross-
protection, CIN I-III, cervical
cancer, coverage 38.9% –
84.3%, 100% efficacy (0–100%
in females with previous HPV
exposure), vaccination of 12–34
year old females, lifelong (10, 20
years) duration of protection, no
booster, 3 sexual activity levels,
assortative mixing, cervical
screening, observation time 100
years, vaccine price e 23.82 or
e 47.64, 3.5% discounting
e 1,946.75
(e 2,154.95 – e
673,676.30)
—
Uusküla et al. [357] 2013 see Elbasha et al. [131] Estonia, HPV 6, 11, 16, 18,
CIN I-III, cervical cancer, gen-
ital warts, 85% (70%, 95%)
coverage, 76% – 96.3% effi-
cacy, vaccination of 12 year
olds, lifelong (20 years) im-
munity, booster application, 3
sexual activity levels, mixing
strategies not reported, cervical
screening, follow-up 100 years,
vaccine price e 59, discounting
at 3%
e 4,889
(e 1,517 –
e 11,148)
2–52% cervical
cancer reduction
Westra et al. [383] 2013 see Kohli et al. [225] Netherlands, comparison of 2-
to 4-valent vaccine, HPV 16, 18,
31, 33, 45, other high-risk, other
low-risk, genital warts, CIN, cer-
vical cancer, 90% (30-70%) cov-
erage, 0-95% efficacy, vaccina-
tion of 12 year olds, lifelong
(20 years) duration of immu-
nity, no booster, sexual activity
and mixing not reported, cervi-
cal screening, lifetime follow-up,
vaccine price per dose e 45 - e
105, 3% (0-4%) discounting
2-valent: e
17600,
4-valent: e
18900
—
Yamabe et al. [387] 2013 see Elbasha et al. [132] Japan, HPV 6, 11, 16, 18,
CIN I-III, cervical cancer, geni-
tal warts, 80% coverage, 50%
catch-up coverage, 90% effi-
cacy, vaccination in 12 year olds,
catch-up in 12–24 year olds, life-
long (10 years) duration of pro-
tection, no booster, sexual ac-
tivity levels and mixing accord-
ing to [132], cervical screen-
ing, observation time period 100
years, vaccine price e 89, 3%
discounting
e 8,711.54
(e 3,811.75 – e
53,727.93)
90.9% cervical
cancer reduction
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Blakely et al. [34] 2014 Static Markov model in MS
Excel, partly probabilistic
model parameters
New Zealand, HPV 6, 11, 16,
18, genital warts, CIN, cervi-
cal, vulvar, oropharyngeal, anal
cancer, vaccine coverage 45-
93%, 99% vaccine efficacy, vac-
cination of 12 year olds, dura-
tion of immunity of 20 years,
no booster, sexual activity and
mixing not reported, cervical
screening, follow-up of 98 years,
vaccine price not reported, 3%
(0-6%) discounting
e 10805.31 – e
17888.79
32-89% HPV
prevalence reduc-
tion
Gomez et al. [169] 2014 see Debicki et al. [109] Chile, HPV 6, 11, 16, 18, gen-
ital warts, CIN, cervical can-
cer, 95% (80%) coverage, 98%
efficacy, 23.4-68.8% efficacy
against non-oncogenic types,
vaccination of 11 year olds,
lifelong duration of protection,
waning immunity, booster, sex-
ual activit and mixing not re-
ported, cervical screening, vac-
cine price e 12.03 (2-valent)
and e 17.85 (12.71) (4-valent),
lifetime follow-up, 6% (3%) dis-
counting
4-valent: e
647.78,
2-valent: e
131.16
14.4% and 21.9%
cervical cancer
cases avoided
(2-valent and
4-valent)
Han et al. [180] 2014 Simulation study Korea, no distinction between
HPV types, CIN, cervical can-
cer, vaccine coverage not re-
ported, vaccine efficacy 88.04%
or 83.99%, vaccination between
11 and 18 years, duration of im-
munity not reported, no booster,
2 sexual activity levels, mixing
not reported, no cervical screen-
ing, duration of follow-up not re-
ported, vaccine price e 123.06,
3% discounting
ICUR e
38991.68
(low-risk group)
and e 7120.74
(high-risk
group)
—
Jit et al. [202] 2014 Static deterministic model in
MS Excel
179 countries, HPV 16, 18,
CIN, cervical cancer, country-
specific data on coverage, effi-
cacy, vaccination age, duration
of protection, vaccine price, dis-
count rate (0-6%), sexual activity
and mixing not reported, cervi-
cal screening, lifelong follow-up
(in most cases)
e 0.9 – e
89823.06
690000 cancer
cases prevented
Khatibi et al. [213] 2014 Static deterministic model Iran, HPV types not distin-
guished, genital warts, CIN, cer-
vical cancer, 70% coverage,
100% efficacy, vaccination of 15
year olds, lifelong (10 years) pro-
tection, booster, sexual activity
and mixing not reported, no cer-
vical screening, follow-up of 59
(85) years
e 13057.3 (e
7476.9 – e
25056.04)
—
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Kiatpongsan et
al. [214]
2014 see Kim et al. [220] Kenya, Uganda, HPV 6, 11,
16, 18, 31, 33, 45, 52, 58,
CIN I, CIN II/III, cervical can-
cer, 100% coverage, 100% ef-
ficacy, vaccination of 12 year
olds, duration of immunity not re-
ported, no booster, sexual ac-
tivity and mixing not reported,
no cervical screening, lifetime
follow-up, vaccine price e 4.04
(4-valent), e 4.13 (2-valent), 9-
valent around e 3 more
9-valent very
cost-effective
when compared
to 2- and
4-valent
—
Aguilar et al. [9] 2015 Markov model in MS Excel
(CERVIVAC) [79]
Honduras, HPV 16 and 18, cer-
vical cancer, 95% (80-100%)
coverage, 94.3% (91.7-96.8%)
efficacy, vaccination in 11 year
old females, lifelong (20 or 30
years) duration of protection,
booster in sensitivity analysis,
no distinction between sexual
activity levels, sexual mixing not
reported, no cervical screening
included, lifetime follow-up, vac-
cine price e 12.02, 3% discount-
ing
e 827.6
(governmental
perspec-
tive)/DALY
62% cervical can-
cer reduction
Burger et al. [68] 2015 see Kim et al. [217,218] Norway, HPV 6, 11, 16, 18, gen-
ital warts, RRP, cervical, vagi-
nal, vulvar, anal, oropharyngeal,
penile cancer, 71% coverage in
12yo, 50% (30%) coverage in
18-26yo, 100% efficacy, vacci-
nation of 12yo, catch-up in 18-26
yo, lifelong immunity, no booster,
4 levels of sexual activity, mixing
not reported, cervical screening,
lifelong follow-up, vaccine price
e 44.68 – e 134.05, 4% (0-3%)
discounting
e 51923.68 – e
173376.83
including
catch-up of
18-26yo
75% reduction in
HPV 16/18 preva-
lence
Georgalis et al. [153] 2015 Probabilistic Markov Spain, HPV 16 and 18, CIN,
cervical cancer, 70% (20-100%)
coverage, 100% efficacy, vacci-
nation of 11 year olds, lifelong
immunity, no booster, sexual ac-
tivity and mixing not reported,
cervical screening, follow-up of
74 years, vaccine pricee 31, 3%
discounting
e 12214– e
70002
40% reduction in
cervical cancer in-
cidence
Graham et al. [172] 2015 see Praditsitthikorn et al. [294] Phillipines, HPV 16, 18, CIN,
cervical cancer, 20-80% cov-
erage, 74% (59-84%) efficacy,
vaccination at age 11 (13, 20
and 25), lifelong (waning) im-
munity, booster, sexual activity
and mixing not reported, cervi-
cal screening, lifetime follow-up,
vaccine price e 51.55, 3.5% dis-
counting
dominant – e
1150.52
—
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Jit et al. [201] 2015 see Jit et al. [204] UK, comparison of two- to three-
dose regimens, HPV 6, 11,
16, 18, genital warts, RRP,
cervical, vulvar, vaginal, anal,
penile, oropharyngeal cancer,
80% coverage, efficacy esti-
mated through meta-analysis,
vaccination of 12 year olds,
catch-up in 18 year olds, life-
long or 10, 20, 30 years pro-
tection (3- vs. 2-dose regi-
men), no booster, sexual activity
and mixing not reported, cervi-
cal screening, follow-up of 100
years, vaccine price e 104.76
(2-valent) and e 112.56 (4-
valent), 3.5% (1.5%) discounting
3 doses: e
22104.19,
compared to
HPV-advise
output (see van
de Velde et
al. [360]) of e
12612.39
73.08% cervi-
cal cancer case
reduction
Levin et al. [243] 2015 see Goldhaber-Fiebert et al.
[159]
China, HPV 16, 18, CIN, cer-
vical cancer, 70% coverage, ef-
ficacy not reported, vaccination
before 12 years of age, life-
long immunity, no booster, sex-
ual activity and mixing not re-
ported, cervical screening, life-
time follow-up, vaccine price e
8.97 - e 179.35, discounting not
reported
e 4045.2 – e
12796.48
51.90% reduction
in lifetime cervical
cancer risk
Novaes et al. [270] 2015 Markov model in MS Excel Brazil, HPV 16, 18, cervical can-
cer, 50% (40-60%) coverage,
94.3% (91.7-96.8%) efficacy,
vaccination age 11 years, life-
long (waning) immunity, booster,
sexual activity and mixing not
reported, cervical screening,
lifetime follow-up, vaccine price
e 11.83 (e 10.64 - e 13.01) per
dose, 5% discounting
e 6544.41 – e
6871.72 per
DALY
43% lifetime risk
reduction of cervi-
cal cancer
Walwyn et al. [373] 2015 Markov model in MS Excel
(CERVIVAC [79])
Belize, HPV 16, 18, cervical
cancer, 95% coverage, 94.5%
(91.7-96.8%) efficacy, vaccina-
tion of 10 year olds, lifelong
(20 years) duration of protec-
tion, booster, sexual activity
and mixing irrelevant due to
static methodology, no cervi-
cal screening, lifetime follow-up,
vaccine price per dose e 12.39
(e 11.75 - e 12.80), 3% (0%)
discounting
e 385.07 —
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B.2 Ordinary differential equation models
The ODE-based models on human papillomavirus in the literature are de-
scribed in further detail in the following.
Deterministic models
The most widely applied ODE-based model in context of CEA of HPV vac-
cination strategies is presented by Elbasha et al. [132, 133]. The model is
developed in an US setting, distinguishes between HPV 6/11 and 16/18,
and includes genital warts, CIN-stages and cervical cancer. A stratifica-
tion by sex, 17 age groups and three sexual activity groups is incorpo-
rated. Over the observation time period, individuals transfer between the
age groups according to population-specific rates. Sexual mixing varies
between fully assortative (like with like individuals) to proportionate (ran-
dom). The vaccine is given to twelve year old individuals with a catch-up
in twelve-24 year olds. In addition, the model is applied to identify cost-
effective female catch-up strategies [134], to evaluate the inclusion of an
extensive amount of HPV-induced diseases [131], and in a variety of interna-
tional settings [49, 100–103, 188, 211, 314, 357, 387], incorporating country-
specific information. In the original setting, the model results in dominating
female-only over universal vaccination. However, once all HPV-induced dis-
eases are considered [131], universal HPV vaccination is deemed to be
cost-effective.
In contrast to Elbasha et al. [132], Jit et al. [204] apply their dynamic
transmission model exclusively in an UK setting. The corresponding equa-
tions are not displayed; therefore, we are unable to evaluate whether the
methodology is based on ODEs or PDEs. The model is sex-, age- and
behavioural-specific and accounts for HPV types 16, 18, other high-risk
types, and types 6 and 11. Details on behaviour groups and sexual mix-
ing are not reported. As for HPV-induced diseases, CIN-stages, cervical
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cancer, non-cervical cancers and genital warts in females are accounted
for. Female-only and universal vaccination strategies are evaluated for the
ages of twelve to 25 years; waning vaccine-induced immunity is accounted
for. PSA is conducted in retrospect through LHS. The model results in cost-
effective and non-cost-effective results for female-only and universal vacci-
nation, respectively. The model is used by Choi et al. [85] to estimate HPV-
induced disease outcome and is extended to compare the bi- to the quadri-
valent vaccine [203], to evaluate vaccination up to 34 years of age [350],
and to compare two to three dose regimens [201].
Barnabas et al. [26] present an innovative sexual mixing algorithm which
is applied by [72, 143, 215, 316, 324, 366]. The PDE-based model is devel-
oped in a Finnish context. Females can acquire a CIN stage or cervical
cancer. The population is stratified into age cohorts of five years, and four
sexual activity levels are considered. The probability of HPV transmission
per partnership is estimated by calibrating the HPV prevalence prediction
of the model to HPV 16 seroprevalence data. The HPV vaccine is given
to 15 year old individuals, and vaccine-specific immunity is assumed to re-
main lifelong.
Hughes et al. [187] modify an ODE-based HPV transmission model adap-
ted from Anderson and May [13] and link it to a disease progression model
accounting for cervical cancer in an US context. The authors account for
HPV 16 transmission and assume 90% vaccine coverage and 75% efficacy.
The vaccination age is not reported. The duration of immunity lasts for 10
years; however, no booster is applied. Three levels of sexual activity are
accounted for. The model predicts a 44% and 30% reduction in HPV preva-
lence for universal and female-only vaccination, respectively.
Tully et al. [349] present an ODE-based model in a Canadian context.
The model is stratified by age, sex and HPV type; seven age groups are
considered, and HPV types are categorized into HPV 16/18 and other types.
The model accounts for CIN and four stages of cervical cancer. The pro-
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gression between the cancer stages is modelled through a submodel in MS
Excel. Sexual mixing depends on age, with males tending to select younger
female partners. The bivalent vaccine is given to twelve year old females.
The model results in a cost-effective outcome.
Lee et al. [240] present the only exception of a static ODE-based model
to investigate HPV infection and progression to cervical cancer in African
American females in the US. The model exclusively includes females and
does not incorporate HPV transmission dynamics between the sexes; the
force of infection accounts for female HPV infection prevalence. The model
is neither age- nor behavioural-specific, and predictions on prevalence or
incidence are not conducted.
Bayesian models
Bogaards et al. [38] present a deterministic PDE-based model for the Nether-
lands; however, Bayesian methods are used to estimate the transmission
probabilities, rates of waning resistance and progression of 14 high-risk
HPV types. The endemic equilibrium is estimated through priors which are
informed by data on HPV prevalence before initial vaccine introduction. The
posterior distributions are updated through clinical trial data on newly ac-
quired, persistent or cleared HPV infections at six and 18 months of follow-
up. The results indicate that per partnership transmission probability is high-
est for HPV 66 (94%) and lowest for HPV 68 (43%). Waning resistance per
year is slowest for HPV 68 and fastest for HPV 56. As for HPV-induced dis-
eases, only CIN-stages are considered. The model parameters on sexual
behaviour are informed by point estimates. Three sexual activity levels are
considered, and individuals are allowed to switch between adjacent levels.
Sexual mixing varies between proportionate and assortative. The model
predicts that female-only vaccination results in a faster HPV prevalence re-
duction than universal vaccination [39]. The transmission model is linked to
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a microsimulation model to result in a hybrid model [37] (see Section 4.4.4).
Another Bayesian ODE-based model is presented by Korostil et al. [229];
the impact of female-only HPV vaccination on genital warts prevalence in
both sexes in Australia is investigated. Other HPV-induced diseases are not
accounted for. Females and males divided into nine age groups populate
the model. Four sexual activity levels are considered; switching between
levels is not possible, however, sexual activity declines with age. Age-,
sex- and behavioural-specific partner acquisition rates remain fixed values,
whereas degrees of assortativity in the sexual mixing matrix, duration of in-
fection, treatment and natural immunity as well transition probabilities are
assigned distributions.
Vänskä et al. [368] present a PDE-based model in a Bayesian context
for Finland. The model accounts for age, sex, and the age- and sex-specific
numbers of partners. HPV-induced diseases are not considered, and sexual
mixing is exclusively proportionate. Partner acquisition rates, HPV trans-
mission probability, clearance rates and waning of natural immunity are as-
signed distributions, whereas all other model parameters are assigned fixed
values. Multiple high-risk HPV infections can affect one individual indepen-
dently at the same time. The model considers HPV infections originating
from new partners and those acquired within persisting partnerships due to
sexual intercourse with a third individual.
B.3 Markov models
In the following, Markov models in the literature on HPV transmission and
induced disease progression modelling are described.
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Models with fixed parameter values
Four publications [17, 248, 345, 370] conduct PSA in Markov models with
fixed parameter values in retrospect once the model output is available and
present CEACs and/or scatterplots obtained through MC sampling proce-
dures.
To conduct PSA, Voko et al. [370], Aponte-Gonzales et al. [17] and Thiry
et al. [345] assign suitable probability distributions to key model parameters.
Luttjeboer et al. [248] inform the parameter distributions through data on
the corresponding ranges. If no data are available, ranges are estimated to
amount to 50%-150% of the base case values.
Probabilistic models
Three authors [81, 136, 358] present Markov models in a Bayesian frame-
work. Chen et al. [81] develop a Bayesian Markov model to estimate the
cost-effectiveness of female-only HPV vaccination in Taiwan, considering
CIN stages and cervical cancer. Cost-effective results are presented, and
PSA is conducted straightforwardly through cost-effectiveness scatterplots
and CEACs.
Van de Velde et al. [358] introduce a static Bayesian Markov model and
calculate the vaccine-induced decrease in the lifetime risk of cervical cancer
in a Canadian setting by accounting for HPV 16 and 18 separately. The
calibration approach is Bayesian; model parameters are fitted to data by
updating the prior distributions into suitable posteriors. Females receive the
vaccine at ages twelve, 15, 20 or 30 years.
The third Bayesian Markov model is introduced in the BEST I1 study
by Favato et al. [136] in an Italian setting and provides the basis for our
research; we extend this static model by a dynamic approach for HPV trans-
1Bayesian modelling assessing the Effectiveness of a vaccination Strategy To prevent
HPV-related diseases
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mission (see Section 5.7) and include a greater variety of HPV-induced
diseases (see Section 5.4) as well as cohorts of males and females (see
Section 5.2 and Table 5.1). Furthermore, we vaccinate both sexes in dif-
ferent intervention scenarios (see Section 5.3). In its original version, the
model does not distinguish between different HPV types and accounts for
the HPV-induced diseases genital warts, CIN-stages and cervical cancer.
Several cohorts of females are vaccinated in parallel, such as twelve and 15
year olds, twelve, 15 and 18 year olds or twelve, 15, 18 and 25 year olds.
The authors report cost-effective results, including extensive PSA.
Praditsitthikorn et al. [294] present a probabilistic semi-Markov model in
MS Excel for Thailand. A semi-Markov model implies that a transition to a
future state does not only depend on the current state; in addition, the time
spent in the state is considered in the transition probabilities. This model
is not based on Bayesian statistics; however, forward simulation in terms
of Monte Carlo sampling is incorporated in order to account for parameter
uncertainty. One female cohort is observed from age 15 throughout their
lifetime. The model accounts for CIN-stages and four stages of cervical
cancer. The vaccine coverage rate is 100% on average, whereas mean
vaccine efficacy is assumed to be 79%. In the base-case, vaccination takes
place in 15 year old females, with catch-up opportunities at the ages of 16-
25, 30, 40, 50, and 60 years, respectively. The authors assume a lifelong
duration of vaccine-induced immunity and account for waning immunity after
five and ten years in sensitivity analyses, involving booster application.
Blakely et al. [34] present a Markov model in MS Excel for New Zealand
including probability distributions on model parameters; details on distribu-
tions are only reported for vaccination coverage. Forward sampling is con-
ducted through 2,000 Monte Carlo simulations. The model accounts for
genital warts, CIN, cervical, vulvar, oropharyngeal and anal cancer. The
vaccine coverage rates vary between 45% and 93%, whereas vaccine effi-
cacy is assumed to be as high as 99%. Vaccination is given to twelve year
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old females, and they are observed for a follow-up of 98 years. Duration of
immunity is assumed to last for 20 years. The effects of herd immunity in un-
vaccinated females and males are accounted for in an indirect way through a
meta-regression on the output of the model described by Brisson et al. [59].
Firstly, the HPV prevalence reduction is estimated; afterwards, the estimate
is multiplied by the incidence on HPV-induced diseases, resulting in reduced
incidence due to indirect consideration of herd immunity. PSA is conducted
in terms of the cost-effectiveness plane and the cost-effectiveness accept-
ability curve. The model results in a cost-effective outcome.
Georgalis et al. [153] present a stochastic Markov model; however, the
authors do not report details on their methodology of incorporating param-
eter uncertainty, and only the mean values of model parameters are dis-
played. The vaccine is given to eleven year old girls at a 70% coverage rate
in the base case, and vaccine efficacy of 100%, inducing lifelong immunity,
is assumed. PSA is not conducted, and the model results in a cost-effective
outcome and predicts a 40% reduction in cervical cancer cases.
B.4 Individual-based models
Accetta et al. [7] present a microsimulation model for Italy. The model is
exclusively populated by females; therefore, sexual mixing does not take
place, and herd immunity cannot be accounted for. Several cervical screen-
ing strategies including the HPV DNA-test are compared to vaccination. The
model includes HPV 16/18, other high-risk and low-risk types. As for HPV-
induced diseases, CIN- stages and cervical cancer are accounted for. The
vaccine is given to eleven year old females at 100% coverage, and 75.9%
vaccine efficacy is assumed. Vaccine-induced immunity lasts for a lifetime
in the base-case; scenarios with booster application are evaluated in addi-
tion. HPV vaccination is cost-effective, and reduces lifetime risk of cervical
cancer by 54%.
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In accordance to Accetta et al. [7], Goldhaber-Fiebert et al. [159] and
Kim et al. [220] present microsimulation models which only include females
and account for the same HPV types and HPV-induced diseases in an US
and Brazilian context, respectively. Acquisition of HPV infection is modelled
in an age-dependent way, not incorporating the effects of herd immunity.
In [159], the transition probabilities to the states of HPV infection can be
modified through the integration of the output of a dynamic transmission
model [215], resulting in a hybrid model. Both vaccine coverage and efficacy
are assumed to be 100%, and females are vaccinated before the age of
twelve. Observation time horizon and duration of immunity are assumed
to be lifelong. The model predicts a reduction in cervical cancer of 55%-
90%, depending on the screening strategy. The purpose of [220] is the
calibration of the model output to Brazilian data, and HPV vaccination does
not take place.
De Kok et al. [108] modify the MISCAN microsimulation model [177] to
specifically account for HPV. The model structure is similar to [7, 159, 220];
however, no distinction according to HPV type is made. The model only in-
corporates females and is therefore static. The vaccine is given to twelve
year old females; scenarios with one or multiple booster doses are evaluated
in addition. In the base case, 85% vaccine coverage with lifelong protec-
tion, 70% vaccine efficacy against cervical cancer and 35% vaccine efficacy
against CIN-stages are assumed. The model is the only one reviewed which
results in non-cost-effective outcome of female-only HPV vaccination.
Vanni et al. [367] present a microsimulation model in a Brazilian context.
Sexual mixing is based on the algorithm presented by Garnett et al. [150]
and Barnabas et al. [26]; yet, difference equations rather than differential
equations are used. The model population consists of 200,000 individuals
which are stratified by sex, four sexual activity groups and 14 age groups.
HPV 16, 18 and 6/11 infections are accounted for. In females, CIN-stages,
cervical cancer and genital warts are accounted for, whereas males are only
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vectors in virus transmission and do not develop genital warts. The vac-
cine is given to twelve year old females at coverage rates of 50%, 70% and
90%. Vaccine efficacy is not reported. Duration of follow-up and vaccine-
induced immunity are lifelong. The model results in cost-effective outcome,
and predicts vaccine-specific HPV type prevalence to be zero 30 years after
vaccine introduction.
Van de Velde and Brisson et al. [58, 360] present by far the most exten-
sive microsimulation model on HPV transmission and disease progression.
In a Canadian setting, 18 HPV types are considered separately. In [58], the
model extension to CIN-stages, cervical cancer, genital warts, and indirect
prevalence reduction of HPV-induced cancers of vulva, vagina, anus, pe-
nis, and head/neck is described. The age-specific sexual mixing algorithm
accounts for four levels of sexual activity, proportionate and assortative mix-
ing, casual and stable relationships and the frequency of sex acts. Individ-
uals are vaccinated at age twelve with a possible catch-up until age 18 in
different scenarios. An economic evaluation is not conducted in [58, 360];
however, [54–57,59,122,125,236,359] investigate the cost-effectiveness of
different vaccination strategies. Laprise et al. [236] compare two- and three-
dose vaccination schedules. In addition, Brisson et al. [55,57] compare the
quadrivalent to the bi- and nonavalent HPV vaccines, respectively.
Only one network model [140] is presented in the literature, which is
modified by Olsen et al. [277] and adapted to an Irish context by Usher et
al. [356]. In a Danish setting, vaccination is given to twelve year old females
with a catch-up in twelve-26 year olds. Sexual mixing takes place with part-
ners in an age range of ten years, and frequency of sexual intercourse as
well as duration of partnerships is accounted for. Olsen et al. [277] account
for HPV 6 and 11 in addition to HPV 16 and 18. As a consequence, individ-
uals can develop genital warts in addition to a CIN-stage or cervical cancer.
Furthermore, an universal vaccination scenario of twelve year old individuals
is included. The model predicts cost-effective results for both universal and
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female-only vaccination. The model is further modified by including anal,
penile, vaginal, vulvar, head/neck cancer and comparing two- and three-
dose vaccination scenarios, resulting in cost-effective results for two-dose
regimens [278]. Usher et al. [356] process the output of the dynamic net-
work model into a CEA in MS Excel. The HPV 16/18 incidence in twelve
year old females predicted by the network model is adjusted in retrospect in
MS Excel, depending on the vaccination scenario under investigation. The
model predicts cost-effective female-only vaccination.
B.5 Hybrid models
Taira et al. [339] combine a probabilistic Markov model [311] estimating the
natural history of HPV infection with a dynamic deterministic transmission
model based on difference equations in an US context.
The hybrid model presented by Horn et al. [185] differs from Taira et al.’s
model by the way HPV transmission is accounted for. Horn et al. apply a
continuous-time ODE-based transmission model [132], whereas Taira et al.
present a discrete-time model. Horn et al. use the output of the ODE-based
transmission model as an input into a Markov model [313] in a German
setting. Horn et al. do not conduct a health economic evaluation.
Kim et al. [218] adapt the sexual mixing algorithm from Barnabas et
al. [26] (see Section B.2), and estimate disease progression through a prob-
abilistic microsimulation model [215] in an US context. In addition to CIN-
stages and cervical cancer, anal and oral cancers as well as recurrent res-
piratory papillomatosis are considered.
Bogaards et al. [37] combine a deterministic ODE-based transmission
model [38] (described in Appendix B.2) to a static, probabilistic microsimu-
lation model for disease progression in a Dutch setting. The authors do not
analyse the cost-effectiveness of female-only vaccination.
Another hybrid approach in publications focussing on female-only vacci-
247
APPENDIX B. FURTHER DETAILS ON THE LITERATURE REVIEW
nation is given by the combination of the microsimulation model presented
by Kim et al. [220] to the PDE-based HPV transmission model presented
by Barnabas et al. [26], modified by Goldie et al. [163], and described in
Appendix B.2. This methodology is used by Goldie et al. [161, 166–168],
Kim et al. [217] and Sharma et al. [316]. Furthermore, Kim et al. [219] com-
bine the same HPV transmission model to the microsimulation model pre-
sented by Goldhaber-Siebert et al. [159]. The microsimulation models are
described in Appendix 4.4.3 and are used to simulate the natural history of
HPV infection, whereas the output of the dynamic HPV transmission model
is integrated into the microsimulation models in order to estimate transitions
to the state of HPV infection. The methodology in [161, 166–168, 217, 316]
is the same; however, the model assumptions and the country-specific input
data differ. Goldie et al. conduct CEAs for the US, 72 developing coun-
tries, Latin America and the Carribbean as well as Vietnam, Kim et al. for
the US, and Sharma et al. for a setting in Thailand. In most models, only
HPV-induced diseases affecting the cervix are considered; however, Kim et
al. [217] include a great variety of HPV-induced diseases.
B.6 Results of the cost-effectiveness analyses
The following section includes further details on the results of the health
economic evaluations for female-only vaccination.
Female-only vaccination
Out of the 110 publications, 44 [7, 9, 16, 17, 34, 37, 75, 81, 83, 96, 99, 108,
109,111,136,153,159,162,168,180,202,213,220,225,229,241,245,248,
263,270,274,294,311,321,328,342,344,345,349,358,365,367,370,388]
introduce newly developed models, whereas 46 [30, 31, 68, 70, 72, 87, 100–
103,113–116,119,120,130,161,164,166,167,169,172,183,211,214,216,
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219,222,226,228,231,234,243,257,273,300,314,316,333,337,348,356,
357,373,387] adjust previously developed methodology to different country-
specific settings, and 20 [36,54,56,57,125,134,160,163,201,203,217,221,
232,303,304,350,359,364,382,383] evaluate an extended aim of research.
The vast majority of newly developed models, altogether 31 [9, 17, 34,
81, 83, 96, 99, 109, 111, 136, 153, 162, 202, 225, 241, 245, 248, 263, 270, 274,
294,311,321,328,342,344,345,358,365,370,388], are static Markov mod-
els. These are not ideal since the effects of herd immunity are either not
considered or only indirectly adjusted for [16, 34, 83, 365, 370]. As for uni-
versal vaccination, ignoring the effects of herd immunity is prone to induce
an incorrect model outcome in female-only vaccination scenarios. In mod-
els incorporating exclusively female cohorts, additional reasons for falsified
model outcome are given by ignoring the role of males as vectors in HPV
transmission and the impact of HPV-induced diseases in males.
In addition to the Markov models, two newly developed ODE-based mod-
els [229, 349], five microsimulation models [7, 108, 159, 220, 367] and two
hybrid models [37,168] are presented in context of female-only vaccination.
The ODE-based models are dynamic by definition and thus account for the
effects of herd immunity; however, apart from [367], the microsimulation
models exclusively observe female individuals and are therefore static. The
hybrid models [37, 168] estimate disease transmission through ODE-based
models [26, 38], and incorporate the predictions on HPV prevalence into
microsimulation models [37,220] which consist of female populations.
For the different interventions compared (cervical screening, vaccination
strategies including catch-up, bivalent, quadrivalent, and nonavalent vac-
cine), the results range from cost-saving in nine publications [70, 120, 161,
166,167,211,219,222,316] to not cost-effective in de Kok et al. [108]. Pos-
sible explanations for the outcome in [108] are the static methodology, the
relatively low vaccine efficacy of only 70% against cervical cancer and 35%
against CIN stages, and the high unit cost of vaccination of e 118 per dose.
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Appendix C
Explanatory diagrams of
HPV-induced cancer boxes
Appendix C shows the contents of the boxes of the HPV-induced diseases,
including precancerous stages and possible transitions to the body areas af-
fected.
We include the states of infection, clearance and reinfection into each ex-
planatory diagram since transitions to and from precancerous stages to the
mentioned states are possible. Furthermore, cancer survivors move to the
state of clearance four years after initial cancer diagnosis. All intraepithe-
lial neoplasiae, the corresponding cancer and the three states of survival
post cancer diagnosis affecting the same body part are displayed in the
same colour. We use different shades to distinguish disease severity, where
darker tones represent more severe conditions.
Figure C.1 displays the contents of the box head/neck cancer. After HPV
infection, individuals move directly to the state of head/neck cancer. The
survivors enter the three tunnel states post cancer diagnosis. With each
passing year, they reduce their probability of dying, potentially moving to
clearance. Having been cured, they can be re-infected and develop a sec-
ond HPV-induced disease.
In addition to head/neck cancer, anal cancer can affect both sexes. We
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Infection Clearance Reinfection
Head & neck
cancer
Year 3Year 2Year 1
Figure C.1: Head/neck cancer can affect both sexes. This figure represents the
contents of the box Head&neck cancer in the overview Figure 5.1
showing the model structure. We assume no precancerous stages
for this HPV-induced cancer. Having been diagnosed with head/neck
cancer, surviving individuals move to the tunnel states post cancer di-
agnosis. Once affected by head/neck cancer, the probability of dying
increases. Those who have survived for four years after diagnosis
move to the state of clearance. A reinfection, resulting in a second
HPV-induced disease, might occur.
include the two precancerous stages LSIL and HSIL, as Figure C.2 shows.
Those infected with HPV can develop a disease or clear their infection. Sim-
ilarly to those suffering from head/neck cancer, we assume that anal cancer
patients either die or enter the three states of cancer survival, possibly re-
sulting in cancer clearance.
The HPV-induced diseases vaginal and vulvar cancer can only affect
females. We display the process of infection, disease progression and re-
gression in Figures C.3 and C.4. We include three precancerous stages in
the vaginal cancer box, and assume only one for vulvar cancer. Comparable
to the HPV-induced cancers described previously, individuals can either die
from the disease or become cured.
HPV can also infect the penis. Penile cancer is the only male-specific
HPV-induced cancer included in our model and the process of disease de-
velopment and clearance is displayed in Figure C.5. Similarly to vulvar can-
cer, we only assume one precancerous stage.
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Infection Clearance Reinfection
Anal
cancer
Anal
LSIL
Anal
HSIL
Year 3Year 2Year 1
Figure C.2: Anal cancer is not a sex-specific disease; however, females are un-
der a higher disease risk than heterosexual males. This figure shows
the contents of the box Anal cancer. We assume the two precancer-
ous stages anal LSIL and HSIL to be part of the disease progression
process. Once infected with HPV, individuals can either move to anal
LSIL or anal HSIL. A direct transition to anal cancer is impossible. After
cancer diagnosis, surviving individuals enter the three stages of post
cancer diagnosis. Those who have not died will move to the state of
clearance. Individuals can possibly be reinfected, initiating a second
disease development in the anus or another organ.
Infection Clearance Reinfection
Vulvar
cancer
VIN
Year 3Year 2Year 1
Figure C.4: In context of vulvar cancer, we only include the precancerous stage
VIN. After acquiring the HPV infection and being affected by VIN, fe-
males can progress to vulvar cancer. In survivors, we assume vulvar
cancer to be cured four years after diagnosis. A reinfection could initi-
ate the same or another disease progression process.
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Infection Clearance Reinfection
Vaginal
cancer
VaIN I VaIN II
VaIN III
Year 3Year 2Year 1
Figure C.3: The contents of the box Vaginal cancer are similar to those of Cervical
cancer as shown in Figure 5.2. For this female-specific disease, we as-
sume females infected with HPV to move in between the three precan-
cerous stages VaIN I-III and to either clear their infection or progress to
vaginal cancer during the process. Having survived vaginal cancer for
four years, we assume females to be cured. A reinfection and repeti-
tion of disease development or the acquisition of another HPV-induced
disease is possible.
Infection Clearance Reinfection
Penile
cancer
PeIN
Year 3Year 2Year 1
Figure C.5: Penile cancer is the only male-specific HPV-induced disease in our
model. Similarly to vulvar cancer, we assume only one precancerous
stage, PeIN. Having moved to PeIN, those who have not cleared their
infection will progress to penile cancer. Having passed the three tunnel
states without dying, we assume males to be cured. From the state of
clearance, they can move to the state of reinfection.
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Appendix D
Continuation of transition
probabilities in females
In Section 5.8, the general approach of constructing the transition probabil-
ities of the HPV model is shown for the states Healthy and Exposure. In
this appendix, we present the remaining transition probabilities which are
not described in the main part of this PhD thesis. In addition, this appendix
includes an overview table (Table D.1) on the numbering of the 36 states of
the female model compartment. This table is essential for an understanding
of the corresponding transition probabilities.
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Table D.1: This table gives an overview of the 36 states included in the female
compartment of the dynamic HPV model with the corresponding num-
bering. This numbering will be considered in the equations of the tran-
sition probabilities.
No. State No. State
1 Healthy 19 Post anal cancer (year two)
2 Exposure 20 Post anal cancer (year three)
3 Infection 21 Head/neck cancer
4 CIN I 22 Post head/neck cancer (year one)
5 CIN II 23 Post head/neck cancer (year two)
6 CIN III 24 Post head/neck cancer (year three)
7 Genital warts 25 VIN
8 Cervical cancer 26 Vulvar cancer
9 Death (for all causes) 27 Post vulvar cancer (year one)
10 Post cervical cancer (year one) 28 Post vulvar cancer (year two)
11 Post cervical cancer (year two) 29 Post vulvar cancer (year three)
12 Post cervical cancer (year three) 30 VAIN I
13 Clearance 31 VAIN II
14 Reinfection 32 VAIN III
15 Anal LSIL 33 Vaginal cancer
16 Anal HSIL 34 Post vaginal cancer (year one)
17 Anal cancer 35 Post vaginal cancer (year two)
18 Post anal cancer (year one) 36 Post vaginal cancer (year three)
From the state Infection
Figure 5.1 indicates that people infected by HPV can either clear the infec-
tion naturally (s = 2) or progress towards mild or moderate cervical neoplas-
tic lesions (CIN I, s = 4, or CIN II, s = 5), genital warts (s = 7), anal LSIL
(s = 15), anal HSIL (s = 16), head/neck cancer (s = 21), vulvar intraepithelial
neoplasm (VIN, s = 25) or vaginal intraepithelial neoplasms (VaIN I, s = 30
or VaIN II, s = 31). Using the parameters specified in Section 5.5, we can
define the transition probabilities.
For intervention i = 1
In intervention i = 1, screening-only, the probabilities of moving towards
the target states are defined according to Equation D.1. We define S = {2,
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3, 4, 5, 7, 9, 15, 16, 21, 25, 30, 31} to be a set of target states. All transitions to
states different from S are impossible and as a consequence set to zero.
The transition probabilities are defined as
piF1,a,3,s = 0∀ s /∈ {S}
piF1,a,3,2 = δFa
piF1,a,3,4 = δ1
piF1,a,3,5 = δ2
piF1,a,3,7 = ψ
(gw)
a,F
piF1,a,3,9 = da,F
piF1,a,3,15 = δ3ρ
F
2
1
ρF3
piF1,a,3,16 = δ4ρ
F
2
1
ρF3
piF1,a,3,21 = ψ
(hn)
a,F
piF1,a,3,25 = δ5
piF1,a,3,30 = δ5
piF1,a,3,31 = δ5
piF1,a,3,3 = 1−
∑
s 6=3
piF1,a,3,s.
(D.1)
The parameter δFa represents age-dependent regression from infection, δ1
and δ2 progression to CIN I and CIN II, respectively, ψ
(gw)
a,F is the observable
variable of the age- and sex-specific acquisition of genital warts and δ3 and
δ4 are the progression probabilities to anal LSIL and HSIL. Since δ3 and
δ4 are taken from publications on anal LSIL and HSIL prevalence in homo-
sexual males and HIV positive females [97, 98], these probabilities have to
be adjusted by the correction factors ρF2 and ρ
F
3 , based on [145, 351] (see
Section 5.5 and Appendix G.1).
The age- and sex-specific probability of the acquisition of head/neck can-
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cer is represented by the observable variable ψ(hn)a,F . The parameter δ5 rep-
resents a transition from the state of infection to VIN as well as VaIN I and
II. The constraint implies that all transition probabilities sum up to one.
For intervention i = 2 and i = 3
Similarly to intervention i = 1, people who receive HPV vaccination in one
of the interventions i = 2 or i = 3 can move to the states S, as Equation D.1
shows. All other transition probabilities are set to zero. Equation D.2 is
based on the indices i = 2; however, these are equivalent to the indices of
i = 3 and can therefore be used equivalently.
The transition probability to the state s = 2 is not affected by vaccina-
tion because HPV-induced diseases do not regress more quickly following
vaccination. The probability of acquiring a HPV-induced disease following
infection is reduced considerably in vaccinated individuals, in accordance to
Equation 5.2 depending on the levels of vaccine coverage and compliance.
In other words, patients who take up the vaccination have a reduced chance
of progressing towards one of the more advanced states, with the reduc-
tion being a function of their compliance level. Those who do not take up
vaccination at all have the same risk as those under intervention i = 1.
In the HPV-induced diseases CIN I and CIN II, in addition to vaccine
efficacy γ1, we assume a cross-protection effect χF against HPV genotypes
different from HPV 16 and 18. At the current stage of research, we can
only consider these protective effects in the two precancerous stages of
the cervix. The corresponding transition probabilities are given as
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piF2,a,3,s = 0∀ s /∈ {S}
piF2,a,3,2 = δ0a
piF2,a,3,4 = α[ν3(1− γ1 − χF)δ1 + (1− ν3)(1− ζγ1)δ1] + (1− α)δ1
piF2,a,3,5 = α[ν3(1− γ1 − χF)δ2 + (1− ν3)(1− ζγ1)δ2] + (1− α)δ2
piF2,a,3,7 = α[ν3(1− γ1)ψ(gw)a,F + (1− ν3)(1− ζγ1)ψ(gw)a,F ] + (1− α)ψ(gw)a,F
piF2,a,3,9 = da,F
piF2,a,3,15 = α[ν3(1− γ2)δ3ρF2
1
ρF3
+ (1− ν3)(1− ζγ2)δ3ρF2
1
ρF3
] + (1− α)δ3ρF2
1
ρF3
piF2/3/4,a,3,16 = α[ν3(1− γ2)δ4ρF2
1
ρF3
+ (1− ν3)(1− ζγ2)δ4ρF2
1
ρF3
] + (1− α)δ4ρF2
1
ρF3
piF2,a,3,21 = α[ν3(1− γ3)ψ(hn)a,F + (1− ν3)(1− ζγ3)ψ(hn)a,F ] + (1− α)ψ(hn)a,F
piF2,a,3,25 = α[ν3(1− γ1)δ5 + (1− ν3)(1− ζγ1)δ5] + (1− α)δ5
piF2,a,3,30 = α[ν3(1− γ1)δ5 + (1− ν3)(1− ζγ1)δ5] + (1− α)δ5
piF2,a,3,31 = α[ν3(1− γ1)δ5 + (1− ν3)(1− ζγ1)δ5] + (1− α)δ5
piF2,a,3,3 = 1−
∑
s 6=3
piF2,a,3,s.
(D.2)
From the state Clearance
People who previously experienced a HPV-induced precancerous stage,
cancer or genital warts and cleared the disease (either naturally or through
intervention) can remain in the state of clearance, be newly exposed to HPV,
or die.
The transition towards the state of reinfection (indicated by s = 14) is
affected at least partially by a set of social and demographic risk factors
(such as age at first sexual intercourse and smoking). A proportion 1 − ζ
of the individuals in the state of clearance after neoplasia do not present
risk factors and thus their chance of becoming reinfected by HPV is the
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same as that of individuals moving from the state of exposure to that of
infection. Conversely, the remaining proportion ζ of subjects, who are at
increased risk, experience a higher chance of becoming reinfected by HPV,
as described by the parameter ρF1 . These assumptions are encoded in
piFi,a,13,s = 0∀ s /∈ {9, 13, 14}
piFi,a,13,9 = da,F
piFi,a,13,14 = (1− ζ)piFi,a,2,3 + ζpiFi,a,2,3ρF1
piFi,a,13,13 = 1−
∑
s 6=13
piFi,a,13,s.
From the state Reinfection
People who become re-exposed to HPV after a previous occurence of a
HPV-induced disease are essentially in the same position as people who
are infected for the first time, except for the effect of the risk factors that
are assumed to be present at this stage. We define a set of target states
K = {4, 5, 9, 13, 14, 15, 16, 21, 25, 30, 31}. Consequently, the transition proba-
bilities are
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piFi,a,14,s = 0∀ s /∈ {K}
piFi,a,14,4 = (1− ζ)piFi,a,3,4 + ζpiFi,a,3,4ρF1
piFi,a,14,5 = (1− ζ)piFi,a,3,5 + ζpiFi,a,3,5ρF1
piFi,a,14,9 = da,F
piFi,a,14,13 = pi
F
i,a,3,2
piFi,a,14,15 = (1− ζ)piFi,a,3,15 + ζpiFi,a,3,15ρF1
piFi,a,14,16 = (1− ζ)piFi,a,3,16 + ζpiFi,a,3,16ρF1
piFi,a,14,21 = (1− ζ)piFi,a,3,21 + ζpiFi,a,3,21ρF1
piFi,a,14,25 = (1− ζ)piFi,a,3,25 + ζpiFi,a,3,25ρF1
piFi,a,14,30 = (1− ζ)piFi,a,3,30 + ζpiFi,a,3,30ρF1
piFi,a,14,31 = (1− ζ)piFi,a,3,31 + ζpiFi,a,3,31ρF1
piFi,a,14,14 = 1−
∑
s 6=14
piFi,a,14,s.
(D.3)
Equation D.3 assumes that the regression towards clearance is not affected
by the risk factors and thus that the parameters ζ and ρF1 are not present.
From the state Genital warts
Females affected by genital warts can move to the state of clearance (s =
13), die (s = 9) or persist in that condition (s = 7), indicated by the parameter
υF . Remaining in the state of genital warts is age-specific; we assume that
younger people have a considerably higher chance to recover in a shorter
period of time when compared to older people [69]. The adjustment to age
dependency is obtained through model calibration, as described in Sec-
tion 6.3, and indicated by λv,a,r,s with indices v, a, r, s representing sex, age
cohort, original state and target state, respectively. Consequently, we model
the possible transition probabilities as
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piFi,a,7,s = 0∀ s /∈ {7, 13, 9}
piFi,a,7,7 = λF,a,7,7υF
piFi,a,7,9 = da,F
piFi,a,7,13 = 1−
∑
s 6=7
piFi,a,7,s.
From the state CIN I
Once females have reached the state CIN I, screening becomes an impor-
tant factor in all three interventions (i = 1, 2, 3). A proportion σa of people will
participate in the screening programme, which makes their diagnosis earlier
and thus increases their chance of clearing the infection (e.g. moving to the
state of clearance, represented by the index s = 13).
Of all females screened, a proportion τ1 will undergo an immediate in-
tervention, conization, which will improve their chance of moving back to
clearance, estimated by the parameter ξ(cerv,1)1,0 . A different proportion τ2
will undergo conization only after a follow-up period; nevertheless, once
the intervention was performed, their chance of regressing to clearance is
again ξ(cerv,1)1,0 . Finally, those who do not undergo conization (a proportion of
1− τ1 − τ2) will have a lower chance of regression, represented by ξ(cerv,2)1,0 .
The remaining individuals (in a proportion 1 − σa) will not be screened
and thus are less likely to move towards the state of clearance. In fact, their
chance of transition is assumed to be the same as that of subjects who have
not undergone conization ξ(cerv,2)1,0 . We encode these assumptions in
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piFi,a,4,s = 0∀ s /∈ {4, 5, 6, 9, 13}
piFi,a,4,5 = σa[(τ1 + τ2)ξ
(cerv,1)
1,2 + (1− τ1 − τ2)ξ(cerv,2)1,2 ] + (1− σa)ξ(cerv,2)1,2
piFi,a,4,6 = σa[(τ1 + τ2)ξ
(cerv,1)
1,3 + (1− τ1 − τ2)ξ(cerv,2)1,3 ] + (1− σa)ξ(cerv,2)1,3
piFi,a,4,9 = da,F
piFi,a,4,13 = σa[(τ1 + τ2)ξ
(cerv,1)
1,0 + (1− τ1 − τ2)ξ(cerv,2)1,0 ] + (1− σa)ξ(cerv,2)1,0
piFi,a,4,4 = 1−
∑
s 6=4
piFi,a,4,s.
From the state CIN I, females can only move to the states CIN II (s = 5),
CIN III (s = 6), death (s = 9) and clearance (s = 13). All other transition
probabilities are set to zero. The constraint of probabilities to sum up to one
is represented by the last row of the system of transition probabilities, which
results in the probability to remain in CIN I.
From the state CIN II
Following the scheme presented for the transitions from the state CIN I, we
model the probabilities for the transitions from the state CIN II as
piFi,a,5,s = 0∀ s /∈ {4, 5, 6, 9, 13}
piFi,a,5,4 = σa[(τ1 + τ2)ξ
(cerv,1)
2,1 + (1− τ1 − τ2)ξ(cerv,2)2,1 ] + (1− σa)ξ(cerv,2)2,1
piFi,a,5,6 = σa[(τ1 + τ2)ξ
(cerv,1)
2,3 + (1− τ1 − τ2)ξ(cerv,2)2,3 ] + (1− σa)ξ(cerv,2)2,3
piFi,a,5,9 = da,F
piFi,a,5,13 = σa[(τ1 + τ2)ξ
(cerv,1)
2,0 + (1− τ1 − τ2)ξ(cerv,2)2,0 ] + (1− σa)ξ(cerv,2)2,0
piFi,a,5,5 = 1−
∑
h6=5
piFi,a,5,s.
Similar interpretations to those in the previous case are applied.
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From the state CIN III
Transitions from the state CIN III are age-specific. The older the female,
the less likely she is to regress to a less severe precancerous stage or to
move to clearance. Furthermore, females in CIN III can progress to cervical
cancer. We assume that older females are more likely to develop cervical
cancer [72, 263]. The age-specific transition probabilities are adjusted by
comparing these to Brazilian data on CIN III prevalence, assuming Italian
CIN III prevalence follows similar age trends as described in Section 6.3.
The age-specific adjustment factor is indicated through the variable λv,a,r,s
and multiplied with the transition probabilities under the assumption of no
conization (ξ(cerv,2)3,y ). The system of equations is defined as
piFi,a,6,s = 0∀ s /∈ {4, 5, 6, 8, 9, 13}
piFi,a,6,4 = λF,a,6,4ξ
(cerv,2)
3,1
piFi,a,6,5 = λF,a,6,5ξ
(cerv,2)
3,2
piFi,a,6,8 = λF,a,6,8ξ
(cerv,2)
3,4
piFi,a,6,9 = da,F
piFi,a,6,13 = λF,a,6,13ξ
(cerv,2)
3,0
piFi,a,6,6 = 1−
∑
s 6=4
piFi,a,4,s.
From the state Cervical cancer
According to our model, patients who have entered the state of cervical
cancer only have two possible options. They either die (which occurs at an
increased rate as compared to individuals without cancer), or progress to
the state of first year after diagnosis (indicated by s = 10). The probabilities
of these transitions vary according to the stage at which the individuals are
diagnosed: subjects who enter the state of cervical cancer at a more ad-
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vanced stage have lower survival rates. The assumptions are encoded by
piFi,a,8,s = 0∀ s /∈ {9, 10}
piFi,a,8,9 = 1−
∑
s 6=8
piFi,a,8,s
piFi,a,8,10 =
4∑
j=1
µ
(cerv)
j φ
♦(cerv)
1,j ,
with µ(cerv)j indicating the probability that a patient is diagnosed with cervical
cancer at stage j, whereas the parameter φ♦(cerv)1,j represents the probability
of one-year survival in stage j.
From the states Post cervical cancer (year one, year two,
year three)
For each HPV-induced cancer, we define three tunnel states of one, two and
three years post cancer diagnosis. We assume that cervical cancer patients
in the first tunnel state post cancer diagnosis can either survive, with an
increased probability compared to the state of cervical cancer (progressing
to two years post cancer diagnosis), or die. Again, the progression to the
next year depends on the disease stage. The transition probabilities from
the state one year post cervical cancer diagnosis are defined as
piFi,a,10,s = 0∀ s /∈ {9, 11}
piFi,a,10,11 =
4∑
j=1
µ
(cerv)
j φ
♦(cerv)
2,j
piFi,a,10,9 = 1− piFi,a,10,11,
(D.4)
where the index s = 11 designates the state two years after the diagnosis
of cervical cancer. Those females who do not survive move to the state of
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death (s = 9).
Having moved to s = 11, individuals can either die or move to the next
year post cancer diagnosis (indicated by s = 12), which is not shown in
Equation D.4; however, the principle is equivalent. The transition probabili-
ties to the cancer survival states s = 10, s = 11 and s = 12 are a combina-
tion of the probabilities of diagnosis µ(cerv)j and the one-to four year survival
probability φ♦(cerv)q,j , where q represents the year of survival and j the cancer
stage, respectively. Moving to the state of death is in each case calculated
by means of the statistical constraint of probabilities to sum up to one. Those
females who survive for four years are assumed to be cured and move to
the state of clearance (s = 13).
From the state Anal LSIL
In contrast to CIN, we assume only two pre-cancerous stages of anal can-
cer. The mildest is anal LSIL, from which a transition to anal HSIL (s = 16)
or anal cancer (s = 17) is possible. Furthermore, patients can clear their in-
fection, die or remain in the state of LSIL. The chance of clearance (s = 13)
is higher in younger patients, whereas the risk of progressing to anal HSIL
(s = 16) is higher in older patients.
The transitions to clearance, HSIL and anal cancer are indicated by the
parameter ξ(an)1,y , representing the transition to states less severe (y = 0)
or more severe (y = 2, 3) than anal LSIL. The exponent (an) shows that
the anal area is infected by HPV. The transitions to s = 13 and s = 16
are adjusted according to age through variables λv,a,r,s, which are estimated
through model calibration as described in Section 6.3. The transition prob-
abilities are given by
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piFi,a,15,s = 0∀ s /∈ {9, 13, 15, 16, 17}
piFi,a,15,9 = da,F
piFi,a,15,13 = λF,a,15,13ξ
(an)
1,0
piFi,a,15,16 = λF,a,15,16ξ
(an)
1,2
piFi,a,15,17 = ξ
(an)
1,3
piFi,a,15,15 = 1−
∑
s 6=15
piFi,a,15,s.
From the state Anal HSIL
The transition probabilities from the state anal HSIL are similar to those from
the state LSIL. People can either clear their intraepithelial neoplasiae, move
to the less severe stage LSIL (s = 15), develop anal cancer (s = 16), remain
in anal HSIL, or die. We assume the transition probabilities to clearance
and anal cancer to be age- and sex-specific, with younger people being
more likely to move to clearance, and older people more likely to develop
anal cancer. Dependency on age is again indicated by the variables λv,a,r,s,
obtained through model calibration. The corresponding equations are pre-
sented as
piFi,a,16,s = 0∀ s /∈ {9, 13, 15, 16, 17}
piFi,a,16,9 = da,F
piFi,a,16,13 = λF,a,16,13ξ
(an)
2,0
piFi,a,16,15 = λF,a,16,15ξ
(an)
2,1
piFi,a,16,17 = ξ
(an)
2,3
piFi,a,16,16 = 1−
∑
s 6=16
piFi,a,16,s.
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From the state Anal cancer
Similarly to all other HPV-induced cancers, the transitions from the state
of anal cancer lead into so-called tunnel states. Once affected by cancer,
people either die (s = 9) or initially survive for one year (s = 18). The prob-
ability of survival depends on whether anal cancer is diagnosed, indicated
by the parameter µ(an)j , with j representing the respective cancer stage. We
assume that the probabilities of diagnosis affect the cancer outcome since
only a recognized cancer can be treated properly and is therefore more likely
to result in prolonged survival. In contrast to the transition probabilities for
stages different from cancer, the probability of dying is no longer the age-
and sex-specific observable variable da,F , but calculated with the constraint
that all probabilities have to sum up to 1. Obviously, the probability of dying
is increased in individuals who suffer from cancer. The transition probabili-
ties are defined as
piFi,a,17,s = 0∀ s /∈ {9, 18}
piFi,a,17,9 = 1− piFi,a,17,18
piFi,a,17,18 =
4∑
j=1
µ
(an)
j φ
♦(an)
1,j .
From the states Post anal cancer (year one, year two, year
three)
Having been diagnosed with anal cancer, people enter a sequence of three
tunnel states. People who survived anal cancer for one year can either sur-
vive for another year, indicated by the probability of diagnosing anal cancer
(µ(an)j ) and the probability of two-year survival (φ
♦(an)
2,j ), or they can die from
the disease. The corresponding transition probabilities are defined as
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piFi,a,18,s = 0∀ s /∈ {9, 19}
piFi,a,18,9 = 1− piFi,a,18,19
piFi,a,18,19 =
4∑
j=1
µ
(an)
j φ
♦(an)
2,j .
Transitions to the states of two and three years after anal cancer (s = 20
and s = 21, respectively) are calculated in a similar way; however, the states
r and s as well as the index q in φ♦q,j have to be adjusted. The year after
cancer diagnosis is represented by q. Having survived anal cancer for two
years, individuals can either die from the disease or survive for another year,
resulting in a survival of altogether three years.
We assume individuals who are still alive four years after diagnosis and
treatment of cancer to be cured and therefore move to the state of clearance,
indicated by s = 13.
From the state Head/neck cancer
In contrast to the other HPV-induced cancers, we assume no precancerous
stages for head/neck cancer. Therefore, following HPV infection, people can
directly move to the state of head/neck cancer. Similarly to the cancer states
previously described, patients diagnosed with head/neck cancer can either
survive for one year, indicated by the parameters µ(hn)j and φ
♦(hn)
1,j , or die
from the disease, which is calculated through the constraint to ensure prob-
abilities sum up to one. The parameter µ(hn)j represents the probability of
diagnosis in stage j = 1, 2, 3, 4, and φ♦(hn)1,j is the vector of one-year survival
probabilities according to stage j. The transition probabilities are given as
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piFi,a,21,s = 0∀ s /∈ {9, 22}
piFi,a,21,9 = 1− piFi,a,21,22
piFi,a,21,22 =
4∑
j=1
µ
(hn)
j φ
♦(hn)
1,j .
From the states Post head/neck cancer (year one, year two,
year three)
Having survived head/neck cancer for one year, patients enter the first tun-
nel state post head/neck cancer diagnosis (s = 22) and can either survive
for another year (s = 23), indicated by the parameters µ(hn)j and φ
♦(hn)
2,j , or
die (j = 9). The transition probability to death is calculated by means of the
constraint of probabilities, and the whole process is given as
piFi,a,22,s = 0∀ s /∈ {9, 23}
piFi,a,22,9 = 1− piFi,a,22,23
piFi,a,22,23 =
4∑
j=1
µ
(hn)
j φ
♦(hn)
2,j .
(D.5)
Similarly, patients in the state two years after diagnosis of head/neck cancer
(r = 23) can either move to the state of three-year survival (s = 24) or die.
Having survived head/neck cancer for three years (r = 24), patients can
either move to the state of clearance, indicated by s = 13, or die. The cor-
responding transition probabilities are calculated as shown in Equation D.5;
however, the states r and s as well as indices q of the cancer survival prob-
abilities φ♦(hn)q,j have to be adjusted accordingly.
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From the state VIN
We assume one precancerous stage in context of vulvar cancer, the so-
called vulvar intraepithelial neoplasia (VIN). Females can either clear their
HPV infection and move to the state of clearance (s = 13), progress to the
state of vulvar cancer (s = 26), die (s = 9) or remain in the state of vulvar
cancer (s = 25). Probabilities of progression and regression are indicated by
the parameter ξ(vin)1,y , where y = 0, 2 represent regression and vulvar cancer,
respectively. Younger females have a higher chance of clearance, indicated
by the variable λv,a,r,s, whereas older females have a higher risk to progress
to vulvar cancer. The probability of remaining in VIN is calculated through
the constraint of probabilities summing up to one. The system of equations
is given as
piFi,a,25,s = 0∀ s /∈ {9, 13, 25, 26}
piFi,a,25,9 = da,F
piFi,a,25,13 = ξ
(vin)
1,0
piFi,a,25,26 = λF,a,25,26ξ
(vin)
1,2
piFi,a,25,25 = 1−
∑
s 6=25
piFi,a,25,s.
From the state Vulvar cancer
Once affected by vulvar cancer, females can either survive for one year
and move to the state of one year post vulvar cancer (s = 27), depending
on the probability of diagnosis of vulvar cancer in the respective stage j,
represented by the parameter µ(vulv)j , and the stage-dependent one-year
survival probability φ♦(vulv)1,j . Those who do not survive move to the state
of death, calculated by means of the constraint for probabilities which must
sum up to one. The corresponding transition probabilities are defined as
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piFi,a,26,s = 0∀ s /∈ {9, 27}
piFi,a,26,9 = 1− piFi,a,26,27
piFi,a,26,27 =
4∑
j=1
µ
(vulv)
j φ
♦(vulv)
1,j .
From the states Post vulvar cancer (year one, year two,
year three)
Females who have survived vulvar cancer for one year after diagnosis can
either move to the state of two years post vulvar cancer (s = 28), or die,
indicated by
piFi,a,27,s = 0∀ s /∈ {9, 28}
piFi,a,27,9 = 1− piFi,a,27,28
piFi,a,27,28 =
4∑
s=1
µ
(vulv)
j φ
♦(vulv)
2,j .
(D.6)
Similarly to the transition probabilities shown in Equation D.6, females who
have survived vulvar cancer for two years (r = 28) can survive for another
year and move to the state of three years post vulvar cancer (s = 29). Those
who do not survive move to the state of death (s = 9). We assume females
who survive vulvar cancer for four years (r = 30) to be cured and therefore
to move to the state of clearance (s = 13). Those who do not survive for
four years die, calculated through the constraint for probabilities. In contrast
to Equation D.6, in order to move to the more advanced survival states, we
have to adjust the numberings of the states r and s as well as the index q,
representing the yearly survival probabilities in φ♦(vulv)q,j .
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From the state VaIN I
Equivalent to the precancerous stages of cervical cancer, we assume three
precancerous stages for vaginal cancer: vaginal intraepithelial neoplasms
(VaIN) stage I, II and III. Females who are in the stage of VaIN I can ei-
ther clear their infection and move to the state of clearance (s = 13), die
(s = 9), remain in VaIN I (s = 30) or move to the more severe states of
VaIN II (s = 31) or VaIN III (s = 32). The probabilities to move within the
VaIN stages or to clear the infection are represented by the parameter ξ(vag)1,y ,
where y = 0, 2, 3 indicate states less or more severe than VaIN I. To remain
in VaIN I is calculated through the constraint of probabilities. The transition
probabilities are presented as
piFi,a,30,s = 0∀ s /∈ {9, 13, 30, 31, 32}
piFi,a,30,9 = da,F
piFi,a,30,13 = ξ
(vag)
1,0
piFi,a,30,31 = ξ
(vag)
1,2
piFi,a,30,32 = ξ
(vag)
1,3
piFi,a,30,30 = 1−
∑
s 6=30
piFi,a,30,s.
From the state VaIN II
Having progressed to VaIN II, females can still clear their infection and move
to the state of clearance (s = 13), regress to VaIN I (s = 30) or progress to
the state of VaIN III (s = 32). These transition probabilities are indicated by
the parameter ξ(vag)2,y , where y = 0, 1, 3 represent states less or more severe
than VaIN II (x = 2). The progression to VaIN III is age-specific, indicated
through the variable λF,a,31,32, with a higher risk in older females. Further-
more, females can die or remain in VaIN II. The corresponding equations
are given as
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piFi,a,31,s = 0∀ s /∈ {9, 13, 30, 31, 32}
piFi,a,31,9 = da,F
piFi,a,31,13 = ξ
(vag)
2,0
piFi,a,31,30 = ξ
(vag)
2,1
piFi,a,31,32 = λF,a,31,32ξ
(vag)
2,3
piFi,a,31,31 = 1−
∑
s 6=31
piFi,a,31,s.
From the state VaIN III
Affected by VaIN III, females can still clear their infection and move to the
state of clearance (s = 13) or regress to VaIN I (s = 30) or VaIN II (s = 31).
Furthermore, their disease can progress to vaginal cancer (s = 33), they
can remain in VaIN III (s = 32), or die (s = 9). Moving between the pre-
cancerous lesions and vaginal cancer is indicated by ξ(vag)3,y with y = 0, 1, 2, 3,
ranging from clearance to vaginal cancer. The risk of developing vaginal
cancer is age-specific, indicated by λF,a,32,33. The transition probabilities are
defined as
piFi,a,32,s = 0∀ s /∈ {9, 13, 30, 31, 32, 33}
piFi,a,32,9 = da,F
piFi,a,32,13 = ξ
(vag)
3,0
piFi,a,32,30 = ξ
(vag)
3,1
piFi,a,32,31 = ξ
(vag)
3,2
piFi,a,32,33 = λF,a,32,33ξ
(vag)
3,3
piFi,a,32,32 = 1−
∑
s 6=32
piFi,a,32,s.
274
From the state Vaginal cancer
Once affected by vaginal cancer, females can either survive and move to
the state of one year post vaginal cancer diagnosis (s = 34) or die. Those
who do not survive obviously die, which is calculated by means of the con-
straint of probabilities to sum up to one. The transition probability of one-
year survival is indicated by the parameter µ(vag)j , the probability of diagnosis
of vaginal cancer in stage j = 1, 2, 3, 4, and the one-year survival probability
according to stage j, φ♦(vag)1,j , as shown in
piFi,a,33,s = 0∀ s /∈ {9, 34}
piFi,a,33,9 = 1− piFi,a,33,34
piFi,a,33,34 =
4∑
r=1
µ
(vag)
j φ
♦(vag)
1,j .
From the states Post vaginal cancer (year one, year two,
year three)
Females who have survived vaginal cancer for one year can either move to
the state of two-year survival post vaginal cancer (s = 35), or die (s = 9).
As for the states post cancer diagnosis, the probability of dying is calcu-
lated through the constraint of probabilities which must sum up to one. The
corresponding transition probabilities are defined as
piFi,a,34,s = 0∀ s /∈ {9, 35}
piFi,a,34,9 = 1− piFi,a,34,35
piFi,a,34,35 =
4∑
r=1
µ
(vag)
j φ
♦(vag)
2,j .
(D.7)
Having survived vaginal cancer for two years, females can either survive for
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another year and move to the state three years post vaginal cancer (s = 36),
or die (s = 9). We assume vaginal cancer to be cured four years after diag-
nosis. Therefore, females who are in the state of three years post vaginal
cancer can either move to the state of clearance (s = 13), or die (s = 9).
These transition probabilities are calculated similarly to Equation D.7; how-
ever, the numberings of the states r and s as well as indices q of the survival
probabilities φ♦(vag)q,j have to be adjusted. The index q = 1, 2, 3, 4 represents
the yearly cancer survival.
From the state Death
As is obvious, all people who end up in the state of death cannot move to
another state (death is said to be an absorbing state). Therefore, we set all
transition probabilities to states apart from s = 9 to zero, and remaining in
the state of death to one, resulting in
piFi,a,9,s = 0∀ s 6= 9
piFi,a,9,9 = 1.
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Appendix E
The male model compartment
Appendix E focusses on the male compartment of the model, reporting each
state in males with its corresponding numbering. Afterwards, the transition
probabilities in males are explained, including a detailed description of all
equations. The corresponding transition probabilities in females are given in
Section 5.8 and Appendix D.
Several aspects of the male model compartment have already been pre-
sented in Section 5.4. The exact numbering of the states in males which is
essential for an understanding of the transition probabilities is given in the
following. As for the transition probabilities, we report those for males in
Appendix E.2.
E.1 Numbering of states in males
In contrast to 36 states in females, there are only 22 states in males since a
smaller number of organs can be affected by HPV. The states are given in
Table E.1. The corresponding numbering is of importance for the transition
probabilities which are described in Appendix E.2.
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Table E.1: Overview of the 22 states included in the male model compartment
No. State No. State
1 Healthy 12 Post anal cancer (year two)
2 Exposure 13 Post anal cancer (year three)
3 Infection 14 Head/neck cancer
4 Genital warts 15 Post head/neck cancer (year one)
5 Death (for all causes) 16 Post head/neck cancer (year two)
6 Clearance 17 Post head/neck cancer (year three)
7 Reinfection 18 PeIN
8 Anal LSIL 19 Penile cancer
9 Anal HSIL 20 Post penile cancer (year one)
10 Anal cancer 21 Post penile cancer (year two)
11 Post anal cancer (year one) 22 Post penile cancer (year three)
E.2 Transition probabilities in males
In this appendix, the transition probabilities in males between the 22 states
included are described in detail. We distinguish between the original states
r and the target states s. We set transition probabilities to states where
movements are not enabled to zero. Furthermore, we use the mathematical
constraint for probabilities to sum up to one to make sure that the sum of
transition probabilities from the same state r cannot take values outside of
the interval [0;1]. From the states Exposure and Infection, the application of
different interventions i plays a role; in these cases, transition probabilities
for the interventions i = 1, 2, 3 are described separately.
The notation of transition probabilities in males, piMi,a,r,s, is similar to piFi,a,r,s
in females (see Section 5.8), where
• i represents the intervention (see Section 5.3);
• a represents the age cohort of the male (see Table 5.1 in Section 5.3);
• r represents the original state;
• s represents the target state.
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In sex-specific model parameters, v indexes the population member’s sex,
where v = F represents females and v = M males. We have to consider
the different numbering of states r, s in males compared to those in females,
reported in Tables E.1 and D.1, respectively.
From the state Healthy
Equivalent to females, the transition probabilities from the state Healthy in
males enable moving to the state of exposure (s = 2) or death (s = 5).
Furthermore, for people who have not had a sexual relationship yet (1−wa),
it is possible to remain in perfect health (s = 1). We assume the probability
of first intercourse, wa, to be age-dependent. Death probabilities da,M in
males are different from those in females (da,F ), since death is not only age-,
but also sex-specific, indicating a longer life expectancy in females. The
corresponding set of equations is defined as
piMi,a,1,s = 0∀ s /∈ {1, 2, 5}
piMi,a,1,2 = wa
piMi,a,1,5 = da,M
piMi,a,1,1 = 1−
∑
s 6=1
piMi,a,1,s.
From the state Exposure
Vaccination in males takes place in intervention i = 3. Interventions i = 1, 2
do not include vaccination in males and therefore do not result in lower tran-
sition probabilities to the state of infection.
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For intervention i = 1 and i = 2
We assume males in interventions i = 1, 2 not to receive the HPV vaccine.
As for females, males move to the state of HPV infection s = 3 through
a dynamic process of sexual mixing, represented by the force of infection
piFM,b,a(It), which is described in detail in Section 5.7.5. This parameter de-
pends on sex, sexual behaviour, age and time interval of observation. Fur-
thermore, people can either die (s = 5) or remain in the state of exposure
which is calculated through the constraint of probabilities which have to sum
up to one. The transition probabilities for intervention i = 1 are given by
piM1,a,2,s = 0∀ s /∈ {2, 3, 5}
piM1,a,2,3 = pi
F
M,b,a(It) (see Section 5.7.5)
piM1,a,2,5 = da,M
piM1,a,2,2 = 1−
∑
s 6=2
piM1,a,2,s;
however, those for i = 2 are equivalent.
For intervention i = 3
In contrast to the previous interventions, we assume males receive the HPV
vaccine in intervention i = 3. Therefore, their transition probability to move to
the state of infection (s = 3) is considerably reduced. The reduction depends
on the vaccine coverage α, the vaccine compliance ν3, the vaccine efficacy
γ1 and the decrease in vaccine efficacy due to incomplete compliance ζ.
Furthermore, males can either die (s = 5) or remain in the state of exposure,
calculated with the constraint of probabilities. We assume vaccine related
parameters not to be sex-specific, and define the transition probabilities as
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piM3,a,2,s = 0∀h /∈ {2, 3, 5}
piM3,a,2,5 = da,M
piM3,a,2,3 = α1[ν3(1− γ1)piFM,b,a(It) + (1− ν3)(1− ζγ1)piFM,b,a(It)] + (1− α)piFM,b,a(It)
piM3,a,2,2 = 1−
∑
s 6=2
piM3,a,2,s.
From the state Infection
Once infected, males can move to a selection of HPV-induced disease states,
remain in the state of infection, regress to the state of exposure or die. Ob-
viously, these transition probabilities are also affected by vaccination which
takes place in males in intervention i = 3.
For intervention i = 1 and i = 2
Males are not vaccinated in interventions i = 1, 2; therefore, the transition
probabilities to HPV-induced disease states are not reduced. Once infected
with HPV, males can either clear their infection and move back to the state
of exposure (s = 2), indicated by δ0a, develop genital warts (s = 7) with
age- and sex-specific probability ψ(gw)a,M or die (s = 5) with age- and sex-
specific probability da,M . Furthermore, they can move to the states anal LSIL
(s = 8), anal HSIL (s = 9), head/neck cancer (s = 14) or penile intraepithelial
neoplasia (PeIN, s = 18).
Penile cancer and its precancerous stage penile intraepithelial neoplasm
(PeIN) are the only HPV-induced diseases included in the model which can
only affect males. Moving to PeIN is indicated by the parameter δ6. The
parameters δ3 and δ4 refer to transitions to anal LSIL and HSIL, respec-
tively. Since the information found in the literature corresponds to homosex-
ual males and HIV-positive females, these parameters are adjusted by ρF3 ,
the risk decrease for heterosexual males when compared to homosexual
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males as described in Section 5.5 and Appendix G.1.
The transition to head/neck cancer is age- and sex-specific and repre-
sented by the variable ψ(hn)a,M . We define the set of states D = {2, 3, 4, 5, 8, 9,
14, 18}. Transitions to states different from D are impossible and therefore
set to zero. Remaining in the state of infection is calculated through the
constraint of probabilities which have to sum up to one. The transition prob-
abilites for screening-only are presented as
piM1,a,3,s = 0∀ s /∈ {D}
piM1,a,3,2 = δ0a
piM1,a,3,4 = ψ
(gw)
a,M
piM1,a,3,5 = da,M
piM1,a,3,8 = δ3
1
ρF3
piM1,a,3,9 = δ4
1
ρF3
piM1,a,3,14 = ψ
(hn)
a,M
piM1,a,3,18 = δ6
piM1,a,3,3 = 1−
∑
s 6=3
piM1,a,3,s;
those for intervention i = 2 are analogue.
For intervention i = 3
In intervention i = 3, males receive the vaccine. Therefore, the correspond-
ing transition probabilities to HPV-induced diseases are functions of vac-
cine related parameters. The vaccine coverage rate is represented by α,
whereas ν3 is the vaccine compliance rate, γ2 the vaccine efficacy against
HPV-induced diseases of the anus, γ3 against head/neck cancer and γ1
against all other HPV-related infections. The parameter χF represents cross-
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protection against HPV genotypes which are not included in the HPV vac-
cine and ζ is the reduction in effectiveness due to non-compliance. The
transition probabilities are given by
piM3,a,3,s = 0∀ s /∈ {D}
piM3,a,3,2 = δ0a
piM3,a,3,4 = α[ν3(1− γ1 − χF)ψ(gw)a,M + (1− ν3)(1− ζγ1)ψ(gw)a,M ] + (1− α)ψ(gw)a,M
piM3,a,3,5 = da,M
piM3,a,3,8 = α[ν3(1− γ2 − χF)δ3
1
ρF3
+ (1− ν3)(1− ζγ2)δ3 1
ρF3
] + (1− α)δ3 1
ρF3
piM3,a,3,9 = α[ν3(1− γ2 − χF)δ4
1
ρF3
+ (1− ν3)(1− ζγ2)δ4 1
ρF3
] + (1− α)δ4 1
ρF3
piM3,a,3,14 = α[ν3(1− γ3 − χF)ψ(hn)a,M + (1− ν3)(1− ζγ3)ψ(hn)a,M ] + (1− α)ψ(hn)a,M
piM3,a,3,18 = α[ν3(1− γ1 − χF)δ6 + (1− ν3)(1− ζγ1)δ6] + (1− α)δ6
piM3,a,3,3 = 1−
∑
s 6=3
piM1,a,3,s.
From the state Clearance
Having cleared their HPV infection or recovered from a HPV-induced dis-
ease, people either die (s = 5), move to the state of reinfection (s = 7) or
remain in the state of clearance. Remaining in clearance is again calculated
by means of the constraint of probabilities. Moving to reinfection is similar
to the transition from exposure to infection; however, if certain risk factors
are present with a probability of ζ, the risk of reinfection is increased by the
factor ρF1 . The corresponding set of equations is defined as
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piMi,a,6,s = 0∀ s /∈ {5, 6, 7}
piMi,a,6,5 = da,M
piMi,a,6,7 = (1− ζ)piMi,a,2,3 + ζpiMi,a,2,3ρF1
piMi,a,6,6 = 1−
∑
s 6=13
piMi,a,6,s.
From the state Reinfection
Once reinfected, males can progress to all disease states equivalent to
those from the state of infection; however, the transition probabilities are
higher in case of the presence of risk factors. Furthermore, people can ei-
ther die (s = 5) or remain in the state of reinfection (s = 7), depending on
the constraint of probabilities. We define a set of states Q = {4, 5, 6, 7, 8, 9,
14, 18}. As previously described, ζ represents the probability of risk factors
and ρF1 the risk increase which occurs as a consequence of their presence
as shown in
piMi,a,7,s = 0∀ s /∈ Q
piMi,a,7,4 = (1− ζ)piMi,a,3,4 + ζpiMi,a,3,4ρF1
piMi,a,7,5 = da,M
piMi,a,7,6 = pi
M
i,a,3,2
piMi,a,7,8 = (1− ζ)piMi,a,3,8 + ζpiMi,a,3,8ρF1
piMi,a,7,9 = (1− ζ)piMi,a,3,9 + ζpiMi,a,3,9ρF1
piMi,a,7,14 = (1− ζ)piMi,a,3,14 + ζpiMi,a,3,14ρF1
piMi,a,7,18 = (1− ζ)piMi,a,3,18 + ζpiMi,a,3,18ρF1
piMi,a,7,7 = 1−
∑
s 6=7
piMi,a,7,s.
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From the state Genital warts
Males who are affected by genital warts can either remain in the correspond-
ing state (s = 4), indicated by the parameter υM , die (s = 5), or move to the
state of clearance (s = 6). As described for females, remaining in the state of
genital warts is age-specific. The adjustment to age dependency is obtained
through model calibration, as described in Section 6.3 and Appendix G.1,
and indicated by λv,a,r,s with indices v, a, r, s representing sex, age cohort,
original state and target state, respectively. According to our assumptions,
dying is age- and sex-specific, and clearing the condition depends on the
other transition probabilities from the state genital warts, calculated through
the constraint of probabilities. The transition probabilities are given by
piMi,a,4,s = 0∀ s /∈ {4, 5, 6}
piMi,a,4,4 = λM,a,4,4υM
piMi,a,4,5 = da,M
piMi,a,4,6 = 1−
∑
s 6=4
piMi,a,4,s.
From the state Anal LSIL
Males who are affected by anal LSIL can either die (s = 5), clear their infec-
tion (s = 6), progress to anal HSIL (s = 9), anal cancer (s = 10) or remain in
the state of LSIL (s = 8). The chance of clearance is higher in younger peo-
ple, whereas the risk of progressing to anal HSIL is higher in older people.
The probabilities of moving to more advanced stages of anal neoplasia,
or to clear the precancerous lesion, are represented by the parameter ξ(an)1,y ,
where y = 0, 2, 3 represent clearance, HSIL and anal cancer, respectively.
The transitions to s = 6 and s = 9 are adjusted according to age through the
variable λv,a,r,s, which is estimated through model calibration as described
in Section 6.3. Remaining in anal LSIL is calculated through the constraint
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of probabilities to sum up to one. The system of equations is given as
piMi,a,8,s = 0∀ s /∈ {5, 6, 8, 9, 10}
piMi,a,8,5 = da,M
piMi,a,8,6 = λM,a,8,6ξ
(an)
1,0
piMi,a,8,9 = λM,a,8,9ξ
(an)
1,2
piMi,a,8,10 = ξ
(an)
1,3
piMi,a,8,8 = 1−
∑
s 6=8
piMi,a,8,s.
From the state Anal HSIL
Males who are affected by anal HSIL, the more severe precancerous lesion,
can still clear their infection (s = 6), progress to anal cancer (s = 10), die
(s = 5) or remain in anal HSIL. We assume the transition probabilities to
clearance and anal cancer to be age- and sex-specific, with younger peo-
ple being more likely to move to clearance, and older males more likely to
develop anal cancer. Dependency on age is again indicated by the variable
λv,a,r,s, obtained through model calibration. The probabilities of progressing
or regressing are indicated by the parameter ξ(an)2,y , where y = 0, 1, 3 repre-
sents states less or more severe than x = 2, anal HSIL. If males remain in
HSIL, we calculate the corresponding probability by applying the statistical
constraint that probabilites have to sum up to one. We present the corre-
sponding equations as
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piMi,a,9,s = 0∀ s /∈ {5, 6, 8, 9, 10}
piMi,a,9,5 = da,M
piMi,a,9,6 = λM,a,9,6ξ
(an)
2,0
piMi,a,9,8 = ξ
(an)
2,1
piMi,a,9,10 = λM,a,9,10ξ
(an)
2,3
piMi,a,9,9 = 1−
∑
s 6=9
piMi,a,9,s.
From the state Anal cancer
Having been diagnosed with anal cancer, males can either move to the state
one year post anal cancer (s = 11) or die (s = 5). The probability of one-year
survival depends on the probability of diagnosis µ(an)j in stage j = 1, 2, 3, 4,
and the probability of surviving for one year, φ♦(an)1,j , depending on stage j.
Once affected by anal cancer, males who do not die enter the tunnel states
of one to three years post anal cancer. The transition probabilities are de-
fined as
piMi,a,10,s = 0∀ s /∈ {5, 11}
piMi,a,10,5 = 1− piMi,a,10,11
piMi,a,10,11 =
4∑
j=1
µ
(an)
j φ
♦(an)
1,j .
From the states Post anal cancer (year one, year two, year
three)
Individuals who have survived anal cancer for one year after diagnosis can
either die (s = 5) or move to two years post anal cancer (s = 12), which is
calculated through the constraint of probabilities, necessarily summing up
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to one. Two years after the diagnosis of anal cancer, patients who are still
alive can either die (s = 5) or move to the state of three years post anal
cancer (s = 13). We assume that patients who have survived anal cancer
for three years finally move to the state of clearance (s = 6), or die (s = 5).
The system of equations is given as
piMi,a,11,s = 0∀ s /∈ {5, 12}
piMi,a,11,5 = 1− piMi,a,11,12
piMi,a,11,12 =
4∑
j=1
µ
(an)
j φ
♦(an)
2,j .
(E.1)
Equation E.1 shows the transition probabilities of moving from the state r =
11; however, transitions from the states r = 12 and r = 13 are similar.
The only changes are the indices of the original and target states r and s
as well as the index q in the anal cancer survival probabilities φ♦(an)q,j , with
q = 1, 2, 3, 4 representing one to four year survival.
From the state Head/neck cancer
In contrast to all other HPV-induced cancers included in the model, we as-
sume that there are no precancerous stages for head/neck cancer. Suffer-
ing from head/neck cancer, patients can either survive and move to the state
one year post head/neck cancer (s = 15), indicated by the stage-dependent
probabilities of diagnosis µ(hn)j and one-year survival φ
♦(hn)
1,j , or die (s = 5).
As usual, the probability of dying is calculated with the constraint of proba-
bilities which must sum up to one. The transition probabilities are defined as
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piMi,a,14,s = 0∀ s /∈ {5, 15}
piMi,a,14,5 = 1− piMi,a,14,15
piMi,a,14,15 =
4∑
j=1
µ
(hn)
j φ
♦(hn)
1,j .
From the states Post head/neck cancer (year one, year two,
year three)
Having survived head/neck cancer for one year, patients can either move
to the state of two years post head/neck cancer (s = 16), or die (s = 5).
Males who are still alive two years after diagnosis of head/neck cancer can
either survive for another year and move to the state of three years post
head/neck cancer (s = 17), or die (s = 5). We assume that patients who
survived head/neck cancer for four years are cured. Therefore, they move to
the state of clearance (s = 6). Those who do not survive for four years move
to the state of death (s = 5). Equation E.2 shows the transition probabilities
of moving from the state one year post head/neck cancer diagnosis (r = 15).
The transition probabilities of moving from the states r = 16 and r = 17 are
similar, only the indices r and s for original and target states as well as the
index q in the parameter φ♦(an)q,j change. The yearly survival probabilities
are represented by the index q = 1, 2, 3, 4. The transition probabilities are
given by
piMi,a,15,s = 0∀ s /∈ {5, 16}
piMi,a,15,5 = 1− piMi,a,15,16
piMi,a,15,16 =
4∑
j=1
µ
(hn)
j φ
♦(hn)
2,j .
(E.2)
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From the state PeIN
After HPV infection, males can move to penile intraepithelial neoplasia (PeIN,
s = 18). We assume that penile cancer only has one precancerous stage in
contrast to most other HPV-induced cancers. Once affected by PeIN, males
can either clear their lesions (s = 6), progress to penile cancer (s = 19), or
die (s = 5). Younger males have a higher chance of clearing their infection,
whereas older males have a higher risk of progressing to penile cancer. This
is indicated by the variable λv,a,r,s. Those who do not move to another state
remain in PeIN, which is calculated through the constraint of probabilities.
The corresponding equations are defined as
piMi,a,18,s = 0∀ s /∈ {5, 6, 18, 19}
piMi,a,18,5 = da,M
piMi,a,18,6 = λM,a,18,6ξ
(pen)
1,0
piMi,a,18,19 = λM,a,18,19ξ
(pen)
1,2
piMi,a,18,18 = 1−
∑
h6=8
piMi,a,18,s.
From the state Penile cancer
Individuals affected by penile cancer can either survive and move to the
state of one year post penile cancer (s = 20), or die (s = 5). The probability
of one-year survival depends on the probability of diagnosis µ(pen)j , where j
represents the respective cancer stage. The probability of dying is calcu-
lated through the constraint of probabilities. The transition probabilities are
given by
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piMi,a,19,s = 0∀ s /∈ {5, 20}
piMi,a,19,5 = 1− piMi,a,19,20
piMi,a,19,20 =
4∑
j=1
µ
(pen)
j φ
♦(pen)
1,j .
From the states Post penile cancer (year one, year two,
year three)
Having survived penile cancer for one year, males can either survive for
another year and move to the state of two years post penile cancer (s = 21),
or die (s = 5). Individuals who are still alive two years after they received
their diagnosis of penile cancer can either move to the state of three years
post penile cancer (s = 22), or die. Our assumptions imply that males who
survived for four years after having been diagnosed with penile cancer are
cured from their disease and move to the state of clearance (s = 6). Those
who are not cured are assumed to die (s = 5). The corresponding transition
probabilities are defined as
piMi,a,20,s = 0∀ s /∈ {5, 21}
piMi,a,20,5 = 1− piMi,a,20,21
piMi,a,20,21 =
4∑
j=1
β
(pen)
j φ
♦(pen)
2,j .
(E.3)
Equation E.3 displays the transition probabilities of moving from the state
one year post penile cancer diagnosis; the transitions from the states post
two and three years are similar, however, the numberings of the states r and
s as well as the indices q of the survival probabilities φ♦(pen)q,j change.
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From the state Death
Equivalent to the corresponding transition probability in females, males who
are in the state of death can only remain there; movements to other states
are no longer possible. Thus, the transition probabilities are defined as
piMi,a,5,s = 0∀ s 6= 5
piMi,a,5,5 = 1.
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Appendix F
Posterior result tables
In this appendix, we present tables including summary statistics of the pos-
terior distributions, distributional assumptions of each model parameter as
well as the corresponding literature sources of prior information. The acronym
EO represents the term Expert Opinion, meaning the assumptions were
based on discussions with medical experts in the field of HPV-induced dis-
eases. The result tables are structured according to the underlying clinical
background.
The assumptions and results of the parameters introduced in
• Table F.1 are related to screening;
• Table F.2 are related to vaccination;
• Table F.3 are related to infection;
• Table F.4 are transition probabilities;
• Table F.5 are diagnostic probabilities;
• Table F.6 are cancer survival probabilities;
• Table F.7 are related to costs;
• Table F.8 are related to utilities.
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F.1 Screening-related model parameters
Table F.1 shows the defined age groups for cervical screening, as well as
the corresponding distributional assumptions, posterior mean values, 95%
credible intervals and the sources of prior information. The three-yearly cer-
vical screening rates increase until the age of 45–54 years, and constantly
decrease afterwards.
Table F.1: Distributional assumptions and estimated values for the annual screen-
ing coverage used in the model. For each age group, the table presents
the mean values and an interval estimation of the expected coverage.
Var. Description Distribution Mean and 95%-CI Source
σa Screening at 12 − 24 yrs Informative Beta 0.0500 [0.0500;0.0500] EO
σa Screening at 25 − 29 yrs Informative Beta 0.1530 [0.1480;0.1590] EO
σa Screening at 30 − 34 yrs Informative Beta 0.2150 [0.2100;0.2190] EO
σa Screening at 35 − 44 yrs Informative Beta 0.2460 [0.2440;0.2470] EO
σa Screening at 45 − 54 yrs Informative Beta 0.2600 [0.2540;0.2660] [157,194,195,244,307]
σa Screening at 55 − 64 yrs Informative Beta 0.2420 [0.2320;0.2520] [157,194,195,244,307]
σa Screening at 65 − 74 yrs Informative Beta 0.1840 [0.1640;0.2020] [157,194,195,244,307]
σa Screening at ≥ 75 yrs Informative Beta 0.1080 [0.0920;0.1250] [157,194,195,244,307]
F.2 Vaccine-related model parameters
Table F.2 shows the distributional assumptions, posterior results and sources
of prior information of vaccine-related parameters. Vaccine efficacies de-
pend on the corresponding body part, where all organs apart from the anus
and the head and neck are summarized into the category cervix. According
to expert opinion, we can only assume cross-protection effects for cervical
diseases and not in the context of anal and head/neck cancers. We assume
people who receive three shots of the vaccine to be fully compliant and fully
protected; this is a conservative estimate, accounting for the fact that new
research results indicate that two shots of the vaccine are already sufficient
for protection [236]. All prior distributions in Table F.2 are informative.
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Table F.2: Distributional values, means, corresponding 95% credible intervals and
sources of prior information of vaccine-related parameters used in the
model
Var. Description Distribution Mean and 95%-CI Source
γ1 Vaccine efficacy cervix Informative LogNorm 0.7816 [0.6847;0.8888] [19,148,233]
γ2 Vaccine efficacy anus Informative LogNorm 0.7019 [0.6055;0.7981] EO
γ3 Vaccine efficacy head/neck Informative LogNorm 0.5008 [0.4563;0.5497] EO
α Vaccine coverage rate (VCR) Informative Beta 0.9048 [0.6597;0.9992] [63,82,215,339], EO
χF Cross-protection effect cervix Informative LogNorm 0.0701 [0.0395;0.1076] [62,384]
ξ Efficacy decrease non-compliance Informative Beta 0.4993 [0.3301;0.7002] [19]
ν1 Probability of receiving 1 shot Informative Beta 0.0241 [0.0062; 0.0526] [193]
ν2 Probability of receiving 2 shots Informative Beta 0.0410 [0.0104; 0.0929] [193]
ν3 Probability of receiving 3 shots Informative Beta 0.9350 [0.8718; 0.9725] [193]
F.3 Infection-related model parameters
Table F.3 focusses on infection-related parameters. All prior distributions are
informative and the corresponding sources are given. The three compart-
ments of the vector ρF represent risk increases and decrease, respectively.
Risk increases are given by ρF1 and ρ
F
2 , and ρ
F
3 is a risk decrease. The
relative risk ρF1 represents the risk increase of HPV reinfection in patients
who smoke, had early sexual debut, show a history of five years or longer
of exposure to hormonal contraception, previously acquired another sexu-
ally transmitted infection such as chlamydia trachomatis, herpes genitalis or
syphillis, or are multipara. The proportion of people under increased risk,
ζ, has a ρF1 times higher probability to move to the state of reinfection. For
a detailed description of these parameters, the reader is referred to Sec-
tion 5.5 and Appendix G.1.
We assume different HPV transmission probabilites for people with fre-
quent partner change in contrast to those in longer, stable relationships,
indicated by the parameters β1 and β2, respectively. We explain the under-
lying assumptions in Section 5.7.1.
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Table F.3: Distributional values, means, corresponding 95% credible intervals and
sources of prior information of infection-related variables used in the
model
Var. Description Distribution Mean and 95%-CI Source
ρF1 Risk increase (relative risk) Informative LogNorm 3.2262 [1.1408;5.4778] [256]
ρF2 Risk increase anal cancer females Informative Gamma 1.6975 [1.5055; 1.9026] [351]
ρF3 Risk decrease anal cancer males Informative Gamma 17.1880 [0.8714; 53.5615] [145]
ζ Population at increased risk Informative Beta 0.3139 [0.2140;0.4054] [319]
τ1 Conization in CIN I (immediate) Informative Beta 0.3029 [0.2101;0.4180] [158]
τ2 Conization in CIN I (delayed) Informative Beta 0.1701 [0.1525;0.1909] EO
β1 HPV transmission (average risk) Informative Normal 0.2532[0.1707; 0.3607] EO
β2 HPV transmission (high risk) Informative Normal 0.5220 [0.2915; 0.7439] EO
F.4 Model parameters related to transition prob-
abilities
In Table F.4, we display all the information on parameters necessary to esti-
mate the transition probabilities between the 36 states in females (see Sec-
tion 5.8 and Appendix D) and 22 in males (see Appendix E.2). For transi-
tions from infection back to exposure, the so-called disease regression, as
well as for all transitions between states affecting the cervix, anus, vulva
and penis, we assume informative prior distributions. The same approach
is conducted in genital warts. In contrast, we assume minimally informative
prior distributions for most transitions in HPV-induced diseases affecting the
vagina and update these by means of data we extract from the literature.
According to Watson et al. [375], a transition from the state anal LSIL to
anal cancer is not possible; only those affected by anal HSIL can develop
cancer. Therefore, we set the parameter ξ(an)1,3 to zero and do not make any
distributional assumptions. Accordingly, based on expert opinion, patients
who underwent conization after diagnosis of a CIN stage cannot regress to
less severe precancerous lesions because we assume the infection to be
cleared after this treatment.
In addition to posterior results, transition probabilities adjusted through
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model calibration as described in Section 6.3 are reported. Rather than
the posterior results of the respective model parameters, the values of the
transition probabilities after calibration (or comparison of age-specific trends
as for CIN III) are reported directly, indicated by piFi,a,r,s and piMi,a,r,s for females
and males, respectively. As described in Section 5.8, the indices i, a, r and
s represent intervention, age cohort, original and target states, respectively.
If transition probabilities in females and males are identical, only those in
females are reported.
Table F.4: Distributional values, means, corresponding 95% credible intervals and
sources of prior information of epidemiological and clinical parameters
used in the model
Var. Description Distribution Mean and 95%-CI Source
Regression
δ0a Infection Exposure (12−24 yrs) Inform. Beta 0.7188 [0.6463;0.7830] [71,78,305,306], EO
δ0a Infection Exposure (25−29 yrs) Inform. Beta 0.6984 [0.5898;0.7952] [71,78,305,306], EO
δ0a Infection Exposure (30−39 yrs) Inform. Beta 0.3503 [0.2860; 0.4188] [71,78,305,306], EO
δ0a Infection Exposure (40−49 yrs) Inform. Beta 0.2048 [0.1118;0.3022] [71,78,305,306], EO
δ0a Infection Exposure (≥ 50 yrs) Inform. Beta 0.1004 [0.0546; 0.1567] [71,78,305,306], EO
Cervix
δ1 Infection CIN I Inform. Beta 0.0450 [0.0279; 0.0661] [71,78,263,305]
δ2 Infection CIN II Inform. Beta 0.0115 [0.0034; 0.0234] [71,263,305,306]
ξ
(cerv,1)
1,3 CIN I CIN III Inform. Beta 0.0464 [0.0098; 0.1297] [71, 78, 158, 263, 305,
306], EO
ξ
(cerv,1)
2,3 CIN II CIN III Inform. Beta 0.3498 [0.0904;0.8654] [71, 78, 105, 158, 263,
305,306], EO
Subject to conization
ξ
(cerv,1)
1,2 CIN I CIN II Inform. Beta 0.1212 [0.0434; 0.2418] [71,305,306], EO
ξ
(cerv,1)
2,1 CIN II CIN I — 0 [0;0] EO
ξ
(cerv,1)
1,0 CIN I Clearance Inform. Beta 0.9003[0.8382; 0.9498] [71, 78, 158, 263, 305,
306], EO
ξ
(cerv,1)
2,0 CIN II Clearance Inform. Beta 0.8588 [0.8153; 0.8965] [71, 78, 105, 158, 263,
305,306], EO
piFi,a,6,4 CIN III CIN I Inform. Beta 0.0392 [0.0077; 0.1148] [71,263], EO
piFi,a,6,5 CIN III CIN II Inform. Beta 0.0579 [0.0132; 0.1555] [71,263], EO
piFi,a,6,8 CIN III Cancer Inform. Beta 0.1019 [0.0189; 0.2906] [71,263], EO
piFi,a,6,13 CIN III Clearance Inform. Beta 0.1576 [0.0017; 0.8977] [71,263], EO
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Not subject to conization
ξ
(cerv,2)
1,2 CIN I CIN II Inform. Beta 0.2240 [0.1608;0.2972] [71,305,306], EO
ξ
(cerv,2)
2,1 CIN II CIN I Inform. Beta 0.2494[0.1994; 0.2992] [71,263], EO
ξ
(cerv,2)
1,0 CIN I Clearance Inform. Beta 0.7008 [0.6077;0.7933] [71, 78, 105, 158, 263,
305,306], EO
ξ
(cerv,2)
2,0 CIN II Clearance Inform. Beta 0.3490 [0.2101;0.5026] [71, 78, 105, 158, 263,
305,306], EO
Genital warts
ψ
(gw)
a,F Infection Genital warts in females Inform. Beta 0.0104 [0.0003; 0.0495] [252], EO
ψ
(gw)
a,M Infection Genital warts in males Inform. Beta 0.0114 [0;0.0467] [252], EO
piFi,a,7,7 Recurrence females Inform. Beta 0.3104 [0; 0.9244] [69,144], EO
piMi,a,4,4 Recurrence males Inform. Beta 0.2847 [0;0.9098] [69,144], EO
Anus
δ3 Infection LSIL Inform. Beta 0.0286 [0.1003;0.1387] [98,145,351]
δ4 Infection HSIL Inform. Beta 0.0104 [0.0008;0.0496] [97,98,145,351]
piFi,a,15,13 LSIL Clearance Inform. Beta 0.1475 [0.0190; 0.4771] [98,285,375]
piFi,a,15,16 LSIL HSIL Inform. Beta 0.0588 [0.0077; 0.1884] [98]
ξ
(an)
1,3 LSIL Anal cancer — 0 [0;0] [375]
piFi,a,16,13 HSIL Clearance females Inform. Beta 0.1576 [0.0017; 0.8977] [145,165]
piMi,a,9,6 HSIL Clearance males Inform. Beta 0.1667 [0.0093; 0.8977] [145,165]
piFi,a,16,15 HSIL LSIL Inform. Beta 0.0997 [0.0810; 0.1209] [98]
piFi,a,16,17 HSIL Anal cancer females Inform. Beta 0.0026 [0; 0.0059] [145,250,375]
piMi,a,9,10 HSIL Anal cancer males Inform. Beta 0.0020 [0; 0.0053] [145,250,375]
Vagina
δ5 Infection VaIN I/II Inform. Beta 0.0073 [0.0053; 0.0096] [147]
ξ
(vag)
1,2 VaIN I VaIN II/VaIN III Min. inf. Beta 0.0270 [0.0021; 0.0782] [10]
ξ
(vag)
1,0 VaIN I Clearance Min. inf. Beta 0.2528 [0.1813; 0.3062] [10]
ξ
(vag)
2,1 VaIN II VaIN I Min. inf. Beta 0.2528 [0.1813; 0.3062] [10]
ξ
(vag)
2,0 VaIN II Clearance Min. inf. Beta 0.2528 [0.1813; 0.3062] [10]
ξ
(vag)
2,1 VaIN II VaIN I Min. inf. Beta 0.2502 [0.1787;0.3075] [10]
piFi,a,31,32 VaIN II VaIN III Min. inf. Beta 0.2656 [0.0066;1] [10], EO
ξ
(vag)
3,1 VaIN III VaIN I Min. inf. Beta 0.2502 [0.1218; 0.3265] [10]
ξ
(vag)
3,2 VaIN III VaIN II Min. inf. Beta 0.2502 [0.1218; 0.3265] [10]
ξ
(vag)
3,0 VaIN III Clearance Inform. Beta 0.2174 [0.0107;0.9229] EO
piFi,a,32,33 VaIN III Vaginal cancer Inform. Beta 0.1576 [0.0017;0.9091] [10]
Vulva
ξ
(vulv)
1,0 VIN Clearance Inform. Beta 0.1579 [0.0017; 0.9091] [207], EO
piFi,a,25,26 VIN Vulvar cancer Inform. Beta 0.0815 [0.0269;0.3538] [207], EO
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Penis
δ6 Infection PeIN Inform. Beta 0.0002 [0;0.0014] [261], EO
piMi,a,18,6 PeIN Clearance Inform. Beta 0.1577 [0.0017; 0.8977] [318], EO
piMi,a,18,19 PeIN Penile cancer Inform. Beta 0.1539 [0.0076; 0.6465] [25], EO
F.5 Model parameters related to diagnostic prob-
abilities
Precancerous stages and cancer can only result in costs and reduced val-
ues in the corresponding utilities after diagnosis. Beforehand, people may
possibly experience symptoms which they might not link to a severe health
condition such as cancer. Many states, for example the cervical lesions
CIN I-III do not cause any symptoms; however, these are serious health
threats. If undiscovered and left untreated, they can progress to cancer and
possibly lead to death.
Table F.5: Distributional values, mean, corresponding 95% credible intervals and
sources of prior information of probabilities of diagnosis used in the
model
Var. Description Distribution Mean and 95%-CI Source
Cervix
η1 Diagnosis CIN II (without screening) Inform. Beta 0.0265 [0.0001;0.1229] EO
η2 Diagnosis CIN III (without screening) Inform. Beta 0.0750 [0.0562; 0.0955] EO
µ
(cerv)
1 Diagnosis FIGO I Min. inf. Dirichlet 0.5498 [0.5333;0.5654] [29,138,142,275],
EO
µ
(cerv)
2 Diagnosis FIGO II Min. inf. Dirichlet 0.1505 [0.1387;0.1626] [29,138,142,275],
EO
µ
(cerv)
3 Diagnosis FIGO III Min. inf. Dirichlet 0.1200 [0.1089;0.1310] [29,138,142,275],
EO
µ
(cerv)
4 Diagnosis FIGO III Min. inf. Dirichlet 0.1797 [0.1668;0.1926] [29,138,142,275],
EO
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Anus
η3 Diagnosis LSIL Informative Beta 0.0500 [0.0404;0.0607] EO
η4 Diagnosis HSIL Informative Beta 0.1000 [0.0904; 0.1096] EO
µ
(an)
1 Diagnosis anal cancer stage I Min. inf. Dirichlet 0.2432 [0.1953;0.2934] [347]
µ
(an)
2 Diagnosis anal cancer stage II Min. inf. Dirichlet 0.4815 [0.4254;0.5371] [347]
µ
(an)
3 Diagnosis anal cancer stage III Min. inf. Dirichlet 0.1235 [0.0887;0.1650] [347]
µ
(an)
4 Diagnosis anal cancer stage IV Min. inf. Dirichlet 0.1521 [0.1113;0.1937] [347]
Head and neck
µ
(hn)
1 Diagnosis head/neck cancer stage I Min. inf. Dirichlet 0.2222 [0.0960;0.4034] [61,184,310,334]
µ
(hn)
2 Diagnosis head/neck cancer stage II Min. inf. Dirichlet 0.2316 [0.1055;0.4239] [61,184,310,334]
µ
(hn)
3 Diagnosis head/neck cancer stage III Min. inf. Dirichlet 0.2748 [0.0880;0.5826] [61,184,310,334]
µ
(hn)
4 Diagnosis head/neck cancer stage IV Min. inf. Dirichlet 0.2878 [0.0937; 0.5925] [61,184,310,334]
Vagina
η5 Diagnosis VaIN I/II Informative Beta 0.1996 [0.1798;0.2204] EO
µ
(vag)
1 Diagnosis vaginal cancer stage I Min. inf. Dirichlet 0.2586 [0.0007;0.9966] [11,197]
µ
(vag)
2 Diagnosis vaginal cancer stage II Min. inf. Dirichlet 0.3431 [0.0009;0.9974] [11,197]
µ
(vag)
3 Diagnosis vaginal cancer stage III Min. inf. Dirichlet 0.2147 [0;1] [11,197]
µ
(vag)
4 Diagnosis vaginal cancer stage IV Min. inf. Dirichlet 0.1836 [0.0010; 0.9893] [11,197]
Vulva
µ
(vulv)
1 Diagnosis vulvar cancer stage I Min. inf. Dirichlet 0.2385 [0.0023;0.9841] [297,361]
µ
(vulv)
2 Diagnosis vulvar cancer stage II Min. inf. Dirichlet 0.3311 [0.0027; 0.9888] [297,361]
µ
(vulv)
3 Diagnosis vulvar cancer stage III Min. inf. Dirichlet 0.2366 [0;1] [297,361]
µ
(vulv)
4 Diagnosis vulvar cancer stage IV Min. inf. Dirichlet 0.1938 [0.0001; 0.9911] [297,361]
Penis
µ
(pen)
1 Diagnosis penile cancer stage I Min. inf. Dirichlet 0.5878 [0.5229;0.6488] [265]
µ
(pen)
2 Diagnosis penile cancer stage II Min. inf. Dirichlet 0.1222 [0.0748;0.1569] [265]
µ
(pen)
3 Diagnosis penile cancer stage III Min. inf. Dirichlet 0.2852 [0.2171;0.3336] [265]
µ
(pen)
4 Diagnosis penile cancer stage IV Min. inf. Dirichlet 0.0048 [0;0.01065] [265]
We assume informative Beta distributions for the diagnostic probabilities of
all precancerous stages. Since we have not found information to inform the
diagnostic probability of penile intraepithelial neoplasiae, PeIN, we assume
the same value as for VaIN I/II, indicated by the parameter η5. According
to expert opinion, the probabilities of diagnosis for VaIN I/II and VIN are
equivalent. For all cancer stages in all organs possibly affected by HPV, we
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define minimally informative Dirichlet prior distributions which are informed
by eligible data from the literature. We account for cancer survival by linking
the probabilities of diagnosis in the respective stage to the survival proba-
bilities since only a detected cancer can be treated properly. Therefore, the
information presented in Table F.5 is of greatest importance.
F.6 Model parameters related to cancer survival
probabilities
Table F.6 provides information on one- to four-year cancer survival, depend-
ing on the affected organ and the respective cancer stage j = 1, 2, 3, 4. We
assume informative Beta distributions for the survival probabilities of cervical
cancer. In contrast, for all other HPV-induced cancers, we assume minimally
informative distributions which are informed by eligible data taken from the
literature. We define both Normal and Beta distributions, corresponding to
the data given. In some cases of minimally informative Normal distributions,
the credible intervals result in extremely wide ranges between [0;1]. This is a
consequence of the definition of the minimally informative priors, assuming
a very large variance in order to avoid convergence problems.
Table F.6: Distributional values, means, corresponding 95% credible intervals and
sources of prior information of cancer survival probabilities used in the
model
Var. Description Distribution Mean and 95%-CI Source
Cervix
φ
♦(cerv)
1,1 1 year surv. cervical cancer stage I Inform. Beta 0.9782 [0.8931;0.9999] [46,89,260], EO
φ
♦(cerv)
1,2 1 year surv. cervical cancer stage II Inform. Beta 0.8275 [0.7648;0.8789] [46,89,260], EO
φ
♦(cerv)
1,3 1 year surv. cervical cancer stage III Inform. Beta 0.5908 [0.5348;0.6504] [46,89,260], EO
φ
♦(cerv)
1,4 1 year surv. cervical cancer stage IV Inform. Beta 0.5025 [0.4490;0.5584] [46,89,260], EO
φ
♦(cerv)
2,1 2 year surv. cervical cancer stage I Inform. Beta 0.9736 [0.8659;1.0000] [46,89,260], EO
φ
♦(cerv)
2,2 2 year surv. cervical cancer stage II Inform. Beta 0.8341 [0.7699;0.8827] [46,89,260], EO
φ
♦(cerv)
2,3 2 year surv. cervical cancer stage III Inform. Beta 0.6918 [0.6405;0.7515] [46,89,260], EO
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φ
♦(cerv)
2,4 2 year surv. cervical cancer stage IV Inform. Beta 0.7819 [0.7296;0.8342] [46,89,260], EO
φ
♦(cerv)
3,1 3 year surv. cervical cancer stage I Inform. Beta 0.9632 [0.8959;0.9974] [46,89,260], EO
φ
♦(cerv)
3,2 3 year surv. cervical cancer stage II Inform. Beta 0.7565 [0.6985;0.8079] [46,89,260], EO
φ
♦(cerv)
3,3 3 year surv. cervical cancer stage III Inform. Beta 0.7780 [0.7161;0.8319] [46,89,260], EO
φ
♦(cerv)
3,4 3 year surv. cervical cancer stage IV Inform. Beta 0.7209 [0.6623;0.7797] [46,89,260], EO
φ
♦(cerv)
4,1 4 year surv. cervical cancer stage I Inform. Beta 0.9873 [0.8924;1.0000] [46,89,260], EO
φ
♦(cerv)
4,2 4 year surv. cervical cancer stage II Inform. Beta 0.8700 [0.8094;0.9224] [46,89,260], EO
φ
♦(cerv)
4,3 4 year surv. cervical cancer stage III Inform. Beta 0.9293 [0.8502;0.9784] [46,89,260], EO
φ
♦(cerv)
4,4 4 year surv. cervical cancer stage IV Inform. Beta 0.9267 [0.8626;0.9692] [46,89,260], EO
Anus
φ
♦(an)
1,1 1 year surv. anal cancer stage I/II Min. inf. Normal 0.9900 [0.9800;1.0000] [391,393]
φ
♦(an)
1,3 1 year surv. anal cancer stage III Min. inf. Beta 0.9629 [0.9209;0.9892] [312]
φ
♦(an)
1,4 1 year surv. anal cancer stage IV Min. inf. Beta 0.9179 [0.8374;0.9751] [312]
φ
♦(an)
2,1 2 year surv. anal cancer stage I/II Min. inf. Normal 0.7554 [0.0003;1] [312,393]
φ
♦(an)
2,3 2 year surv. anal cancer stage III Min. inf. Beta 0.8902 [0.8317;0.9418] [312]
φ
♦(an)
2,4 2 year surv. anal cancer stage IV Min. inf. Beta 0.7691 [0.6507;0.8692] [312]
φ
♦(an)
3,1 3 year surv. anal cancer stage I/II Min. inf. Normal 0.5979 [0;1] [393]
φ
♦(an)
3,3 3 year surv. anal cancer stage III/IV Min. inf. Beta 0.5438 [0.4269;0.6527] [347]
φ
♦(an)
4,1 4 year surv. anal cancer stage I/II Min. inf. Normal 0.6493 [0.0503;0.9732] [390,393]
φ
♦(an)
4,3 4 year surv. anal cancer stage III/IV Min. inf. Beta 0.4351 [0.2231;0.6783] [390]
Head/neck
φ
♦(hn)
1,1 1 year surv. head/neck cancer stage I Min. inf. Beta 0.9839 [0.9334;1] [126]
φ
♦(hn)
1,2 1 year surv. head/neck cancer stage II Min. inf. Beta 0.9522 [0.8829;0.9929] [126]
φ
♦(hn)
1,3 1 year surv. head/neck cancer stage III/IV Min. inf. Normal 0.8587 [0.6212;0.9757] [126,235]
φ
♦(hn)
2,1 2 year surv. head/neck cancer stage I Min. inf. Normal 0.8424 [0.0078;1] [86,126,310]
φ
♦(hn)
2,2 2 year surv. head/neck cancer stage II Min. inf. Normal 0.7995 [0.0053;1] [86,126,310]
φ
♦(hn)
2,3 2 year surv. head/neck cancer stage III Min. inf. Normal 0.6624 [0.2273;0.9365] [126,235,310]
φ
♦(hn)
2,4 2 year surv. head/neck cancer stage IV Min. inf. Normal 0.6129 [0.4496;0.7600] [126,235,310]
φ
♦(hn)
3,1 3 year surv. head/neck cancer stage I Min. inf. Beta 0.9040 [0.7645;0.9846] [126]
φ
♦(hn)
3,2 3 year surv. head/neck cancer stage II Min. inf. Beta 0.6812 [0.5429;0.8031] [126]
φ
♦(hn)
3,3 3 year surv. head/neck cancer stage III/IV Min. inf. Normal 0.4528 [0.0028;0.9988] [235,290]
φ
♦(hn)
4,1 4 year surv. head/neck cancer stage I Min. inf. Beta 0.9057 [0.7747;0.9833] [126]
φ
♦(hn)
4,2 4 year surv. head/neck cancer stage II Min. inf. Beta 0.6642[0.5269;0.7775] [126]
φ
♦(hn)
4,3 4 year surv. head/neck cancer stage III/IV Min. inf. Normal 0.5060 [0;1] [235]
Vagina
φ
♦(vag)
1,1 1 year surv. vaginal cancer stage I Min. inf. Beta 0.9531 [0.8014;0.9999] [11]
φ
♦(vag)
1,2 1 year surv. vaginal cancer stage II Min. inf. Beta 0.8882 [0.7601;0.9695] [11]
φ
♦(vag)
1,3 1 year surv. vaginal cancer stage III Min. inf. Beta 0.6859 [0.3856;0.9167] [11]
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φ
♦(vag)
1,4 1 year surv. vaginal cancer stage IV Min. inf. Beta 0.3150 [0.0674;0.6392] [11]
φ
♦(vag)
2,1 2 year surv. vaginal cancer stage I Min. inf. Beta 0.9542 [0.7809;1] [11]
φ
♦(vag)
2,2 2 year surv. vaginal cancer stage II Min. inf. Beta 0.7263 [0.5488;0.8634] [11]
φ
♦(vag)
2,3 2 year surv. vaginal cancer stage III Min. inf. Beta 0.6797 [0.3821;0.9011] [11]
φ
♦(vag)
2,4 2 year surv. vaginal cancer stage IV Min. inf. Beta 0.1885 [0.0152;0.4877] [11]
φ
♦(vag)
3,1 3 year surv. vaginal cancer stage I Min. inf. Beta 0.7685 [0.4827;0.9569] [11]
φ
♦(vag)
3,2 3 year surv. vaginal cancer stage II Min. inf. Beta 0.6946 [0.5313;0.8399] [11]
φ
♦(vag)
3,3 3 year surv. vaginal cancer stage III Min. inf. Beta 0.4945 [0.2322;0.7459] [11]
φ
♦(vag)
3,4 3 year surv. vaginal cancer stage IV Min. inf. Beta 0.1856 [0.0157;0.4972] [11]
φ
♦(vag)
4,1 4 year surv. vaginal cancer stage I Min. inf. Beta 0.7736 [0.5058;0.9594] [11]
φ
♦(vag)
4,2 4 year surv. vaginal cancer stage II Min. inf. Beta 0.7914 [0.6321;0.9122] [11]
φ
♦(vag)
4,3 4 year surv. vaginal cancer stage III Min. inf. Beta 0.4965 [0.2067;0.7576] [11]
φ
♦(vag)
4,4 4 year surv. vaginal cancer stage IV Min. inf. Beta 0.1862 [0.0138;0.4925] [11]
Vulva
φ
♦(vulv)
1,1 1 year surv. vulvar cancer stage I Min. inf. Normal 0.7808 [0;1] [338]
φ
♦(vulv)
1,2 1 year surv. vulvar cancer stage II Min. inf. Normal 0.7251 [0;1] [338]
φ
♦(vulv)
1,3 1 year surv. vulvar cancer stage III Min. inf. Normal 0.6406 [0;1] [338]
φ
♦(vulv)
1,4 1 year surv. vulvar cancer stage IV Min. inf. Normal 0.4909 [0;1] [338]
φ
♦(vulv)
2,1 2 year surv. vulvar cancer stage I Min. inf. Normal 0.7264 [0;1] [338]
φ
♦(vulv)
2,2 2 year surv. vulvar cancer stage II Min. inf. Normal 0.7106 [0;1] [338]
φ
♦(vulv)
2,3 2 year surv. vulvar cancer stage III Min. inf. Normal 0.5853 [0;1] [338]
φ
♦(vulv)
2,4 2 year surv. vulvar cancer stage IV Min. inf. Normal 0.4317 [0;1] [338]
φ
♦(vulv)
3,1 3 year surv. vulvar cancer stage I Min. inf. Normal 0.7639 [0;1] [338]
φ
♦(vulv)
3,2 3 year surv. vulvar cancer stage II Min. inf. Normal 0.7001[0;1] [338]
φ
♦(vulv)
3,3 3 year surv. vulvar cancer stage III Min. inf. Normal 0.5946 [0;1] [338]
φ
♦(vulv)
3,4 3 year surv. vulvar cancer stage IV Min. inf. Normal 0.4081 [0;1] [338]
φ
♦(vulv)
4,1 4 year surv. vulvar cancer stage I Min. inf. Normal 0.7396 [0;1] [338]
φ
♦(vulv)
4,2 4 year surv. vulvar cancer stage II Min. inf. Normal 0.6903 [0;1] [338]
φ
♦(vulv)
4,3 4 year surv. vulvar cancer stage III Min. inf. Normal 0.5625 [0;1] [338]
φ
♦(vulv)
4,4 4 year surv. vulvar cancer stage IV Min. inf. Normal 0.4018 [0;1] [338]
Penis
φ
♦(pen)
1,1 1 year surv. penile cancer stage I Min. inf. Beta 0.8933 [0.7584;0.9822] [32]
φ
♦(pen)
1,2 1 year surv. penile cancer stage II/III Min. inf. Beta 0.8196 [0.6391;0.9538] [32]
φ
♦(pen)
1,4 1 year surv. penile cancer stage IV Min. inf. Beta 0.4244 [0.2770;0.5845] [171]
φ
♦(pen)
2,1 2 year surv. penile cancer stage I Min. inf. Beta 0.8594 [0.6984;0.9623] [32]
φ
♦(pen)
2,2 2 year surv. penile cancer stage II/III Min. inf. Beta 0.6291 [0.4154;0.8170] [32]
φ
♦(pen)
2,4 2 year surv. penile cancer stage IV Min. inf. Beta 0.2030 [0.0926;0.3495] [171]
φ
♦(pen)
3,1 3 year surv. penile cancer stage I Min. inf. Beta 0.7820 [0.6008;0.9227] [32]
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φ
♦(pen)
3,2 3 year surv. penile cancer stage II/III Min. inf. Beta 0.4751[0.2711;0.6867] [32]
φ
♦(pen)
3,4 3 year surv. penile cancer stage IV Min. inf. Beta 0.2003 [0.0880;0.3395] [171]
φ
♦(pen)
4,1 4 year surv. penile cancer stage I Min. inf. Beta 0.7422 [0.5611;0.8858] [32]
φ
♦(pen)
4,2 4 year surv. penile cancer stage II/III Min. inf. Beta 0.4284 [0.2284;0.6388] [32]
φ
♦(pen)
4,4 4 year surv. penile cancer stage IV Min. inf. Beta 0.2033 [0.0929; 0.3405] [171]
F.7 Model parameters related to costs
In order to conduct the cost-effectiveness analysis, estimating the costs and
utilities presented in Tables F.7 and F.8 is essential. All unit costs are defined
in e and all assumptions on costs are based on Log-Normal distributions.
For the costs of most diagnostic procedures and disease states related to
the cervix, we assume informative prior distributions; similarly for genital
warts and anal LSIL. In contrast, all other cost parameters are based on
minimally informative priors.
Table F.7: Distributional values, means, corresponding 95% credible intervals and
sources of prior information of cost variables used in the model (unit cost
in e)
Var. Description Distribution Mean and 95%-CI Source
Vaccination and diagnostic procedures
cadm Administration cost Inform. LogNorm 6.64 [5.05;8.65] [21,95,258]
cacq Cost per dose Inform. LogNorm 56.10 [36.48;77.43] EO
cpap Pap test Inform. LogNorm 17.07 [14.05;20.83] [112]
ccol Colposcopy Inform. LogNorm 54.27 [49.63;59.49] [112]
ccyt Anal cytology Min. inf. LogNorm 43.03 [23.59;83.06] [238]
canbiop Anoscopy/biopsy Min. inf. LogNorm 348.33 [234.58;487.13] [98,238]
cdna HPV DNA test Inform. LogNorm 79.10 [76.98;81.13] [6,369]
Cervix
ccin1 CIN I Inform. LogNorm 309.33 [225.36;405.64] [94,158]
ccin2 CIN II Inform. LogNorm 1,342.30 [1,032.51;1,701.10] [158]
ccin3 CIN III Inform. LogNorm 1,750.03 [1,381.00;2,193.80] [158]
ccerv1 FIGO I Inform. LogNorm 14,782.17 [2,459.13;44,084.05] [139]
ccerv2 FIGO II Inform. LogNorm 24,924.69 [8,620.06; 54,870.83] [139]
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ccerv3 FIGO III Inform. LogNorm 35,270.93 [6,132.54; 130,201.47] [139]
ccerv4 FIGO IV Inform. LogNorm 34,517.86 [2,396.80; 173,662.38] [139]
Genital warts
cgw Genital warts Inform. LogNorm 283.48 [242.04;328.56] [94,259]
Anus
clsil LSIL Inform. LogNorm 115.46 [76.56;166.75] [165]
chsil HSIL Min. inf. LogNorm 2,389.34 [1,165.65;4,360.13] [98,238]
can1 Anal cancer stage I Min. inf. LogNorm 7,618.94 [3,885.66;12,058.58] [23,340]
can2 Anal cancer stage II Min. inf. LogNorm 11,548.85 [5,984.78; 20,078.67] [23,340]
can3 Anal cancer stage III Min. inf. LogNorm 17,966.93 [9,369.01;31,605.76] [23,340]
can4 Anal cancer stage IV Min. inf. LogNorm 11,767.32 [6,247.62; 20,102.68] [23,340]
Head/neck
chn1 Cancer stage I/II Min. inf. LogNorm 10,081.71 [5,457.09;18,036.06] [23,110,385]
chn3 Cancer stage III/IV Min. inf. LogNorm 28,437.01 [14,792.75; 48,955.00] [23,110,308,385]
Vagina
cvain VaIN I/II/III Min. inf. LogNorm 3,236.98 [1,686.22;5,376.87] [179]
cvag1 Vaginal cancer stage I Min. inf. LogNorm 2,939.32 [1,684.02;5,029.46] [23,149]
cvag2 Vaginal cancer stage II Min. inf. LogNorm 12,274.97 [6,126.71;20,723.95] [23,189]
cvag3 Vaginal cancer stage III Min. inf. LogNorm 20,973.04 [10,751.42;39,290.42] [23,91]
cvag4 Vaginal cancer stage IV Min. inf. LogNorm 29,617.99 [19,467.22;43,391.43] [23,261]
Vulva
cvin VIN Min. inf. LogNorm 3,158.80 [1,920.52;5,405.63] [179]
cvulv1 Vulvar cancer stage I Min. inf. LogNorm 8,304.24 [4,650.56;14,302.42] [149]
cvulv2 Vulvar cancer stage II Min. inf. LogNorm 11,691.60 [5,822.31;20,301.77] [149]
cvulv3 Vulvar cancer stage III Min. inf. LogNorm 15,770.82 [7,903.39;28,129.61] [149]
cvulv4 Vulvar cancer stage IV Min. inf. LogNorm 20,003.88 [10,306.98;34,978.37] [149]
Penis
cpein PeIN Min. inf. LogNorm 437.13 [63.13;811.13] [126]
cpen Penile cancer Min. inf. LogNorm 5,807.15 [3,472.35;9,233.68] [126,315]
Vaccine costs are a combination of administration (cadm) and acquisition
costs (cacq), respectively. The actual value of cacq is crucial since it largely
influences the outcome of the cost-effectiveness analysis. We assume a
mean unit cost per dose of e56.10 with corresponding 95% credible inter-
val of [e36.48;e77.43], estimated according to expert opinion. Individuals
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need three vaccine shots to be fully protected; therefore, these costs as well
as the administration costs have to be multiplied by three.
HPV-induced diseases related to the cervix produce costs which are a
combination of the expenses for two Pap-tests (cpap) and two colposcopies
(ccolp) in females affected by a CIN stage or cervical cancer. Moreover, the
costs of a HPV-DNA test (cdna) in those suffering from CIN III or cervical can-
cer have to be considered, in addition to the costs caused by the disease.
Neoplasiae in the anus lead to costs induced by the diagnostic proce-
dures of anal cytology (ccyt) in addition to anoscopy and biopsy (canbiop).
Furthermore, obviously, the treatment costs of the disease have to be con-
sidered. For all other HPV-induced diseases, we assume that the informa-
tion we found in the literature does not only include treatment costs, but
additionally those of all diagnostic procedures involved.
F.8 Model parameters related to utilities
Table F.8 shows the utilities we assume for the different states in the model.
We define informative Beta distributions for all parameters. Since we have
not found information on utilities for all HPV-induced diseases considered,
we assume the utilities of the precancerous stages of vaginal and vulvar
cancers to be equivalent to those of anal LSIL and HSIL, and those of vagi-
nal and vulvar cancers equivalent to cervical cancer. In penile cancer and
its precancerous stage, we assume the same utility for all cancer stages,
estimating an average value. For more information about the sources to
inform costs and utilities, see Section 5.5.1.
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Table F.8: Distributional values, means, corresponding 95% credible intervals and
sources of prior information of utilities used in the model
Var. Description Distribution Mean and 95%-CI Source
Cervix
uascus ASCUS Inform. Beta 0.8302 [0.5725;0.9767] [256]
ucin1 CIN I Inform. Beta 0.8396 [0.2058;0.9999] [256]
ucin2 CIN II Inform. Beta 0.7967 [0.0469;0.9999] [256]
ucin3 CIN III Inform. Beta 0.8396 [0.1845;0.9999] [256]
ucerv1 FIGO I Inform. Beta 0.5769 [0.2766;0.8641] [256]
ucerv2 FIGO II Inform. Beta 0.5228 [0.2254;0.8085] [256]
ucerv3 FIGO III Inform. Beta 0.5656 [0.3915;0.7413] [256]
ucerv4 FIGO IV Inform. Beta 0.4472 [0.1562;0.7456] [256]
Genital warts
ugwM Genital warts in males Inform. Beta 0.6961 [0.1172;0.9999] [256]
ugwF Genital warts in females Inform. Beta 0.7761 [0.0520;0.9999] [256]
Anus
ulsil LSIL Inform. Beta 0.9793 [0.9517;0.9955] [210]
uhsil HSIL Inform. Beta 0.9793 [0.9480;0.9959] [210]
uan1,M Cancer stage I in males Inform. Beta 0.6654 [0.1847;0.9850] [256,341]
uan2,M Cancer stage II in males Inform. Beta 0.6145 [0.1207;0.9783] [256,341]
uan3,M Cancer stage III in males Inform. Beta 0.4540 [0.0486;0.9157] [256,341]
uan4,M Cancer stage IV in males Inform. Beta 0.2165 [0;0.8309] [256,341]
uan1,F Cancer stage I in females Inform. Beta 0.7275 [0.0669;0.9999] [256,341]
uan2,F Cancer stage II females Inform. Beta 0.6776 [0.0268;1] [256,341]
uan3,F Cancer stage III females Inform. Beta 0.4917 [0.0105;0.9929] [256,341]
uan4,F Cancer stage IV females Inform. Beta 0.2739 [0;0.9796] [256,341]
Head/neck
uhn1,M Cancer stage I/II males Inform. Beta 0.8171 [0.0135;1] [110,256]
uhn3,M Cancer stage III/IV males Inform. Beta 0.5937 [0.0160;0.9979] [110,137,256,308]
uhn1,F Cancer stage I/II females Inform. Beta 0.7413 [0.2500;0.9911] [110,256]
uhn3,F Cancer stage III/IV females Inform. Beta 0.5377 [0.1450;0.9021] [110,137,256,308]
Vagina
uvain1 VaIN I see anal LSIL — EO
uvain2 VaIN II see anal HSIL — EO
uvain3 VaIN III see anal HSIL — EO
uvag1 Cancer stage I see cervical cancer stage I — EO
uvag2 Cancer stage II see cervical cancer stage II — EO
uvag3 Cancer stage III see cervical cancer stage III — EO
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uvag4 Cancer stage IV see cervical cancer stage IV — EO
Vulva
uvin VIN see anal HSIL — EO
uvulv1 Cancer stage I see cervical cancer stage I — EO
uvulv2 Cancer stage II see cervical cancer stage II — EO
uvulv3 Cancer stage III see cervical cancer stage III — EO
uvulv4 Cancer stage IV see cervical cancer stage IV — EO
Penis
upen PeIN, cancer all stages Inform. Beta 0.7922 [0.7489;0.8455] [91]
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Appendix G
Continuation of calibration
results
In Section 6.3, the visual calibration approach of the BMM applied to human
papillomavirus is described in detail. The terms “incidence” and “preva-
lence” are explained; in addition, calibration results of the model outcome
on HPV prevalence to data are presented. Furthermore, the calibration re-
sults for cervical cancer are shown. This appendix includes the calibra-
tion results of genital warts as well as HPV-induced diseases of the anus,
head/neck, vagina, vulva and penis. As explained in Section 6.3, the re-
sults are displayed separately for the two sexes and the three interventions
screening-only, female-only vaccination and universal vaccination.
G.1 Anal cancer and genital warts
Anal cancer incidence data for the general population are given by Cancer
Research UK [351]. The age- and sex-specific yearly incidence rates are
reported in age groups of five years. To the best of our knowledge, research
on the development of precursors of anal cancer is solely conducted for ho-
mosexual males. Thus, we use prevalence data on LSIL and HSIL from the
US on this subpopulation [84]. These are adjusted by the relative risk of on
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average 17.2 of homosexual males to develop anal cancer when compared
to the general population, informed by Danish data [145] and indicated by
the parameter ρF3 in Section 5.5. In females, we assume an on average 1.7
times higher risk of acquiring anal precancerous lesions when compared to
heterosexual males; we estimate this by comparing the UK data on female
and male anal cancer incidence [351]. The corresponding adjustment factor
is indicated by ρF2 .
The transition probabilities from the state LSIL to Clearance, LSIL to
HSIL, HSIL to Clearance and HSIL to LSIL are modified in an age- and sex-
specific way, multiplied by λF,a,15,13, λF,a,15,16, λF,a,16,13, λF,a,16,15 in females
and λM,a,8,6, λM,a,8,9, λM,a,9,6, λM,a,9,8 in males, respectively.
Due to non-existing Italian data, we calibrate the age- and sex-specific
model output on genital warts prevalence by means of Canadian prevalence
data reported by Marra et al. [253]. These are displayed in age groups of five
years from the ages of 15 to 85, and we interpolate these to a starting age
of twelve years. In the model, genital warts prevalence includes individuals
who newly acquire the condition, and those who suffer from a relapse. In
accordance to a literature source from the US [69], we assume genital warts
recurrence to be age-specific with an around five to twelve times higher
probability in older individuals when compared to the younger, indicated by
λF,a,7,7 in females and λM,a,4,4 in males.
Until the age of 52 years, we estimate the age- and sex-specific transition
probabilities of moving to the state of Genital warts in age groups of five
years; as a consequence, the model output does not look like a smooth
curve, but saw-toothed.
Our calibration results in Figure G.1 show that our model estimates both
female and male LSIL and HSIL prevalence reasonably well, whereas anal
cancer and genital warts in males are under- and overestimated in older
people, respectively. Since the overall anal cancer incidence is extremely
small and the effects of discounting are considerably high in the older, we
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G.1. Anal cancer and genital warts
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(a) The calibration result of anal LSIL shows that the
model outcome fits the data reasonably well; female
prevalence is higher than male prevalence as a re-
sult of different sexual behaviour.
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(b) The model outcome on anal HSIL shows a good ap-
proximation to the data, peak prevalence in older
people is realistically estimated.
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(c) The model outcome fits the trend of increasing anal
cancer incidence by age; however, the data show a
steeper increase, especially in older people.
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(d) Genital warts prevalence in females is well esti-
mated by our model, whereas it is overestimated
especially in older males. However, both due to the
small number of old age cohorts in our model and
discounting, these effects are not relevant.
Figure G.1: Calibration results for anus-related, HPV-induced diseases and geni-
tal warts. The prevalence of the precancerous stages anal LSIL and
anal HSIL is realistically estimated, whereas anal cancer incidence
and male genital warts prevalence are under- and overestimated in
older individuals, respectively.
assume that this underestimation does not have an impact on the results of
the health economic evaluation. As for genital warts prevalence, the over-
estimation in older males does not falsify the results (following the same
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reasoning as for anal cancer).
G.2 Other HPV-induced cancers
The calibration of the model outcome on head/neck cancer is relatively
straightforward since we do not account for a precancerous stage. The
expression “head/neck cancer” summarizes cancers located in the nasal
cavity, pharynx, tongue, lips, larynx, esophagus and trachea; however, only
20-25% of all head/neck cancers seem to be HPV-associated, with a higher
percentage of 60-70% in oropharyngeal cancers. Cancers in other parts of
the head and neck are mainly attributed to excessive smoking and drink-
ing [284]. As a consequence, we use age- and sex-specific data on oral
cancer incidence in the UK, reported by Cancer Research UK [352]. In or-
der to avoid an underestimation of head/neck cancer incidence, especially
in older ages, we incorporate the incidence rates reported into the lower
bounds of the corresponding prior distributions, assuming high variance. As
a consequence, we result in wide distributions, incorporating a large amount
of parameter uncertainty.
UK penile cancer incidence data are reported by the National Cancer
Date Repository of the Office for National Statistics [267]. These data sum-
marise penile cancer incidence over three years and therefore have to be
adjusted. As for anal and oral cancer, age-specific incidence rates on vulvar
as well as vaginal cancer are reported by Cancer Research UK [353, 354].
Despite an extensive literature review, we neither found prevalence data on
penile intraepithelial neoplasm (PeIN) nor on the precancerous stage of vul-
var cancer (VIN) or the three precancerous stages of vaginal cancer (VaIN
I-III); yet, incidence data on PeIN [266], VaIN and VIN [271] were found.
However, incidence data on these precancerous stages cannot be used for
model calibration since the corresponding model outcome does not refer to
those who newly acquire the condition as described in Section 6.3.1.
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G.2. Other HPV-induced cancers
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(a) The calibration result of head/neck cancer incidence
shows a good fit to the data in both sexes.
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(b) Penile cancer incidence is sufficiently well estimated
in younger ages and underestimated in older ages.
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(c) The calibration results of vulvar cancer incidence
are comparable to those of penile cancer.
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(d) As for penile and vulvar cancer incidence, vaginal
cancer incidence is estimated well in younger indi-
viduals, and the fit to the data becomes less optimal
in older ages.
Figure G.2: The model outcome on incidence of the rare HPV-induced cancers
in the head/neck, penis, vulva and vagina is displayed and compared
to data. We account for sex-specific incidence in head/neck cancer
with males under higher risk; the other cancers presented are sex-
specific. Incidence in the sex-specific cancers in the older ages is
underestimated. However, due to discounting and the relatively low
number of old age cohorts in the model, this does not falsify the results
of the cost-effectiveness analysis.
As a consequence, we estimate the prevalence of these precancerous
stages in a way to result in realistic outcomes of the corresponding can-
313
APPENDIX G. CONTINUATION OF CALIBRATION RESULTS
cers. We assume that young individuals clear a precancerous stage more
easily and are as a result less likely to progress to cancer. In contrast, the
probability of developing cancer considerably increases in older individuals
affected by PeIN or VIN. In the vaginal cancer compartment, we adjust the
transition probabilities to clear VaIN III and to move to vaginal cancer in an
age-specific way to increase vaginal cancer incidence in the older.
All assumptions are supported by the data on incidence, indicating con-
siderably higher incidence of the precancerous lesions in the older. Given
these data, we can assume that if incidence in older individuals is higher,
prevalence must be as well. For the age- and sex-specific variables λv,a,r,s,
see Section 5.8 and Appendices D and E.2.
We show the calibration results of the rare HPV-induced diseases head/
neck, penile, vulvar and vaginal cancer in Figure G.2. As for genital warts,
we estimate the transition probabilities to the state head/neck cancer in age
groups of five years, resulting in saw-toothed curves. For both sexes, the
output fits the data well. In penile cancer, the model estimates the age-
specific trend of a peak incidence in the oldest fairly well; however, the in-
crease in incidence is steeper in the data. Similar effects can be seen in
vulvar and vaginal cancer.
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